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Abstract
A systematic review and economic evaluation of diagnostic
strategies for Lynch syndrome
Tristan Snowsill,1* Nicola Huxley,1 Martin Hoyle,1
Tracey Jones-Hughes,1 Helen Coelho,1 Chris Cooper,1
Ian Frayling2 and Chris Hyde1
1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School,
Exeter, UK
2Institute of Medical Genetics, Cardiff University, Cardiff, UK
*Corresponding author
Background: Lynch syndrome (LS) is an inherited autosomal dominant disorder characterised by an
increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the
deoxyribonucleic acid (DNA) mismatch repair genes.
Objective: To evaluate the accuracy and cost-effectiveness of strategies to identify LS in newly diagnosed
early-onset CRC patients (aged < 50 years). Cascade testing of relatives is employed in all strategies for
individuals in whom LS is identified.
Data sources and methods: Systematic reviews were conducted of the test accuracy of microsatellite
instability (MSI) testing or immunohistochemistry (IHC) in individuals with CRC at risk of LS, and of
economic evidence relating to diagnostic strategies for LS. Reviews were carried out in April 2012 (test
accuracy); and in February 2012, repeated in February 2013 (economic evaluations). Databases searched
included MEDLINE (1946 to April week 3, 2012), EMBASE (1980 to week 17, 2012) and Web of Science
(inception to 30 April 2012), and risk of bias for test accuracy was assessed using the Quality Assessment
of Diagnostic Accuracy Studies-2 (QUADAS-2) quality appraisal tool. A de novo economic model of
diagnostic strategies for LS was developed.
Results: Inconsistencies in study designs precluded pooling of diagnostic test accuracy results from a
previous systematic review and nine subsequent primary studies. These were of mixed quality, with
significant methodological concerns identified for most. IHC and MSI can both play a part in diagnosing LS
but neither is gold standard. No UK studies evaluated the cost-effectiveness of diagnosing and managing
LS, although studies from other countries generally found some strategies to be cost-effective compared
with no testing.
The de novo model demonstrated that all strategies were cost-effective compared with no testing at a
threshold of £20,000 per quality-adjusted life-year (QALY), with the most cost-effective strategy utilising
MSI and BRAF testing [incremental cost-effectiveness ratio (ICER)= £5491 per QALY]. The maximum health
benefit to the population of interest would be obtained using universal germline testing, but this would not
be a cost-effective use of NHS resources compared with the next best strategy. When the age limit was
raised from 50 to 60 and 70 years, the ICERs compared with no testing increased but remained below
£20,000 per QALY (except for universal germline testing with an age limit of 70 years). The total net health
benefit increased with the age limit as more individuals with LS were identified. Uncertainty was evaluated
through univariate sensitivity analyses, which suggested that the parameters substantially affecting
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cost-effectiveness: were the risk of CRC for individuals with LS; the average number of relatives identified
per index patient; the effectiveness of colonoscopy in preventing metachronous CRC; the cost of
colonoscopy; the duration of the psychological impact of genetic testing on health-related quality of life
(HRQoL); and the impact of prophylactic hysterectomy and bilateral salpingo-oophorectomy on HRQoL
(this had the potential to make all testing strategies more expensive and less effective than no testing).
Limitations: The absence of high-quality data for the impact of prophylactic gynaecological surgery and
the psychological impact of genetic testing on HRQoL is an acknowledged limitation.
Conclusions: Results suggest that reflex testing for LS in newly diagnosed CRC patients aged < 50 years is
cost-effective. Such testing may also be cost-effective in newly diagnosed CRC patients aged < 60 or
< 70 years. Results are subject to uncertainty due to a number of parameters, for some of which good
estimates were not identified. We recommend future research to estimate the cost-effectiveness of testing
for LS in individuals with newly diagnosed endometrial or ovarian cancer, and the inclusion of aspirin
chemoprevention. Further research is required to accurately estimate the impact of interventions
on HRQoL.
Study registration: This study is registered as PROSPERO CRD42012002436.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
BRAF A human gene that makes a protein called B-raf (a member of the Raf kinase family).
BRAF V600E A mutation of the BRAF gene detected in a range of carcinomas, including colorectal cancer.
Constitutional genetic testing Tests for mutations that affect all cells in the body and have been
present since conception (also known as germline testing).
Constitutional mutation A genetic mutation present in all cells (also known as germline).
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between costs
and outcomes of alternative health-care interventions.
Distant metastases Cancer that has spread from the original (primary) tumour to distant organs or
distant lymph nodes.
DNA mismatch repair A process that corrects mismatches generated during deoxyribonucleic acid
(DNA) replication.
Dysplastic Abnormal development or growth of tissue, organs or cells.
False negative Incorrect negative test result (number of diseased persons with a negative test result).
False positive Incorrect positive test result (number of non-diseased persons with a positive test result).
Germline Inherited material that comes from the eggs or sperm and is passed on to offspring.
Germline mutation A detectable and heritable variation in the lineage of germ cells, which is
subsequently transferred to offspring and gives rise to constitutional mutation.
Immunoreactivity A measure of the immune reaction caused by an antigen.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Locoregional metastases Metastasis (spread) of a cancer only within the region in which it arose.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
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Metachronous Occurring or starting at different times.
Metastatic disease The spread of cancer from one organ or body part to another.
Microsatellite instability Abnormal patterns of microsatellite repeats observed when DNA is amplified
from a tumour with defective mismatch repair compared with DNA amplified from surrounding
normal tissue.
Microsatellite stable No evidence of abnormal patterns of microsatellite repeats or defective
mismatch repair.
Net survival The survival calculated from the estimated excess hazard of mortality caused by a condition.
Optimum cut-off The cut-off score which demonstrates the best trade-off between sensitivity
and specificity.
Polymerase chain reaction A technology used for amplifying DNA sequences.
Predictive testing Testing for known mutations.
Primary tumour A tumour growing at the anatomical site where tumour progression began.
Proband The first affected family member.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Receiver operating characteristic curve A graph which illustrates the trade-offs between sensitivity and
specificity which result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test, against which the index test
is compared.
Regional metastases The spread of cancer beyond the initial site to regional lymph nodes.
Relative survival The observed survival within a group (e.g. people with colorectal cancer) as a
proportion of the expected survival for a group with the same age and sex distribution.
Sensitivity Proportion of individuals with the target disorder who have a positive test result.
Single-gate study Study in which a single sample of individuals is assessed by both the index test and
reference standard.
Specificity Proportion of individuals without the target disorder who have a negative test result.
Sporadic colorectal cancer Colorectal cancer with no apparent hereditary component.
T1, T2, T3, T4 Stages of cancer.
Two-gate study Studies which employ separate sampling schemes for diseased and non-diseased
participants, with both groups being assessed by the index test.
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Plain English summary
Lynch syndrome (LS) is a genetic disease which increases the chances of developing cancer for peoplewith the disease. If a parent has LS there is a 50 : 50 chance that his or her child will also have it.
The most common cancer for people with LS is bowel cancer. Around one in three people with LS would
develop bowel cancer by the age of 70 years if no action was taken to reduce the risk.
It is recommended that people with LS have a colonoscopy at least once every 2 years, from age 25 to
around age 75 years. Colonoscopy can find pre-cancerous growths, which can be removed to reduce the
risk of bowel cancer. Colonoscopy can also identify cancer in early stages, improving the chances of
surviving bowel cancer.
It has been suggested that people diagnosed with bowel cancer under the age of 50 years should be
tested for LS, and their relatives should also be tested if LS is found.
In this report a number of common testing strategies were compared against no testing, as well as the
strategy of offering genetic testing to all people diagnosed with bowel cancer under the age of 50 years.
It was found that all strategies improved health outcomes compared with no testing, at a cost generally
considered acceptable to the NHS. The strategy of genetic testing for all bowel cancer patients aged under
50 years was not a good use of NHS resources compared with strategies involving additional tests before
genetic testing.
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Scientific summary
Background
l Lynch syndrome (LS), previously known as hereditary non-polyposis colorectal cancer (HNPCC), is an
inherited autosomal dominant disorder characterised by an increased risk of colorectal cancer (CRC)
and cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary tract, urinary tract, brain
and skin, among others. The lifetime cancer risk is highest for CRC (range 22–82% by age 70 years).
l LS accounts for 0.3–2.4% of CRC, with a general population prevalence of 1 : 3100. It is caused by
mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes, specifically MutL homologue 1
(MLH1), MutS homologues 2 (MSH2) and 6 (MSH6), and postmeiotic segregation increased 2 (PMS2).
Loss of MMR proficiency in a cell leads to an inability to repair DNA mismatches and the proliferation
of genetic mutations. These mutations are more likely in repetitive DNA sequences known as
microsatellites, a phenomenon known as microsatellite instability (MSI).
l Identification of family members carrying a MMR gene defect is desirable, in order to offer
colonoscopic surveillance and prophylactic surgery as appropriate.
l If LS is identified, biennial colonic surveillance commencing at 25 years is recommended. Surveillance
should cease for individuals testing negative for a characterised pathogenic germline mutation present
in family members.
l Currently, clinical criteria [Amsterdam criteria (AC) II or Revised Bethesda criteria] are used to assist with
the diagnosis of LS. Laboratory techniques are also available, including testing tumour tissue using
immunohistochemistry (IHC), MSI testing (now included in the Revised Bethesda criteria) and genetic
testing for MMR mutations. Supplementary tests include BRAF V600E and methylation of MLH1.
¢ MSI testing involves identifying reference markers. Tumours with no instability in any of the
markers are considered microsatellite stable. Those with one, or more than one, mutated reference
marker are considered to have low MSI or high MSI respectively (in the case of a five
marker panel).
¢ IHC is performed on MLH1, MSH2, MSH6 and PMS2 proteins. Negative staining indicates a
mutation in the corresponding MMR gene, thus identifying the gene(s) most likely to harbour
a mutation.
¢ A limitation of IHC and MSI testing is the existence of MLH1 silencing in approximately 15% of
sporadic CRC cases, leading to a false-positive LS result.
¢ Multiple methods have been used for constitutional genetic testing in LS. Multiplex
ligation-dependent probe amplification is the preferred technique in the UK.
Objective
i. To determine the accuracy of tests for LS in all newly diagnosed persons with CRC < 50 years of age,
and those considered according to clinical criteria to be at high risk.
ii. To determine the diagnostic utility and cost-effectiveness of genetic testing for LS in all newly
diagnosed persons with CRC < 50 years of age, and those of strategies to test their close relatives.
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Methods
Test accuracy systematic review
l The assessment comprises a systematic review of evidence on the accuracy of LS laboratory tests.
A literature search was conducted on 30 April 2012 in a range of electronic databases [including
MEDLINE (1946 to April week 3, 2012), EMBASE (1980 to week 17, 2012) and The Cochrane Library
(inception to 30 April 2012)] and in trial registries. The European Medicines Agency website and
Google were also searched.
l Studies were included if:
¢ the persons presenting with CRC were < 50 years of age, considered at risk of LS or close relatives
of individuals with proven LS
¢ they compared tumour-based tests against constitutional genetic testing
¢ the outcome related to diagnostic accuracy, for example sensitivity and specificity.
l No study design was excluded unless evidence on the test was already available from higher-level
study designs.
l Data extraction and critical appraisal [using Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2)] was performed by two reviewers. Individual results were summarised in tables and text.
Data pooling was not possible due to study heterogeneity.
Cost-effectiveness systematic review
l This aimed to review cost-effectiveness studies related to the identification and management of
individuals with LS. A literature search was conducted on 29 February 2012 (updated 5 February 2013)
in a range of electronic databases including MEDLINE (1946 to February week 3, 2012; updated search
1946 to January week 4, 2013), EMBASE (1980 to week 8, 2012; updated search 1980 to week 5,
2013) and The Cochrane Library (inception to 29 February 2012; updated search, inception to Issue 1
of 12, January 2013). Studies were included where:
¢ the population was persons who have or may have LS
¢ the intervention was a strategy or strategies that identify and/or manage LS in a given population
¢ the comparator was current clinical practice
¢ outcomes included costs or clinically relevant outcomes [e.g. life-years or quality-adjusted life-years
(QALYs) gained, CRCs prevented, mutations detected]
¢ the study design was a decision-analytic model, evaluation of cost-effectiveness within trials, cost or
resource use study, or guideline from a national institution or a professional or international body.
l Data extraction was carried out by two reviewers. Included studies were assessed for quality using the
Drummond checklist. Data were synthesised using tables and text.
Peninsula Technology Assessment Group cost-effectiveness analysis
Our model of the cost-effectiveness of systematic screening for LS comprises a diagnostic and a
survival component.
Diagnostic model
This is a decision tree model of short-term outcomes of diagnosis in probands and relatives.
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We considered the following strategies to identify LS in probands:
1. No genetic testing, subdivided:
1(1) no testing
1(2) AC II.
2. IHC four-panel test, followed by genetic testing.
3. IHC, followed by BRAF testing then genetic testing.
4. MSI testing followed by genetic testing.
5. MSI testing, followed by BRAF testing, followed by genetic testing.
6. MSI testing, followed by BRAF testing, followed by IHC testing, followed by genetic testing.
7. IHC testing, followed by genetic testing if result abnormal. For normal IHC results: MSI testing, followed
by BRAF testing for MSI result, followed by genetic testing for negative BRAF test.
8. Universal genetic testing.
The diagnosis of LS in relatives of a newly diagnosed CRC proband directly depended on the diagnosis
of the proband, and predictive genetic testing was used when applicable.
A proportion of probands and relatives diagnosed with LS were assumed to undertake biennial surveillance
colonoscopy and prophylactic total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO).
The prevalence of LS and the sensitivities and specificities of individual tests were taken from published
literature. Acceptance of tests was primarily based on expert opinion. Numbers of probands and relatives
were taken from UK sources (Office for National Statistics data, published studies and unpublished data).
The costs of the preliminary tumour tests and genetic tests were obtained directly from laboratories in the
UK or from experts. The costs of genetic counselling and family history assessment were estimated using
the Personal Social Services Research Unit and expert advice.
The psychological impact of testing for LS and prophylactic TAHBSO were incorporated into overall
health-related quality of life (HRQoL), using data from the literature.
Survival model
This uses an individual patient simulation of thousands of hypothetical patients from time of LS diagnosis
to death (or age 100 years). For each person, total costs and QALYs were calculated using methodology
recommended by the National Institute for Health and Care Excellence, with costs and benefits discounted
at 3.5% per annum. The model only considers the risks of CRC and endometrial cancer (EC).
Patient state at any time is defined by the following characteristics: age, sex, EC/CRC status, previous
surgery (bowel or TAHBSO), LS status and diagnosis, acceptance of LS surveillance and whether or not the
patient is alive.
Age at entry is a function of sex, true LS status and whether proband or relative. In the base-case analysis,
the maximum age of probands is 50 years.
Simulated clinical events included incidence of CRC and EC; surgery for CRC and EC; colonoscopies
(including bleeding and perforation); and mortality from CRC, EC, colonoscopy and background causes.
The events determine costs incurred and HRQoL for each simulated patient. These are used to estimate the
total discounted costs and QALYs for each testing strategy.
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Parameters of the natural histories of diseases, the effectiveness of interventions and the impact on quality of
life of diseases and interventions were sourced, where possible, from national statistics and published literature.
Costs of interventions were estimated from Department of Health reference costs 2011–12 with inflation
to 2013–14 prices, or from published literature with appropriate conversion. The cost of a colonoscopy
was adjusted to allow for the fact that the effectiveness of colonoscopy was taken from a regime of
3-yearly colonoscopy.
Uncertainty
We investigated uncertainty using scenario analyses and univariate sensitivity analyses upon the majority
of parameters.
Results
Test accuracy systematic review
l Ten published papers were included (nine test accuracy studies and one technology assessment (TA)
commissioned by the US Department of Health and Human Services).
l The TA found minimal published information on the analytical validity of laboratory testing for LS. Results
ranged from 18% to 100% for sensitivity and 25% to 100% for specificity, with wide confidence intervals.
¢ Many primary studies recruited preselected patients (e.g. from registries or pre-tests). However,
those studies recruiting from a population that had no prior testing may include an increased
number of false positives (FPs) due to MLH1 methylation found in sporadic CRC. Other issues
include: the reference standard was often not performed on all patients; sample sizes were
generally small; and details on patient characteristics and robustness of testing were often lacking.
l Owing to the range of study designs, pooling of data was not possible.
l IHC sensitivity ranged from 73.3% to 100.0% and specificity from 12.5% to 100.0%. Specificity is the
greatest concern; a high number of FPs means that individuals may be told they have LS when they do not.
l MSI sensitivity ranged from 88% to 100% and specificity from 68% to 84%. However, no two
included studies used the same panel of markers.
Cost-effectiveness systematic review
l Thirty-two separate studies were identified, which examined strategies only identifying LS (15 studies);
strategies only managing patients with LS (four studies); and strategies to both identify and manage LS
(13 studies).
l The studies that included diagnosis and management were most relevant to our assessment. None of
these were UK studies. Populations, settings and diagnostic strategies varied across the studies, and
most only considered CRC in the long term. Quality assessment found that one consistent problem was
the reporting of study viewpoint. Depth of detail related to modelling was mixed and, in particular, the
justification for ranges of values in the sensitivity analyses was poorly reported. Study design was
predominantly decision modelling. Most studies reported life-years and costs as their main outcomes,
with two explicitly modelling QALYs.
l Generally, strategies that identified LS were found to be cost-effective compared with no LS screening.
There was little consistency in terms of which strategies were the most cost-effective.
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Peninsula Technology Assessment Group cost-effectiveness analysis
Base-case results
l Life expectancy of probands and relatives with LS improves by up to 1.6 years with testing.
l The expected total number of colonoscopies performed for probands aged < 50 years and their relatives in
England, per year, increased from approximately 4200 in those given no testing to 8600 in strategy 8.
l The expected number of new CRC cases for the entire cohort in England, per year, reduces by up to 32
with testing.
l The expected annual number of ECs in England is reduced by up to nine with testing.
l Incremental cost-effectiveness ratios (ICERs) (vs. no testing) varied from £5491 per QALY for strategy 5
to £9571 per QALY for strategy 8.
l The testing strategies on the efficiency frontier were strategies 1(1), 5, 7 and 8. The remaining
strategies were either dominated (less effective and more expensive than at least one other strategy) or
extended dominated (less effective and more expensive than some combination of two other
strategies). On the efficiency frontier, the ICER of strategy 5 versus no testing was £5491 per QALY.
The ICER of strategy 7 versus strategy 5 was £25,106 and the ICER of strategy 8 versus strategy 7 was
£82,962 per QALY.
l At a willingness-to-pay threshold of £20,000 per QALY, strategies 4, 5, 6 and 7 offered the best value
for money, with similar cost-effectiveness. These strategies are predicted to result in an additional 130
discounted QALYs per year (or the total discounted QALYs accrued over the lives of approximately five
people) in England compared with no testing.
Increasing the maximum age of probands
l When the age limit for proband testing was raised to 60 or 70 years, strategies became worse value for
money versus no testing compared with the base case. At the age limit of 60 years, all ICERs compared
with no testing remained below the £20,000-per-QALY threshold, but at age 70 years the ICER for
strategy 8 was above the £20,000-per-QALY threshold.
l The incremental net health benefit (INHB) at the population level compared with no testing increased in
most strategies compared with the base case. Strategy 5 gave the greatest INHB at a willingness-to-pay
of £20,000 per QALY in both cases: 193 discounted QALYs for the population of England per year
when the age limit was 60 years, and 271 discounted QALYs when the age limit was 70 years.
Endometrial cancer excluded
l This scenario resulted in reduced costs and slight increase in life expectancy (therefore reduced ICERs),
plus no disutility from EC, compared with base case. Thus, all strategies became more cost-effective
compared with no testing. The ranking of cost-effectiveness among strategies remained the same.
BRAF replaced by methylation testing
l When BRAF testing was replaced by methylation testing in strategies 3, 5, 6 and 7, their
cost-effectiveness changed marginally.
l The INHB of all four strategies decreased versus no testing at a threshold of £20,000 per QALY.
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Univariate sensitivity analyses
l Several univariate sensitivity analyses were conducted to investigate the impact of various parameters
on the cost-effectiveness results. Incidence of CRC for individuals with LS, mean number of relatives
identified per proband, hazard ratio for colonoscopy in the prevention of metachronous CRC,
cost of colonoscopy and length of time of psychological disutilities all had a substantial impact on
cost-effectiveness, but the testing strategies all remained cost-effective at a threshold of £20,000
per QALY.
l When a disutility of 0.1 for prophylactic TAHBSO was assumed, all strategies resulted in greater costs
and reduced QALYs compared with no testing.
Suggested research priorities
We recommend further research as follows:
l Model the cost-effectiveness of testing for LS in probands newly diagnosed with EC and, separately,
probands presenting with ovarian cancer and perhaps rarer LS-associated cancers.
l Incorporate aspirin (CRC prevention) in the model.
l Investigate disutilities for patients with CRC and disutilities after TAHBSO, particularly because the cost-
effectiveness of genetic testing is very sensitive to the latter.
l Research the psychological impact of genetic testing for LS on HRQoL. The current evidence is
extremely weak.
l Investigate the accuracy of individual tests when they are performed in sequence after early tests, i.e. in
enriched populations.
l The cost-effectiveness model could be adapted for use in other countries.
Study registration
This study is registered as PROSPERO CRD42012002436.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Nature of disease
Lynch syndrome (LS) is the most common form of genetically defined, hereditary colorectal cancer (CRC),
accounting for 1–3% of all such tumours. Historically, a variety of names have been used for the disease,
originally identified by Aldred Scott Warthin in 1913 and then rediscovered by Henry T Lynch in 1966.
Lynch coined the terms ‘site-specific colon cancer’ and ‘family cancer’ syndromes. During a workshop in
Amsterdam in 1989, the participants agreed upon the name hereditary non-polyposis colorectal cancer
(HNPCC), as at that time the syndrome was unknown to most doctors.1 The appropriateness of the name
was discussed again at the international collaborative group on HNPCC meeting in Bethesda, MD, in 2004
where, as the syndrome is also associated with many other tumours, it was proposed that the name ‘Lynch
syndrome’ should be reintroduced.1
Lynch syndrome is inherited as an autosomal dominant disorder, whereby if one parent has the disease,
there is a 50% chance that each of his or her children will inherit it. It is characterised by an increased risk
of CRC and cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary tract, urinary tract,
brain and skin among others, with the lifetime cancer risk highest for CRC (Table 1).
Overall, LS accounts for between 0.3% and 2.4% of CRCs, and its prevalence in the general population is
of the order of 1 : 3100 (although this may be subject to underestimation due to the current lack of
systematic testing).9,10 The risk of a second primary CRC in individuals with LS is high (estimated at 16%
within 10 years) and the risk of a LS cancer in a first- or second-degree family member is approximately
45% for men and 35% for women by age 70 years.1
Lynch syndrome is caused by mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes,
namely MutL homologue 1 (MLH1), MutS homologues 2 and 6 (MSH2 and MSH6) and postmeiotic
segregation increased 2 (PMS2).4,11 Loss of DNA MMR activity in a cell, due to mutations in both alleles of
one of the MMR genes, leads to an inability to repair base–base mismatches and small insertions and
deletions, resulting in genetic mutations which may then progress to cancer.12 Mutations occur all over the
genome, but especially in repetitive DNA sequences, such as microsatellites. These cause abnormal
patterns of microsatellite repeats to be observed when DNA is amplified from a tumour with defective
MMR compared with DNA amplified from surrounding normal tissue. This phenomenon is known as
microsatellite instability (MSI).
Based on data from 12,624 observations worldwide, MLH1 accounts for 39%, MSH2 34%, MSH6 20%
and PMS2 8% of entries in the International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
database (www.insight-group.org/mutations/). However, all such estimates are subject to bias, because
these are generally mutations found in families referred to genetics clinics, subject to fulfilment of local
referral guidelines.
Diagnosis/testing
Currently, the Amsterdam criteria (AC) II and Revised Bethesda criteria, as seen in Table 2, may be used to
assist with diagnosis of LS. In 1989, the AC were proposed in order to provide uniform family material
required for international collaborative research studies. In 1999, these criteria were revised to include
extracolonic tumours.1 However, with the development of techniques to investigate tumours, such as MSI
and MMR immunohistochemistry (IHC), in 1997 the Bethesda guidelines were developed to aid selection
of tumours for testing and subsequently identifying individuals with LS. These guidelines were revised in
2004. It should be noted that all AC must be met whereas only one Bethesda criterion is necessary.
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The Bethesda criteria include MSI-high (MSI-H). This refers to MSI testing where the National Cancer
Institute (NCI) has recommended a panel of five markers, known as Bethesda (or NCI) markers, which
include two mononucleotides (BAT25 and BAT26) and three dinucleotide repeats (D2S123, D5S346 and
D17S250). Tumours with no instability in any of the markers are considered to be microsatellite stable
(MSS). When one reference marker is mutated, a tumour is considered to be MSI-low (MSI-L), and if two
or more markers are altered, it is considered to be MSI-H.12 In some cases an additional panel of five
markers is used; if 3 out of 10 show instability then it is classified as MSI-H, and if two or fewer, MSI-L.
TABLE 2 Criteria used to assist diagnosis of LS
AC II Revised Bethesda guidelines
At least three separate relatives with CRC or a
LS-associated cancer
CRC diagnosed in a patient aged < 50 years
One relative must be a FDR of the other two Presence of synchronous, metachronous colorectal or other
LS-related tumours, regardless of age
At least two successive generations affected CRC with MSI-H phenotype diagnosed in a patient aged
< 60 years
At least one tumour should be diagnosed before the age
of 50 years
Patient with CRC and a FDR with a LS-related tumour, with
one of the cancers diagnosed at age < 50 years
FAP excluded in CRC case(s) Patient with CRC with two or more FDRs or SDRs with a
LS-related tumour, regardless of age
Tumours pathologically verified
FAP, familial adenomatous polyposis; FDR, first-degree relative; MSI-H, MSI-high; SDR, second-degree relative.
TABLE 1 Lifetime cancer risk in LS
Cancer
Estimated lifetime cancer risk
for individuals with LS (%)
Estimated lifetime cancer risk
in the general population (%)
Colorectal by age 70 years Men: 382 5–63
Women: 312
Endometrial Women: 332 Women: 2–33
Gastric 0.72 13
Ovarian Women: 92 Women: 1–23
Small bowel 0.62 0.013
Bladder 43 1–33
Urinary tract 1.9–8.45 46,7
Brain 43 0.63
Kidney, renal pelvis 33 13
Biliary tract 0.62 0.53
Pancreas 0.4–3.75 1.48
Prostate Men: 9.1–30.05 Men: 13.28
Breast Women: 5.4–14.45 Women: 12.98
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Unfortunately, there are limitations to MSI testing due to MLH1 silencing commonly occurring in
non-hereditary cancers. Thus, MSI is found in approximately 15% of sporadic CRC cases (i.e. CRC with no
apparent hereditary component),1 and according to Umar and colleagues, as many as 50% of suspected
cases of LS are not confirmed by a genetic defect (that is, mutation in one of the known MMR genes).12
Hence, the Bethesda criteria have been criticised as being insensitive and non-specific, because strictly
applied they would result in approximately 25% of all CRC being tested. In turn, this has stimulated the
development of additional tests for the diagnosis of LS, as presented in Table 3.
Current evidence supports genetic testing for LS to include:13
1. evaluation of tumour tissue for MSI through molecular MSI testing and/or IHC of the four MMR
proteins (MLH1, MSH2, MSH6 and PMS2)
2. molecular genetic testing of the tumour for MLH1 gene methylation and/or somatic BRAF V600E
mutation to help identify those tumours more likely to be sporadic than hereditary, as the presence of a
BRAF V600E mutation makes LS very unlikely1
3. molecular genetic testing of the MMR genes to identify a constitutional (germline) mutation when
findings are consistent with LS.
Prognosis
Colorectal tumours in LS appear to evolve through the adenoma–carcinoma sequence. However, this
progression is accelerated compared with CRC in sporadic and other familial settings, i.e. 2–3 years as
opposed to 8–10 years.12,14 Furthermore, adenomas in LS often occur in younger individuals and tend to
be larger and more severely dysplastic than in sporadic cases.14 That said, recent studies have confirmed
early suspicions that patients with CRC from LS families survive longer than sporadic CRC patients with
same-stage tumours.15 The reasons for the favourable survival rate with CRC in this syndrome remain
unclear, but are likely related to a reduced propensity to metastasise. Explanations include that
immunological host defence mechanisms may be more active in tumours of the MSI Pathology Research
International 3 phenotype, and that the relatively high mutational load that occurs in tumours with
defective DNA repair systems is detrimental to their survival.14
Furthermore, there is definite evidence for a genotype–phenotype correlation in LS; for example, one study
found that MSH6 mutation carriers had markedly lower cancer risks overall than MLH1 or MSH2 mutation
TABLE 3 Overview of tests to assist with diagnosis of LS
Test Description
MSI Preliminary test performed on tumour tissue. Those with high instability
proceed to either DNA analysis or IHC. However, the presence of MSI in the
tumour alone is not sufficient to diagnose LS as sporadic CRC may exhibit MSI
IHC Preliminary test performed on tumour tissue to identify one of four MMR
proteins (MLH1, MSH2, MSH6 and PMS2). Those with negative staining
proceed to DNA analysis of the gene/genes indicated
IHC testing helps to identify the MMR gene that most likely harbours a
constitutional (‘germline’) mutation, as abnormal expression of a MMR protein
points to a mutation in that gene
Methylation of MLH1 and/or BRAF V600E
testing of tumour tissue
Preliminary molecular genetic test performed on tumour tissue of patients with
negative staining for MLH1 on IHC
The presence of BRAF V600E mutation or hypermethylation of MLH1 make
LS unlikely
DNA analysis of MMR genes (MLH1,
MSH2, MSH6, PMS2)
Diagnostic test, typically performed on blood. DNA analysis (gene sequencing,
deletion/duplication testing) of MLH1, MSH2, MSH6, PMS2
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carriers.2 Carriers of a MMR gene mutation have a very high risk of developing CRC (25–70%) and
endometrial cancer (EC) (30–70%) and an increased risk of developing other tumours.5
Management of disease
Surveillance
As LS is a hereditary condition, identification of family members carrying a MMR gene defect is desirable,
as colonoscopic surveillance, and possibly prophylactic and/or altered surgical management, may be
offered to high-risk individuals.
Given that screening for a mutation is time-consuming and expensive – largely because four genes may
have to be analysed and their mutational spectra are wide (Vasen 20071) – the British Society of
Gastroenterology (BSG) and the Association of Coloproctology of Great Britain and Ireland (ACPGBI)9
recommend that individuals with a substantially elevated personal risk of gastrointestinal malignancy be
offered surveillance on the basis of one or more of the following criteria:
l a family history (FH) consistent with an autosomal dominant cancer syndrome
l pathognomonic features of a characterised polyposis syndrome personally or in a close relative
l the presence of a constitutional (‘germline’) pathogenic mutation in a CRC susceptibility gene
l molecular features of a familial syndrome in a CRC arising in a first-degree relative (FDR).
Individuals fulfilling at least one of the above criteria should be referred to a NHS regional genetics centre
for assessment, genetic counselling and mutation analysis of relevant genes, where appropriate.
Vasen and colleagues (2007)1 highlight a study in which 10-year surveillance of 22 LS families reduced the
development of CRC by 60% and also decreased mortality.10,16 Appropriately targeted surveillance also
means that those without a gene defect may be spared intensified surveillance, which is costly and carries
not insignificant risks of morbidity and mortality.1
If LS has been identified, large bowel surveillance is recommended by the BSG and ACPGBI for probands
and family members as follows:9
Total colonic surveillance (at least biennial) should commence at age 25 years. Surveillance
colonoscopy every 18 months may be appropriate because of the occurrence of interval cancers in
some series. Surveillance should continue to age 70–75 years or until co-morbidity makes it clinically
inappropriate. If a causative mutation is identified in a relative and the consultand is a non-carrier,
surveillance should cease and measures to counter general population risk should be applied.
Reproduced from Gut, Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al.,
Volume 59, pp. 666–89, 2010 with permission from BMJ Publishing Group Ltd.
l Families fulfilling Amsterdam criteria, but without evidence of DNA mismatch repair gene defects
(following negative analysis of constitutional DNA and negative tumour analysis by microsatellite
instability testing/immunohistochemistry), require less frequent colonoscopic surveillance.
l Gastrointestinal surveillance should cease for people tested negative by an accredited genetics
laboratory for a characterised pathogenic germ-line mutation shown to be present in the family,
unless there was a significant, coincidental finding on prior colonoscopy.
l The evidence for upper gastrointestinal surveillance in all of these disorders is weak, but limited
evidence suggests it may be beneficial.
Reproduced from Gut, Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al.,
Volume 59, pp. 666–89, 2010 with permission from BMJ Publishing Group Ltd.
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Debate continues regarding the appropriate age for and frequency of surveillance, but the above criteria
are in agreement with further published data.1 However, the situation becomes more complex when
the proband does not have a detectable DNA alteration associated with LS, or when an alteration with
an unclear significance is identified.4 Vasen and colleagues (2007)1 suggest that this is the case for
approximately 30% of families meeting the AC I, for whom a less intensive surveillance protocol may be
recommended (i.e. colonoscopy at 3–5 year intervals, starting 5–10 years before the first diagnosis of CRC
or at > 45 years).
Surgical management
Several studies have shown that patients with LS have an increased risk of developing multiple
(synchronous and metachronous) CRCs.1 The type of surgery received, i.e. total or subtotal colectomy,
depends on the location of the tumour and the stage of the cancer. Studies have shown that adenomas in
patients with LS are located mainly in the proximal colon (ascending and transverse);14 therefore, a subtotal
colectomy is favoured, which involves removal of most of the colon, leaving a small amount to be
reattached to the rectum. Clinicians may also discuss prophylactic colectomy as a reasonable option in
mutation carriers for whom colonoscopy is painful or difficult, or for a patient with adenomas that cannot
be removed easily; however, this remains controversial.
Chemotherapy
At least three chemotherapeutic agents have been proven to be effective in the treatment of CRC – 5-FU
(also known as fluorouracil) with or without leucovorin (also known as folinic acid), oxaliplatin and
irinotecan – although experimental and clinical studies suggest that MSI-H tumours are resistant to
5-FU-based chemotherapy. Therefore, according to Vasen and colleagues (2007),1 prospective clinical trials
are needed before definitive recommendations can be given.
Epidemiological studies have demonstrated that non-steroidal anti-inflammatory drugs (e.g. aspirin) reduce
the risk of CRC.14 A recent study showed that a daily dose of aspirin reduced the incidence of CRC in
carriers of LS after 56 months’ follow-up.17 The mechanisms by which aspirin prevents the development
of cancer are unknown, though some have suggested that aspirin may be proapoptotic in the early stages
of CRC development. Importantly, the Colorectal Adenoma/Carcinoma Prevention Programme 2 (CAPP2)
trial of aspirin prophylaxis in LS has demonstrated that aspirin treatment for up to 3 years reduces,
a decade later, the overall incidence of LS-associated cancers, including CRC, by 63%.17 A further dosage
determination trial (CAPP3) is therefore planned in LS patients worldwide (www.capp3.org) and highlights
the importance of identifying individuals and families with LS.
Description of technologies under assessment
The major laboratory tests used in the evaluation of patients suspected of having LS include testing of
tumour tissue using IHC, MSI testing and constitutional testing for MMR mutations (generally from
peripheral blood mononuclear cells). Family members undergo predictive genetic testing for the pathogenic
mutation identified in the proband (unless they have also developed a relevant cancer).4 Other tests which
may be carried out on tumours include BRAF V600E and methylation of MLH1.
Immunohistochemistry
In families with an increased probability of a MMR gene mutation, IHC analysis for MMR proteins MSH2,
MLH1 and MSH6 in tumour tissue may be used as the first step to confirm the presence of MMR
deficiency. Pathogenic mutations in MMR proteins frequently lead to the absence of a detectable gene
product, or expression of the protein in an abnormal location, for example in the cytoplasm rather than
the cell nucleus. Therefore, when tumour tissue from patients suspected of having LS is stained for MMR
proteins, a negative or less intense nuclear staining may be visible as compared with the surrounding
normal colonic tissue used as a positive control.4,18
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The advantage of IHC, as opposed to MSI, is that abnormal staining of a specific MMR protein is related
to the underlying gene defect and can therefore direct further genetic mutation analysis.1 IHC is a
well-established technique widely available in cell pathology laboratories; however, when used to analyse
MMR proteins in the setting of LS diagnosis, it must be performed to an adequate standard. Hence, at a
workshop in 2006 it was decided that MMR IHC should only be available within the NHS via a laboratory
accredited to Clinical Pathology Accreditation standards, obliged to participate in the UK National External
Quality Assessment Scheme Immunocytochemistry (NEQAS ICC) for MMR proteins.19 This workshop made
a number of recommendations, including that MMR IHC should be performed for all four main MMR
proteins, in part to address the issue of tissue fixation artefact. Care must also be taken in histopathological
interpretation of MMR IHC that an adequate and representative tissue sample has been analysed.
Although MMR IHC can give useful and informative results, its sensitivity is limited by a number of factors,
for example tissue fixation, the variety and different performance characteristics of primary antibodies
and the fact that some pathogenic mutations may result in catalytically inactive but antigenically intact
proteins.15,20–23 Hence, there is a place for MSI analysis in cases with a high prior probability of LS, but with
apparently normal expression of the MMR proteins.1
A particular issue with IHC is that approximately 15% of sporadic colon cancers lose expression of MLH1
because of somatic hypermethylation of the gene’s promoter. Therefore, whereas abnormal expression of
MSH2, MSH6 or PMS2 is in itself reasonably good evidence that a tumour was due to LS, loss of MLH1 in
itself is not. Other evidence must be used in interpretation in these circumstances, and thus testing for
BRAF V600E and/or MLH1 promoter methylation may also be performed. The presence of the BRAF V600E
mutation indicates a sporadic rather than LS-associated CRC, but the absence of BRAF V600E does not
distinguish between sporadic tumours and those caused by LS. Similarly, MLH1 promoter methylation is
highly correlated with a sporadic origin for a tumour, but is not absolutely conclusive, because individuals
and families are described with constitutional MLH1 promoter methylation defects.24
Microsatellite instability testing
Microsatellite instability refers to the variety of patterns of microsatellite repeats observed when DNA is
amplified from a tumour with defective MMR compared with DNA amplified from surrounding normal
colonic tissue. Repetitive mono- or dinucleotide DNA sequences (microsatellites) are particularly vulnerable
to defective MMR.4 MSI is prevalent in tumours from patients with MMR mutations, and in patients
meeting either AC.4 Therefore, microsatellite analysis is commonly used as the first diagnostic screening
test for LS.18
Microsatellite instability testing involves amplification of a standardised panel of DNA markers
(Bethesda/National Institutes of Health markers), although laboratories may use 10 or more markers and,
more recently, a commercially available kit based on five mononucleotide markers has become popular as
mononucleotide microsatellites may be the most sensitive markers for use in detecting MSI.4 The process
involves microdissection of tumour tissue, followed by extraction of DNA which is then amplified and run
on a DNA fragment length analyser. Using such microsatellite markers, additional peaks in tumour tissue
DNA in comparison with normal tissue DNA indicate MSI.25 Instability in 30% or more of the markers
is considered MSI-H, less than 30% MSI-L and no shifts or additional peaks MSS. However, if instability is
observed at any mononucleotide markers, MSI may be diagnosed. For this reason, MSI testing is moving to
a smaller panel of mononucleotide markers, making the process more efficient and cheaper.
As for any molecular pathological analysis, tissue to be selected for MSI analysis must be first assessed by a
histopathologist, prior to some degree of microdissection, which aids in maximising sensitivity. There is
debate regarding the relative costs of MMR IHC and MSI testing, but NHS service laboratory costings
indicate there is little to choose between the two. MSI may be more reproducible and can be performed
with smaller amounts of tissue.26 As there is not yet a UK NEQAS scheme for MSI, the reproducibility of
MSI compared with IHC is not established.
BACKGROUND
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BRAF V600E and methylation testing
The presence of MSI in the tumour by itself is not sufficient to diagnose LS because 10–15% of sporadic
CRCs exhibit MSI.25 MSI in non-LS tumours is usually caused by hypermethylation of the MLH1 gene.
This acquired epigenetic inactivation of MLH1 is typically associated with mutations in the BRAF gene
(specifically the V600E mutation), which has been described in ≈ 35% of sporadic MSI-H CRCs.25
Therefore, identification of hypermethylation of MLH1 and/or BRAF V600E is an indication that a patient
does not have the LS germline mutation.
Ideally, tests would be performed together as the presence of the BRAF V600E mutation theoretically
reduces the chance of LS as the cause of that tumour; however, because any test has a finite false
negative (FN) rate, it is still a possibility. Additionally, if MLH1 promoter methylation is present but the
BRAF V600E mutation is not, this would highlight the small possibility that the patient may have LS due to
a constitutional MLH1 methylation defect. It is also possible that he or she could have an inherited MLH1
genetic mutation and could have acquired MLH1 promoter methylation as the ‘second hit’ in the tumour.
In these cases, loss of heterozygosity of chromosome 3p (where MLH1 is located) is observed.25
Constitutional genetic testing
Multiple methods have been used for constitutional genetic testing (tests for mutations that affect all cells
in the body and have been there since conception) in LS, in order to find inherited or, if de novo,
potentially inheritable MMR gene mutations. The method(s) used should ideally be able to detect any
possible mutation associated with LS, for example nonsense, missense and frameshift mutations, genomic
deletions, duplications and rearrangements, as explained in Tables 4 and 5.4
TABLE 4 Mutation types associated with LS
Mutation Description
Missense A change in one DNA base pair that results in the substitution of one amino acid for another in the
protein made by a gene
Nonsense A change in one DNA base pair that results in a premature signal to stop building a protein. This type
of mutation results in a shortened protein that may function improperly or not at all
Insertion Changes the number of DNA bases in a gene by adding a piece of DNA. As a result, the protein made
by the gene may not function properly
Deletion Changes the number of DNA bases by removing a piece of DNA. Small deletions may remove one or a
few base pairs within a gene, while larger deletions can remove an entire gene or several neighbouring
genes. The deleted DNA may alter the function of the resulting protein(s)
Duplication Consists of a piece of DNA that is abnormally copied one or more times. This type of mutation may
alter the function of the resulting protein
Frameshift
mutation
Occurs when the addition or loss of DNA bases changes a gene’s reading frame. A reading frame
consists of groups of three bases that each code for one amino acid. A frameshift mutation shifts the
grouping of these bases and changes the code for amino acids. The resulting protein is usually
nonfunctional. Insertions, deletions and duplications can all be frameshift mutations
Splice site Causes abnormal mRNA processing, generally leading to in-frame deletions of whole exons or
out-of-frame mRNA mutations leading to nonsense-mediated decay of mRNA. Mutations may be
located deep in intronic sequences
Promoter Mutations in the controlling region of a gene leading to its non-expression. Epigenetic mutations,
i.e. abnormal methylation of CpG sites may give rise to the same effect
CpG, —C—phosphate—G—; mRNA, messenger ribonucleic acid.
Adapted from Genetics Home Reference.27
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Measuring the accuracy of diagnostic tests for Lynch syndrome
One aspect of the evaluation of new tests is measuring their accuracy by calculating their sensitivity and
specificity. This requires specification of the best available method of identifying the target condition
of interest, known as the reference standard. Most mutations causing LS are point mutations or small
insertions or deletions, suitably detected by DNA sequencing. However, some LS-associated mutations are
deletions/duplications of exons in MLH1 and MSH2. These are more difficult to detect and, currently, the
most appropriate technology available is multiplex ligation-dependent probe amplification (MLPA), which is
a multiplex polymerase chain reaction (PCR) method able to simultaneously detect copy number changes
across multiple DNA sequences within one sample. Therefore, the ideal reference standard is considered to
be sequencing plus MLPA.
TABLE 5 Genetic testing in LS
Test Description Comments
High-output
screening
techniques
SSCP
CSGE
DGGE
DHPLC
These methods all take advantage of the
observation that alteration of DNA confers
chemical properties that allow it to be
differentiated from normal DNA (now
considered obsolescent/obsolete in the UK)
DNA sequencing This can be used following a high-output
screening technique or as a primary approach
when IHC patterns allow for targeting of a
MMR gene
The main method used in the UK for detecting
most MMR gene mutations. However, it does
not reliably allow for detection of deletions or
rearrangements, which are also important in
LS. DNA sequencing has become automated
in recent years, greatly reducing the required
time, costs and expertise4
Methods to detect
large structural
DNA abnormalities
MLPA is the preferred technique in the UK Large structural DNA abnormalities are an
important cause of LS (5–25% of cases,
depending on the gene) but are not generally
detected by high-output screening techniques
or DNA sequencing. There are several methods
for detecting these defects. MLPA, which
involves measurement of the relative copy
number of DNA sequences, has evolved to
become a standard approach for analysing
MMR genes for deletions4
Conversion analysis Only a single allele is analysed at a time. This can
increase the yield of genetic testing but is
technically complicated, expensive and not
widely available
CSGE, conformation-sensitive gel electrophoresis; DGGE, denaturing gradient gel electrophoresis; DHPLC, denaturing
high-performance liquid chromatography; MLPA, multiplex ligation-dependent probe amplification; SSCP, single-strand
conformational polymorphism.
BACKGROUND
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Chapter 2 Definition of the decision problem and
review question
The question addressed by this health technology assessment (HTA) is as set out in the final scopepublished by the National Institute for Health Research (NIHR), and is reproduced here for
reader convenience.
A protocol was developed a priori by the authors to address the decision problem.
The methods used to address specific aspects of the decision problem are detailed at the beginning of
each of the relevant chapters which follow.
Test accuracy review question
What is the accuracy of tumour-based tests for LS in all newly diagnosed persons with CRC under 50 years
of age, and those considered according to clinical criteria to be at high risk?
Population
l All newly diagnosed patients under the age of 50 years with CRC.
l Participants considered to be at high risk of LS, i.e. those fulfilling AC II or Bethesda criteria.
l Individuals with personal cancer history or FH indicators.
Intervention
Tumour-based tests for evidence of mutations in the genes encoding the MLH1, MSH2, MSH6 and PMS2
DNA MMR enzymes. These tests include MSI, IHC, BRAF and methylation.
Comparators
Genetic testing by sequencing followed by MLPA is considered the gold standard.
Design
An evidence synthesis by systematic review to determine the accuracy of tumour-based tests.
Health-care setting
Primary and secondary care settings.
Test outcomes
The outcomes of interest include measures of:
l diagnostic test accuracy
l test failure rate
l discordant test results.
Decision problem
We will compare genetic testing of all identifiable close relatives with no genetic testing (extreme case
analysis) and with a level of genetic testing similar to that carried out in the local health-care setting, which
we believe is reasonably typical of current practice across the NHS.
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For clarity we would restate and define the suggested specific outcomes contributing to the general aim of
assessing effectiveness, cost-effectiveness and cost–utility, as follows:
l diagnostic accuracy of identifying LS in those presenting with CRC < 50 years of age
l patient outcome, considering both quantity and quality of life, in those presenting with CRC < 50 years
of age
l diagnostic accuracy of identifying LS in close family members of those presenting with CRC < 50 years
of age
l patient outcome, considering both quantity and quality of life, in close family members of those
presenting with CRC < 50 years of age
l contributing to patient outcome, the number of cancers, particularly CRCs detected, their severity and
their age at onset
l cost of alternative strategies
l contributing to cost (and patient outcome), the number of surveillance investigations, particularly check
colonoscopies, undertaken.
Outcomes of interest are the cost-effectiveness and cost–utility of different strategies for testing probands
and their close relatives, the diagnostic accuracy and yield of different strategies for high-risk subjects, and
cases of surveillance avoided. Data on these outcomes are likely to be used along with clinical utility scores
to estimate quality-adjusted life-years (QALYs).
Modelling will be employed to identify the cost-effectiveness of strategies for the investigation of all new
cases of CRC in individuals < 50 years of age for markers of HNPCC. The models will explore the yield of
individuals at high risk of HNPCC among the close relatives of probands and identify to what extent
unnecessary surveillance (by colonoscopy or other methods) can be avoided. The analysis will also briefly
examine whether or not it could be more cost-effective to undertake genetic testing alone without IHC
or MSI.
Cost considerations
The cost analysis will be based on the UK NHS setting and will be from an NHS and Personal Social
Services (PSS) perspective.
The costs for consideration include:
l cost of equipment, any additional tests (pre screening), reagents and consumables, participation
in NEQAS
l staff and training of staff
l maintenance of equipment
l costs associated with surgeon time and the management of operating theatre time
l medical costs arising from ongoing care following test results, including those associated with clinical
genetics, surgery, time spent in hospital and treatment of cancer.
DEFINITION OF THE DECISION PROBLEM AND REVIEW QUESTION
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Chapter 3 Assessment of test accuracy
Methods for reviewing test accuracy
The diagnostic accuracy of the tests IHC and MSI was assessed by a systematic review of research
evidence. The review was undertaken following the principles published by the NHS Centre for Reviews
and Dissemination.28
Identification of studies
The search used clusters for LS and HNPCC, joined together using the Boolean connector OR for
sensitivity. The following databases were searched: MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, PsycINFO, Health Management Information Consortium (HMIC) (all via Ovid), The
Cochrane Library (all), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost),
Applied Social Sciences Index and Abstracts (ASSIA) [via Cambridge Scientific Abstracts (CSA)] and Web of
Science [via Institute for Scientific Information (ISI)]. The search was limited to human-only populations and
to the English language, but did not use any methodological search filters. The National Research Register
(NRR), Current Controlled Trials, ClinicalTrials.gov, the Food and Drug Administration (FDA) website,
the European Medicines Agency (EMEA) website and Google were also searched. The search is recorded
in Appendix 1.
Searches were deduplicated and managed using EndNote X5 (Thomson Reuters, CA, USA). Relevant
studies were then identified in two stages. Titles and abstracts returned by the search strategy were
examined independently by two researchers (TJH and HC) and screened for possible inclusion.
Disagreements were resolved by discussion. Full texts of the studies which could not be excluded were
obtained. Two researchers (TJH and HC) examined these independently for inclusion or exclusion, and
disagreements were again resolved by discussion.
Inclusion and exclusion criteria
Population
Persons at risk of LS according to any of the following clinical or FH indicators:
l age < 50 years at diagnosis
l clinical criteria (e.g. AC II or Bethesda criteria)
l FH indicators
l personal cancer history indicators
l combinations of the above.
In the case of two-gate diagnostic accuracy studies, the population could be persons with any CRC, but
must have included a subsample with a known mutation in the genes encoding the MLH1, MSH2, MSH6
and PMS2 DNA MMR enzymes.
Interventions and comparators
The use of tumour-based tests, such as MSI and IHC, to look for evidence of mutations in the genes
encoding the MLH1, MSH2, MSH6 and PMS2 DNA MMR enzymes.
The assessment of test accuracy assumed a genetic definition of LS. The reference standard for test
accuracy studies was, therefore, genetic testing by sequencing.
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Outcomes
Studies were included if outcomes were relevant to diagnostic test accuracy, i.e. if data were available to
populate a 2 × 2 table and/or sensitivities and specificities were provided. Additionally, data on test failure
rates were included in the review.
Study design
For the review of test accuracy, the protocol allowed inclusion of all study designs, unless evidence on the
intervention and outcome of interest was already available from more rigorous study designs (as judged
with reference to standard hierarchies of evidence).
Systematic reviews were used as a source for finding further studies and to compare with our systematic
review. For the purpose of this review, a systematic review was defined as one that has:
l a focused research question
l explicit search criteria that are available to review, either in the document or on application
l explicit inclusion/exclusion criteria, defining the population(s), intervention(s), comparator(s) and
outcome(s) of interest
l a critical appraisal of included studies, including consideration of internal and external validity of
the research
l a synthesis of the included evidence, whether narrative or quantitative.
Studies were excluded if they did not match the inclusion criteria, and in particular if they were:
l pre-clinical or in animals
l reviews, editorials and opinion pieces
l case reports
l studies with < 10 participants.
Data extraction strategy
Data were extracted by one reviewer (TJH) using a standardised data extraction form and checked by a
second reviewer (HC). Disagreements were resolved by discussion, with involvement of a third reviewer if
necessary. Appendix 2 shows the blank data extraction forms used.
Critical appraisal strategy
The methodological quality of the studies was assessed according to criteria specified by the Quality
Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool for test accuracy studies.29
Quality was assessed by one reviewer and judgements were checked by a second. Any disagreement
was resolved by discussion, with involvement of a third reviewer as necessary. The two instruments are
summarised below. Results were tabulated and the relevant aspects described in the data extraction forms.
Internal validity
The QUADAS-2 quality appraisal tool sought to assess the following considerations:
l Description of patient selection.
l Was a consecutive or random sample of patients enrolled?
l Was a case–control design avoided?
l Did the study avoid inappropriate exclusions?
l Could the selection of patients have introduced bias?
l Are there concerns that the included patients do not match the review question?
l Description of index and reference tests.
l Was the index test assessor blind to the results of the reference standard and vice versa?
l Was a threshold pre-specified?
ASSESSMENT OF TEST ACCURACY
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l Could the conduct or interpretation of the index test or reference standard have introduced bias?
l Are there concerns that the conduct or interpretation of the question have introduced bias for the
index test or reference standard?
l Is the reference standard likely to classify the target condition?
l Description of patient flow and timing.
l Did all patients receive a reference standard and was it the same test for each?
l Were all patients included in the analysis?
l Could the patient flow have introduced bias?
External validity
External validity was judged according to the ability of a reader to consider the applicability of findings to
a particular patient group and service setting. Study findings can only be generalisable if they provide
enough information to consider whether or not a cohort is representative of the affected population at
large. Therefore, studies that appeared to be typical of the UK CRC population with regard to these
considerations were judged to be externally valid.
Methods of data synthesis
Details of the extracted data and quality assessment for each individual study are presented in structured
tables and as a narrative description. Any possible effects of study quality on the effectiveness data are
discussed. Data on test accuracy are presented as sensitivity and specificity, where available.
In most of the studies, the accuracy of the interventions has been evaluated against the reference (gold)
standard of constitutional genetic testing and thus, for the purpose of this assessment of test accuracy, a
genetic definition of LS is assumed. The results are generally reported as follows:
l Sensitivity: true positive (TP)/(TP+ FN). This is the probability of detecting LS in someone with LS.
l Specificity: true negative (TN)/[false positive (FP)+ TN). This is the probability of not detecting LS in
someone without LS.
l Positive predictive value (PPV): TP/(TP+ FP). This is the probability of someone with a positive result
actually having LS.
l Negative predictive value (NPV): TN/(TN+ FN). This is the probability of someone with a negative test
result actually not having LS.
l Accuracy or concordance with reference standard: (TP+ TN)/(TP+ TN+ FP+ FN). This is the percentage
of test results correctly identified by the test, i.e. the rate of agreement with the reference standard.
l Discordance: cases of disagreement between the reference and index test.
Results
The results of the assessment of test accuracy will be presented as follows:
1. an overview of the quantity and quality of available evidence together with a table summarising all
included trials (see Table 9), a table of patient characteristics (see Table 10) and a summary table of key
quality indicators (see Table 11)
2. a critical review of the available evidence, covering:
i. the quantity and quality of available evidence
ii. a summary table of the study characteristics
iii. a summary table of the population characteristics
iv. study results in terms of sensitivity and specificity analysis, presented in narrative and tabular form
v. quantity and quality of research available.
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Number of studies identified
The electronic searches retrieved a total of 3713 titles and abstracts. A total of 3640 papers were
excluded, based on screening of title and abstract. As a relevant technology assessment (TA) was retrieved
in the search [Bonis and colleagues (2007)4], rather than duplicate effort, we included studies dated from
2005 onwards, and provide a summary of findings by the previous TA. Full text of the remaining 73 papers
was requested for more in-depth screening, to give a total of 10 published papers included in the review.
The process of study selection is shown in Figure 1.
Number of excluded studies
Papers were excluded for at least one of the following reasons: duplicate publication; narrative review;
and publication (systematic review or individual primary study) not considering the relevant intervention,
population, comparison or outcomes. The bibliographic details of the 73 studies retrieved as full papers
and subsequently excluded, along with the reasons for their exclusion, are detailed in Appendix 3.
Number and description of included studies
Bonis and colleagues (2007)
This review continues from a well-presented and thorough systematic review produced by Bonis and
colleagues (2007), which is a TA commissioned by the US Department of Health and Human Services.4
As such, an overview of the findings is discussed. The assessment of multiple systematic reviews (AMSTAR)
quality assessment criteria for systematic reviews are displayed below (Table 6).30 The one concern
regarding the quality of the Bonis and colleagues (2007) TA is that MEDLINE was the only database
searched. However, other sources included clinical experts and bibliographies of reviews.
Titles and abstracts identified
(n = 3713)
Full-text paper retrieved
(n = 73)
Does not fulfill inclusion criteria
(n = 3640)
Not an appropriate study design
or relevant systematic review
(n = 10)
Reasons for exclusion (hierarchical):
•  No relevant population, n = 41
•  No relevant comparison, n = 4
•  No relevant outcome, n = 6
•  Abstract only, n = 2
Included: 9 studiesa
1 HTA (Bonis et al.4)
FIGURE 1 Summary of study selection. a, It is unclear whether or not two of the included studies are from the
same population.
ASSESSMENT OF TEST ACCURACY
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TABLE 6 AMSTAR30 quality assessment of systematic review by Bonis and colleagues (2007)4
AMSTAR criterion Response
Was an ‘a priori’ design provided? Yes ✓
No
Cannot answer
Not applicable
Was there duplicate study selection and data extraction? Yes ✓
No
Cannot answer
Not applicable
Was a comprehensive literature search performed? Yes
No ✓a
Cannot answer
Not applicable
Was the status of publication (i.e. grey literature) used as an inclusion criterion? Yes
No ✓
Cannot answer
Not applicable
Was a list of studies (included and excluded) provided? Yes ✓
No
Cannot answer
Not applicable
Were the characteristics of the included studies provided? Yes ✓
No
Cannot answer
Not applicable
Was the scientific quality of the included studies assessed and documented? Yes ✓
No
Cannot answer
Not applicable
Was the scientific quality of the included studies used appropriately in formulating conclusions? Yes ✓
No
Cannot answer
Not applicable
Were the methods used to combine the findings of studies appropriate? Yes ✓
No
Cannot answer
Not applicable
continued
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The characteristics of the studies relevant to this review which were included in Bonis and colleagues
(2007) are presented in Table 7.
In terms of test accuracy results, Bonis and colleagues (2007)4 found very little published information
related to the analytic validity of laboratory testing for LS and there was some concern that there may be
variability between testing facilities. They found that genomic rearrangements and large deletions were
missed when only sequencing and gene screening was performed, with limited evidence to suggest that
approximately one-quarter to one-third of the identified MMR mutations were large genomic deletions/
rearrangements. Most studies identified cases from cancer registries or used other selection strategies to
TABLE 6 AMSTAR30 quality assessment of systematic review by Bonis and colleagues (2007)4 (continued )
AMSTAR criterion Response
Was the likelihood of publication bias assessed? Yes
No ✓
Cannot answer
Not applicable
Was the conflict of interest stated? Yes ✓
No
Cannot answer
Not applicable
a MEDLINE was the only database searched. Additional literature sources included technical experts and hand-searching of
review references.
AMSTAR quality assessment criteria reproduced from Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,
et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.
BMC Med Res Methodol 2007;7:10.30
TABLE 7 Study characteristics for relevant studies identified by Bonis and colleagues (2007)4
Author and
location Population Analysis
Calistri 200031
Italy
Multicentre
45 unrelated patients with CRC either fulfilling
AC; from families meeting 2/3 AC; diagnosed
with CRC at age < 50 years but with no FH;
having at least one FDR with CRC; or having
multiple neoplasms
Tissue samples from cancer analysed for MSI.
DNA from peripheral blood samples analysed
for MSH2 and MLH2
Christensen 200232
and Katballe 200233
Denmark
Single centre
42 patients with CRC selected based upon
clinical and FH meeting either AC I (n= 11) or a
suggestive FH
MSH2 and MLH1 genes sequenced in
31 patients. MSI obtained in 35 patients;
IHC performed in 40 patients. Compared
sensitivity/specificity of these tests against
sequencing as the reference standard
Debniak 200034
Poland
Single centre
168 consecutive patients with CRC in whom FAP
was excluded
Group A: 43/143 patients apparently sporadic,
i.e. late onset (age > 40 years), no FH of
LS-related tumours and no synchronous or
metachronous cancer
Group B: 25 were LS based on age ≤ 40 years,
familial LS-related cancer or synchronous or
metachronous cancer. The remainder were
apparently sporadic
IHC performed in all patients. MSI examined in
all. Sequencing performed in all from group B
and those from group A who showed
abnormal IHC or MSI
ASSESSMENT OF TEST ACCURACY
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TABLE 7 Study characteristics for relevant studies identified by Bonis and colleagues (2007)4 (continued )
Author and
location Population Analysis
Dieumegard 200035
France
Multicentre
34 patients with CRC who represented one of
three groups: (1) AC I, (2) incomplete AC I
(missing at least one criterion but strong FH),
(3) age < 50 years and absence of LS-related
cancers in family
All patients tested for MSI. Patients with MSI-H
and nine MSS cases underwent germline
testing for MMR. IHC was performed in all but
four patients
Durno 200536
Canada
Multicentre
Patients with CRC at age ≤ 24 years (selected
from a total of 1382 patients in a cancer registry)
Tumours analysed for MSI, IHC and blood
for MMR
Farrington 199837
Scotland
Multicentre
50 unrelated patients with CRC at age <30 years.
Identified retrospectively from cancer registrations
since 1970 compared with 26 age-matched
volunteers without cancer
Detailed FH obtained from cases,
paraffin-embedded archival tumour material
obtained along with matched normal tissue from
42 patients. Tumour and normal tissue analysed
for MSI. Genomic sequencing done on all
patients and controls using peripheral blood
Peel 200038
USA
Multicentre
Referral of LS-case families (AC). These were
from the ICG HNPCC group database (but they
give MSI-HL vs. MSS which is not covered in the
other papers)
MSI testing was performed in 10 families;
diagnostic mutation testing of MSH2 and
MLH1 was performed in 11 families
Shia 200511
USA
Single centre
A group of 112 colorectal adenocarcinomas
(n= 83) or adenomas (n= 29) obtained from
110 patients treated at the cancer centre. These
cases had a FH that fulfilled one of the following
criteria: (1) AC I or II, (2) a set of relaxed AC
that we referred to as ‘HNPCC-like’ and
(3) Bethesda criteria
All patients started with MSI testing, followed
by mutation analysis
Southey 200539
Australia
Single centre
Men and women from the Victorian Colorectal
Cancer Family Study who were younger than age
45 years when diagnosed with a histologically
confirmed, first primary adenocarcinoma of the
colon or rectum. A random selection of
222 patients were asked to participate
Patients answered a risk factor questionnaire,
and received IHC and MSI screening. Germline
MMR mutation testing was conducted for all
patients with one or more of the following
characteristics: a FH that fulfilled the AC for
LS; a tumour that was MSI-H, MSI-L, or that
lacked expression of at least one MMR
protein; and presence in a random sample of
23 patients selected from those who had
tumours that were MSS and did not lack
expression of any MMR protein
Terdiman 200140
USA
Single centre
Eligible families had to have two or more FDRs
with CRC at any age, an individual with CRC
diagnosed before 50 years of age or a single
individual with synchronous or metachronous
CRCs. Probands were selected based on
convenience and age at cancer diagnosis.
When multiple family members were available
for molecular testing, the individual with cancer
diagnosed at the youngest age was selected
as proband
Paraffin-embedded tumour samples were
obtained from all probands for MSI analysis
and MSH2/MLH1 immunostaining. Subjects
found to have tumours demonstrating MSI-H
(n= 47) were invited for germline genetic
testing of MSH2 and MLH1. Gene testing was
carried out in 32 of the 47 eligible families.
Eight probands refused testing for fear of
insurance discrimination. In seven instances,
the proband was deceased (n= 4) or could not
be recontacted (n= 3)
Wahlberg 200241
USA
Single centre
Families were identified by self- or health-care
provider referral and were enrolled on the basis
of multiple cases of CRC, early age of CRC
diagnosis or the familial association of CRC with
other LS-associated tumours
Sequencing and MSI analysis of tumour
samples from 48 families. IHC analysis of 24
tumour samples (subset of 48 for MSI analysis)
of sufficient quality for IHC
FAP, familial adenomatous polyposis; ICG, International Collaborative Group; MSI-HL, MSI-H or MSI-L.
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target patients at risk of LS. Although this is a valid recruitment technique from a clinically relevant
population, the definition of high risk differs from study to study (among the selected populations) and this
may or may not reflect the criteria used to refer for testing in clinical practice.
A summary of the relevant test accuracy results from Bonis and colleagues (2007)4 is presented in Table 8.
The sample sizes of the studies were generally small. Sensitivity and specificity for both MSI and IHC
appear variable with very broad confidence intervals (CIs).
Included primary research studies
Nine test accuracy papers were included, five investigating IHC as the index test, one MSI and three
studying both IHC and MSI. No papers were identified on tests for BRAF V600E and methylation of MLH1.
All included citations are summarised in Table 9.
Study characteristics
The majority of included studies employed a single-gate design where one sample of individuals was
assessed by both the index test and reference standard. Only Barrow and colleagues (2010 and 2011) used
a two-gate design, where the index test was performed on a group of participants with a known (positive)
mutation status and a smaller group of controls with no applicable mutation status.20,42 However, despite
most studies being of a single-gate design, not all participants received the reference standard. Many
studies cited cost as a reason for not performing genetic testing on participants who appeared to be MSS
TABLE 8 Test accuracy results taken from Bonis and colleagues (2007)4
Author and
location Reference test
Index
test n
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Risk of bias according
to Bonis and colleagues Qualitya
Calistri 200031
Italy
Multicentre
PCR → SSCP MSI 56 100 (59 to 100)b 44 (14 to 79)b Comment: Study sample
assembled with unclear
selection process
Verification bias: No
C
Christensen
200232 and
Katballe
200233
Denmark
Single centre
PCR → SSCP
and HD →
sequencing
of abnormal
patterns
IHC 42 69 (39 to 91)c 83 (59 to 96)c Comment: Selection from
a population of 1514
incident CRCs
Verification bias: No
B
11 50 (7 to 93)d 100 (48 to 100)d
MSI 45 100 (69 to 100)b 87 (66 to 97)b
Debniak
200034
Poland
Single centree
PCR →
sequencing
IHC 168 18 (2 to 51)c 100 (94 to 100)c Comment: Sampled from
consecutive CRCs,
selection process not
transparent
Verification bias: Yes; only
43/143 apparently
sporadic CRCs were
tested, but it is unclear
how they were selected
C
MSI 168 83 (36 to 100)b 87 (76 to 94)b
Dieumegard
200035
France
Multicentre
PCR → SSCP →
sequencing of
abnormal
patterns
IHC 34 57 (18 to 90)c 64 (35 to 87)c Comment: Sampled with
unclear selection process
Verification bias: Yes; only
seven sporadic CRCs
underwent genetic testing
B
10 50 (7 to 93)d 50 (7 to 93)d
MSI 34 100 (66 to 100)b 60 (32 to 84)b
10 100 (54 to 100)f 25 (0 to 81)f
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TABLE 8 Test accuracy results taken from Bonis and colleagues (2007)4 (continued )
Author and
location Reference test
Index
test n
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Risk of bias according
to Bonis and colleagues Qualitya
Durno 200536
Canada
Multicentre
PTT and
sequencing
IHC 16 75 (19 to 99)c 75 (19 to 99)c Comment: Retrospective
cohort of CRC patients
aged < 24 years at
diagnosis who were still
alive (since 1970)
Verification bias: No
C
MSI 16 100 (48 to 100)b 25 (0 to 81)b
Farrington
199837
Scotland
Single centre
PCR → IVSP →
sequencing
PCR →
sequencing
MSI 50 86 (57 to 98)b 73 (52 to 88)b Comment: Retrospective
cohort of CRC patients
aged < 30 years at
diagnosis who were still
alive (since 1970)
Verification bias: No
B
Peel 200038
USA
Multicentre
PCR →
sequencing
MSI 11 100 (29 to 100)b 83 (36 to 100)b Comment: Referral
HNPCC cases, other than
the 1134 CRC probands
who were also included
but were not assessed
with laboratory tests
Verification bias: No
C
100 (29 to 100)f 83 (36 to 100)f
Terdiman
200140
USA
Single centre
MSI → PCR →
DGGE →
sequencing
IHC 114 94 (71 to 100)g 13 (4 to 30)g Comment: Retrospective
cohort of CRC probands
with ≥ 2 CRCs in FDRs,
age < 50 years at
diagnosis or multiple
tumours in same patient
Verification bias: Yes; only
patients with MSI-H
were assessed
B
Wahlberg
200241
USA
Single centre
PCR →
sequencing
IHC 70 55 (23 to 83)c 88 (69 to 97)c Comment: Selection
among referrals to a
specialised centre
Verification bias: No
B
MSI 70 100 (77 to 100)b 59 (41 to 75)b
CI, confidence interval; DGGE, denaturing gradient gel electrophoresis; HD, heteroduplex formation; IVSP, in vitro
synthesised protein test; PTT, protein truncation test (assay).
a Bonis rated the quality of studies as follows: A=most or all of the QUADAS criteria are fulfilled and the conclusions of
the study would be very unlikely to be affected by those that are not; B= some of the QUADAS criteria are fulfilled and
the conclusions of the study would be unlikely to be affected by those that are not; C= few or no QUADAS criteria were
fulfilled and the conclusions of the study would be thought likely or very likely to be altered by multiple omissions in the
required criteria for an acceptable study.
b Ability of MSI to identify MLH1 and MSH2 mutation carriers among CRC probands selected for high LS risk.
c Ability of IHC to identify MLH1 and MSH2 mutation carriers among CRC probands selected for high LS risk.
d Ability of IHC to identify MLH1 and MSH2 mutation carriers among CRC probands selected for high LS risk, including
fulfilment of AC I.
e According to Bonis it was not entirely clear, although likely, that this study was single centre.
f Ability of MSI to identify MLH1 and MSH2 mutation carriers among CRC probands selected for high LS risk, including
fulfilment of AC I.
g Ability of IHC to identify MLH1 and MSH2 mutation carriers among CRC probands selected for high LS risk who also
have MSI-H tumours.
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TABLE 9 Summary information of included test accuracy studies
Author and
year Patients (n) Test
Centre and
country Design Outcomes
aBarrow
201120
Sample, 36
Control, 6
IHC Single centre,
UK
Two-gate
Sample patients retrospectively identified
with mutation
Control patients consecutively recruited
Supported in part by grants from the
Bowel Disease Research Foundation and
Central Manchester and Manchester
Children’s University Hospitals NHS Trust
research grant scheme. This study group is
supported by the NIHR Manchester
Biomedical Research Centre
ROC curves,
sensitivity and
specificity at
optimum cut-offs
aBarrow
201042
Sample, 51
Control, 17
IHC Single centre,
UK
Two-gate
Sample patients retrospectively identified
with mutation
Control patients consecutively recruited
Supported by MAHSC and the NIHR
Manchester Biomedical Research Centre
and by a grant from the Bowel Disease
Research Foundation
ROC curves,
sensitivity and
specificity at
optimum cut-offs
Becouarn
200543
197 IHC Unclear,
France
Single-gate
Recruitment not described
Funded by PHRC from the Délégation
Régionale à la Recherche Clinique
d’Aquitaine
Sensitivity,
specificity
Limburg
201144
195 IHC Unclear,
USA/Canada/
Australia
Single-gate
Recruitment described as random, but no
further details
Funded by Myriad Genetic Laboratories,
Salt Lake City, UT. The Colon Cancer
Family Registry is supported by NIH
National Cancer Institute grants
Sensitivity,
specificity,
NPV, PPV
Niessen
201221
281 IHC and
MSI
Unclear, the
Netherlands
Single-gate
Recruitment not described
Funded by the Dutch Cancer Society
Sensitivity,
specificity,
NPV, PPV
Shia 200511 110 IHC and
MSI
Single centre,
USA
Single-gate
Recruitment not described
Funded in part by the Kleber Foundation,
the Sloan Kettering Institute, the Byrne
Foundation and the Tavel-Reznik Fund for
Colon Cancer Research
Sensitivity,
specificity
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(i.e. those with no evidence of abnormal patterns of microsatellite repeats). This often led to confusing
patient numbers and apparent missing data. In general, sample sizes were relatively small with poor
reporting of patient characteristics. Details on robustness of testing were often lacking (e.g. results being
checked by a second assessor), particularly for IHC, which may be prone to interobserver variability.
Barrow and colleagues (2010 and 2011) Barrow and colleagues (2010)42 present a two-gate,
single-centre UK study investigating the semi-quantitative assessment of IHC for MMR proteins in LS. Patients
with LS which had already been confirmed by germline mutation in one of the MMR genes – MLH1, MSH2
or MSH6 – and previous histologically proven CRC were identified through the North West Regional Genetics
Lynch Syndrome Database. The control cases were consecutive unselected patients aged > 60 years with
histologically proven left-sided colonic or rectal cancer (i.e. considered to be sporadic CRC as opposed to LS).
A relatively small LS sample (n= 51) was recruited, with an even smaller control group (n= 17). IHC methods
were described in detail; sections of tumour tissue were incubated with antibodies against the MMR proteins
or antigens MLH1, MSH2, PMS2 and MSH6. The intensity of immunoreactivity (a measure of the reaction
between the antibody and antigens of the tumour cells) was measured on a 0–3 scale, based on comparison
of intensity of reactivity of the tumour cells with the positive control cells. A score of 0= no tumour cell
immunopositivity; 1= 1–10% positive tumour cells; 2= 11–50% positive tumour cells; 3= 51–80% positive
tumour cells; and 4=≥ 80% positive tumour cells. Information on the reference standard was not provided.
Outcomes were receiver operating characteristic (ROC) curves and sensitivity and specificity at optimum
cut-offs (the cut-off score which demonstrates the best trade-off between sensitivity and specificity).
However, raw data were not provided to populate a 2 × 2 table of positive and negative results.
The second paper by Barrow and colleagues (2011)20 appears to use the same pool of participants
as the previous study, although with lower numbers. In this instance, the aim was to compare two novel
methodologies: quantitative 3,3′-diaminobenzidine IHC (DAB-IHC) and quantitative quantum dot IHC
(QD-IHC) in the identification of MMR mutation carriers. Also a two-gate design, this study had an LS
TABLE 9 Summary information of included test accuracy studies (continued )
Author and
year Patients (n) Test
Centre and
country Design Outcomes
Southey
200539
131 IHC and
MSI
Single centre,
Australia
Single-gate
Random recruitment
Funded by grants from the National
Health and Medical Research Council
(Australia) and the Victorian Health
Promotion Foundation
Sensitivity,
specificity,
NPV, PPV
Stomorken
200545
250b IHC Single centre,
Norway
Single-gate
Consecutive recruitment
Funded by the Norwegian Cancer Society
Sensitivity,
specificity
Wolf 200646 81 MSI Single centre,
Austria
Single-gate
Recruitment not described
Funded by the Medical Scientific Fund of
the University of Vienna Medical School
and the Medical Scientific Fund of the
Mayor of Vienna
Sensitivity,
specificity
MAHSC, Manchester Academic Health Sciences Centre; NIH, National Institutes of Health; PHRC, Programme Hospitalier de
Recherche Clinique; ROC, receiver operating characteristic.
a Unclear if this is the same study.
b Number of families recruited.
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sample size of 36, and a control group of only six. As per the previous study, participants had already
received germline mutation testing, although details were not provided.
With regard to the DAB-IHC, sections were incubated with antibodies against the MMR proteins MLH1,
MSH2, MSH6 and PMS2. With control positive tissue (normal colon), the protocol was optimised to a level
that maximised specific nuclear immunoreactivity, while minimising non-specific background reactivity.
For the QD-IHC, only staining for MLH1 and MSH2 was performed.
Again, relevant outcomes include ROC curves, and sensitivity and specificity at optimum cut-off, yet the
raw data were not provided to populate a 2 × 2 table of positive and negative results.
Becouarn and colleagues (2005) A French study presented by Becouarn and colleagues (2005)43
examines a strategy to detect LS in patients by combining clinical selection (patient age at onset of cancer
< 50 years or FH of HNPCC tumours) and MSI testing plus IHC, leading to MMR germline mutation
analysis. It should be noted that only IHC was considered to be the index test, with MSI the prior test.
It is not clear how many centres were involved; however, the sample size was reported to be 197.
Recruited participants were diagnosed with CRC between 1998 and 2001, and deemed high risk for LS
owing to young age at onset or FH. Patient flow throughout the study is somewhat unclear and complex.
It appears that testing by MSI took place in order to group participants according to MSI-H, MSI-L and
MSS. Only patients who were MSI-H and MSI-L and those with valid IHC results for MLH1 and MSH2
received germline testing.
For IHC, the search for MMR proteins MLH1 and MSH2 was conducted on fixed tissue embedded in
paraffin. Loss of MLH1 or MSH2 expression was defined as the absence of nuclear staining in tumour cells,
in the presence of positive controls; preservation of protein expression was defined as the presence of
nuclear staining in tumour cells and internal controls; non-interpretable staining was defined as the
absence of staining in tumour cells and internal controls or slice detachment. For the reference standard,
the search for mutations of the MSH2 and MLH1 genes was performed in MSI-H and MSI-L tumour
tissues. The search for germline mutations and their characterisation was based on denaturing
high-performance liquid chromatography (DHPLC) screening and/or direct sequencing using an automatic
sequencer. The search for large MSH2 and MLH1 gene rearrangements was performed in certain patients
when point mutations were not identified. For IHC, data were provided to populate a 2 × 2 table,
therefore sensitivity and specificity could be calculated.
Limburg and colleagues (2011) Limburg and colleagues (2011)44 present a study examining the
prevalence of mutations in MLH1, MSH2 and MSH6 via IHC in a population-based sample of patients with
young-onset (age at onset < 50 years) CRC. Employing six centres across Canada, the USA and Australia,
a random sample of 195 CRC cases were recruited during phase 1 of the Colon Cancer Family Registry
collaboration (1997–2002). No prior testing was performed and no preselection based on FH, so high risk
for LS was based on age criterion alone. Minimal details are given for the index test, with MMR protein
expression reported as present, absent or inconclusive.
The reference standard uses extracted DNA samples from peripheral blood for full mutation analyses of
MLH1, MSH2 and MSH6. DNA was amplified by PCR and then directly sequenced. Large rearrangement
testing for MLH1 and MSH2 was performed by Southern blot analysis in conjunction with MLPA. Germline
alterations were categorised as deleterious/suspected deleterious, likely neutral or variant of uncertain
significance. Reported outcomes were sensitivity, specificity, NPV and PPV, with raw data available to
populate a 2 × 2 table.
Niessen and colleagues (2006) The study by Niessen and colleagues (2006)21 investigated the sensitivity
and specificity of IHC and MSI, the aim being to analyse the value of FH, MSI analysis and MMR protein
staining in the tumour to predict the presence of a MMR gene mutation in such patients. Performed in the
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Netherlands (although it is unclear how many centres were involved), 281 individuals with CRC, who were
high risk for LS according to young onset or personal cancer history, were recruited.
Microsatellite instability markers included two mononucleotide repeats (BAT25 and BAT26) and three
dinucleotide repeats (D2S123, D5S346 and D17S250). For MSI analysis, control DNA was obtained from
normal tissue or from peripheral blood lymphocytes from the same patient. Cancers were classified as
MSI-H when two or more markers showed MSI and as MSI-L when no more than one marker showed MSI.
The authors state that as a limited number of markers were analysed, the classification MSS was not used.
IHC for the MLH1, MSH2 and MSH6 proteins was also carried out. The sections were scored as either
negative (i.e. absence of detectable nuclear staining of cancer cells) or positive for MLH1, MSH2 and MSH6
staining. Protein expression in normal tissue adjacent to the cancer served as an internal positive control.
Mutation analysis of the MLH1, MSH2 and MSH6 genes was carried out on DNA isolated from
peripheral blood lymphocytes by denaturing gradient gel electrophoresis, followed by direct sequencing.
For the detection of large deletions (exonic deletions or deletions of a complete gene) and duplications,
MLH1/MSH2 exon deletion MLPA was used. Cases that had deletions of more than one exon in the MLH1
or MSH2 gene were confirmed by Southern blot analysis. Sensitivity, specificity, PPV and NPV were
reported along with data to populate a 2 × 2 table.
Shia and colleagues (2005) Shia and colleagues (2005)11 report a single-centre study performed in the
USA with 110 participants. The study objective is not clearly described. Participants were recruited from
1995 to 2003 by a FH questionnaire administered in gastrointestinal endoscopy and oncology clinics, by
personal interview of persons undergoing surgery for CRC or by referrals to the clinical genetics service.
In order to be included, participants had to have a FH that fulfilled one of the following criteria: (1) AC I or II,
(2) a set of relaxed AC (three or more CRCs among first- and second-degree relatives of a family) or
(3) Bethesda criteria.
The study started with MSI testing, followed by germline analysis of MLH1 and MSH2 in all cases that
exhibited MSI and cases with carcinoma that did not exhibit MSI. Cases that showed no mutation in MLH1
or MSH2 were tested for mutation in MSH6.
Microsatellite instability testing was performed on microdissected DNA from paraffin-embedded tissue
blocks using a standard PCR method. All tissue was tested with seven markers: four mononucleotide
markers (BAT25, BAT26, BAT40, PAX6); two dinucleotide markers (D2S123, D17S250); and one mixed
dinucleotide and trinucleotide marker (MYCLI). IHC was performed using antibodies against MLH1, MSH2
and MSH6. Normal colon mucosa were used as a positive control and MSI tumours known to lack MLH1
or MSH2 protein expression were used as a negative control. Tumours displaying a total absence of
nuclear staining while adjacent normal mucosa or stromal/lymphoid cells showed presence of nuclear
staining were scored ‘negative’ for expression of protein. Tumours were scored according to
staining intensity:
l weak if < 10% of the tumour was stained and the intensity was weak
l heterogeneous if two or more of the following staining patterns were identified, each present in at
least 20% of the tumour: (1) no nuclear staining, (2) weak nuclear staining, (3) moderate nuclear
staining and (4) strong nuclear staining.
Mutation analysis was performed using DHPLC and direct sequencing. Cases with tumours that exhibited
MSI but in which a point mutation in MLH1, MSH2 or MSH6 was not detected were analysed for large
deletions in MLH1 and MSH2. Mutations were determined to be disease-causing based on sequencing
results, segregation analysis and published data and mutation databases. Outcomes include sensitivity and
specificity with raw data available.
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Southey and colleagues (2005) An investigation into the relationship between MMR protein expression,
MSI, FH and germline MMR status was performed by Southey and colleagues (2005).39 The study took
place in a single centre in Australia. One hundred and thirty-one patients with young-onset CRC were
randomly recruited, i.e. patients who were younger than 45 years when diagnosed with a histologically
confirmed, first primary adenocarcinoma of the colon or rectum. Sensitivity and specificity results for both
IHC and MSI were reported.
For IHC, the expression of MLH1, MSH2, MSH6 and PMS2 was assessed on paraffin-embedded sections
using antibodies MLH1, MSH2, MSH6 and PMS2. Normal colonic epithelium adjacent to tumour and
lymphocytes served as positive controls. A gastrointestinal pathologist scored the tumours as positive when
nuclear staining in tumour tissue was present, or negative when staining was absent.
Microsatellite instability testing was performed on invasive tumour cells microdissected from 5-µm sections
of paraffin-embedded archival tumour tissue. DNA extracted from histologically normal cells microdissected
from colonic or lymph node tissue, or DNA extracted from peripheral-blood lymphocytes, was used as a
negative control. Ten microsatellite markers were assessed: three dinucleotide repeats (D5S346, D17S250
and D2S123) and seven mononucleotide repeats (BAT25, BAT26, BAT40, MYB, TGFβRII, IGFIIR and BAX).
The degree of instability in each tumour was scored as MSS, MSI-L and MSI-H when zero to one, two to
five and six to 10 markers, respectively, were identified as unstable.
For the reference standard, MLH1, MSH2, MSH6 and PMS2 genes were screened for germline mutations
using sequencing approaches, except for exon 4 of MSH6, which was screened in eight overlapping
fragments using DHPLC. Putative mutations were confirmed via direct automated sequencing. Variants
were defined as deleterious if they could be predicted to produce a shortened or truncated protein
product, or if they were missense mutations that have been reported previously to be deleterious. The
MLPA assay to detect large genomic alterations in MLH1 and MSH2 was performed on samples from
10 patients who had tumours lacking at least one MMR protein expression and for which no previous
mutation had been identified by sequencing. Mutation testing was conducted on participants with one or
more of the following characteristics: a FH that fulfilled the AC for HNPCC; a tumour that was MSI-H,
MSI-L or that lacked expression of at least one MMR protein; and a random sample of 23 patients selected
from those who had tumours that were MSS.
Stomorken and colleagues (2005) Stomorken and colleagues (2005)45 report on a single-centre study
based in Norway. Two hundred and fifty families were consecutively recruited according to their FH of CRC
and other cancers. Inclusion criteria consisted of AC I or II, aggregation of four or more LS-related cancers
on one side of the family, patients with ‘very early onset’ CRC and those with multiple primaries including
colorectal or endometrial cancers. It should be noted that the participants with CRC provided a subsample
of 105 families. The aim of the study was to validate the sensitivity, specificity and predictive value of IHC,
compared with various clinical criteria, to select LS relatives for mutation testing.
Immunohistochemistry of all tumours for the presence of MLH1, MSH2 and MSH6 MMR proteins was
performed using a formalin-fixed, paraffin-embedded tissue block containing tumour tissue and normal
adjacent mucosa. Staining of tumours was evaluated using normal epithelial cells, stromal cells or
lymphocytes in the same slide as controls. The percentage of nuclear staining was graded as follows:
complete absence of detectable nuclear staining (0); positive staining in < 30% of the tumour cells (1+);
positive staining in 30–60% of the tumour cells (2+); or positive staining in > 60% of the tumour cells (3+).
MLH1 and MLH2 genes were sequenced by Myriad Genetics Inc. (Salt Lake City, UT). All index persons
without a mutation demonstrated by sequencing and with a lack of MMR protein expression were
subjected to analyses for large rearrangements in the MLH1 and MSH2 genes. The remaining individuals
who were lacking gene products of MSH2 and/or MSH6 genes were subjected to mutation analysis of the
MSH6 gene by sequencing. Large rearrangements in MSH6 were not tested for. Data were available to
populate a 2 × 2 table, although sensitivity and specificity were not reported.
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Wolf and colleagues (2006) Wolf and colleagues (2006)46 report an Austrian study where participants
were selected retrospectively from among individuals with suspected hereditary CRC from 2000 to 2003.
The sample size was 81, with all tumours obtained by surgical resection. The aim of the study was to
evaluate the revised AC and Bethesda guidelines (therefore the index test under scrutiny was MSI).
Nuclear DNA was isolated from paraffin-embedded tissue after histological verification by an experienced
pathologist, prior to PCR amplification. DNA was also taken from blood samples.
For MSI, two groups of five markers each were selected: group 1 consisted of D5S346, HSCAP53L,
D2S123, BAT26 and D18S34, while group 2 consisted of D5S82, D2S134, D13S175, D11S904 and
BAT25. In the event of instability, additional smaller fragments were identified in the tumour sample
compared with the corresponding normal tissue. If only one of the markers in the first group showed
instability, five further markers (group 2) were used. The degree of instability was evaluated according to
the percentage of markers showing band shifts. MSI-H was considered to exist when at least 30% of the
analysed markers were unstable; any lower degree of instability, or no instability, was interpreted as MSS.
The exons of MLH1 and MSH2 as well as the promoter regions of each gene underwent sequence
analysis. If DNA from tumour tissue was available, analysis of DNA from corresponding normal tissue or
peripheral blood was performed on fragments containing a mutation. If no mutation was found in the
tumour, sequence analysis was performed with DNA from normal tissue or peripheral blood.
Appropriate outcomes for this review were sensitivity and specificity, with raw data provided.
Population characteristics
In general, patient characteristics were poorly reported, as were inclusion and exclusion criteria, although
patients were often filtered by prior testing. Comparable characteristics are presented in Table 10.
Barrow and colleagues (2010 and 2011)20,42 did not report participants’ characteristics. Southey and
colleagues (2005)39 provided no information on characteristics other than stating that participants were
adult men and women who were younger than 45 years when diagnosed with a histologically confirmed,
first primary adenocarcinoma of the colon or rectum.
Overall, owing to the sparseness of the data, it is difficult to draw a conclusion regarding the
heterogeneity of the participants both within and between studies.
Assessment of study quality
A summary of the quality assessment of studies included in this review is shown in Table 11.
Concerns included lack of detail on patient recruitment, minimal information on patient characteristics and
unclear tissue sampling methods; for example, little evidence was given of sample replicates and
reproducibility for molecular analysis. Furthermore, test failures, such as operator or instrumental error,
were rarely reported. It was also often not mentioned whether or not the outcome assessors were blinded.
Papers were also unclear on robustness of IHC, for example whether or not results were checked by a
second party. Often, not all patients received both the index and reference test, likely owing to the cost of
constitutional genetic testing. This frequently caused a lack of clarity regarding patient flow and resulted in
all studies being at high risk of bias.
Two-gate studies
Barrow and colleagues (2010) The study by Barrow and colleagues (2010)42 used a two-gate design, i.e.
a group with LS confirmed by germline testing and a control group. Methods of recruitment were unclear,
with no patient characteristics described. The LS sample was small (n= 51), with an even smaller control
group (n= 17). No technical details were provided for the reference standard. More positively, to minimise
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interobserver variation, a semiquantitative scoring system was used. The slides were scored by an
experienced consultant gastrointestinal pathologist who was blinded to the mutational status of the
participants. Test failures and attrition were not reported.
The second study by Barrow and colleagues (2011)20 appeared to use consecutively recruited participants
from the previous study’s population. Again, this was a two-gate design with a small LS sample (n= 36)
and much smaller control (n= 6). No details were provided on participant characteristics, outcome
assessors or blinding. Test failures and attrition were not reported.
Single-gate studies
Becouarn and colleagues (2005) The study reported by Becouarn and colleagues (2005)43 only
performed the reference standard on MSI-H and MSI-L patients. Therefore, there are insufficient data to
populate a 2 × 2 table for MSI versus reference standard, and only IHC can be deemed to be an index test
for the purposes of this review. Moreover, this means that the data for IHC versus reference standard are
based upon a sample who had received prior MSI testing (with a MSI-H/MSI-L result). There also appear to
be missing data; of the 33 patients receiving the reference standard, 10 did not receive IHC, and the
reasons for this are unclear. Dropouts were only reported for the reference standard. Additionally, there
was one IHC test failure. No blinding or outcome assessor details were reported, and the recruitment
method was unclear.
Limburg and colleagues (2011) Limburg and colleagues (2011)44 recruited participants randomly,
although the method was not given. Details of the outcome assessor for IHC were unclear; however,
Southern blot and MLPA were subjected to dual reviews involving technical personnel and at least one
laboratory director for confirmation. The testing centre was blinded to all clinical data associated with the
specimens. On receipt, samples were assigned a unique bar code for robotic specimen tracking. From
the initial sample of 201 cases, six were excluded based on tumour location (appendix, n= 4; anus, n= 2).
Not all patients received IHC because tumour phenotype was not considered a primary study end point. As
such, complete IHC data were only available for 155 (79%) of 195 subjects. No test failures were reported.
Results for sensitivity and specificity were given, but no raw data were available.
Niessen and colleagues (2006) The study reported by Niessen and colleagues (2006)21 lacked clarity in a
number of areas, including number of centres and method of recruitment. Although IHC staining was
scored blinded to the MSI or mutation status, no further details were provided on the outcome assessor.
Unfortunately, data provided for IHC were inconsistent, so a 2 × 2 table could not be populated. The data
for MSI appear more reliable. However, not all participants received mutation analysis for MLH1 and
MSH2, and this was on the basis of MSI results (i.e. for the final third of patients, mutations in MLH1 and
MSH2 were sought only for those with an MSI-H tumour).
Shia and colleagues (2005) Shia and colleagues (2005)11 report on a single-gate, single-centre study,
with an exceptionally confusing patient flow. The number of test failures was unclear as were excluded
data. It appears that five samples for IHC could not be interpreted (4 of 108 for MSH6 and 1 of 110 for
MSH2), and only results for 81 IHC samples and 73 MSI samples are reported (of 110 and 104 samples,
respectively). It was not clear why the numbers used for IHC and MSI versus germline were fewer than the
numbers reported to have received the tests. Individuals with adenomas met AC I or II, or Bethesda criteria,
but it is possible that they did not have CRC themselves and are therefore only includable in this review as
relatives of those with CRC. Methods of recruitment, blinding and checking of outcome assessor were
not reported.
Southey and colleagues (2005) The study by Southey and colleagues (2005)39 was single gate and
single centre, with unspecified randomised recruitment. An assessment via MSI testing was not successful
for 13 (12%) tumour samples because of technical reasons related to DNA quality, which left 105 tumours
tested. No blinding or patient characteristics were reported. Tumour samples were obtained for
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118 of 131 patients (six did not consent to release tissue to the study and two laboratories had not agreed
to release the remaining seven samples); however, of these, not all patients received germline testing.
Instead, germline testing was conducted only on those with a FH that fulfilled the AC for LS; those who
were MSI-H, MSI-L or lacked expression of at least one MMR protein; and a random sample (n= 23) of
individuals who were MSS and did not lack expression of any MMR protein. For untested persons, data
were imputed based upon the results of the randomly sampled individuals who were MSS and did not lack
expression of any MMR protein.
Stomorken and colleagues (2005) Stomorken and colleagues (2005)45 report a study of 250
consecutively recruited families, although the relevant population with CRC reduces this number to 105,
as other cancers are included in the paper. No participant characteristics were given. Furthermore,
the study flow was very unclear, contributing to bias, as participants were selected for the reference test
based upon their index test results. No test failures were reported and there appeared to be missing data
(e.g. from 21 families, blocks for IHC were not available and from 30 families blocks were not asked for).
Scoring of the tumour was performed by pathologists without any knowledge of patients’ FH or results of
mutation analyses.
Wolf and colleagues (2006) The study reported by Wolf and colleagues (2006)46 was single centre
with no mention of recruitment method, blinding or outcome assessors. It was also unclear whether or
not some patients had already had MSI testing. Sample size was small (n= 81), with limited patient
characteristics provided. No test failures were reported. Twenty-six patients had no tumour tissue of
suitable quality for DNA examination; however, all patients received index test (IHC) and germline testing.
Assessment of test accuracy
Individual results for this review from 2005 to 2012 are presented alongside a narrative description below.
Summary tables are displayed at the end of this section (see Tables 23 and 24).
Immunohistochemistry
Two-gate studies
Unfortunately, neither of the papers by Barrow and colleagues (2010) provide data to populate a
2 × 2 table; however, results for sensitivity and specificity are presented.42 For the identification of
MLH1 germline mutation, at optimum cut-off (where the trade-off between sensitivity and specificity
is optimum) sensitivity was 100.0% (95% CI 84.0% to 100.0%) and specificity was 91.5%
(95% CI 79.6% to 97.6%); for PMS2 stain, sensitivity was 95.2% (95% CI 76.2% to 99.9%)
and specificity was 91.5% (95% CI 79.6% to 97.6%).
For the identification of MSH2 germline mutation, MSH2 staining was less sensitive and specific (sensitivity
87.5%, 95% CI 61.7% to 98.4%; specificity 88.5%, 95% CI 76.5% to 95.6%), and MSH6 staining had
an even lower performance (sensitivity 81.3%, 95% CI 54.4% to 96.05%; specificity 80.8%, 95% CI
67.5% to 90.4%).
The authors discuss that staining does not show a binary response to the presence or absence of a
mutation; for example, a pathogenic nonsense mutation may theoretically lead to a shorter, non-functional
protein. Where this happens, in theory, immunoreactivity may be preserved.
In this study, sensitivity and specificity were greater for MLH1 than for MSH2. The authors acknowledge
this may be a reflection of small sample size and use of different antibodies. Other variables include poor
fixation and degraded tissue in archived paraffin blocks.
In the second paper, Barrow and colleagues (2011)20 examine two forms of IHC: QD-IHC and DAB-IHC.
At the optimum cut-offs, MLH1 DAB-IHC had a sensitivity of 89.5% (95% CI 66.9% to 98.7%) and a
specificity of 78.3% (95% CI 56.3% to 92.5%). MSH2 DAB-IHC had a sensitivity of 86.7% (95% CI
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59.5% to 98.3%) and a specificity of 77.8% (95% CI 57.7% to 91.4%). Sensitivity and specificity were
not given for the other test under investigation (QD-IHC); however, the authors state that DAB-IHC
demonstrated superior results. Suggested reasons for this include variability in manual staining for QD-IHC
and practical difficulties in fluorescence imaging.
Single-gate studies
Becouarn and colleagues (2007) As mentioned in Assessment of study quality above, the study reported
by Becouarn and colleagues (2007)43 investigated IHC and MSI; however, the reference standard is only
performed on MSI-H and MSI-L patients. Therefore, there are insufficient data to populate a 2 × 2 table for
MSI. Table 12 shows the data for IHC, which give a sensitivity of 73.3% (95% CI 44.8% to 92.2%) and a
specificity of 28.5% (95% CI 3.7% to 71.0%).
Both the sensitivity and specificity are poor, although the small sample size should be noted and the
authors mention failures due to defective tissue fixation and detachment of the histological slice during
antigenic revelation. IHC was also limited to proteins MLH1 and MSH2, whereas the reference standard
may have detected additional mutations. Furthermore, there are also some concerns regarding missing
data with this study because, of the 33 patients receiving the reference standard, 10 did not receive IHC
and the reasons for this are unclear.
The authors discuss that IHC demonstrated poor sensitivity in four patients with LS in whom a causal
mutation was detected. Two of these had missense mutations, which possibly alter protein function
but not translation and therefore would not be detected by IHC, which evaluates protein expression.
The other two patients had a germline splicing mutation or large rearrangement which could lead to either
(i) preserved reading frame with persistent expression by IHC; or (ii) total loss of expression of the
mutated allele. Again, the authors consider the produced protein to have deficient function but not a
total loss of expression.
Limburg and colleagues (2011) Sensitivity and specificity for MLH1, MSH2 and MSH6 by IHC were
reported by Limburg and colleagues (2011)44 as 85.7% (95% CI 42.1% to 99.6%) and 91.9% (95% CI
86.3% to 99.7%), respectively. The sample size was reasonable for a study in this area, with randomly
recruited participants without prior testing. Data for IHC are shown in Table 13.
TABLE 12 Correlation between IHC and germline testing for Becouarn and colleagues (2007)43
IHC
Reference standard
Positive Negative Total
Positive 11 5 16
Negative 4 2 6
Total 15 7 22
TABLE 13 Correlation between IHC and germline testing for Limburg and colleagues (2011)44
IHC
Reference standard
Positive Negative Total
Positive 6 12 18
Negative 1 136 137
Total 7 148 155
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The authors consider that the 12 FPs may be due to epigenetic modification (i.e. MLH1 promoter
hypermethylation), recently described mutations not detectable by the applied methodology or mutations
in other, non-analysed genes that interact with the MMR proteins tested.
Niessen and colleagues (2006) The results presented for IHC by Niessen and colleagues (2006)21 appear
inconsistent, and therefore a 2 × 2 table was not possible. However, according to the text the sensitivity
and specificity of IHC staining for MLH1 were 80% (95% CI 38% to 96%) and 89% (95% CI 84% to
93%), respectively; for MSH2 the sensitivity and specificity were 100% (95% CI 57% to 100%) and 96%
(92% to 98%), respectively; and for MSH6 the sensitivity and specificity were 86% (95% CI 49% to 97%)
and 93% (95% CI 88% to 96%), respectively. The sample size was 174; however, despite this, the CIs for
MLH1 and MSH6 sensitivities were wide.
Shia and colleagues (2005) Shia and colleagues (2005)11 report on IHC results for 83 adenocarcinomas
and 29 adenomas. Negative (i.e. abnormal) IHC staining was observed in 25 patients with carcinoma, for a
sensitivity of 81% (95% CI 61% to 93%), but false abnormal IHC staining was present in four tumours,
for a specificity of 89% (95% CI 75% to 97%).
The sensitivity of IHC was particularly low in detecting MLH1 gene mutation, which the authors attribute
partly to missense mutations that result in mutant proteins that are catalytically inactive but antigenically
active. In addition, truncating mutations in MLH1 may result in a protein that reacts with the MLH1
antibody. IHC was more favourable in detecting MSH2 (21 of 23) and MSH6 (four of five) gene mutations.
The difference in sensitivities between adenomas and carcinomas was reported as not significant (p= 1.00).
Data for participants with carcinomas and adenomas are shown in Tables 14 and 15, respectively.
The results could not be interpreted in five samples owing to a lack of definitive staining in normal cells on
the same slide and diffuse and strong cytoplasmic staining in the tumour cells and normal cells. It was also
noted that not all IHC positive cases showed uniform positivity throughout the tumour, and weak or focal
expression of a MMR protein may be associated with MSI or gene mutation, or both.
TABLE 15 Correlation between IHC and germline testing for participants with adenomas,
Shia and colleagues (2005)11
IHC
Reference standard
Positive Negative Total
Positive 8 0 8
Negative 4 5 9
Total 12 5 17
TABLE 14 Correlation between IHC and germline testing for participants with carcinomas,
Shia and colleagues (2005)11
IHC
Reference standard
Positive Negative Total
Positive 21 4 25
Negative 5 34 39
Total 26 38 64
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Southey and colleagues (2005) The study presented by Southey and colleagues (2005)39 gives a
sensitivity of 100% (95% CI 82% to 100%) and a specificity of 91% (95% CI 83% to 96%). Data for IHC
are shown in Table 16.
The authors suggest that if they had not conducted IHC testing for all four proteins, evidence would have
been missed for some carriers; for example, by not testing for MSH6 or PMS2, two patients with large
deletions in MLH1 and all four patients with MSH6 mutations would not have been detected. It should be
noted that not all patients received germline testing.
Stomorken and colleagues (2005) Owing to the inclusion of extra colonic cancers, the number of
participants for calculating sensitivity and specificity for IHC is relatively small for the study presented by
Stomorken and colleagues (2005).45 Proteins tested for were MLH1, MSH2 and MSH6, to give a sensitivity
of 100.0% (95% CI 75.2% to 100.0%) and a very low specificity of 12.5% (95% CI 0.3% to 52.7%),
due to seven FPs (four FPs were MLH1, which might possibly be due to methylation) and only one TN.
When investigating all cancers, a specificity of 82% was reported. Table 17 shows the correlation between
IHC and germline testing.
Microsatellite instability
Niessen and colleagues (2006)
The sensitivity and specificity calculated using the results in the 2 × 2 table are 88.0% (95% CI 68.7% to
97.4%) and 68.1% (95% CI 61.7% to 74.1%), respectively, for the study reported by Niessen and
colleagues (2006)21 (Table 18).
TABLE 18 Correlation between MSI and germline testing, Niessen and colleagues (2006)21
MSI
Reference standard
Positive Negative Total
Positive 22 75 97
Negative 3 160 163
Total 25 235 260
TABLE 17 Correlation between IHC and germline testing, Stomorken and colleagues (2005)45
IHC
Reference standard
Positive Negative Total
Positive 13 7 20
Negative 0 1 1
Total 13 8 21
TABLE 16 Correlation between IHC and germline testing, Southey and colleagues (2005)39
IHC
Reference standard
Positive Negative Total
Positive 18 8 26
Negative 0 79 79
Total 18 87 105
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The authors mention that interobserver variation can occur when scoring MSI and that sporadic CRCs
show MSI as a result of hypermethylation of the promoter region of MLH1, hence the high number of FPs.
Shia and colleagues (2005)
Shia and colleagues (2005)11 produced a sensitivity and specificity for participants with carcinoma
investigated by MSI of 100% (95% CI 86% to 100%) and 84% (95% CI 68% to 94%), respectively.
The sensitivity for adenomas is lower at 86% and the specificity is 80%. Data for participants with
carcinomas and adenomas are shown in Tables 19 and 20.
Presence of MSI was also seen in 7 of 42 carcinomas and adenomas that did not harbour any detectable
germline mutations. The seven false MSI-present cases included the four false-negative IHC cases.
The difference in sensitivities between adenomas and carcinomas were reported as not significant for IHC
or MSI (IHC, p= 1.00; MSI, p= 0.25).
Southey and colleagues (2005)
Southey and colleagues (2005)39 report a sensitivity and specificity of 94% (95% CI 73% to 100%) and
80% (95% CI 71% to 88%), respectively. Table 21 shows that for every TP, MSI testing produces a FP. It
should be noted that this study used a panel of 10 markers, unlike the NCI panel, which tests five markers.
TABLE 21 Correlation between MSI and germline testing, Southey and colleagues (2005)39
MSI
Reference standard
Positive Negative Total
Positive 17 17 34
Negative 1 70 71
Total 18 87 105
TABLE 20 Correlation between MSI and germline testing for participants with adenomas,
Shia and colleagues (2005)11
MSI
Reference standard
Positive Negative Total
Positive 6 1 7
Negative 1 4 5
Total 7 5 12
TABLE 19 Correlation between MSI and germline testing for participants with carcinomas,
Shia and colleagues (2005)11
MSI
Reference standard
Positive Negative Total
Positive 24 6 30
Negative 0 31 31
Total 24 37 61
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Wolf and colleagues (2006)
Wolf and colleagues (2006)46 state that MSI was associated with a high sensitivity (100.0%; 95% CI
71.7% to 100.0%), although specificity is lower, with nine FPs (78.6%; 95% CI 62.8% to 89.2%). Data
are shown in Table 22.
Summary of test accuracy studies
Nine primary research studies and one technology appraisal were identified for inclusion in this review.
Four studies investigated MSI testing and eight investigated IHC. As tests to identify LS are a rapidly
evolving area, and in the knowledge that a TA was already in existence which had identified studies up to
2005, only studies from 2005 onwards were included in this review.
Overall, the quality of the studies was mixed and, as many studies were not directly comparable owing to
variations in design, the data could not be pooled. The results are summarised in Tables 23 and 24.
Immunohistochemistry
Immunohistochemistry is a technique in which the abnormal staining of a specific MMR protein is related
to the underlying gene defect. As such, this test has the advantage of directing further genetic mutation
analysis. Its sensitivity is, however, limited by tissue fixation, the variability of staining and the problem of
inactive but intact proteins (e.g. caused by methylation of MLH1 in sporadic CRC).1
The sensitivity and specificity for IHC are wide-ranging, varying from 73.3% to 100.0% and from 12.5%
to 100.0%, respectively, although not all studies searched for all proteins and some of the results were
combined. The raw data were not supplied for all studies and therefore could not be verified. CIs were
generally wide and sample sizes small. Clearly, specificity is the greatest concern with IHC, as the high number
of FPs means that individuals may be told they have LS when they do not. Furthermore, those studies
recruiting from a population that had no prior testing may include an increased number of FPs due toMLH1
methylation found in sporadic CRC. A test is available to detect methylation ofMLH1. However, no studies
that tested for MLH1 methylation were identified as includable for this review.
A major methodological concern was that often the reference standard was applied according to the
results of the index test. Therefore, because of attempts to minimise costs, only patients testing positive for
LS by IHC or MSI received germline testing. As a result, this introduced an element of bias and often
caused a confusing flow of patients through the study and difficulties creating a 2 × 2 table. Another
concern was that IHC is dependent on the quality of the staining and the experience of the pathologist;
however, there was rarely any indication of initial results being confirmed by a second party.
TABLE 22 Correlation between MSI and germline testing, Wolf and colleagues (2006)46
MSI
Reference standard
Positive Negative Total
Positive 13 9 22
Negative 0 33 33
Total 13 42 55
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TABLE 23 Summary of test accuracy results for IHC
First
author Patients (n) Reference standard Protein TP TN FP FN
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Barrow
201042
68 No details
Germline testing
performed before
recruitment
MLH1 NR NR NR NR 100
(84 to 100)
91.5
(79.6 to 97.6)
PMS2 NR NR NR NR 95.2
(76.2 to 99.9)
91.5
(79.6 to 97.6)
MSH2 NR NR NR NR 87.5
(61.7 to 98.4)
88.5
(76.5 to 95.6)
MSH6 NR NR NR NR 81.3
(54.4 to 96.0)
80.8
(67.5 to 90.4)
Barrow
201120
42 No details
Germline testing
performed before
recruitment
MLH1 NR NR NR NR 89.5
(66.9 to 98.7)
78.3
(56.3 to 92.5)
MSH2 NR NR NR NR 86.7
(59.5 to 98.3)
77.8
(57.7 to 91.4)
Becouarn
200543
197a Direct sequencing
with search for large
mutations if point
mutation not
identified
MLH1 and
MSH2
11 2 5 4 73.3
(44.9 to 92.2)b
28.6
(3.7 to 71.0)b
Limburg
201144
195 Direct sequencing
with Southern blot
and MLPA
MLH1, MSH2
and MSH6
6c 136c 12c 1c 85.7
(42.1 to 99.6)b
91.9
(86.3 to 95.7)b
Niessen
200621
281 Direct sequencing
and MLPA
MLH1 NR NR NR NR 80
(38 to 96)
89
(84 to 93)
MSH2 NR NR NR NR 100
(57 to 100)
96
(92 to 98)
MSH6 NR NR NR NR 86
(46 to 97)
93
(88 to 96)
Shia
200511
110a Direct sequencing
and large deletion
analysis
MLH1, MSH2
and MSH6
21 34 4 5 80.8
(60.6 to 93.4)b
89.5
(75.2 to 97.1)b
Southey
200539
131d Direct sequencing
and MLPA
MLH1, MSH2
and MSH6
18 79 8 0 100
(82 to 100)
91
(83 to 96)
Stomorken
200545
250e Direct sequencing
and large
rearrangement
analysis
MLH1, MSH2
and MSH6
13 1 7 0 100
(75.3 to 100.0)b
12.5
(0.3 to 52.7)b
NR, not reported.
a It is unclear why the number of results is lower than the original recruited number.
b CIs calculated by Peninsula Technology Assessment Group.
c Values calculated from results in text by Peninsula Technology Assessment Group; not all patients received IHC.
d Not all patients received germline analysis.
e Not all patients had CRC, therefore smaller sample size.
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TABLE 24 Summary of test accuracy results for MSI
First author Patients (n) Reference standard
Panel of
markers TP TN FP FN
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Niessen 200621 281a Direct sequencing
and MLPA
BAT25
BAT26
D2S123
D5S346
D17S250
22 160 75 3 88.0
(68.8 to 97.5)b
68.1
(61.7 to 74.0)b
Shia 200511 110c Direct sequencing
and large deletion
analysis
BAT25
BAT26
BAT40
PAX6
D2S123
D17S250
MYCL1
24 31 6 0 100
(85.8 to 100.0)b
84
(68.0 to 93.8)b
Southey 200539 131a Direct sequencing
and MLPA
D5S346
D17S250
D2S123
BAT25
BAT26
BAT40
MYB
TGFβRII
IGFIIR
BAX
17 70 17 1 94
(73 to 100)
80
(71 to 88)
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Microsatellite instability
The MSI test uses preselected markers to identify the existence of defective MMR within vulnerable DNA
sequences. Although there is a standardised panel of five markers, many laboratories may use 10 or more
mono- or dinucleotide sequences. As displayed in Table 24, no two studies included in this review have
used the same panel and therefore a comparison is difficult and results vary.
The sensitivity for MSI ranged from 88% to 100% and specificity from 68 to 84%. The study by Niessen
and colleagues (2006)21 used only five markers and displayed the lowest sensitivity and specificity
(88% and 68%, respectively); however, the study reported by Wolf and colleagues (2006)46 also used five
markers with improved results (sensitivity 100% and specificity 79%). In all cases the CIs were wide,
signifying heterogeneity. As with IHC, not all patients received the reference standard and no information
was given on robustness of the test, for example number of sample replicates.
TABLE 24 Summary of test accuracy results for MSI (continued )
First author Patients (n) Reference standard
Panel of
markers TP TN FP FN
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Wolf 200646 55 Sequence analysis D5S346
HSCAP53L
D2S123
BAT26
D18S34
Or
D5S82
D2S134
D13S175
D11S904
BAT25
13 33 9 0 100
(71.7 to 100.0)
78.6
(62.8 to 89.2)
a Not all patients received germline analysis.
b CIs calculated by Peninsula Technology Assessment Group.
c It is unclear why the number of results is lower than the recruited number.
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Chapter 4 Assessment of cost-effectiveness:
systematic review
Systematic review of existing cost-effectiveness evidence
The aim of this section is to identify and assess cost-effectiveness studies related to the identification and
management of persons with LS. The assessment of cost-effectiveness comprises a systematic review of
the literature on the cost-effectiveness of identification and management of persons with LS.
Methods
Searches of electronic databases were devised by a trained information specialist (CC) and applied to the
following databases:
l MEDLINE (via Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l EMBASE (via Ovid)
l PsycINFO (via Ovid)
l HMIC (via Ovid)
l EconLit (via EBSCOhost)
l CINAHL (via EBSCOhost)
l Web of Science (via ISI)
l The Cochrane Library
l NRR
l Web of Science Proceedings
l Current Controlled Trials
l ClinicalTrials.gov
l FDA website
l EMEA website.
A search filter was used to identify economic evaluations, as used for identifying studies for inclusion in the
NHS Economic Evaluation Database (NHS EED). No publication date limit was imposed. Searching was
limited to the English language and to human-only populations.
Study selection criteria and procedures
Titles and abstracts obtained from searching were screened by four reviewers (NH, CH, RM and TS) using
inclusion criteria described in Table 25, with disagreements resolved by discussion between two reviewers
(NH and TS). An inclusion criterion relating to guidelines was included to assist in the understanding of LS.
Full papers of citations that met these criteria were obtained and assessed for inclusion in the review by
two reviewers (NH and TS), with disagreements resolved by discussion by the same two reviewers.
Study quality assessment
A quality appraisal was conducted on cost-effectiveness studies or other economic evaluations, using the
well-established Drummond checklist,47 following advice from CH.
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Data extraction strategy
For those studies which were of relevance to the current decision problem, data were extracted by two
researchers (NH, TS) into three data extraction tables: one to describe the study design of each economic
evaluation, one to describe the main results, and the third a checklist of review-specific criteria that the
two reviewers had previously agreed upon. Examples of the study design and results tables are provided in
Tables 26 and 27, with the review-specific criteria checklists presented in Tables 28–30, respectively.
In the study design table, the sections included study, publication type, setting/perspective, industry role/
conflicts of interest, population, study purpose, outcomes measured, diagnostic strategies, treatment
strategies, study approach, health states, model duration/cycle length, the approach to uncertainty analysis,
base-year prices and discount rate.
In the results table, the components were the analysis year, the base-case results and the main sensitivity
analysis results.
Items on the review-specific checklist included the types of cancers included in the analysis (both in the
input population and in the management section); whether or not the interactions of these cancers in
the long term were considered appropriately; whether or not the diagnostic strategies used FH; which MMR
gene mutations were tested for; whether or not differences in LS cancer incidence due to these MMR gene
mutations, and the improved survival of LS CRCs relative to sporadic CRCs, were accounted for; whether or
not the study considered the difference in CRC incidence between males and females; whether or not
adherence to counselling, genetic testing and management strategies was included; whether or not the
psychological impact of genetic testing was accounted for; and whether or not the study assessed the
impact of diagnostic errors.
Synthesis of extracted evidence
The evidence base was assessed using narrative synthesis supported by abridged data extraction tables.
TABLE 25 Inclusion criteria for systematic review of cost-effectiveness
PICO criteria Inclusion criteria
Population Persons who have or may have LS
Intervention Any of the following (including combinations):
l strategies to identify LS in the population
l strategies to manage LS in the population
l strategies to manage patients in whom LS is identified
Comparator Current clinical practice (may or may not include efforts to identify LS)
Outcomes Any of the following:
l costs
l clinically relevant outcomes (e.g. life-years gained, QALYs, CRCs prevented)
l mutations detected
Study type Any of the following:
l decision-analytic models (with or without a cost-effectiveness component)
l evaluations of cost-effectiveness within trials (including cost-effectiveness, cost–utility and
cost–benefit studies; no requirement for randomisation)
l cost or resource use studies
l guidelines from national institutions, professional bodies and international bodies
(including working groups)
PICO, population, intervention, comparator and outcomes.
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TABLE 26 Example data extraction table for study characteristics
Study Ladabaum et al. 201148
Publication type Peer-reviewed journal paper
Setting, perspective USA, third-party payer
Industry role/conflicts
of interest
Primary funding source: NIH
Authors’ potential conflicts of interest: Epigenomics, Quest Diagnostics, Abbott Molecular,
Given Imaging, Roche Diagnostics, GE Healthcare, GeneNews, Archimedes
Population All persons with newly diagnosed CRC and their relatives
Study purpose Cost-effectiveness analysis of strategies to identify LS
Outcomes measured Life-years, cancer cases and deaths, costs and ICERs
Diagnostic strategies Referent strategy (no attempt to identify LS)
Clinical criteria strategies
l (AC, Bethesda, MMRpredict, MMRpro, PREMM) followed by germline testing
l (AC, Bethesda, MMRpredict, MMRpro, PREMM) followed by IHC, followed by guided
germline testing
Tumour-testing strategies
l (IHC, IHC with BRAF, MSI, MSI plus IHC, MSI plus IHC with BRAF) followed by
germline testing
Up-front germline testing
Treatment strategies Surveillance: annual colonoscopy, TVU and endometrial sampling
Prophylactic surgery: TAHBSO at age 40 years, subtotal colectomy (unclear when)
Study approach Decision tree with Markov subtrees
Health states Unclear (includes at least healthy, CRC, EC, OC and dead)
Model duration
(cycle length)
Lifetime (1 year)
Uncertainty analysis Scenario analyses
Univariate sensitivity analyses
Partial PSA (not all parameters varied)
Base year prices 2010 US dollars
Discount rate 3%
ICER, incremental cost-effectiveness ratio; NIH, National Institutes of Health; OC, ovarian cancer; PREMM, prediction of
mismatch repair gene mutations; PSA, probabilistic sensitivity analysis; TVU, transvaginal ultrasound.
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TABLE 27 Example data extraction table for study results
Study Ladabaum et al. 201148
Analysis year 2010
Summary of findings Key findings
If clinical criteria strategies are excluded then IHC with BRAF is a clinically effective and
cost-effective measure with ICER of $36,206 per LY gained (0.2248 LYs gained at a cost of $8139)
Referent strategy resulted in 23.5071 discounted LYs per person at a discounted cost of $11,242
Clinical criteria strategies resulted in 23.5565–23.7292 discounted LYs per person at a discounted
cost of $12,933–18,737 per person. Strategies using IHC as a second-line test were generally
cheaper but provided fewer discounted LYs than those going direct from clinical criteria to
germline testing. Only Bethesda and MMRpro strategies are on the cost-effectiveness frontier
(others dominated or extended dominated)
Tumour-testing strategies resulted in 23.7319–23.7711 discounted LYs per person at a discounted
cost of $19,551–23,642. Strategies involving BRAF testing dominated equivalent strategies without
BRAF testing
Up-front germline testing resulted in 23.8047 LYs per person at a cost of $33,492 per person
(ICER $293,155 per LY gained)
Results of
sensitivity analysis
Scenario analyses
l Instituting an age limit for probands improved cost-effectiveness but resulted in some
probands with LS not being tested; using MSI with BRAF testing, the ICER was $88,700 for
no age limit vs. an age limit of 70 years
l The number of relatives tested per proband had a significant impact on the
cost-effectiveness; three to four relatives were required for most strategies to have ICER
< $50,000 per LY gained
One-way sensitivity analyses
Cost-effectiveness of IHC with BRAF testing vs. the referent strategy was sensitive to (i.e. ICER
exceeded $50,000 per LY for values within the analysis):
l discount rate (discount rate of 5% → ICER $54,000 per LY)
l age of relative (age 60 or 70 years → ICER $55,500 or $77,300 per LY)
l probability of germline mutation in a relative of a person with LS (probability of 0 → ICER
$344,000 per LY)
l prevalence of LS (prevalence of 0.01 in CRC cases → ICER $55,700 per LY)
l relative risk for CRC in LS patients adhering to recommendations (relative risk 0.82 → ICER
$60,500 per LY)
Probabilistic sensitivity analysis
(Note: not all parameters about which there was uncertainty were varied in the PSA)
CEACs for individual strategies vs. the referent strategy are overlaid in figure 3, showing that
apart from (MSI+ IHC, MSI+ IHC/BRAF testing, up-front germline testing) all strategies were
cost-effective (ICER≤ $50,000/LY with p> 0.5) compared to referent strategy
The authors indicate that at a threshold of $50,000 per LY gained, IHC/BRAF testing is the
optimal strategy in 53% of iterations
CEAC, cost-effectiveness acceptability curve; ICER, incremental cost-effectiveness ratio; LY, life-year; PSA, probabilistic
sensitivity analysis.
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Results
The flow diagram of papers is summarised in Figure 2. In summary, 2036 citations were identified, 227 of
which were ordered in full. Three of these could not be retrieved but the information available from the
titles and abstracts did not suggest that they would have a high probability of remaining included studies.
Of the 224 which were retrieved, 7 were duplicates and 119 were excluded. Of the remaining 98, 1 was
an opinion piece, 55 were guidelines only, 3 were previous reviews of cost-effectiveness studies, 5 were
purely effectiveness models (kept for their insight into modelling this problem) and the remaining 34
included papers represented cost-effectiveness studies of some form. An additional three cost-effectiveness
papers, one of which was an update of a previously identified paper, and one additional review were
identified during the update search. Of the final 37 cost-effectiveness papers, 16 looked at the short-term
cost-effectiveness of identifying LS, 5 looked only at the long-term cost-effectiveness of management of LS
and 16 examined the long-term impact on cost-effectiveness of both the strategies to identify and
manage LS. Of the 16 sources that only looked at short-term cost-effectiveness, there were 15 distinct
studies (one of the papers was an abstract of a study written up in full in another paper). Of the five that
looked purely at management of LS, only four were distinct studies (as one paper was an abstract of
preliminary results which were reported in full in another paper). Of the 16 sources that looked at the
cost-effectiveness of both the strategies to identify and manage LS, there were two papers on the same
study, one abstract of another paper and a commentary on a paper, making the total number of distinct
studies 13. The most common reasons for exclusion were on the basis of a study design or population not
relevant to the review.
We did not formally review the papers that included guidelines, but they were generally consistent in their
suggestions for the management of LS, i.e. routine surveillance for CRC by 1- to 2-yearly colonoscopy. As
our criteria for guidance were quite inclusive, we included a wide range of sources for this, from different
study groups including working groups and HTA groups, among others.
TABLE 30 Review-specific criteria to assess included cost-effectiveness studies that compared strategies to
manage LS (no diagnosis)
Criteria
Vasen et al.
199873
Dunlop et al.
200274
Kwon et al.
200875
Yang et al.
201176
The study considers CRC ✓ ✓ ✓ ✗
The study considers EC N/A ✗ ✓ ✓
The study considers OC N/A ✗ ✓ ✓
The study considers other LS-associated cancers ✗ ✗ ✗ ✗
The study considers interactions of cancers appropriately N/A N/A ? ?
Colonoscopic surveillance in the study is explicitly justified
(e.g. with reference to guidelines or clinical practice)
✓ ✓ N/A N/A
The study considers patients declining recommended
surveillance
✗ ✗ ✗ ✗
The study considers the difference in incidence of CRC
between males and females
N/A ✗ N/A N/A
The study considers the difference in incidence of
LS-associated cancers between mutations of different
MMR genes
✗ ✗ ✗ ✗
The study accounts for the improved survival of LS CRCs
relative to sporadic CRCs
? ✗ ✓ N/A
The study considers the potential psychological impact of
genetic testing
✗ ✗ ✗ ✗
N/A, not applicable; OC, ovarian cancer.
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2036 papers screened by title and abstract
227 papers appeared to meet inclusion
criteria
 
43 papers meeting criteria other than guidelines, plus 4 identified
by update search:
•  Opinion piece, n = 1
•  Cost-effectiveness reviews, n = 4 
•  Effectiveness models, n = 5
•  Cost-effectiveness papers, n = 37 
 
 Diagnostic only, n = 16 (15 individual studies) 
 Management only, n = 5 (4 individual studies) 
 Diagnostic and management, n = 16 (13 individual studies) 
119 papers excluded
•  Population, n = 17
•  Intervention, n = 2
•  Study design, n = 99
•  Language, n = 1
 
 
55 papers only meeting
criteria for guidelines 
(not presented in detail)
224 papers screened by full text
 
 
27 papers duplicates
1782 papers excluded by
title and abstract 
3 papers unobtainable
7 papers duplicates 
 
FIGURE 2 Flow diagram of the search, retrieval and inclusion of articles in the systematic review of evidence on the
economic evaluations to identify and manage LS.
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Summary of previous cost-effectiveness reviews
There were four papers identified whose cost-effectiveness section consisted purely of a review of previous
cost-effectiveness studies,77–80 as well as two cost-effectiveness model papers65,69 that contained a review
section. The purpose of reviewing these studies was to investigate whether or not a systematic review had
been conducted previously, and also to check for any additional studies that our search may have missed.
Only two reviews77,78 were studies from the last 10 years (2006 and 2012, respectively) and were clear on
their search strategy and methods, but neither of them looked exclusively at LS. Furthermore, neither
review identified more than four studies related to LS. Between them they identified only seven separate
reviews,23,49,50,59,61,81,82 of which all but one had already been identified by our review. The one study we had
not identified, by Hagen and colleagues,82 was written in German and therefore excluded from our review.
The only results presented by Antonanzas and colleagues were from the Barrow and colleagues (2008)81
paper, which we excluded on the basis of population. The four studies23,49,50,59 reported by Rogowski and
colleagues77 were all included in our review, which had a more comprehensive set of studies.
Of the other two papers with a review of previous cost-effectiveness studies, only one could be considered
an actual review. The other,79 from 2001, mentions the findings of the 1998 study by Vasen and
colleagues,73 but no further details are given. This study was excluded from our review on the basis of
study design. The other review,80 from 2008, identified six studies, two of which were not identified by
Rogowski and colleagues.53,73
Two of the included cost-effectiveness studies also conducted reviews of previous cost-effectiveness
studies.65,69 Again, the details of these reviews are not in depth and did not identify any additional papers
that we had not already screened.
In the reports where authors made conclusions about the studies they had identified, the main conclusion
was that strategies to identify and manage LS could be cost-effective, depending on the cost-effectiveness
threshold of the relevant health-care provider, but that there was no conclusive evidence as to which
strategies would be most cost-effective. Phillips and colleagues (2008)80 suggested that further research
was needed, particularly as the understanding of LS has changed in recent years. This assumption also
explained the conclusion of Palomaki and colleagues (2009),65 who criticised the studies they had
included51,53,73,83 for being inadequate as they did not include certain tests and did not address the
differences in performance of these tests for different MMR gene mutations. These reviews identified
12 studies that were relevant to our review; this was significantly fewer than the number our search had
identified, suggesting that there might be further work that these previous reviews had missed and
justifying the need for our own systematic review. As our search had already identified the 12 studies that
these reviews had also included, we were confident of the completeness of our review.
Summary of previous effectiveness models
As part of our review, we identified and assessed previous studies that included effectiveness models.
This was to provide insight into what modelling had previously been done in this area and to help guide
our own modelling efforts. We identified five previous studies that included some attempt at modelling
without costs.83–87 Four of these studies83,85–87 looked exclusively at management strategies for people with
LS; three related to the management (such as use of aggressive colorectal surgery to prevent further CRCs)
and prevention of CRC, and one examined the prevention of EC. The study on EC85 appeared to have
been later updated to include costs, in a paper by Yang and colleagues (2011).76 The general finding of
these studies was that management strategies were effective for LS patients and that aggressive
prophylactic surgery [total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO) for EC
or proctocolectomy/total colectomy for CRC] was generally the most effective strategy. All of the CRC
studies employed some form of Markov modelling and the EC model was quoted to be a decision model
built in TreeAge 2004 (TreeAge Software, Inc., Williamstown, MA, USA). The final paper84 was a resource
minimisation study employing a test accuracy study and a decision tree to compare strategies of testing for
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LS, and finding that a strategy that included BRAF testing was more effective than one without (reducing
the number of genetic tests by 17%, for the same number of mutations identified).
These models were not of great use as they each focused on one aspect of LS and so did not give much
insight into how to model both the diagnostic and management pathways for LS, including more than one
cancer, as was required of our model. They did, however, indicate that a new model may be necessary.
Summary of cost-effectiveness studies
For the purposes of the review, we split the 32 cost-effectiveness studies into the three subgroups:
those that looked at the short-term cost-effectiveness of identifying LS; those that looked only at the
long-term cost-effectiveness of management of LS; and those that examined the long-term impact on
cost-effectiveness of both the strategies to identify and manage LS.
Given the large number of studies which our review identified, we do not report each study in great detail,
preferring to identify important similarities and differences and potential areas of improvement for which
our model was intended to provide information. The summary tables of characteristics and results are
shown below (see Tables 31–36). Our model was required to look at the long-term consequences of
diagnosis and management of LS, so these studies were the main focus of our review. As such, the other
two subgroups are reported in less depth, though their summary tables are reported in similar detail.
Following on from the summaries, we also present the results of our quality appraisal for these studies.
Lynch syndrome diagnosis-only studies
This was the largest subgroup of cost-effectiveness studies identified, including 15 studies looking exclusively
at the short-term cost-effectiveness of strategies to diagnose LS.34,59–72 All studies were published between
2000 and 2012 and summary details of each study can be found in Tables 31 and 32.
There was consistency in the perspective of these studies, as all but one were from a health-care
perspective; the other67 was from the perspective of a third-party payer. Most other aspects of the studies
were quite varied.
There were six studies from the USA,59,65,67–69,71 six from European countries,34,60–63,66 one from China64 and
two where the setting was not clear.70,72 Most studies were not specific about the ‘current practice’ in their
respective countries, but their strategies were generally compared against a no testing strategy, implying
that there was no standard ‘current practice’ in each of the countries or that no testing for LS was the
‘current practice’. Relevant to our assessment, one of the European studies was based in the UK,60 but this
was 9 years old at the time of writing and was not consistent with our input population; Pigatto and
colleagues60 investigated families referred for genetic testing, rather than newly diagnosed CRC patients
aged < 50 years, who were the focus of our investigation.
With regards to the other studies’ input populations, one looked at EC patients67 and three (including the
UK study) examined families who were referred to genetic testing centres,60,62,66 neither of which were
the target population of our TA. The other 11 studies followed newly diagnosed CRC patients, and three
of these59,65,72 included the impact on relatives of the CRC patients.
As well as having different study populations, the different studies also assessed different tests, which
included the following subsets: clinical criteria/FH,34,59–61,63,64,67,68,70 prediction models,66 tumour
testing65,34,59–64,66–72 and genetic testing.65,34,59–64,66–72 Genetic testing was split into gene sequencing for
probands and targeted genetic testing for relatives. Not all genetic testing was conducted on all four
known LS genes, primarily because MSH6 and PMS2 are more recent discoveries. All of the studies had
strategies that included universal genetic testing and at least one that included a tumour-based test
followed by genetic testing. Most also included some variant of clinical criteria, FH criteria or a prediction
model based on these criteria.
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TABLE 32 Results of cost-effectiveness studies that compared strategies to identify LS (no management)
Author and
year
Outcomes
measured Base results
Sensitivity analysis
approach
Main sensitivity analysis
resultsa
Debniak et al.
200034
Mutations detected
Costs
Dominated
PCD → GT
PCD → MSI → GT
Not dominated
PCD → IHC → GT detected
five mutations at total cost
of €4400 (ICER €880 per
mutation)
PCD → IHC → (MSI) → GT
detected one additional
mutation (ICER $6202 per
additional mutation
detected)
N/A N/A
Reyes et al.
200259
Mutations detected
Costs
Incremental cost per
mutation detected
In order of efficiency
(strategy 1 least effective,
strategy 3 most effective)
Strategy 2 vs. strategy 1 had
ICER of $6832 per case
detected, but strategy 2
extended dominated by
strategy 4, which had an
ICER of £6441 per case
detected compared with
strategy 1. Strategy 3
compared with strategy 4
had ICER of $51,151 per
case detected
Univariate sensitivity
analyses
When AC II positive rate
greater than 0.025, strategy 4
(mixed) is most effective and
dominates strategy 3
Increasing the numbers of
FDRs tested improves
cost-effectiveness of
all strategies
Pigatto et al.
200460
Mutations detected
Cost
‘B’ strategies dominate
‘Any CC’
IHC2 strategies dominate
MSI1 and IHC2+MSI1
strategies
Cost-effectiveness
frontier:
AC+ IHC2: 10 mutations,
€7150
B1–3+ IHC2: 14 mutations,
ICER €1237 per mutation
MA: 37 mutations, ICER
€2441 per mutation
B1–3: 45 mutations, ICER
€3847 per mutation
B: 49 mutations, €136,024,
ICER €9256 per mutation
N/A N/A
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TABLE 32 Results of cost-effectiveness studies that compared strategies to identify LS
(no management) (continued )
Author and
year
Outcomes
measured Base results
Sensitivity analysis
approach
Main sensitivity analysis
resultsa
Pinol et al.
200561
Cost per mutation
detected
Accuracy
Using Revised Bethesda
guidelines before IHC
($13,837 per case detected)
or MSI ($15,586 per case
detected) was more
cost-effective than directly
using the tumour tests
themselves (IHC $49,343 per
case detected; MSI $41,782
per case detected)
N/A N/A
Engel et al.
200662
Mutations detected
Costs
Strategies equally sensitive
and specific
Using proposed strategy
would achieve cost reduction
of ≈ 25%
Univariate
sensitivity analysis
Cost reductions of 25–27%
are achieved as the ratio of
the cost of MSI to IHC is
varied from 3.25 to 5.00
Bessa et al.
200863
Mutations detected
Costs
All strategies equally sensitive
MSI+ BRAF+GT cheapest if
CC not used (€35,230 per
mutation detected)
CC+ IHC+ BRAF+GT
cheapest if CC used
(€11,450 per mutation
detected)
N/A N/A
Yan et al.
200864
Cost per mutation
detected
Regardless of FH, the
IHC+methylation testing
strategy had the lowest cost
per mutation detected (from
$653 using AC II to $3600
using L-CRC). MSI had the
highest cost per mutation
detected as it did not inform
gene sequencing (from
$2220 using AC II to
$22,800 using L-CRC). AC II
were the most cost-effective
FH criteria
N/A N/A
Palomaki et al.
200965
Mutations detected
Cost
Universal genetic testing
most effective (4041
mutations detected) but
most expensive ($71,800 per
mutation)
IHC with BRAF as preliminary
tests detected fewest
mutations and had lowest
cost per mutation detected
($12,600)
Incremental cost of detecting
mutations for other strategies
was over $300,000
per mutation
Probabilistic
sensitivity analysis
90% CIs for average cost per
mutation detected
Universal genetic testing
$49,000–101,000
MSI as preliminary test
$20,000–44,000
IHC as preliminary test
$9000–20,000
IHC with BRAF as preliminary
test $8000–18,000
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TABLE 32 Results of cost-effectiveness studies that compared strategies to identify LS
(no management) (continued )
Author and
year
Outcomes
measured Base results
Sensitivity analysis
approach
Main sensitivity analysis
resultsa
Ramsoekh
et al.
200966
Mutations detected
Costs
Cost per mutation
detected
Direct GT most expensive
(€9100 per mutation
detected). TT less expensive
(€3800 per mutation
detected). PMs lower costs,
but fewer mutations
detected
Threshold analysis,
adjusting probability
cut-offs for PMs to
optimise them
Leiden and UK-Ams optimised
at cut-off of < 5%, UK-Alt
and PREMM1,2 at ≥ 5%,
Edinburgh at ≥ 10%
Resnick et al.
200967
Mutations detected
Cost
ICERs
Universal genetic testing
most effective (920
mutations detected) but not
cost-effective (ICER $1.4M
per mutation)
Genetic testing for all aged
< 60 years dominated
AC II strategy detects 83 at
cost of $7M
IHC strategy detects 858
(ICER $13,812 per mutation)
(deemed cost-effective)
Threshold analysis Cost of sequencing three
genes from $2474 to $600 →
age < 60 years, strategy
cost-effective (ICER $12,318
per mutation)
Age cut-off 50 years → no
longer dominated (ICER
$16,931 per mutation)
Horwitz et al.
201068
Mutations detected
Costs
Average cost per mutation
detected $8492
N/A N/A
Gudgeon et al.
201169
Mutations detected
Costs
Cost per case
detected
Sensitivity of
screening protocol
IHC with methylation with
BRAF cheapest ($10,369 per
case detected), second-to-last
sensitivity (91.26%
compared with IHC with
methylation 91.25%)
IHC straight to GT had
highest sensitivity (92.90%)
Univariate
sensitivity analyses
Most sensitive to prevalence
of LS, sensitivity and specificity
of IHC
Perez-Carbonell
et al. 201170
Mutations detected
Cost
Both strategies identified 11
germline mutations; universal
IHC identified more that
were ‘probably LS’
Universal IHC cost €43,114
per mutation detected
Revised Bethesda followed by
IHC cost €16,109 per
mutation detected
N/A N/A
Williams et al.
201171
Cases detected
Costs
Cost per case
detected
Cases missed
Cost per LS case detected
(age limit): $10,684 (no age
cut-off); $9673 (age 80 years);
$7952 (age 70 years);
$5656 (age 60 years);
$3353 (age 50 years)
Percentage of LS cases missed
increased as age limit
lowered. At age 50 years,
54.5% cases missed
N/A N/A
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In addition to the different individual tests, each of the studies evaluated a different combination and
sequence of tests. In general, these combinations fell into the pattern of clinical criteria/FH/prediction
model followed by tumour testing followed by genetic testing, though in some strategies certain steps in
this sequence included multiple tests or were missed out entirely. Most studies included at least one
strategy that did not include FH. Our assessment attempted to cover all plausible, well-recognised
strategies and therefore included strategies similar to those presented in some of these studies.
As well as the testing strategies, we were interested in the acceptance of genetic testing and genetic
counselling. Ten of the studies from this section59,61–69 mentioned appropriate informed genetic counselling
(two were unclear71,72), but only four61,65,68,69 explicitly modelled the acceptance associated with it or
genetic testing. This indicated that this was an area where our model could provide added value.
With regards to the study design, nine papers34,60–64,66,68,70 included primary research (prospective or clinical)
and 1234,59–63,65–67,69,71,72 included some form of decision modelling, usually using a decision tree approach.
Six papers34,60–63,66 used a combination, using the study to inform the decision tree results. In every study,
the costs and numbers of people with mutations detected were reported, and therefore the cost per
mutation detected and the related incremental cost-effectiveness ratios (ICERs) could be calculated if they
were not reported. In general, genetic testing alone had larger ICERs than strategies with other forms of
testing included, and was stated to be more cost-effective, but as these ICERs are based on cost per case
detected and not on life-years or QALYs of patients, this is not a measure of cost-effectiveness that has
any meaning within our TA framework. For the other tests, there were mixed results for which were most
effective, but, in general, when tumour-based tests were tested against FH or clinical criteria (CC) they
were found to have lower ICERs compared with no testing. Given that the measure of cost-effectiveness
has little meaning to our decision process – and that there are several different tests within the subgroups
tumour-based tests, FH and CC – the results do not indicate which individual test is the most
cost-effective.
Of the 12 studies34,59–63,65–67,69,71,72 that included models, seven59,62,65–67,69,72 conducted a sensitivity analysis
(four univariate sensitivity analyses,59,62,69,72 one probabilistic sensitivity analysis,65 two threshold
analyses66,67). The only consistent results from these sensitivity analyses were that the most influential
parameters were the prevalence of LS and cost of testing for LS.
TABLE 32 Results of cost-effectiveness studies that compared strategies to identify LS
(no management) (continued )
Author and
year
Outcomes
measured Base results
Sensitivity analysis
approach
Main sensitivity analysis
resultsa
Gausachs
et al. 201272
Cases detected
Costs
Cost per case
detected
Incremental cost per
case detected
Strategy 1 dominated by
strategy 2
ICER for strategy 3 vs.
strategy 2 was €27,220 per
additional case detected for
probands and €7991 per
additional case detected for
FDRs/SDRs
Univariate
sensitivity analysis
All results most sensitive to
mutation prevalence and unit
cost of GT
B, Bethesda (original Bethesda guidelines); B1–3, Bethesda criteria 1–3; CC, clinical criteria; GT, genetic testing; ICER,
incremental cost-effectiveness ratio; IHC2, immunohistochemical analysis of MLH1 and MSH2; L-CRC, late-onset CRC
(age > 50 years); MA, modified Amsterdam; MSI1, microsatellite instability analysis of single marker (BAT26); N/A, not
applicable; PCD, pedigree/clinical data; PM, prediction model; PREMM1,2, prediction of mutations in MLH1 and MSH2;
SDR, second-degree relative; TT, tumour testing; UK-Alt, UK-Alternative; UK-Ams, UK-Amsterdam Plus.
a Variables that had a significant effect.
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Lynch syndrome management-only studies
This group of studies, which only assessed the long-term cost-effectiveness of management strategies for
LS, was the smallest subgroup of studies identified by our systematic review. The earliest study was
published in May 199873 and the most recent in May 2011.76 Details of these studies can be found in
Tables 33 and 34. There were four included studies,73–76 three from a health-care provider perspective73,74,76
(one of which claimed to be societal) and one from a societal perspective.75 Again there was a range of
settings: two US,75,76 two European.73,74 As with the diagnostic studies, there was one study based in the
UK,74 which assessed the cost-effectiveness of biennial colonoscopic surveillance in families meeting the AC
or with confirmed MMR gene mutations. This was also the only study with a mixed-sex cohort and was
therefore more relevant to our assessment. However, it only considered colonoscopic surveillance, and
therefore CRC, as long-term concerns for LS patients. Of the other three studies, two investigated the
cost-effectiveness of gynaecological surveillance and prophylactic gynaecologic surgery on an all-female
cohort aged 30 years,75,76 and one investigated the cost-effectiveness of colonoscopic surveillance (annually
or 2.5-yearly) for an all-male cohort aged 25 years.73 All populations were assumed to be asymptomatic at
the start of each model.
TABLE 33 Characteristics of cost-effectiveness studies that compared strategies to manage LS (no diagnosis)
Author and
year Setting, perspective Population Study purpose Study approach Treatment strategies
Vasen et al.
199873
Western population
(data from the
Netherlands),
international
health-care systems
Male LS
carriers aged
25 years
Cost-effectiveness
analysis of
colonoscopic
surveillance
Decision tree Colonoscopy every
2.5 years
Annual colonoscopy
No surveillance
Dunlop
et al. 200274
UK hospital Families
meeting AC or
with MMR
gene
mutations
Cost-effectiveness
analysis of
colonoscopic
surveillance
Decision tree
(implicit)
Biennial colonoscopy
from age 25 to
75 years
Kwon et al.
200875
USA, societal LS women
aged 30 years
without
gynaecological
cancer
Cost–utility analysis of
surveillance and PS for
gynaecological cancers
Markov cohort
model
Markov
microsimulation
No prevention
PS at age 30 years
PS at age 40 years
Annual screening from
age 30 years
Combined (annual
screening from age
30 years and PS at
40 years)
Yang et al.
201176
USA, societal stated
(health-care
system assumed)
Women with
LS aged
30 years
Cost–utility analysis of
gynaecological
surveillance vs. PS
Decision model
using TreeAge
Annual gynaecological
examination (with
possibility of TAHBSO)
Annual gynaecological
surveillance including
TVU, endometrial
biopsy and serum
CA125 testing (with
possibility of TAHBSO)
No surveillance,
prophylactic TAHBSO
at age 30 years
PS, prophylactic surgery; TVU, transvaginal ultrasound.
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TABLE 34 Results of cost-effectiveness studies that compared strategies to manage LS (no diagnosis)
Author and
year
Outcomes
measured
Discount
rate Base results
Sensitivity analysis
approach
Main sensitivity
analysis resultsa
Vasen et al.
199873
Life expectancy
Costs
Number of
colonoscopies and
polypectomies
5% costs Both surveillance
arms dominate no
surveillance
Annual surveillance
vs. 2.5-yearly
surveillance has an
ICER of $39 per LYG
Univariate sensitivity
analysis
Cost-effectiveness of
2.5-yearly surveillance
increased as CRC risk
during surveillance
decreased
Reducing the proportion
of early CRC diagnosed
during surveillance
reduced LE and increased
costs for surveillance,
but surveillance still
dominated no
surveillance
Dunlop et al.
200274
Lives saved
Costs
Not
discounted
Cost per life
saved £14,925
N/A N/A
Kwon et al.
200875
QALYs
Costs
ICERs
3% Combined strategy
most effective
(18.9766 QALYs per
patient) but not
cost-effective (ICER
$194,650/QALY)
PS at age 40 years
cost-effective
(18.9430 QALYs at
$11,477/QALY
relative to no
prevention)
PS at age 30 years
extended dominated
by no prevention and
PS at 40 years
Annual screening
dominated by
all interventions
Univariate sensitivity
analysis
Threshold analysis
Univariate sensitivity
analysis
Combined strategy
remains not cost-effective
as surveillance start age
varied from 30 years to
35 years
Threshold analysis
Age of PS in combined
strategy> 42 years→ PS
at age 40 years most
effective
Utility of PS< 0.88 → PS
at age 40 years
dominates PS at 30 years
Yang et al.
201176
QALYs
Costs
Cost per QALY
3% For average cost per
QALY, PS strategy
was most
cost-effective at $904
per QALY. The next
most cost-effective
was annual
gynaecological
surveillance at $2718
per QALY; annual
examination strategy
was $4085 per QALY
Threshold analysis
Univariate and
multivariate
sensitivity analysis
Threshold analysis
When prophylactic
surgery cost less than
$90,000 per patient,
it was always most
cost-effective
Univariate sensitivity
analysis
Model most sensitive to
cost and surgical
mortality of PS, but at
WTP of $50,000 PS still
an optimal strategy
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The modelling approach in these studies varied: both studies investigating colonoscopic surveillance used
decision tree modelling;73,74 Kwon and colleagues’ study75 on gynaecological surveillance/prophylactic
surgery used a Markov cohort model and Markov microsimulation approach; and Yang and colleagues’
similar study76 used a decision model built in TreeAge.
All studies reported costs, but they reported different measures of effectiveness. Both studies investigating
gynaecological management reported QALYs,75,76 Vasen and colleagues73 reported life expectancy and
Dunlop and colleagues74 reported lives saved. Generally in these studies, the authors concluded that
any management strategies could be cost-effective. For EC, prophylactic surgery was seen as more
cost-effective than gynaecological surveillance, even under sensitivity analysis. For preventing CRC,
colonoscopic surveillance dominated no surveillance in the Vasen and colleagues study,73 even under
sensitivity analysis, and the cost per life saved in the Dunlop and colleagues study74 was £14,925, which
they concluded was a ‘favourable’ result.
Studies that incorporated both diagnosis and management of Lynch syndrome
This subgroup contained 13 studies22,23,48–58,88 focused on the cost-effectiveness of strategies to first
identify and then manage LS, published over a period of 18 years (1995–2012). Six of these were
published between 2010 and February 2013. As Ladabaum and colleagues (2011)48 and Wang and
colleagues (2012)57 were based on the same model, they are discussed as the same study in this section of
the review.
Details of all these studies can be found in Tables 35 and 36.
TABLE 34 Results of cost-effectiveness studies that compared strategies to manage LS (no diagnosis) (continued )
Author and
year
Outcomes
measured
Discount
rate Base results
Sensitivity analysis
approach
Main sensitivity
analysis resultsa
Multivariate
sensitivity analysis
Monte Carlo simulation
showed PS dominant in
99.97% of trials. At a
WTP of $50,000 per
QALY, surgery was
cost-effective compared
with surveillance in
100% of trials and
surveillance was
cost-effective compared
with examination in
99.98% of trials
LE, life expectancy; LYG, life-year gained; N/A, not applicable; PS, prophylactic surgery; WTP, willingness to pay.
a Variables that had a significant effect.
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Methods As with the previous two groups of studies, the majority of these studies were from a health
sector perspective. There was also one which was conducted from a government perspective51 and one
from a third-party payer perspective.48,57 The majority of studies were set in the USA, with one from
Singapore,58 one from Australia,51 two from Denmark52,53 and one from the Netherlands.50 No UK studies
were reported. The most common input population in the studies, occurring in five separate studies, was
newly diagnosed CRC patients and their relatives.23,48,49,50,54,57 These studies were particularly relevant to
our assessment as our input population lay within this group of patients. Other input populations included
healthy, unaffected members of the general population;22,55,88 FDRs of known LS mutation carriers;51,58
families referred to a genetics registry;52,53 and, in one study, newly diagnosed EC patients.56
Similar to the diagnostic-only studies, the majority of the diagnostic strategies in these studies included
some form of CC/FH, tumour testing and genetic testing. Steps such as FH were sometimes missed out
entirely, or strategies included several tests. CC/FH included the Bethesda and Revised Bethesda guidelines
and AC I/II (and selected criteria from either guideline), as well as prediction models such as PREMM
(prediction of mismatch repair gene mutations), MMRPro and MMRpredict. These prediction models were
algorithms that used specified patient history, CC and FH to determine the likelihood of LS for a patient.
Tumour testing in these studies included MSI, IHC, BRAF and methylation. The level of testing was not
always the same; MSI was conducted on different numbers of markers in different studies, and sometimes
IHC was conducted only for specific MMR proteins rather than all four. Genetic testing was divided into
sequencing tests for probands and predictive tests for their relatives. Each of the studies used a different
set and combination of these tests, making it difficult to decide which strategies were most
commonly used.
Across the studies, the management strategies for CRC were fairly consistent. Colonoscopy every
1–2 years from age 25 years, with more aggressive colorectal surgery on diagnosis of CRC to prevent
further CRCs, was the management strategy for patients diagnosed with LS in the majority of studies.
This was consistent with the current published guidance identified by our systematic review. For the
studies that considered EC, the management strategies included gynaecological surveillance/screening
with prophylactic TAHBSO at an appropriate age and were once again fairly consistent across the studies.
The design of these studies was predominantly decision modelling with a mix of decision trees, Markov
cohort modelling and a variety of ad hoc modelling.
As knowledge about LS has altered over recent years, we thought it prudent to assess how up to date the
various studies were with regards to this knowledge. One parameter we thought particularly influential to
the cost-effectiveness analysis was the risk of CRC in LS patients, as a lower estimate of CRC risk was likely
to make strategies for diagnosing and managing LS less cost-effective. We summarise the values (and
sources) for this parameter used in the studies in Table 37. There was a divide between those studies that
were more than 5 years old, where lifetime CRC risk in LS patients was generally around 80%, and the
more recent studies, in which lifetime CRC risk for LS patients was reported to be closer to 40–50%. This
divide also provided us with information on which studies’ results were more likely to be comparable with
ours; only 6 of the 13 studies48,54–58 used a lower (40–50%) estimate of CRC risk. The risk of CRC is also
known to be different in males and females, which was only modelled explicitly in two of the studies.48,55
These were also the only two studies to consider more than CRC in the long term, suggesting that this
was an area where further modelling could add value.
Modelling of imperfect adherence to testing and management of LS appears to occur in over half of the
studies; however, it is not always clear what patients are exactly complying with. In the genetic testing
process, there is adherence to both genetic counselling and genetic testing. Some studies were explicit
about the two separate sections; some appeared to treat this as one adherence issue; and some did not
state it at all. Adherence to colonoscopic surveillance was included in a much clearer manner and was
modelled in most studies, so that those who complied initially with surveillance continued to do so.
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TABLE 37 Colorectal cancer risk parameter included in cost-effectiveness studies
Author and year CRC risk and source
Diagnosis and management
Brown et al. 199622 Not stated
Ramsey et al. 200123 Not explicitly stated, but:
l Sporadic CRC ages and stages (SEER 200089)
l LS CRC ages and stages (Patrice Watson, Creighton International HNPCC Registry,
11 April 2001, personal communication)
Ramsey et al. 200349 Above holds, and:
l Proband probability of second CRC, 95% (Ponz de Leon 1996,90 Lynch and Smyrk 1999,91
Vasen et al. 199392)
l FDR probability of first CRC, 80% (Boland 199893)
Kievit et al. 200550 CRC risk in LS patients with/without surveillance not stated (Jarvinen et al. 200094)
Sporadic CRC risk also not stated
Breheny et al. 200651 Age-related population risk of CRC in 2000 (Australian Institute of Health and Welfare 200395)
Age-specific LS CRC risk based on 72% penetrance by age 50 years and 80% by age 75 years
(Renkonen-Sinisalo et al. 2000,96 Green et al. 200297)
DACEHTA 200752
(summary)
The risk of metachronous CRC is four times greater for CRC patients with LS than those with
sporadic CRC
Lifetime risk of CRC for FDRs of patients with LS mutation confirmed, 80%; for FDRs of
patients with LS mutation unknown (pedigree-based assumption), 40% (no sources stated)
Olsen et al. 200753 Lifetime risk of CRC for LS carriers: low risk, 3.3%; moderate risk, 10.8%; high risk (unknown
mutation), 46%; high risk (known mutation), 80–90% (Jarvinen et al. 1995,16 Statens Institut
for Medicinsk Teknologivurdering 200198)
Mvundura et al. 201054 Risk of developing CRC for LS carriers, 40%
Risk of second CRC diagnosis for LS carriers, 16% (Palomaki et al. 200965)
Dinh et al. 201155 Lifetime risk for female carriers of MLH1 or MSH2 mutations: almost 50%; separate risks for
males and females and for carriers of MSH6 mutations and PMS2 mutations (meta-analysis
of results from Hendriks et al. 2004,99 Buttin et al. 2004,100 Dunlop et al. 1997,101
Quehenberger et al. 2005,102 Hampel et al. 2005,103 Wagner et al. 2001,104 Senter et al. 2008,105
Barrow et al. 2008,81 Stoffel et al. 2009106)
Kwon et al. 201156 LS, surveillance,a 15% (Syngal et al. 1998,83 Vasen et al. 1998,73 Jarvinen et al. 2009,107
Jarvinen et al. 2000,94 Vasen et al. 2010108)
LS, no surveillance, 40% (Jarvinen et al. 2000,94 de Jong et al. 2006109)
Sporadic surveillance,a 3% (Cotterchio et al. 2005,110 Boursi et al. 2009,111 Rundle et al.
2008112)
Sporadic, no surveillance, 5% (National Cancer Institute/SEER 2010113)
Ladabaum et al. 201148 CRC risk by age 70 years:
l Average risk: women, 2.5%; men, 3.0%
l LS: women, 46%; men, 54%
Wang G et al. 201257 See Ladabaum et al. 201148
Wang VW et al. 201258 Lifetime CRC risk for LS carriers, 43% (Jenkins et al. 2006,114 Altekruse et al. 2010115)
Sporadic CRC risk taken from SEER (Altekruse et al. 2010115)
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Results The majority of studies reported life-years and costs (and the respective ICERs) as their main
outcomes. Two studies, the update to Ladabaum and colleagues (2011)57 and Dinh and colleagues
(2011),55 reported QALYs rather than life-years and one study51 reported CRC-free years as the main
outcome. Mvundura and colleagues (2010)54 reported QALYs as a scenario analysis, scaling their ICERs by
1.18 life-years per QALY, which is an approach that demands that a number of assumptions be made.
One early study22 reported the short-term outcome of cost per mutation identified, as well as the
long-term cost per life-year saved. A range of discount rates were used in the long-term calculations,
generally ranging from 3–5% per year for both costs and benefits.
In general, the studies concluded that strategies that screened for LS were cost-effective compared with no
screening, with all finding at least one strategy that fell below a pre-specified threshold. However, given
the different strategies and costs for each country, there was little consistency over which strategies or
individual tests were the most cost-effective. In two studies,48,54 IHC with BRAF appeared to be the most
cost-effective strategy. In all studies where strategies with additional tests were included, universal genetic
testing was not cost-effective.48,49,54,56,57
The minimum uncertainty analysis performed by these studies was a univariate sensitivity analysis. Most
studies looked at a large number of parameters in their univariate analysis, but only reported those that
were most influential on the cost-effectiveness results, which made comparison between them difficult.
Influential parameters that were identified by more than one study included age of population, number of
relatives, cost of testing, effectiveness of the diagnostic and management strategies, and prevalence of LS
in the population.
Quality appraisal of cost-effectiveness studies
Though the studies were assessed using all of the criteria from the Drummond checklist,47 specific criteria
are reported in Table 38.
One consistent problem in terms of the quality of the studies was that the reporting of perspective was
poorly done, with 25 studies not stating and justifying their perspective.22,23,34,49,50,52,53,55–60,62–66,68–73,76 This
included three studies55,64,66 not stating a perspective, two70,72 not stating a setting and two23,76 incorrectly
stating a health-care perspective as societal.
The depth of detail related to modelling (when it was reported) was mixed and ranged from brief
descriptions to full details. Sensitivity analysis was conducted in seven of the diagnostic papers,59,62,65–67,69,72
three of the management papers73,75,76 and all of the diagnostic-plus-management papers.22,23,48–58
Justification for ranges used in sensitivity analyses was poorly given, if at all. Reporting of sources was
generally well done, as was the reporting of sources and methods of estimation for unit costs
and quantities.
TABLE 37 Colorectal cancer risk parameter included in cost-effectiveness studies (continued )
Author and year CRC risk and source
Management only
Vasen et al. 199873 CRC risk for LS carriers by age 75 years (for men), 80–85% (Vasen et al. 1996116)
Dunlop 200274 Lifetime CRC risk for LS carriers diagnosed by FH, 80% (Vasen et al. 1995,117 Aarnio et al.
199515); diagnosed systematic analyses, 74% men, 30% women (Dunlop et al. 1997101)
Kwon et al. 200875 Lifetime CRC risk for LS carriers, 42% (Aarnio et al. 1999,118 Dunlop et al. 1997101)
Yang et al. 201176 N/A
DACEHTA, Danish Centre for Evaluation and Health Technology Assessment; N/A, not applicable; SEER, Surveillance,
Epidemiology, and End Results.
a Surveillance appropriate for diagnosis.
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TABLE 38 Selected quality appraisal criteria from the Drummond checklist
Author
and year
The
viewpoint(s)
of the analysis
are clearly
stated and
justified
The
source(s) of
effectiveness
estimates
are stated
Methods for
the estimation
of quantities
and unit costs
are described
Currency
and price
date are
recorded
Details
of any
models
used are
given
Time
horizon
of costs
and
benefits
is stated
The ranges
over which
the variables
are varied
are justified
Diagnosis and management
Brown et al.
199622
✗ ✓ ✓ ✓ ✗ ✓ ✗
Ramsey et al.
200123
✗ ✓ ✓ ✓ ✓ ✓ ✓
Ramsey et al.
200349
✗ ✓ ✓ ✓ ✗ ✓ ✓
Kievit et al.
200550
✗ ✓ ✓ ✓ ✓ ✓ ✓
Breheny et al.
200651
✓ ✓ ✓ ✓ ✓ ✓ ✗
DACEHTA
200752
✗ ✗ ✗ ✗ ✗ ✓ ✗
Olsen et al.
200753
✗ ✓ ✓ ✓ ✓ ✗ ✓
Mvundura et al.
201054
✓ ✓ ✓ ✓ ✓ ✓ ✓
Dinh et al.
201155
✗ ✓ ✓ ✓ ✓ ✗ ✗
Kwon et al.
201156
✗ ✓ ✓ ✓ ✓ ✓ ✗
Ladabaum et al.
201148
✓ ✓ ✓ ✓ ✓ ✓ ✓
Wang G et al.
201257
✗ ✓ ✓ ✓ ✓ ✓ ✓
Wang VW et al.
201258
✗ ✓ ✓ ✓ ✓ ✓ ✓
Diagnosis only
Debniak et al.
200034
✗ ✓ ✗ ✗ ✗ N/A
Reyes et al.
200259
✗ ✓ ✓ ✓ ✓ ✓
Pigatto et al.
200460
✗ ✓ ✓ ✗ ✗ N/A
Pinol et al.
200561
✓ ✓ ✓ ✗ ✗ N/A
Engel et al.
200662
✗ ✓ ✓ ✗ ✓ ✓ ✓
Bessa et al.
200863
✗ ✓ ✓ ✗ ✗ N/A
Yan et al.
200864
✗ ✓ ✓ ✗ N/A N/A
ASSESSMENT OF COST-EFFECTIVENESS: SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
TABLE 38 Selected quality appraisal criteria from the Drummond checklist (continued )
Author
and year
The
viewpoint(s)
of the analysis
are clearly
stated and
justified
The
source(s) of
effectiveness
estimates
are stated
Methods for
the estimation
of quantities
and unit costs
are described
Currency
and price
date are
recorded
Details
of any
models
used are
given
Time
horizon
of costs
and
benefits
is stated
The ranges
over which
the variables
are varied
are justified
Palomaki et al.
200965
✗ ✓ ✓ ✗ ✗ ✗
Ramsoekh et al.
200966
✗ ✓ ✓ ✗ ✗ ✗
Resnick et al.
200967
✓ ✓ ✓ ✓ ✓ ✗
Horwitz et al.
201068
✗ ✓ ✗ ✗ N/A N/A
Gudgeon et al.
201169
✗ ✓ ✓ ✓ ✓ ✓
Perez-Carbonell
et al. 201170
✗ ✓ ✗ ✗ N/A N/A
Williams et al.
201171
✗ ✓ ✓ ✗ ✗ N/A
Gausachs et al.
201272
✗ ✓ ✓ ✗ ✓ ✓
Management only
Vasen et al.
199873
✗ ✓ ✓ ✓ ✓ ✓ ✗
Dunlop et al.
200274
✓ ✓ ✓ ✓ ✓ ✗ ✗
Kwon et al.
200875
✓ ✓ ✓ ✓ ✓ ✓ ✗
Yang et al.
201176
✗ ✓ ✓ ✓ ✓ ✓ ✓
DACEHTA, Danish Centre for Evaluation and Health Technology Assessment; N/A, not applicable.
Criteria reproduced from BMJ, Drummond MF, Jefferson TO, Volume 313, pp. 275–83, 1996 with permission from BMJ
Publishing Group Ltd.
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Of the three groups of studies (diagnostic, management and diagnostic plus management), diagnostic
studies seem to be the least well reported; as well as only two61,67 clearly stating and justifying their
setting and viewpoint, only three59,67,69 reported a currency and/or price date and only 5 of the
12 models59,62,67,69,72 gave details of the modelling.
As one of our included papers was only a summary,52 it did poorly in the quality assessment. The
accompanying full report was in Danish and could not be quality assessed as it was not included in our report.
The small number of management-only papers made it difficult to draw overall conclusions about their
quality, but again it appeared to be mixed, with similar problems to the other two groups of studies.
Conclusions
Despite the large number of studies identified by this review, there was still the need for a new model to
be developed to address our decision problem.
Firstly, the majority of studies identified by this review addressed either diagnosis or management of LS
only, and were further divided by their disease focus (predominantly CRC or EC). Therefore, each of these
studies could only attempt to answer part of our study question.
The remaining studies that looked at both diagnosis and management were hindered by the
advancements in understanding of LS, and populations and country settings not relevant to our analysis.
On the basis of population and the parameter used for CRC risk, the studies could therefore be narrowed
down to two that would be directly comparable with our model: Ladabaum and colleagues (2011)48
[plus Wang and colleagues (2012)57] and Mvundura and colleagues (2010).54 Neither of these were
UK-based studies and therefore the results could not necessarily be translated to the NHS.
The wide range of diagnostic strategies across all the studies did not make it clear which tests or
combinations thereof would be most cost-effective, particularly in a NHS setting. This therefore justified
further modelling.
There had also been little investigation into the modelling of more than one cancer in the long term; in
those studies that did investigate more than one cancer, the methods were not clear in terms of whether
or not the modelling of interactions between them was actually appropriate. Additionally, adherence to
genetic counselling was also something rarely touched upon in detail in the studies. Both of these
concerns provided other areas where our model could add value to those that had come before.
Our review agreed with the conclusions of those reviews that had been conducted previously, and this
supported our justification for conducting further research into this area.
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Chapter 5 Assessment of cost-effectiveness:
description of the economic model
Summary of the Peninsula Technology Assessment Group
cost-effectiveness analysis
Our model of the cost-effectiveness of systematic screening for LS is comprised of two distinct
components: a decision tree model of the short-term outcomes of diagnosis of probands and relatives, and
an individual patient simulation model to assess the survival of these patients (the ‘survival’ or ‘long-term
outcomes’ model).
The cost-effectiveness of the testing strategies is calculated by comparing the total discounted costs and
QALYs across strategies. In keeping with the National Institute for Health and Care Excellence (NICE) reference
case, the economic perspective is NHS and PSS, and costs and benefits are discounted at 3.5% per annum.
Costs of interventions were estimated from Department of Health reference costs 2011–12 with inflation
to 2013–14 prices or, where this was not possible, from published literature with appropriate conversion
and inflation.
Parameters of the natural histories of diseases, the effectiveness of interventions and the impact on quality
of life of diseases and interventions were sourced, where possible, from national statistics and published
literature (where such parameters were not available, expert opinion and grey data were used).
For each testing strategy, the total discounted cost is calculated as the total cost of testing plus the total
discounted cost of treatment after testing. For each testing strategy, the total discounted QALYs are
calculated for the patients after testing.
Diagnostic model
The diagnosis of LS is performed for probands with newly diagnosed CRC and their relatives. It is assumed
that all diagnosis occurs at time zero.
We consider the following strategies to identify LS in probands:
1. No genetic testing, subdivided:
1(1) no testing
1(2) AC only.
2. IHC four-panel test for MLH1, MSH2, MSH6 and PMS2, followed by genetic testing if IHC
result abnormal.
3. IHC four-panel test, followed by BRAF testing for abnormal MLH1 results. Genetic testing is done for
any other (not MLH1) abnormal IHC result or for a negative BRAF test (negative for V600E).
4. MSI testing, followed by genetic testing for MSI result.
5. MSI testing, followed by BRAF testing for MSI result, followed by genetic testing for negative BRAF test.
6. MSI testing, followed by BRAF testing for MSI result, followed by IHC testing for negative BRAF test.
Genetic testing occurs regardless of IHC result.
7. IHC testing, followed by genetic testing if result abnormal. For normal IHC results: MSI testing, followed
by BRAF testing for MSI result followed by genetic testing for negative BRAF test.
8. Universal genetic testing.
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There are three possible diagnoses that result from each of these testing strategies: LS mutation positive,
LS assumed and LS negative. LS mutation positive occurs when a proband receives a positive genetic test
result and LS negative occurs when a proband is ruled out by one of the tests prior to genetic testing, or
by FH when genetic testing is either declined or uninformative. ‘LS assumed’ can occur when genetic
testing is either uninformative or simply not done (the proband declines testing) and is informed by the
proband’s FH. Probands who test mutation positive or LS assumed are offered LS management. It is
assumed that only a proportion of probands diagnosed as LS positive or LS assumed accept an offer
of LS surveillance.
The diagnosis of LS in relatives of a newly diagnosed CRC proband directly depends on the diagnosis
of the proband. Relatives of probands who test mutation positive can be identified as LS positive with a
predictive genetic test. FDRs of probands diagnosed as LS assumed cannot be tested, but instead are also
assumed to have LS and are offered LS management. Relatives of a higher degree are assumed to be LS
negative, as are relatives of probands diagnosed LS negative.
The main outcomes for each testing strategy are:
l the overall sensitivity and specificity for probands alone
l the overall sensitivity and specificity for probands and relatives combined
l the numbers of probands and relatives according to true LS status, diagnosis and
management strategy.
The accuracy of individual tests, given by sensitivity and specificity, with regard to either LS in general or to
particular genes, were taken from published literature, particularly the Evaluation of Genomic Applications
in Practice and Prevention (EGAPP) Working Group Review.65 Owing to a lack of evidence, the sensitivities
and specificities of individual tests are treated as independent of tests performed previously, except for the
BRAF test. In common with other cost-effectiveness models [Mvundura and colleagues (2010)54 and
Ladabaum and colleagues (2011)48], we assume that the test accuracies apply to all qualities of tumour/
blood sample and that tests are always available and successfully produce a result. The only known
exception to this is the IHC test, where the failure rate is specifically included in the sensitivity.
There is little published evidence on the rate of acceptance of testing. The following assumptions were
made: that the rate of acceptance of a test was independent of any previous tests, and acceptance of one
genetic test implied acceptance of all genetic testing. The rate of acceptance of IHC and BRAF was
assumed to be the same as for MSI, which was the only tumour-based test for which an estimate was
available. The rate of acceptance of genetic counselling allowed for the rate of acceptance of FH
screening. For patients who decline genetic counselling and for strategies where genetic testing is not
offered, rate of acceptance of FH is estimated separately.
The number of probands aged < 50 years per year in England, 1699, was taken from the Office for
National Statistics (ONS).119 Of these, 8.4%120 were assumed to have LS. These probands were then
subdivided into the number with each gene associated with LS.
The number of relatives per proband is set to five in the base case to balance the values from two main
UK sources: Barrow and colleagues121 and unpublished data supplied by Ian Frayling (Cardiff University,
2012). Based on two published studies114,120 and these unpublished data, the proportion of relatives that
are first degree is estimated at 42%. Next, we estimate that the proportion of relatives that test positive
for LS is 44%, based on a random-effects meta-analysis.
The costs of the preliminary tumour tests were obtained either directly from laboratories in the UK or from
experts. Costs for genetic tests (for probands and relatives) are taken directly from genetic testing
laboratories, identified from the UK Genetic Testing Network (UKGTN). As genetic testing becomes
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routine, these costs are expected to decrease. We performed a sensitivity analysis to reflect this. The cost
of genetic counselling was also included.
The psychological impacts of testing for LS and prophylactic TAHBSO were incorporated into overall
health-related quality of life (HRQoL), using data from the literature. All disutilities were assumed to apply
for 4 months.
l A disutility of 0.04 was applied to people declining testing.
l A disutility of 0.02 was applied to people accepting testing and subsequently being diagnosed with LS.
l A disutility was applied to people offered TAHBSO and a further disutility was applied if TAHBSO
was declined.
Survival model
Survival model structure
The survival/management section of the model takes the form of an individual patient simulation
(individual sampling model), in which thousands of hypothetical patients are simulated from the time of LS
diagnosis to death or age 100 years (whichever occurs first).
Patients with LS are assumed to have an increased risk of CRC and EC compared with the general
population. Other cancers associated with LS, such as ovarian cancer (OC), are not modelled.
The patient state at any time is defined by the following properties, which collectively provide all the
information necessary to simulate appropriate treatment pathways and calculate risks of events:
l whether or not the patient is alive
l the patient’s age (at the start of the year)
l the patient’s sex
l previous bowel surgery
l whether or not the patient has CRC, and if so, the Dukes’ stage
l whether or not the patient has had TAHBSO
l whether or not the patient has EC
l the patient’s LS status and diagnosis status
l the patient’s acceptance of LS surveillance if it is offered.
The following clinically important events are simulated:
l mortality events
¢ mortality due to CRC
¢ mortality due to EC for women with LS
¢ mortality due to causes other than CRC or EC (general mortality)
¢ mortality (and morbidity) due to adverse events from surveillance colonoscopies
¢ mortality due to adverse events from prophylactic TAHBSO
l non-mortality events
¢ index (primary) CRC incidence for relatives only (all probands enter model with recently diagnosed
index CRC)
¢ metachronous CRC incidence for probands and relatives
¢ CRC surgery
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¢ EC incidence for women with LS
¢ TAHBSO for women diagnosed with EC
¢ prophylactic TAHBSO for women diagnosed with LS
¢ biennial surveillance colonoscopies for patients diagnosed with LS accepting surveillance
¢ adverse events from surveillance colonoscopies (bleeding and perforation).
The events determine costs incurred and HRQoL for each simulated patient. These are used to estimate the
total discounted costs and QALYs for each testing strategy.
Twenty-four patient groups are simulated in the management section of the model, according to:
l whether proband or relative
l true LS status
l whether or not LS has been diagnosed
l whether or not increased surveillance is accepted as a result of a diagnosis of LS
l whether male or female.
In the base-case analysis, the maximum age of probands is 50 years. In sensitivity analyses, this is increased
to 60 years and separately to 70 years.
Age at entry is a function of sex, true LS status and whether proband or relative. The median age at onset
of CRC was 45 years in male probands and 70–74 years for males in the general population.
Colorectal cancer
The rate of incidence of CRC is dependent on the following patient characteristics:
l age
l sex
l whether or not the patient has had a previous CRC
l time since first CRC
l LS status
l whether or not the patient is receiving LS colonoscopic surveillance
l previous colorectal surgery.
The cumulative risk of CRC to age 70 years is 38% for males with LS and 31% for females with LS,
compared with 2.8% for males without LS and 1.8% for females without LS.
The Dukes’ stage of index and metachronous CRCs was recorded. The site of CRCs (colon or rectum) is
dependent on sex, LS status and any previous surgery. No disutility was assumed for CRC at Dukes’ stages
A–C, but a disutility of 0.13 was assumed for Dukes’ stage D CRC.
People diagnosed with LS are offered 2-yearly colonoscopies. The cost of a colonoscopy was adjusted from
£553 to £395 to allow for the fact that the effectiveness of colonoscopy was taken from a regime of
3-yearly colonoscopy. People with CRC who are not diagnosed with LS are offered 5-yearly colonoscopies.
The regime of colonoscopies for people either tested LS positive or assumed to have LS was assumed to
reduce the incidence of CRC and to improve the stage distribution of incident CRCs.
l A hazard ratio (HR) of 0.387 was applied to the incidence of index (first) CRC given LS surveillance
colonoscopies compared with no surveillance, and a HR of 0.533 was applied to incidence of
metachronous CRC given LS surveillance colonoscopies compared with non-LS surveillance.
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l The CRC stage distribution was improved (69% Dukes’ A, 11% Dukes’ B, 13% Dukes’ C,
8% Dukes’ D) versus individuals not receiving LS surveillance (16% Dukes’ A, 32% Dukes’ B,
27% Dukes’ C, 25% Dukes’ D).
l The initial rate of adherence to enhanced CRC surveillance depends on whether the person is a
proband or relative and whether he or she has tested LS positive or is LS assumed. It is assumed that
patients who initially accept LS surveillance continue to receive biennial colonoscopies, and that
patients initially declining LS surveillance do not take it up subsequently.
l No disutility was assumed for people receiving LS surveillance colonoscopies.
Mortality due to CRC is assumed
l to be higher for more advanced stages of the disease (e.g. Dukes’ D).
l to be higher for older patients
l to depend on time since diagnosis
l to be lower for patients with Dukes’ A or B CRC with LS than for patients without LS. Mortality for
Dukes’ C and D CRC is not altered.
The following surgical treatments for CRC are modelled: segmental resection, subtotal colectomy, anterior
resection and proctocolectomy. The type of surgery depends on the location of the CRC, the nature of
previous surgery and whether or not the patient has been diagnosed with LS. The incidence of CRC was
assumed to reduce according to the type of surgery. In the base-case analysis, no additional disutility
was assumed for surgery that reduces the risk of CRC. Disutilities were assumed in sensitivity analyses.
The costs of the following treatments for CRC were included: primary surgery, chemotherapy and
radiotherapy for primary CRC, follow-up surveillance, stoma care, surgery and chemotherapy for CRC
recurrence and palliative care.
Endometrial cancer
Most published models of the cost-effectiveness of testing for LS consider only CRC, not EC and OC.
In our model, in addition to CRC we also consider EC, but not OC. If OC were included in our model, it is
likely that our estimates of the cost-effectiveness of testing would improve. This is because, though we
already cost for prophylactic TAHBSO surgery, which eliminates the risk not just of EC but also of OC, we
do not model the associated reduction in the risk of OC.
We do not subdivide EC by stage. Surveillance for EC was not modelled as evidence for its effectiveness is
lacking and as it seems unreasonable to include the substantial cost of surveillance with no associated
benefit. The cumulative risk of EC at age 70 years was assumed to be 34% for women with LS and 0%
for women without LS.
All women are assumed to have a TAHBSO on diagnosis of EC, at a cost of £3900. Prophylactic TAHBSO,
at a cost of £3300, is offered to women diagnosed with LS when they reach age 45 years or upon
diagnosis of LS if older, with 55% of women accepting TAHBSO. TAHBSO is assumed to eliminate the risk
of EC completely. As in previous cost-effectiveness analyses, we do not model complications of TAHBSO,
owing to their low incidence. However, we model surgical mortality because it clearly has an impact on
total QALYs.
Mortality from EC was assumed to be dependent on time since diagnosis and independent of LS status.
Costs for chemotherapy and radiotherapy for EC were modelled.
In the base-case analysis, no disutility was assumed for having EC, nor after TAHBSO. Disutilities were
assumed in sensitivity analyses. The cost-effectiveness of genetic testing was found to be very sensitive to
the assumed disutility after prophylactic TAHBSO.
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Uncertainty
Cost-effectiveness analyses often employ probabilistic sensitivity analysis, whereby uncertainty in many of
the parameters is simultaneously considered. We did not use probabilistic sensitivity analysis. Instead, we
investigated uncertainty as follows. First, we performed the following scenario analyses.
l EC and prophylactic TAHBSO were excluded to assess their impact on the cost-effectiveness results.
l The maximum age of probands was increased from the base case of 50 years to 60 years, and
separately to 70 years.
l BRAF testing, which was assumed in some testing strategies in the base case, was replaced by
methylation testing.
Second, the sensitivity of cost-effectiveness to individual parameters was assessed either by doubling and
halving the parameter value (e.g. the cost of all genetic tests), or by selecting a different plausible data
source (e.g. for the disutilities due to CRC).
Model structure
To model the impact of systematically screening for LS, we created a model with two distinct sections: a
decision tree model to investigate the short-term outcomes of strategies to identify LS patients, and an
individual patient simulation model to assess the long-term implications of strategies to identify and
manage LS. These are discussed in detail in the following sections.
Diagnostic testing model
Here, we consider two groups: the newly diagnosed CRC patients aged under 50 years (the probands),
and their biological relatives. These groups are connected, as shown in Figure 3. This section of the model
was built as a decision tree and has no time component. It therefore assumes that diagnosis occurs
instantaneously, though the diagnosis of LS may actually take up to several months or even years;
laboratories report waiting times of around 20 working days for tumour-based tests, 40 working days for
gene sequencing for probands and 10–20 working days for predictive genetic testing for relatives.122–126
This also does not account for the time taken to collect a tissue/blood sample, transport the sample
and arrange counselling sessions, nor when in a proband’s treatment this process is begun. According to
our clinical experts (Carole Brewer and Ian Daniels, Royal Devon and Exeter NHS Trust), it is also not
standard practice to have LS results available before the proband’s treatment is given. Therefore, to
emulate standard practice, where the proband’s LS status is not yet known, we assume that he or she
receives standard treatment for CRC. In most cases this is surgical resection with the possibility of
chemotherapy or radiotherapy, depending on the stage of the cancer.
Diagnostic strategies for probands
Probands follow one of nine diagnostic strategies, chosen on the basis of available tests, existent
cost-effectiveness models, expert advice and requirements of the project scope. As the only conclusive
test for LS is constitutional (‘germline’) genetic testing, this is used in every testing strategy. We use three
well-documented preliminary tumour-based tests: IHC, MSI and BRAF. There is little consistency in the
literature about the usage of these tests, either in sequence or individually, so we include a variety of
testing strategies. Although FH, for example assessed by the AC, is no longer recommended as a selection
tool for the diagnosis of LS, we include it as one of the testing strategies for comparison with the genetic
testing strategies.13 We compare the following eight strategies:
1. No systematic testing to identify LS
i. No testing to identify LS
ii. AC
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2. IHC four-panel test for MLH1, MSH2, MSH6 and PMS2, followed by genetic testing if IHC
result abnormal.54
3. IHC four-panel test, followed by BRAF testing for abnormal MLH1 results. Genetic testing is done for
any other (not MLH1) abnormal IHC result or for a negative BRAF test (negative for V600E).54
4. MSI testing followed by genetic testing for MSI result.54
5. MSI testing, followed by BRAF testing for MSI result, followed by genetic testing for negative BRAF test
(advised by Ian Frayling).
6. MSI testing, followed by BRAF testing for MSI result, followed by IHC testing for negative BRAF test.
Genetic testing occurs regardless of IHC result (advised by Ian Frayling).
7. IHC testing, followed by genetic testing if result abnormal. For normal IHC results: MSI testing, followed
by BRAF testing for MSI result followed by genetic testing for negative BRAF test (advised by
Ian Frayling).
8. Universal genetic testing (i.e. as first and only test for all) (asked for in the project scope).
Figures 4–11 show further details of these eight strategies.
There are three possible diagnoses given by these testing strategies: LS mutation positive, LS assumed and
LS negative. LS mutation positive occurs when a proband receives a positive genetic test result and LS
negative occurs when a proband is ruled out by one of the tests prior to genetic testing, or by FH when
genetic testing is either declined or uninformative.
‘LS assumed’ can occur when genetic testing is either uninformative or simply not done (the proband
declines testing). For example, we assume that a negative genetic test result is uninformative for probands,
meaning that although the test did not detect LS, it does not rule it out. This is because there is still debate
over which genes and mutations cause LS, some of which will not be identified by current genetic tests.
Our experts agree that this is a plausible interpretation as current practice does not necessarily rule out LS
on the basis of a genetic test, especially with regard to LS management strategies. The outcome allows us
to reflect clinical practice, whereby management strategies are offered to both LS mutation-positive and
LS-assumed probands (regular surveillance) and with regard to strategies identifying LS in relatives of both
probands diagnosed as LS mutation positive and LS assumed. In practice, the decision to diagnose a
proband as LS assumed is informed by FH and we model it similarly. As our probands already fulfil the
Revised Bethesda guidelines, we model this based on the AC II. We also use this approach to decide how
many of the probands who tested negative for mutations in MLH1, MSH2 and MSH6 should be put
forward for PMS2 testing. We do this to reflect the smaller number of PMS2 tests carried out in current
practice, compared with testing for MLH1, MSH2 and MSH6. This occurs because testing PMS2 is
technically challenging and hence more expensive, and there are correspondingly fewer laboratories
capable of testing PMS2 (in the UK there is currently only one126). Using the AC II, instead of a fixed
proportion, allows the flexibility of a changing population; the proportion of patients at diagnosis of CRC
with a FH will not be the same as the proportion of patients with a FH after tumour testing.
Figures 5–11 show that we split genetic testing into simultaneous testing for MLH1, MSH2 and MSH6
(abbreviated to M126), and a separate test for PMS2 where necessary. This strategy has been adopted
in current practice where available, and is likely to become standard as three-gene sequencing becomes
more widely available, according to our expert advisors. The only strategy where this differs slightly is
strategy 3, where probands with a MLH1 (with or without a PMS2) abnormal IHC result, followed by
a BRAF test where V600E is not found, have a single genetic test for MLH1. This is to reflect the
phenomenon that a mutation in the MLH1 gene can cause abnormal MLH1 with abnormal PMS2 results
in IHC; PMS2 mutations can only cause abnormal IHC results for PMS2; MSH2 mutations can cause
abnormal MSH2 and MSH2 with MSH6 IHC results; and MSH6 mutations can only cause abnormal MSH6
IHC results.127 Those with an abnormal IHC result in any of the other genes follow the genetic testing
route of the other strategies, M126 followed by PMS2. In all other strategies, we do not attempt to
identify the gene responsible before the genetic testing process, as there can be discrepancies in the
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quality and interpretation of tumour testing (particularly IHC) between laboratories.128 It is also assumed
that if a proband complies with some genetic testing, he or she agrees to all of it.
It is assumed that only a proportion of probands diagnosed as LS positive or LS assumed accept an offer of
LS surveillance.
In Figures 5–10, IHC refers to IHC testing associated with all four known LS genes (MLH1, MSH2, MSH6
and PMS2). Though MSI is simply the initialised form of ‘microsatellite instability’, in our case we use it to
mean the associated test for microsatellite instability rather than the state itself. In the diagrams, all
positive test results indicate (do not rule out) LS. In other words, the test results reflect the LS diagnosis;
so, for example, a positive BRAF test result for V600E is indicated as a negative test result for LS.
In the strategies using MSI, test sensitivities are higher for MLH1 and MSH2 than for MSH6 and PMS2, to
reflect the known reduced sensitivity associated with the last two genes.65 Thus, the MSI section of the
model is split into MLH1 with MSH2 (M12) and MSH6 with PMS2 (M6P2), with results reported for both
individual genes and overall (as it is actually only one test). The individual gene results are then
incorporated into the prevalence at the next stage of the strategy by combining them appropriately. For
example, in the case of strategies using MSI, the prevalence after MSI is split between M12 and M6P2
(given the information we have for the sensitivity and specificity of MSI), but as the genetic test for M126
only looks at three of those genes, the input prevalence for the M126 genetic test must only include
the prevalences of mutations in MLH1, MSH2 and MSH6. The prevalence for P2 is carried through in the
negative population so that it is later used in PMS2 genetic testing.
Testing outcomes for probands
The primary outputs from the short-term model for each testing strategy that lead into the survival
(i.e. long-term) section of the model are:
l number of probands with LS receiving LS surveillance
l number of probands with LS not receiving LS surveillance (probands will receive some surveillance in
line with BSG guidelines9); these are split into those identified as LS positive but who declined
surveillance, and those who were diagnosed LS negative
l number of probands without LS receiving LS surveillance
l number of probands without LS who do not receive LS surveillance (probands will receive some
surveillance in line with BSG guidelines9); these are split into those identified as LS positive but who
declined surveillance, and those who were diagnosed LS negative.
Other outcomes include overall sensitivity and specificity of each diagnostic strategy. Probands who are
diagnosed as LS (either mutation positive or assumed), but who refuse surveillance may still be offered
prophylactic surgery for metachronous CRC.
Diagnostic strategies for relatives
Testing of relatives depends on whether the proband was diagnosed as LS positive, LS assumed or LS
negative, as follows.
Relatives of probands diagnosed as Lynch syndrome mutation positive
The decision tree for relatives of these probands is shown in Figure 12.
Relatives of probands who receive a positive genetic test result are offered a predictive genetic test which
targets the particular gene (MLH1, MSH2, MSH6 or PMS2) found to be mutated in the proband. Relatives
who accept are then diagnosed as LS mutation positive or LS negative depending on their test result.
We assume that the targeted testing for relatives is 100% accurate, so we do not include an option for
inconclusive tests. This assumption is confirmed as current best practice by our expert advisors and is also
made in other models.54 Additionally, on advice from our clinical experts, the small numbers of relatives at
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high risk of LS, but who decline targeted genetic testing, are diagnosed as LS assumed and are offered LS
surveillance. Relatives diagnosed as LS mutation positive or LS assumed are offered risk-reducing surgery if
they develop CRC, regardless of their surveillance status.
Relatives of probands diagnosed as Lynch syndrome assumed
The decision tree for relatives of these probands is shown in Figure 13.
As agreed by our advisors, FDRs of probands who are diagnosed as LS assumed are also assumed to have
LS and are therefore at sufficiently high risk of LS to be offered LS surveillance, as targeted genetic
testing for relatives cannot be done without a specific mutation for which to test. Higher-degree relatives
(e.g. cousins, grandchildren, nieces and nephews, etc.) of this group are assumed to be LS negative,
and therefore do not warrant being offered LS surveillance.
Relatives of probands diagnosed as Lynch syndrome negative
All relatives of probands who are diagnosed LS negative are assumed to be LS negative also, and these
relatives are subject to no LS tests or LS surveillance (Figure 14).
Testing outcomes for relatives
The primary short-term model outputs are:
l number of relatives with LS receiving LS surveillance
l number of relatives with LS not receiving LS surveillance (split into those identified as LS positive but
who declined surveillance, and those who were diagnosed LS negative)
l number of relatives without LS receiving LS surveillance
l number of relatives without LS who do not receive surveillance (split into those identified as LS positive
but who declined surveillance, and those who were diagnosed LS negative).
The sensitivity and specificity for each testing strategy for relatives is recorded.
Long-term management model
All patients continue from the diagnostic section of the model to the survival section (this includes all
probands and their relatives, irrespective of their adherence and diagnosis), in which a number of
outcomes are simulated.
Offer FDRs LS
surveillance
Proband diagnosed LS
assumed
Accept LS
surveillance
Decline, no
further action
Decline
Accept
FIGURE 13 Decision tree for relatives of probands diagnosed LS assumed.
Proband No LS
No further
action
FIGURE 14 Decision tree for relatives of probands diagnosed as LS negative.
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Outcomes are simulated for 24 patient groups, which are all combinations of:
l male/female
l proband/relative
l truly LS positive/negative
l LS diagnosed and surveillance accepted/LS diagnosed and surveillance declined/LS not diagnosed.
The survival section of the model is an individual sampling model. Each patient is simulated for 1 year at a
time and starts each year in a particular health state. A cycle length of 1 year was chosen because it was
judged reasonable to assume constant hazard from various risks for a year, and indeed most parameters
informing the model are based on annual measurements of risk.
During each year there are a number of competing risks (Table 39) to which the patient may be exposed,
and these are all assumed to have a constant hazard rate throughout the year (with the exception of
colonoscopies, which have a different mechanism; see Morbidity and mortality of Lynch syndrome
surveillance colonoscopy). For each competing risk, a time to event is drawn randomly according to the
hazard rate of that event. If none of the times is within a year, then no event has occurred and the patient
commences the next year in the same state. If at least one of the times is within a year, then the earliest of
the times determines which event occurs and the state is updated accordingly for the next year. Figure 15
gives a graphical representation of the events and states in the model, in the form of an
influence diagram.
Description of individual sampling model
The structure of the economic model has been described as an ‘individual sampling model’ in two review
articles,129,130 defined as a model which tracks individual patients independently. This is to be contrasted
with models which allow for interactions between patients, for example for infectious diseases, and
models that track groups or cohorts of patients simultaneously. Barton and colleagues (2004)129
recommend individual sampling models when there are no interactions between patients, and when a
cohort-based model would require an excessive number of health states.
Indeed, we chose an individual sampling model structure for precisely these two reasons. Patient
interactions are assumed to be completed during the diagnostic testing and do not factor into long-term
management. A cohort-based model would require an excessive number of health states to represent the
TABLE 39 Competing and non-competing events in the Peninsula Technology Assessment Group model for
different patient groups
Patient group Competing events Non-competing events
All patients General mortality
Patients undergoing LS surveillance
(aged 25–75 years)
Mortality following colonoscopy Adverse events (includes bleeding and
perforation) following colonoscopy
Patients with CRC (aged < 75 years) Mortality following colonoscopy Adverse events (includes bleeding and
perforation) following colonoscopy
Patients with CRC CRC mortality
Patients with an index CRC
(without metachronous CRC)
Metachronous CRC incidence
Patients without CRC CRC incidence
LS females without EC EC incidence
LS females with EC EC mortality
Females diagnosed with LS without EC Mortality following prophylactic
TAHBSO
Prophylactic TAHBSO
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complexity of the natural histories of multiple diseases (CRC and EC) and the health-care processes
to prevent and treat those diseases (colonoscopy, risk-reducing surgery). For example, if we chose to
construct a cohort model in which up to two CRCs were modelled (including their Dukes’ stages), with
four surgery types and EC and TAHBSO modelled (which would approach the complexity of the individual
sampling model), we would require almost 150 different health states (Table 40). Even with this many
health states, we would need to make simplifications to fit the Markov memory-less property for
transitions between states, and the model would need to be replicated 24 times to cover the different
subgroups of patients.
More specifically, our model structure is denoted ‘D2’ in the notation of Brennan and colleagues (2006),130
as it is at the patient level, does not simulate patient interactions and does not assume the Markov
memory-less property for transitions between health states.
The model uses a hybrid approach between discrete and continuous time periods, in which there are
discrete cycles of length 1 year but events may occur at any point during that year, rather than being
assumed to occur at the beginning, end or midpoint, as is the case in general discrete time models.
Figures 16–18 demonstrate this.
In Figure 16 a time to event of 9.0 years is drawn for CRC incidence and a time to event of 5.3 years is
drawn for general mortality. Neither of these events falls within 1 year, so no event occurs and time in the
TABLE 40 Combinatorial explosion of Markov states
Adaptation
Additional states
required
Total number of
Markov states
Basic model: healthy/CRC/dead 3 3
MCRC +1 4
Dukes’ stages (four first CRC, 16 first/second CRC pairs) +18 22
Surgery types (none,a segmental resection,b anterior resection,b
subtotal colectomy, proctocolectomy)
+28 50
EC +49 99
TAHBSO +49 148
MCRC, metachronous CRC.
a Only for healthy patients (no CRC).
b Only for first CRC.
General
mortality
CRC
incidence
1
Time to event (years)
−5 0 5 10
FIGURE 16 No event occurs.
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model moves on by a year. In Figure 17 a time to event of 0.8 years is drawn for CRC incidence and a
time to event of 8.8 years is drawn for general mortality. CRC incidence falls within 1 year, and hence
CRC incidence occurs at a time of 0.8 years. In Figure 18 a time to event of 0.6 years is drawn for CRC
mortality and a time to event of 0.9 years is drawn for general mortality. Both times fall within 1 year but
0.6 years is the earliest, and hence CRC mortality occurs.
Tables 41–44 below give example individual patient simulation (IPS) traces from the model. Note that
many of the times generated seem implausible, for example general mortality is predicted to be thousands
of years in the future; this is because in each cycle the incidence rate is constant, and note that the only
important aspect in these instances is that the time generated is greater than 1 year. Events occur when a
simulated time to event is generated which is < 1 year (see shaded areas).
Patient state
The patient state at any time is defined by a number of properties, which collectively provide all the
information necessary to select appropriate treatment pathways and calculate risks of events. The patient
state is composed of:
l whether or not the patient is alive
l the patient’s age (at the start of the year)
l the patient’s sex
l the patient’s bowel state (defined below)
l whether or not the patient has had TAHBSO
l whether or not the patient has EC
l the patient’s LS status and diagnosis status
l the patient’s acceptance of LS surveillance if it is offered.
General
mortality
CRC
incidence
Time to event (years)
1−5 0 5 10
FIGURE 17 Colorectal cancer incidence occurs.
General
mortality
CRC
mortality
Time to event (years)
1−5 0 5 10
FIGURE 18 Colorectal cancer mortality occurs.
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TABLE 42 Example IPS trace for a male proband without LS
Cycle
Age
(years)
Alive
(yes/no)
Bowel
state
Times to competing
events (years)
Times to non-competing
events (years)
General
mortality
CRC
mortality MCRC incidence
0 41 Yes Dukes’ A 1918 178.6 5165
1 42 Yes Dukes’ A 515.0 27.55 17,602
2 43 Yes Dukes’ A 6.666 14.22 16,369
. . . . . . . . . . . . . . . . . . . . .
25 66 Yes Dukes’ A 36.49 1.174 1320
26 67 Yes Dukes’ A 50.85 0.287 69.67
27 68 No N/A N/A N/A N/A
Total
life-years
26.287
MCRC, metachronous CRC; N/A, not applicable.
TABLE 41 Example IPS trace for a male relative with undiagnosed LS
Cycle
Age
(years)
Alive
(yes/no)
Bowel
state
Times to competing
events (years)
Times to non-competing
events (years)
General
mortality
CRC
mortality CRC incidence
0 30 Yes Healthy 1502 N/A 703.1
1 31 Yes Healthy 4297 N/A 583.0
2 32 Yes Healthy 151.8 N/A 2.719
. . . . . . . . . . . . . . . . . . . . .
57 87 Yes Healthy 9.423 N/A 1159
58 88 Yes Healthy 0.279 N/A 150.7
59 89 No N/A N/A N/A N/A
Total
life-years
58.279
N/A, not applicable.
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Patient bowel state
The patient bowel state encapsulates whether or not the patient has a clinically diagnosed CRC and the
extent of any bowel surgery. Though it is possible within an individual sampling model to track a number
of primary CRCs and their properties, we make the simplifying assumption that each patient will have no
more than two primary CRCs throughout his or her life (as in other decision models, e.g. Mvundura
and colleagues54).
The Dukes’ CRC stage is used as a measure of how advanced a CRC is, from A to D, as described in
Table 45. More recently the tumour node metastasis (TNM) system has been used to stage cancers, but we
did not identify data sources for incidence or survival according to TNM stage and so use Dukes’ stage.
In the model we keep track of the Dukes’ stages of both primary cancers (as appropriate) and how long it
has been since the cancer was diagnosed. For example, a patient may have experienced a first CRC Dukes’
A 12 years ago and a metachronous CRC with Dukes’ stage C 2 years ago.
We model two portions of the bowel: the colon and the rectum. CRCs can develop in any portion of the
bowel still intact. We model four surgery types, based on the extent of bowel removed (Table 46). This is a
small extension to the three surgery types used in Maeda and colleagues86 to account for the fact that
rectal cancer can be the first primary cancer in our cohort. See Colorectal cancer surgical management
pathways for details on surgical management.
TABLE 45 Dukes’ stages of CRC and their descriptions
Dukes’ stage AJCC stage TNM equivalent Description
A I T1
T2
N0
N0
M0
M0
Tumour invades submucosa or tumour invades
muscularis propria; no regional lymph node metastasis;
no distant metastasis
B IIA T3 N0 M0 Tumour invades through the muscularis propria into
pericolorectal tissues or tumour penetrates to the
surface of the visceral peritoneum or tumour directly
invades or is adherent to other organs or structures; no
regional lymph node metastasis; no distant metastasis
IIB T4a N0 M0
IIIC T4b N0 M0
C IIIA T1–T2
T1
N1/N1c
N2a
M0
M0
Tumour invades submucosa or tumour invades
muscularis propria or tumour invades through the
muscularis propria into pericolorectal tissues or tumour
penetrates to the surface of the visceral peritoneum or
tumour directly invades or is adherent to other organs
or structures; metastasis in at least one regional lymph
node; no distant metastasis
IIIB T3–T4a
T2–T3
T1–T2
N1/N1c
N2a
N2b
M0
M0
M0
IIIC T4a
T3–T4a
T4b
N2a
N2b
N1–N2
M0
M0
M0
D IVA Any T Any N M1a Distant metastasis (in one or more organ or site)
IVB Any T Any N M1b
AJCC, American Joint Committee on Cancer; TNM, tumour node metastasis.
Used with permission of the AJCC, Chicago, IL, USA. The original and primary source for this information is the AJCC
Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media.131
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Outcomes
For each diagnostic testing strategy, the primary outcomes of the survival model are the QALYs lived and the
total care costs accrued, both discounted and undiscounted. These are then combined with the outcomes
from each diagnostic testing strategy to obtain the overall expected QALYs and costs for each strategy.
The following secondary outcomes are also reported:
l life-years lived (discounted and undiscounted)
l number of incident CRCs
l number of incident ECs
l number of colonoscopies performed
l disaggregated costs (costs of surveillance, colonoscopy complications, CRC diagnosis, surgery,
chemotherapy and follow-up, EC surgery and treatment), discounted and undiscounted.
Perspective, discounting, time horizon
The perspective of the analysis is that of the NHS and PSS. In keeping with the NICE reference case,132
costs and benefits are discounted at 3.5% per annum and the time horizon is lifetime or age 100 years
(whichever is earlier).
Surveillance pathways
Surveillance pathways are based on published guidelines by the BSG and ACPGBI,9 NICE guidance133 and a
report commissioned by the Department of Health.134
Surveillance pathways are different for patients affected and unaffected by CRC, as patients affected by CRC
are at risk of cancer recurrence and metastatic disease. Surveillance pathways are also different for patients
diagnosed with LS or suspected/assumed to have LS because the risk of CRC incidence is greatly increased.
There are no evidence-based standard follow-up pathways for CRC,9,133,134 although there is some evidence
that follow-up improves overall survival. NICE guidelines make some minimum recommendations:133
A minimum of two CTs [computerised tomography scans] of the chest, abdomen and pelvis in the first
3 years.
Regular serum carcinoembryonic antigen tests (at least every 6 months in the first 3 years).
Offer a surveillance colonoscopy at 1 year after initial treatment. If this investigation is normal consider
further colonoscopic follow-up after 5 years, and thereafter as determined by cancer networks.
Trueman and colleagues134 describe 3-monthly carcinoembryonic antigen (CEA) tests as common for the
first 2 years, followed by 6-monthly tests for the following 3 years. The BSG/ACPGBI guidelines suggest
that 5-yearly colonoscopies should continue until comorbidities outweigh the benefits.9
TABLE 46 Extent of bowel removed for included surgeries
Surgery Bowel removed
Segmental colon resection Part (but not all) of the colon
Subtotal colectomy All of the colon
Anterior resection All of the rectum
Proctocolectomy All of the colon and rectum
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The BSG/ACPGBI guidelines suggest that patients diagnosed with LS should receive 2-yearly colonoscopy
commencing at age 25 years until the age of 70–75 years, or until comorbidity makes colonoscopy
clinically inappropriate, and also suggest that surveillance every 18 months may be appropriate.9
Table 47 describes the surveillance pathways as included in the model, which are an attempt by the
Peninsula Technology Assessment Group (PenTAG) to unify the various recommendations.
Colorectal cancer surgical management pathways
Colorectal cancer surgical pathways are based on published guidelines9 with input from clinical experts.
Patients undergo surgical management if they are diagnosed with CRC and the cancer is deemed to be
operable (this includes surgery where intent is palliative rather than curative). We make the simplifying
assumption that all patients diagnosed with CRC undergo surgical management [over 75% of patients
in the National Bowel Cancer Audit (2011)135 were treated surgically]. In each case, surgery would remove
the bowel portion affected by the cancer, and in some cases additional portions, depending on previous
surgery and whether or not LS had been diagnosed [Figure 19, adapted from Maeda and colleagues
(2010)86]. Our clinical expert advice is that, in general, surgery for patients without LS tends to be
conservative, without a risk-reducing element.
Clinical guidelines indicate that there is a place for more aggressive surgery, with a risk-reducing element,
for patients known to have LS upon CRC diagnosis, in particular that ‘For patients with proximal tumours,
colectomy and ileorectal anastomosis is most relevant.’9 Input from our clinical expert has suggested that
this particular guidance would rarely be followed as it is from a low category of evidence (evidence
obtained from expert committee reports or opinions, or clinical experiences of respected authorities) and
colonoscopic surveillance is deemed effective enough to negate the need for aggressive surgery. To resolve
this disagreement, we include a parameter in the model which defines the probability that more aggressive
TABLE 47 Surveillance pathways for patients in the model
Patient type Surveillance Source
Affected by CRC;
diagnosed with LS
CEA test every 3 months for 2 years after resection
CEA test every 6 months from 2 years after resection until 5 years
after resection
CT scan of chest, abdomen and pelvis 1 and 2 years after resection
Colonoscopy 1 year after resection
2-yearly colonoscopy to age 75 years
NICE 2011133
BSG/ACPGBI 20109
Trueman et al. 2007134
Affected by CRC;
not diagnosed with LS
CEA test every 3 months for 2 years after resection
CEA test every 6 months from 2 years after resection until 5 years
after resection
CT scan of chest, abdomen and pelvis 1 and 2 years after resection
Colonoscopy 1 year after resection
5-yearly colonoscopy to age 75 years
NICE 2011133
BSG/ACPGBI 20109
Trueman et al. 2007134
Unaffected by CRC;
diagnosed with LS
2-yearly colonoscopy from age 25 to age 75 years BSG/ACPGBI 20109
Unaffected by CRC;
not diagnosed with LS
None
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surgery would be used for LS patients, which can be varied from 0 (ignore guidelines; surgical treatment
not affected by LS diagnosis) to 1 (full adherence to guidelines; aggressive surgery always used).
When surgery removes the rectum because of cancer in the rectum there are two common operations:
anterior resections which preserve the anus and abdominoperineal excisions of the rectum (APERs) which
result in permanent stoma. We group these operations together and assume that they are equally effective
at preventing metachronous rectal cancer. Some patients would require a permanent stoma, which would
affect HRQoL and costs. Rather than modelling this on an individual patient basis, we assume an average
effect across all patients.
Any subsequent surgery depends on the location of the CRC, the nature of previous surgery and
whether or not the patient has been diagnosed with LS (unless the parameter described above is 0)
(Tables 48 and 49).
Includes right hemicolectomy, extended right hemicolectomy,
transverse colectomy, left hemicolectomy and sigmoid colectomy
Includes anterior resection, APER
and Hartmann’s procedureNone No surgery
SEG Segmental colon resection
AR Anterior resection
SUB Subtotal colectomy
IPAA Ileal pouch anal anastomosis (total protocolectomy)
SEG
SUB
None
AR
IPAA
1
5
6
3
8
7
2
4
1
2
3
4
5  /  7
6  /  8
Colon cancer
Rectal cancer
Synchronous colon cancer or polyps in distant sections of colon or aggressive management of colon
cancer in LS patient
Synchronous colon and rectal cancer or synchronous rectal cancer and colonic polyps or aggressive
management of rectal cancer in LS patient
Metachronous colon cancer
Metachronous rectal cancer
FIGURE 19 Surgical management pathways for CRC.
TABLE 48 Probability of different surgery types for colon cancer patients not diagnosed with LS
Previous surgery
Segmental
resection
Subtotal
colectomy
Anterior
resection Proctocolectomy Source
None 96%a 4%b 0% 0% NHS Bowel Cancer Audit
report 2011135
Segmental resection 0% 100% 0% 0% Assumption
Subtotal colectomy N/A N/A N/A N/A Assumption
Anterior resection 0% 0% 0% 100% Assumption
Proctocolectomy N/A N/A N/A N/A Assumption
N/A, not applicable.
a 8850 colon cancer patients underwent right hemicolectomy (n= 6627), transverse colectomy (n= 86), left
hemicolectomy (n= 978) or sigmoid colectomy (n= 1159).135
b 325 colon cancer patients underwent total or subtotal colectomy.135
N/A because subtotal colectomy and proctocolectomy are assumed to completely eliminate the risk of colon cancer.
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
Surgery distributions for CRC patients diagnosed with LS are adjusted by the parameter representing the
probability of aggressive surgery. If we denote this probability as p then for colon cancer patients:
Pr(SEGjLS diagnosed) ¼ (1− p) Pr(SEGjLS not diagnosed) (1)
Pr(SUBjLS diagnosed) ¼ 1− Pr(SEGjLS diagnosed) (2)
where Pr is probability, SEG is segmental resection and SUB is subtotal colectomy. For rectal
cancer patients:
Pr(ARjLS diagnosed) ¼ (1− p) Pr(ARjLS not diagnosed) (3)
Pr(IPAAjLS diagnosed) ¼ 1− Pr(ARjLS diagnosed) (4)
where AR is anterior resection and IPAA is ileal pouch–anal anastomosis (total proctocolectomy). Our
estimate of this parameter is given and justified in More aggressive colorectal cancer surgery for individuals
diagnosed with Lynch syndrome.
Characteristics of the model population
Age on entry
In the base case, probands enter the model below the age of 50 years as a result of the age targeting
of testing, and all relatives enter the model below the age of 75 years to reflect the small number of
interventions after this age. In scenario analyses, we investigate the impact of increasing the maximum age
of probands to 60 and 70 years separately.
The ages of probands without LS in the simulation are distributed to reflect the ages observed in CRC
registration statistics for England between 2006 and 2010 inclusive.119,136–139 The distribution of ages of
probands with LS is approximated using our estimated rates of incidence of CRC for individuals with LS not
receiving risk-reducing interventions (see Incidence rates in patients with Lynch syndrome).
The difference in the age distributions between individuals with and without LS (Figure 20) is accounted
for by the earlier average age at onset of CRC in individuals with LS [in the study by Bonadona and
TABLE 49 Probability of different surgery types for rectal cancer patients not diagnosed with LS
Previous
surgery
Segmental
resection
Subtotal
colectomy
Anterior
resection Proctocolectomy Source
None 0% 0% 98%a 2%b NHS Bowel Cancer Audit
report 2011135
Segmental
resection
0% 0% 0% 100% Assumption
Subtotal
colectomy
0% 0% 0% 100% Assumption
Anterior
resection
N/A N/A N/A N/A Assumption
Proctocolectomy N/A N/A N/A N/A Assumption
N/A, not applicable.
a 4341 rectal cancer patients underwent anterior resection (n= 2890), APER (n= 1139) or Hartmann
procedure (n= 312).135
b 82 rectal cancer patients underwent total or subtotal colectomy.135
N/A because anterior resection and proctocolectomy are assumed to completely eliminate the risk of rectal cancer.
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colleagues (2011)2 the median age at onset of CRC was 45 years, whereas it is 70–74 years in the general
population119]. We do not show the analogous age distribution for females as it shows the same pattern.
It was assumed that all relatives would be aged between 18 and 75 years because it would be unusual to
offer predictive testing for LS to individuals under the age of 18 years (and concomitantly, intervention
would be unlikely to take place until age 20–25 years), and because intervention is rarely continued after
age 75 years. Age distributions for relatives with and without LS were adjusted accordingly.
The ages of relatives without LS are distributed according to the ages of the general population of England
and Wales.140,141 The ages of relatives with LS are estimated similarly, but with an adjustment to reflect
substantially greater mortality (currently only from CRC) for individuals with LS compared with the general
population. Although we have some limited data on age of relatives who are tested for LS, these are from
a relatively small sample size, and we were unable to find data on age distributions in the literature. This
adjustment used incidence rates of CRC for individuals with LS as described in Incidence rates in patients
with Lynch syndrome, Dukes’ stage distributions as described in Dukes’ stage on diagnosis and 1- to
10-year survival, calculated according to parameters described in Mortality due to colorectal cancer for
patients with Lynch syndrome to estimate the proportion of individuals with LS that would survive to a
certain age if CRC was the only cause of death. This was then applied to the age distribution of the
population of England and Wales, resulting in LS relatives being more likely to be younger (Figure 21).
The proportion of relatives with LS is relatively higher for younger ages owing to the additional mortality
experienced by individuals with LS from CRC. We do not show the analogous figure for females as it
follows the same pattern.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Age group (years)
General population male probands
LS male probands
0−9 10−19 20−29 30−39 40−49 50−59 60−69 70−79
Pr
o
p
o
rt
io
n
 o
f 
p
ro
b
an
d
s
FIGURE 20 Age distribution of male probands on diagnosis of CRC.
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FIGURE 21 Age distribution of male relatives when the proband is diagnosed with CRC.
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Bowel state on entry
All probands enter the model with an index CRC (i.e. without a metachronous CRC). The Dukes’ stage for
probands is sampled randomly using the distribution described in Dukes’ stage on diagnosis.
Probands entering the model were randomly assigned a surgical state in accordance with the estimated
probability that they had colon cancer versus rectal cancer (Table 50) and the probabilities of different
types of surgery for those cancers (Table 51). Table 52 gives the resulting distribution of initial surgical
states for probands entering the model, according to their sex and LS status.
Relatives enter the model without CRC, i.e. they are at risk of up to two CRCs (index and metachronous).
In reality some relatives would be survivors of previous CRC.
Table 53 gives an estimate of what proportion of relatives would be survivors of previous CRC. Estimates
for relatives without LS are based on 10-year CRC prevalence published by the (UK) National Cancer
TABLE 50 Probability that index CRC of proband entering PenTAG model is colon cancer [International
Classification of Diseases, Tenth Edition (ICD-10) code C18]
Proband
type Male Female Source
With LS 0.94 0.94 Dinh online appendix55
Without LS 0.58 0.61 ONS Cancer Registration Statistics, England119
TABLE 51 Surgery for CRC according to location in general population
Location
of CRC
Surgery
(% of cases) Source Notes
Colon Segmental
resection (96)
Subtotal
colectomy (4)
NHS Bowel
Cancer
Audit 2011135
Included in segmental resection:a right hemicolectomy, transverse
colectomy, left hemicolectomy, sigmoid colectomy
Included in subtotal colectomy:a total/subtotal colectomy
Excluded:a anterior resection, APER, Hartmann procedure
Rectum Anterior
resection (98)
Proctocolectomy (2)
NHS Bowel
Cancer
Audit 2011135
Included in anterior resection:b anterior resection, APER,
Hartmann procedure
Included in proctocolectomy:b total/subtotal colectomy
Excluded:b right hemicolectomy, transverse colectomy,
left hemicolectomy, sigmoid colectomy
a Where cancer site recorded as colon.
b Where cancer site recorded as rectum.
TABLE 52 Initial surgical state for probands entering the model
Surgery
With LS Without LS
Male Female Male Female
Segmental resection 0.907 0.907 0.564 0.587
Subtotal colectomy 0.033 0.033 0.021 0.022
Anterior resection 0.059 0.059 0.408 0.384
Proctocolectomy 0.001 0.001 0.008 0.007
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Intelligence Network (NCIN),142 assuming that the proportion of CRC survivors with colon cancer is the
same as the proportion of incident CRCs which are colon cancer. Prevalence of previous CRC for relatives
with LS is estimated by multiplying by a scale factor of 45%/2.6%= 17.4 for males and 35%/1.7%= 20.3
for females, where 45% and 35% are estimates of the cumulative risk of CRC to age 70 years for males
and females with LS, respectively,65 and 2.6% and 1.7% are estimates of the cumulative risk of CRC to
age 70 years for males and females without LS, respectively, calculated using population, CRC incidence
and CRC mortality statistics for England and Wales in 2010.119,143–145 Again, it was assumed that the
proportion of survivors with colon cancer would match the proportion of incident cases, this time
estimated by Dinh and colleagues.55
Relatives with previous CRC would experience a higher mortality rate and, therefore, preventing a further
CRC would be expected to give a smaller life-year gain than in relatives without previous CRC. These CRC
survivors would be likely to have early-stage CRC, to have undergone segmental resection and to be
followed up for recurrence or metachronous cancer.
The model incorporates initial surgical states for relatives entering the model (Table 54; proportions based
on surgical choice for people not known to have LS and prevalence of colon and rectal cancer as in
Table 53). Most relatives have no previous surgery (as most relatives have no previous CRC), and of those
with previous surgery, the majority have a previous segmental resection which imparts no risk reduction in
the model. A very small number (<< 1%) of relatives enter the model with previous surgery which does
impart a risk reduction. As all these relatives enter with risk reduction irrespective of the diagnostic
strategy, this would decrease the potential life-year gain of correctly identifying relatives as having LS; we
therefore expect that including initial surgical states has a very small (probably negligible) negative impact
on cost-effectiveness of strategies identifying LS (i.e. strategies made less cost-effective).
Gynaecological cancers
Gynaecological cancers in models of testing for Lynch syndrome
Most published models of the cost-effectiveness of testing for LS consider only CRC, not EC and OC
(Table 55). Two analyses, Dinh and colleagues (2011)55 and Kwon and colleagues (2011),56 consider only
TABLE 53 Estimated proportion of relatives who would previously have had CRC
CRC prevalence
With LS Without LS
Male Female Male Female
None 0.9628 0.9717 0.9979 0.9986
Colon cancer 0.0350 0.0266 0.0012 0.0009
Rectal cancer 0.0022 0.0017 0.0009 0.0005
TABLE 54 Initial surgical state for relatives entering the model
Surgery
With LS Without LS
Male Female Male Female
None 0.9628 0.9717 0.9979 0.9986
Segmental resection 0.0338 0.0256 0.0012 0.0009
Subtotal colectomy 0.0012 0.0009 0.0000 0.0000
Anterior resection 0.0022 0.0017 0.0009 0.0005
Proctocolectomy 0.0000 0.0000 0.0000 0.0000
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EC in addition to CRC, and five analyses consider both EC and OC in addition to CRC: Chen and
colleagues (2007)85 (clinical effectiveness only), Kwon and colleagues (2008),75 Ladabaum and colleagues
(2011),48 Wang and colleagues (2012)57 (extension of analysis by Ladabaum and colleagues48) and
Yang and colleagues (2011)76 (extension of Chen and colleagues85 analysis).
Ladabaum and colleagues (2011) Ladabaum and colleagues (2011)48 modelled the occurrence of EC
and OC. They modelled annual gynaecological screening with transvaginal ultrasonography and
endometrial sampling, starting at age 35 years. Gynaecological screening was assumed to incur costs
but yield no benefits, given that no proven benefit was found. The authors note that this biases
cost-effectiveness against genetic testing for LS.
Ladabaum and colleagues (2011) also modelled prophylactic TAHBSO at age 40 years, after completion
of childbearing,48 and they assumed that this eliminates the risk of EC and OC, citing Schmeler and
colleagues (2006).146 It was predicted that 19% of probands and 18% of relatives with LS respectively
would accept TAHBSO. The death rate from TAHBSO was estimated at 0.0003.
This screening and surgical regime was also offered to (a) relatives whose status was uncertain because
they had declined genetic testing, but who had a 50% risk for carrying a mutation; (b) probands in whom
TABLE 55 Summary of incorporation of gynaecological cancers in published models of the cost-effectiveness of
testing for LS
Cost-effectiveness
analysis EC OC
Breheny et al. 200651 No No
Brown et al. 199622 No No
Chen et al. 200785 Clinical effectiveness model (no costs). Stages I to IV of both EC and OC modelled.
Screening assumed to yield clinical benefits. TAHBSO assumed
DACEHTA 200752 No No
Dinh et al. 201155 Endometrial biopsy and TVU, assumed to incur costs but yield no benefits.
TAHBSO offered to women with EC and those LS positive without. TAHBSO
assumed to eliminate risk of EC. Stage of cancer not modelled
No
Kievit et al. 200550 No No
Kwon et al. 200875 Stages I to IV of both EC and OC modelled. Screening assumed to yield
clinical benefits. Prophylactic gynaecological surgery assumed to remove risk of
gynaecological cancers
Kwon et al. 201156 EC modelled, but very little detail concerning incidence, screening or surgery No
Ladabaum et al. 201148 Gynaecological screening starting at age 35 years, assumed to incur costs but
yield no benefits. Prophylactic TAHBSO at age 40 years, assumed to eliminate risk
of gynaecological cancers. Stage of cancer not modelled
Mvundura et al. 201054 No No
Olsen et al. 200753 No No
Ramsey et al. 200123 No No
Ramsey et al. 200349 No No
Reyes et al. 200259 No No
Wang et al. 201257 Same as Ladabaum et al. 201148
Yang et al. 201176 Similar to clinical effectiveness model of Chen et al. 200785 with addition of utilities and costs
for screening, gynaecological surgery, cancer care, chemotherapy and radiotherapy
DACEHTA, Danish Centre for Evaluation and Health Technology Assessment; TVU, transvaginal ultrasound.
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LS was diagnosed on the basis of AC II and tumour features, despite the lack of a detectable mutation;
and (c) their FDRs.48 Individuals whose tumours showed abnormal IHC or MSI results, but who had normal
genetic results and did not meet the AC II, were not offered the regime, because such cases were deemed
most likely to represent FP results on tumour tests rather than FN results on genetic tests.48
Ladabaum and colleagues (2011) modelled the probabilities that women with and without LS develop EC
and OC. For example, the probability that a woman with LS develops EC was estimated as 37% by age
70 years, and the probability of dying from EC within 5 years from diagnosis was estimated as 0.17.
In the base case, deaths from EC and OC were reduced by between 1% and 6% according to the testing
strategy for LS. Testing was predicted to benefit women more than men. For example, given universal
acceptance of genetic testing and perfect adherence to screening, female probands were predicted to
survive an additional 0.47 years given genetic testing versus the referent strategy, compared with an
additional 0.22 years for male probands. The sex difference was attributed to prevention of gynaecological
cancers by TAHBSO and to women having a greater life expectancy than men.
Dinh and colleagues (2011) Dinh and colleagues (2011)55 modelled the occurrence of EC, but not OC.
The incidence of EC in individuals with LS was estimated from a meta-analysis conducted by the authors,
but unfortunately the incidence rates are not published.
In common with Ladabaum and colleagues (2011),48 in their survey of the literature Dinh and colleagues
(2011) found that the clinical benefit of surveillance for EC for women with LS is not clear. Although Dinh
and colleagues (2011) assumed that women with positive genetic test results for LS were screened by
endometrial biopsy and transvaginal ultrasound (TVU), in common with Ladabaum and colleagues (2011)
they also assumed that surveillance has no effect on the incidence of and survival from EC.
Dinh and colleagues (2011) assumed that women with positive genetic test results for LS were offered
TAHBSO, assuming a mortality of 0.02% for this operation. The adherence rate for TAHBSO for women
without EC and without CRC was estimated to increase with age, from 0% for women aged under
30 years to 75% for those aged 80 years. Slightly higher rates were assumed for women without EC but
with CRC. The adherence rate for women with EC was estimated at 100%. As in the study by Ladabaum
and colleagues (2011),48 the chance of developing EC after hysterectomy was assumed to be zero. Also in
common with Ladabaum and colleagues (2011),48 any costs and morbidities due to oestrogen therapy
following TAHBSO were ignored.
Dinh and colleagues (2011) assumed that mortality due to EC for individuals with LS affected by EC is the
same as for individuals without LS, and this was taken from the US Surveillance, Epidemiology, and End
Results (SEER) database. However, the authors do not publish these rates.
Kwon and colleagues (2008) Kwon and colleagues (2008)75 modelled the occurrence of both EC and
OC. Five treatment strategies of various combinations of screening and risk-reducing surgery were
modelled. Unlike Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 the stages I to IV
of both cancers were modelled explicitly.
A lifetime risk of 50% for EC and 10% for OC was assumed.
In common with Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 Kwon and
colleagues (2008) also modelled gynaecological screening, and found that the evidence on the clinical
benefit of screening for EC was mixed. Unlike Ladabaum and colleagues (2011)48 and Dinh and colleagues
(2011),55 Kwon and colleagues (2008) assumed that screening for gynaecological cancers leads to clinical
benefits, albeit at substantial cost. Screening is assumed to give an improved stage distribution for
gynaecological cancers at detection.
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
In common with Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 Kwon and
colleagues (2008) assumed that prophylactic gynaecological surgery removes the risk of gynaecological
cancers. Unlike Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 100% adherence to
surveillance and surgery was assumed.
As in the studies by Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 costs of
adjuvant radiotherapy or chemotherapy were not modelled.
Kwon and colleagues (2011) In their model of the cost-effectiveness of testing for LS in women with EC,
Kwon and colleagues (2011)56 modelled the occurrence of EC, but not OC. Unfortunately, no details are
given concerning screening or surgery for EC, and only outline data are provided on incidence of EC.
Chen and colleagues (2007) In their analysis of the clinical (as opposed to cost-) effectiveness of
prophylactic TAHBSO surgery versus surveillance for women with LS, Chen and colleagues (2007)85
modelled both EC and OC. As in the study by Kwon and colleagues (2008),75 the stages I to IV of both
cancers were modelled explicitly, in particular at diagnosis and at the time of surgery. Two types of
surveillance were compared: lifetime annual gynaecological examination only versus annual gynaecological
TVU, endometrial biopsy and serum CA125 testing. All interventions were assumed to start at age 30 years.
Unlike Ladabaum and colleagues (2011)48 and Dinh and colleagues (2011),55 but in common with Kwon
and colleagues (2008),75 it was assumed that screening for gynaecological cancers yields clinical benefits.
Screen-detected EC was assumed to have a similar stage distribution as for EC diagnosed at risk-reducing
surgery. Survival from gynaecological cancers was taken from the US SEER database.
Yang and colleagues (2011) The analysis of the cost-effectiveness of prophylactic TAHBSO surgery
versus surveillance for women with LS by Yang and colleagues (2011)76 was performed by the same
authors as the clinical effectiveness model of Chen and colleagues (2007).85 The model of Yang and
colleagues (2011) builds on the model of Chen and colleagues (2007)85 by additionally incorporating
utilities and the following costs: screening, gynaecological surgery, cancer care, chemotherapy
and radiotherapy.
Ovarian cancer in the Peninsula Technology Assessment Group model
Only 7 of the 16 models of LS (see Table 89) consider EC, and fewer still (five) consider OC [Chen
and colleagues (2007),85 Kwon and colleagues (2008),75 Ladabaum and colleagues (2011),48 Wang and
colleagues (2012)57 and Yang and colleagues (2011)76]. Further, two of these models are simply extensions
of previous models [Wang and colleagues (2012)57 is an extension of Ladabaum and colleagues (2011),48
and Yang and colleagues (2011)76 is an extension of Chen and colleagues (2007)85].
Lynch syndrome is associated with an increased incidence of many cancers, including colorectal,
endometrial, ovarian, stomach, small intestine, hepatobiliary tract, urinary tract, brain and skin.5 Given time
and data constraints, it has not been possible to model all LS-associated cancers. Therefore, it is judicial to
model only those cancers which are likely to substantially affect the cost-effectiveness of genetic testing for
probands with CRC with LS. Of the gynaecological cancers, we model EC, but not OC. This is because the
incidence of OC in women with LS is substantially lower than that of EC. In particular, as stated below
(see Incidence rates in patients with Lynch syndrome), a recent study of 10,283 individuals from several
French clinics,2 which appears well conducted, estimated the cumulative risk of EC by the age of 70 years
as 34% and that of OC as 9%. We approximated the cumulative risk of death from each cancer by age
75 years by multiplying the cumulative risk to age 70 years by the proportion of affected individuals not
surviving to 5 years from diagnosis (i.e. 100% minus 5-year survival). This gives a cumulative risk of death
of 34%× (100%− 76.7%)= 7.9% for EC and 9%× (100%− 44.0%)= 5.0% for OC.147 This justifies
modelling EC ahead of OC.
If OC were included in our model, it is likely that our estimates of the cost-effectiveness of testing would
improve, as follows. We already cost for TAHBSO prophylactic surgery, which eliminates the risk
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not just of EC, but also of OC. If we were to model OC, then testing for LS would eliminate the incidence
of OC for those female probands who present with CRC and who accept TAHBSO, and for those female
relatives who accept TAHBSO. Therefore, the estimated QALYs for those strategies that test for LS would
increase. If we were to assume no or relatively low costs for treating OC, the estimated total cost of all
testing strategies would change little.
Endometrial cancer in the Peninsula Technology Assessment Group model
Table 56 gives a summary of the parameters concerning EC in the PenTAG model. The model assumes
that neither the relatives nor probands have previously had EC (or TAHBSO) before entering the model.
This would be an additional complexity that would be unlikely to have a large impact on cost-effectiveness,
because patients with a prior EC or TAHBSO would have both reduced costs and reduced benefits in
our model.
Surgery for endometrial cancer Of the seven analyses that include EC,48,55–57,75,76,85 six assume that some
patients will receive either a hysterectomy or TAHBSO (see Table 55). It is not clear whether or not the
seventh analysis, by Kwon and colleagues (2011)56 included such surgery. In the PenTAG base-case
analysis, we assume TAHBSO, rather than just hysterectomy, as this is the usual treatment for EC155
(see Table 56). Further, our clinical experts advise that either total laparoscopic hysterectomy (TLH) or
laparoscopic-assisted vaginal hysterectomy (LAVH) is now preferred. As we are not able to differentiate the
costs of hysterectomy with bilateral salpingo-oophorectomy from hysterectomy alone, we do not perform
any sensitivity analysis in which hysterectomy alone is performed. We assume that surgery may be
performed in either of two cases: on diagnosis of EC, and prophylactically for women who do not have
EC, but have tested positive for LS.
Surgery on diagnosis of endometrial cancer The main treatment for EC in the UK is hysterectomy.156
For stage I EC, patients usually have a TAHBSO; a radical hysterectomy is possible for stages II or III cancer,
and for stage IV cancer, debulking surgery (removal of as much cancer as possible).156 We assume 100%
adherence to TAHBSO for all stages of disease (see Table 56).
Prophylactic surgery It is assumed that female probands who either test positive for LS or are assumed
LS, who present with CRC and are younger than 45 years of age, are offered a TAHBSO at age 45 years,
on advice from our clinical experts. Those aged 45 years or older are offered an immediate TAHBSO. The
age of 45 years is chosen to coincide with the end of child-rearing.
Next, it is assumed that female relatives who either test positive for LS or are assumed LS, and who are
younger than 45 years, are offered a TAHBSO at age 45 years, again as suggested by our clinical experts.
Those aged 45 years or older are offered an immediate TAHBSO.
TABLE 56 Summary of parameters related to EC in the PenTAG cost-effectiveness model
Parameter Base-case value Source
Alternative
values
Cumulative incidence
of EC
0% by age 30 years, 2% by age 40
years, 8% by age 50 years, 23% by
age 60 years, 34% by age 70 years,
35% by age 80 years
Bonadona et al. 20112 N/A
Screening for EC Not modelled Assumption; see Screening for
endometrial cancer
N/A
Probability of dying
of EC each year
after diagnosis
9.9% in first year, 5.0% per annum in
years 2–3, 2.6% per annum in years
4–5, 0.7% per annum in years 5–10,
0% thereafter
ONS,148 NCIN149 and Cancer
Research UK150
N/A
continued
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TABLE 56 Summary of parameters related to EC in the PenTAG cost-effectiveness model (continued )
Parameter Base-case value Source
Alternative
values
Surgery
Use of TAHBSO on
diagnosis of EC
100% Expert opinion N/A
Age when given
prophylactic TAHBSO
45 years for individuals aged
≤ 45 years, otherwise age when
tested positive for LS
Expert opinion N/A
Acceptance of
prophylactic TAHBSO
for LS-positive
probands
55% Lorraine Cowley, Northern Genetics
Service, 2012,
personal communication
20%, 90%
Acceptance of
prophylactic TAHBSO
for LS-positive relative
55% Lorraine Cowley,
personal communication
20%, 90%
Probability of
mortality from
TAHBSO
0.0002 Average over studies reported in
Palomaki et al. 200965
N/A
Incidence of EC
after TAHBSO
0% Schmeler et al. 2006146 N/A
Cost of prophylactic
TAHBSO
£3322 £3104 (Department of Health
reference costs 2011/12:151 MA07,
MA08) inflated over 2 years; see Cost
of endometrial cancer prevention
N/A
Cost of TAHBSO
for EC
£3877 £3622 (Department of Health
reference costs 2011/12:151 MA06)
inflated over 2 years; see Cost of
surgery for endometrial cancer
N/A
Other treatment for EC
EC stage at diagnosis 73% stage I, 18% stages II and III,
9% stage IV
Based on US SEER database
(http://seer.cancer.gov)
via Havrilesky et al. 2009152
N/A
Use of radiotherapy 33% of stage I patients, 100% of
stage II and III patients, 50% of stage
IV patients
Havrilesky et al. 2009152 N/A
Cost of course
of radiotherapy
£5856 Havrilesky et al. 2009152 adjusted for
purchasing power and inflation
N/A
Chemotherapy for EC Six cycles of TAP (paclitaxel,
doxorubicin, cisplatin)
Havrilesky et al. 2009152 N/A
Use of chemotherapy 50% of stage II and III patients,
100% of stage IV patients
Havrilesky et al. 2009152 N/A
Cost of course of
chemotherapy (TAP)
£2974 Drug costs from eMit database,153
drug administration costs from NHS
reference costs 2008–9154
£1487 and
£5947
Cost of follow-up
management for EC
Zero See Cost of follow-up management of
endometrial cancer
N/A
eMit, electronic Market Information Tool; N/A, not applicable.
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Surgical complications Risks from hysterectomy vary by surgical technique (abdominal, laparoscopic,
vaginal) and include infection (3–33%), bleeding (3–9%), organ injury (1–3%) and rarely
death (0.00–0.04%).65
Death is the only complication following surgery modelled by any of the seven previous cost-effectiveness
analyses that considered endometrial cancer (see Table 55). Chen and colleagues85 report a mortality rate
of approximately 0.2% within 30 days of surgery for women aged 40–49 years for EC, which they took
from the US SEER database. Dinh and colleagues55 assumed a mortality rate of 0.02% for TAHBSO, which
they state is a weighted average of the rates reported in nine studies.65 Ladabaum and colleagues48
assumed a mortality rate of 0.03% for TAHBSO, citing Palomaki and colleagues.65 It appears that Kwon
and colleagues75 modelled no complications from prophylactic surgery.
As in previous cost-effectiveness analyses, we do not model infection, bleeding or organ injury owing to
low incidence. However, we model surgical mortality because it clearly has an impact on total QALYs. As in
the study by Dinh and colleagues,55 we assume a probability of death of 0.0002, which is a weighted
average of the rates reported in nine studies,65 although this only applies to prophylactic TAHBSO because
surgical mortality for EC patients is already included in the first year of EC mortality (see Mortality due to
endometrial cancer).
Oophorectomy in premenopausal women induces the sudden onset of menopause.65,146 However, we do
not model the effect of this because premature menopause can usually be managed with hormonal or
non-hormonal medication (which is inexpensive)146 and because we model oophorectomy at a minimum
age of 45 years, which is at the early stages of natural menopause.
Non-surgical treatment for endometrial cancer The approach to modelling treatments for EC varies
widely among the seven previous cost-effectiveness analyses that considered EC (see Table 55).
Ladabaum and colleagues (2011)48 assumed a cost of care for EC of $31,027, citing a study of the
cost-effectiveness of screening for EC.152 However, this figure is not given in the source publication and
Ladabaum and colleagues48 do not explain how they derived the figure from the publication. Further,
although not stated, we assume that this refers to the total mean lifetime cost of care for EC per person.
In addition, no indication is given of the nature of the treatment.
Yang and colleagues (2011)76 is the only study to model the treatment of EC in detail. They assumed the
following cumulative care costs: $127,711 for 5-year survival, $218,497 for 10-year survival and $164,685
for a cure, citing a US Medicare study157 published in 1989. They also assumed a cost of $8418 for
radiation treatment for EC, citing the University of California, San Francisco Department of Radiation
Oncology billing office. Patients with stage III or IV EC were assumed to receive six cycles of chemotherapy.
It appears that Chen and colleagues (2007)85 did not model care for EC. Kwon and colleagues (2008)75 say
that they did not include costs for adjuvant radiotherapy or chemotherapy. Indeed, it appears that they do
not include any costs for care for EC. Dinh and colleagues (2011)55 assume a total cost of $24,291 for
treatment for EC, citing Kwon and colleagues (2008).75 However, we do not see this figure in Kwon and
colleagues (2008).75
Ideally, we would cost for the treatment of EC using published clinical guidelines specifically for the UK.
However, NICE have not published such guidelines.158 Instead, treatment is described in two other
sources.156,159 The main treatment for EC in the UK is hysterectomy.156 This is sometimes followed by
radiotherapy, depending on the stage and grade of the cancer.156 Chemotherapy may also be used for
stage III or IV EC.156
Radiotherapy is recommended if there is a significant risk that the cancer could return in the pelvis, and
may also be used to slow the spread of cancer when a surgical cure is not possible.156 Two types of
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radiotherapy are used to treat EC: internal radiotherapy (brachytherapy) and external radiotherapy.
A course of external radiotherapy is usually given as an outpatient for 5 days a week, over approximately
4 weeks.156 Most women with stage II or III EC have radiotherapy after surgery.159
Chemotherapy for stage III or IV EC can be used after surgery to try to prevent the return of the cancer or,
in cases of advanced cancer, to slow the spread of the cancer and relieve symptoms.159 Chemotherapy
is usually given in an outpatient setting. There is a range of possible chemotherapies for EC, including
single-agent carboplatin or paclitaxel, combination carboplatin plus paclitaxel and combination paclitaxel,
doxorubicin and cisplatin (TAP).160
In a US study of the cost-effectiveness of screening for EC,152 the following costs were assumed:
l external beam pelvic radiotherapy for 33% of stage I cancer patients, 100% of stage II and III patients,
and 50% of stage IV patients at a total cost of $7895 per patient
l six cycles of TAP (paclitaxel, doxorubicin, cisplatin) chemotherapy for 50% of stage II and III patients
and 100% of stage IV patients at a cost of $19,462 for six cycles.
The following distribution of stages of EC at diagnosis was assumed in this study: 70% stage I,
17% stages II and III, 9% stage IV, 4% unknown (taken from the US SEER database).152
In our model, we assume the same treatment regime and distribution of stages of cancer as Havrilesky and
colleagues152 because it is consistent with the treatment of EC in the UK, described above. More precisely,
the following split across stages at diagnosis is assumed: 73% stage I, 18% stages II and III, 9% stage IV,
where the 4% unknowns are spread across the stages.
Disease natural history parameters and assumptions
Colorectal cancer
Colorectal cancer incidence
Colorectal cancer incidence rates
Colorectal cancer incidence rates in the model are dependent on the following patient characteristics:
l age
l sex
l whether or not the patient has had a previous CRC
l time since first CRC
l LS status.
These are in addition to risk-reducing measures, i.e. regular colonoscopies, as described in Effect of
colonoscopy on index colorectal cancer incidence rates and Effectiveness of colorectal cancer surgery.
Different annual incidence rates are provided for the eight combinations of sex, previous cancer (yes/no)
and LS status, and then risk-reducing measures are incorporated as HRs which have a simple multiplicative
effect on the incidence rate.
Incidence rates in the general population The incidence rates for males and females without previous
cancer and without LS were estimated from pooled registration statistics for CRC in England between
2006 and 2010 inclusive119,136–139 and the estimated population in the midpoints of those years.144
Following the methodology adopted by the ONS,119 we calculate the age-specific rate of CRC incidence by
dividing the number of CRC registrations within a time period by an estimate of the person-years lived
during that period. Incidence figures were pooled across 5 years to achieve a large sample size, but not
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further back than 2006 as such data may not reflect more recent developments in cancer detection
and registration.
Cancer registration statistics are not provided for each year of age but for age groups, generally of 5 years.
We assumed that within each of these age groups the incidence rate would remain constant. The resulting
cumulative risk of CRC for individuals without LS is shown in Figure 22.
We estimated the incidence of metachronous CRC (i.e. the incidence in individuals who had a previous
CRC) for individuals without LS by adjusting the incidence of first CRC by a HR of 1.4 for the first 3 years
after first CRC and 1.3 for the following 7 years, from Mulder and colleagues.161 Mulder and colleagues
studied 10,283 Dutch patients with CRC undergoing standard follow-up. After 10 years no additional
hazard was applied.
Incidence rates in patients with Lynch syndrome The estimation of CRC incidence rates in patients
with LS is complicated by a number of factors, as detailed in Table 57. Estimated incidence rates are also
much less often reported than estimated cumulative risks (normally to age 70 years).
We identified three papers – Palomaki and colleagues,65 Dinh and colleagues55 and Bonadona and
colleagues2 – which had searched the literature for papers reporting cumulative risk to age 70 years. We
also examined previous cost-effectiveness studies as identified in the systematic review of cost-effectiveness
for evidence on the risk of CRC in LS. The findings of these studies and their characteristics with regard to
possible biases are presented in Appendix 5.
Estimates of cumulative risk vary substantially according to whether or not there is proper correction for
ascertainment bias. Table 58 shows central estimates for cumulative risks from studies with appropriate
correction for ascertainment bias [excluding van Vliet and colleagues (2011)164 as parent-of-origin effects
are beyond the scope of this project]. A picture emerges that cumulative risks are generally higher for
males and may be higher for MSH2 carriers than for MLH1 carriers, but that cumulative risks for both of
these are significantly higher than those for MSH6 and PMS2 carriers, which are similar to each other.
Although some studies estimated cumulative risks for combined sets of MMR genes, these will ultimately
be less useful than risk estimates for individual genes because different case mixes will be observed and
less intense risk-reducing strategies may be suggested for MSH6 and PMS2.167
In cost-effectiveness analysis it is important not only to model the correct lifetime risk of a disease but also
to correctly model the cumulative risk over a range of ages to get the appropriate incidence rate at each
age. Of the studies presented in Appendix 5, which adjust appropriately for ascertainment bias, seven
report the cumulative risk of CRC to different ages, and these are summarised in Table 59.
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FIGURE 22 Cumulative risk of CRC for persons without LS (note: does not account for non-CRC mortality).
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TABLE 58 Cumulative risks to age 70 years for different MMR genes across studies with appropriate correction
for ascertainment
Genes included
Individuals
(male and female) Males Females
MLH1, MSH2,
MSH6, PMS2
45% (Jenkins et al. 2006114) 38% (Jenkins et al. 2006114)
MLH1, MSH2,
MSH6
35% (Bonadona et al. 20112) 38% (Bonadona et al. 20112)
34% (Stoffel et al. 2009106)
31% (Bonadona et al. 20112)
32% (Stoffel et al. 2009106)
MLH1, MSH2 47% (Alarcon et al. 2007165)
56% (Jenkins et al. 2006114)
27% (Quehenberger et al. 2005102)
33% (Alarcon et al. 2007165)
48% (Jenkins et al. 2006114)
22% (Quehenberger et al. 2005102)
MLH1 41% (Bonadona et al. 20112) 22% (Quehenberger et al. 2005102) 18% (Quehenberger et al. 2005102)
MSH2 48% (Bonadona et al. 20112) 30% (Quehenberger et al. 2005102) 25% (Quehenberger et al. 2005102)
MSH6 12% (Bonadona et al. 20112) 22% (Baglietto et al. 2010166) 10% (Baglietto et al. 2010166)
PMS2 20% (Senter et al. 2008105) 15% (Senter et al. 2008105)
TABLE 57 Sources of bias when estimating the incidence of CRC in persons with LS
Source
of bias Explanation Methods to avoid/overcome bias References
Ascertainment
bias
If LS is only sought in CRC patients below a
certain age or with a particular FH, this will
result in a biased identification of LS towards
families with more penetrance
Use genotype-restricted likelihood methods
conditioned on the likelihood of
ascertaining the proband (including the
phenotype of relatives if necessary)
Carayol and
Bonaïti-Pellie
(2004)162
MMR genes
included
It has been observed in many studies that
incidence rates are higher for mutations of
the MLH1 and MSH2 genes than for the
MSH6 and PMS2 genes. Studies which only
include a subset of the genes may
overestimate the average risk in LS patients
Screen for mutations in all four genes
If MMR functionality is assessed through
MSI or IHC as gatekeepers for germline
mutation testing, ensure that these are
sufficiently sensitive for all four genes
Bonadona
et al. 20112
Senter et al.
2008105
Mutation
detection
method
Sequencing techniques are less able to detect
large deletions and rearrangements
Screen for mutations using sequencing and
large deletions and rearrangements (usually
by MLPA)
Bonis et al.
20074
Inclusion
of VUS
Some mutations (usually missense mutations)
cannot be instantly classified as polymorphic
or deleterious without detailed investigation
of functional effect and segregation analysis.
Excluding or including all VUS may bias the
penetrance estimate
Make fullest attempts to classify
VUS correctly
Rasmussen
et al. 2012163
Presence of
founder
mutations
In countries with a significant prevalence of
founder mutations, the penetrance of the
founder mutation may be over-represented
Separate analyses with/without founder
mutations included
Risk-reducing
interventions
Incidence should be reduced when
risk-reducing interventions are implemented
Censor at the earliest risk-reducing
intervention
Bonadona
et al. 20112
Follow-up
period
If cancers informing the cumulative risk
analysis are from many decades ago there
may be differences in baseline incidence due
to changes in diet, etc.
Restriction to recent cancers or adjustment
for period
VUS, variants of unknown significance.
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TABLE 59 Studies which adjust appropriately for ascertainment bias reporting cumulative risks to various ages
Study (number of families) MMR genes included
Cumulative risk
of CRC for males
Cumulative risk
of CRC for females
Bonadona et al. 20112 (n= 537) MLH1, MSH2, MSH6 (From figure) (From figure)
20y 0.3% 20y 0.3%
30y 2.2% 30y 0.8%
40y 7.5% 40y 4.2%
50y 17.3% 50y 10.1%
60y 28.0% 60y 20.0%
70y 38.4% 70y 31.3%
80y 43.4% 80y 38.4%
van Vliet et al. 2011164 (n= 17)a MLH1, MSH2, MSH6, PMS2 Paternal origin Paternal origin
30y 3% 30y 5%
40y 7% 40y 12%
50y 16% 50y 22%
60y 29% 60y 34%
70y 41% 70y 42%
80y 48% 80y 47%
Maternal origin Maternal origin
30y 9% 30y 4%
40y 22% 40y 9%
50y 44% 50y 17%
60y 67% 60y 27%
70y 81% 70y 34%
80y 88% 80y 38%
Baglietto et al. 2010166 (n= 113) MSH6 50y 3% 50y 2%
60y 9% 60y 5%
70y 22% 70y 10%
80y 44% 80y 20%
Senter et al. 2008105 (n= 55) PMS2 50y 2% 50y 2%
60y 8% 60y 6%
70y 20% 70y 15%
Alarcon et al. 2007165 (n= 36) MLH1, MSH2 (From figure 2) (From figure 2)
40y 7% 40y 5%
50y 16% 50y 14%
60y 30% 60y 25%
(From abstract) (From abstract)
70y 47% 70y 34%
continued
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As the study by Bonadona and colleagues (2011)2 is recent and large [537 families compared with the next
largest study by Baglietto and colleagues (2010)166 with 113 families], and uses statistically rigorous
techniques to adjust for ascertainment bias and interventions, we decided that this was the most relevant
study and used its estimates of cumulative risk to inform CRC incidence in our model.
A logistic model for cumulative risk was fitted to this as in Dunlop and colleagues,101 with the following
parameterisation:
f (x) ¼ β0
1þ exp (− β1(x− β2))
(5)
These parameters are interpreted as follows: β0 is the hypothetical maximum risk (the proportion of
individuals who would be affected by CRC if there were no competing risks such as general mortality);
β1 controls the gradient of cumulative risk around β2; β2 is the time by which half the maximum risk has
been experienced. The parameter values were obtained by ordinary least squares regression and are shown
in Table 60. Bonadona and colleagues2 provide 95% CIs for the cumulative risks at age 70 years for males
and females (males 25–59%, females 19–50%), and these are used to inform the parameters of our
model in sensitivity analysis, such that we scale β0 to set the cumulative risk at age 70 years equal to the
lower and upper bounds of the CI (see Table 60; Figures 23 and 24). We do not conduct sensitivity
analyses on the parameters β1 and β2.
Figure 25 gives a comparison of the estimated cumulative risks of CRC for people with and without MMR
mutations. As can be seen, the lifetime cumulative risk is substantially greater for people with LS.
Figure 26 shows the impact of surveillance colonoscopy (as described in Effect of colonoscopy on index
colorectal cancer incidence rates) in reducing CRC incidence.
We estimated the risk of metachronous CRC for individuals with LS not undergoing regular surveillance
jointly for men and women, according to cumulative risk estimates from Parry and colleagues.168
TABLE 59 Studies which adjust appropriately for ascertainment bias reporting cumulative risks to
various ages (continued )
Study (number of families) MMR genes included
Cumulative risk
of CRC for males
Cumulative risk
of CRC for females
Jenkins et al. 2006114 (n= 17) MLH1, MSH2, MSH6, PMS2 50y 41% 50y 22%
70y 45% 70y 38%
Jenkins et al. 2006114 (n= 12) MLH1, MSH2 50y 51% 50y 36%
70y 56% 70y 48%
Quehenberger et al. 2005102 (n= 84) MLH1, MSH2 30y 0.5% 30y 0.6%
40y 2.3% 40y 2.5%
50y 8.9% 50y 9.0%
60y 19.8% 60y 17.6%
70y 26.7% 70y 22.4%
80y 28.5% 80y 23.7%
a Reproduced with permission from van Vliet CM, Dowty JG, van Vliet JL, Smith L, Mead LJ, Macrae FA, et al.
Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genes.
Hum Mutat 2011;32:207–12. Copyright © 2011, Wiley-Liss, Inc.
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TABLE 60 Parameters for CRC incidence model in patients with LS found by least squares regression
Parameter Base case Sensitivity analysis
β0 Male 0.464 Male 0.303–0.715
Female 0.435 Female 0.265–0.697
β1 Male 0.107 None
Female 0.108
β2 Male 55.5 None
Female 61.3
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FIGURE 24 Model of cumulative risk of CRC for female MMR mutation carriers.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0C
u
m
u
la
ti
ve
 r
is
k 
o
f 
C
R
C
 f
o
r 
m
al
e 
M
M
R
m
u
ta
ti
o
n
 c
ar
ri
er
s
Age (years)
Data
Model
95% CI
10020 40 60 80
FIGURE 23 Model of cumulative risk of CRC for male MMR mutation carriers.
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As patients in the study by Parry and colleagues168 underwent regular colonoscopic surveillance, and given
that we require incidence rates of metachronous CRC without regular surveillance, we apply a HR equal
to the inverse of the HR for colonoscopic surveillance as described in Effect of colonoscopy on index
colorectal cancer incidence rates. As a result, if these individuals do undergo colonoscopic surveillance, the
incidence of metachronous CRC will be equal to that reported by Parry and colleagues. Figure 27 shows
the cumulative risk of metachronous CRC in the PenTAG model for individuals with LS according to
whether or not they received regular colonoscopic surveillance.
Dukes’ stage on diagnosis
The Dukes’ stage on diagnosis is an important predictor of survival. Here we describe our assumptions and
data sources for the Dukes’ stage on diagnosis where there are no LS surveillance colonoscopies. The
effect of colonoscopy on Dukes’ stage is addressed below (see Effect of colonoscopy on Dukes’ stage of
incident colorectal cancers).
We assumed that the Dukes’ stage on diagnosis would be independent of age, sex, LS status and whether
it was the first (index) CRC or a metachronous CRC (Fajobi and colleagues169 conclude that Dukes’ stages
for metachronous CRC are no worse than for index CRC, and there was no consensus on whether or not
they might be better). We also assumed that Dukes’ stage on diagnosis of metachronous CRC was
independent of the stage of the index CRC and that the Dukes’ stage was independent of the CRC site.
Dukes’ stage was assumed to depend only on whether or not the person was undergoing LS
surveillance colonoscopies.
We estimated the Dukes’ stage distribution for individuals not undergoing LS surveillance colonoscopies by
using data published in the National Bowel Cancer Audit Report (2011),135 as shown in Table 61. This
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FIGURE 25 Cumulative risks of CRC for people with and without MMR mutations.
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FIGURE 26 Impact of colonoscopy (age 25–75 years) in reducing cumulative risk of CRC for people with LS.
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report is based on data collected in England and Wales relating to patients diagnosed with bowel cancer
between 1 August 2009 and 31 July 2010. We did not use data published in the 2012 report because it
did not give stages in Dukes’ classification but in the TNM classification, and it was not possible to map
these to Dukes’ stages because the incident population is not described by full TNM codes (e.g. T1N0M0),
but is characterised by tumour, lymph nodes and distant metastases separately, with a significant number
of data missing.
Colorectal cancer incident site
As stated previously (see Patient bowel state), we model two sections of the bowel: the colon and the
rectum. We grouped rectosigmoid cancer [International Classification of Diseases, Tenth Edition (ICD-10)
code C19] into rectal cancer. The site of incident CRCs was dependent on sex, whether or not the person
has LS and any previous surgery (Table 62).
TABLE 61 Dukes’ stage at diagnosis
Dukes’ stage Colon Rectosigmoid Rectum All sites
Proportion with Dukes’ stage
(excluding unknown)
Dukes’ A 1771 206 1495 3472 0.164
Dukes’ B 4831 349 1518 6698 0.317
Dukes’ C 3789 317 1617 5723 0.271
Dukes’ D 3482 331 1416 5229 0.248
Unknown 3875 388 2727 6990
Total (excluding
unknown)
13,873 1203 6046 21,122
Total (including
unknown)
17,748 1591 8773 28,112
Source: adapted from table 4.2 of the National Bowel Cancer Audit 2011 report.135 Copyright © 2011, reused with the
permission of the Health and Social Care Information Centre. All rights reserved.
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FIGURE 27 Cumulative risk of metachronous CRC for individuals with LS.
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It is assumed that all CRCs are colon cancers following anterior resection, and that all CRCs are rectal
cancers following subtotal colectomy. If there is no previous surgery or a previous segmental resection, the
probability of the CRC being situated in the colon for a person with LS is estimated as 0.94, based on Dinh
and colleagues.55 For males and females without LS, the probability of colon cancer is estimated from ONS
cancer registration statistics for patients aged under 50 years.119 Estimating from patients of all ages would
not significantly affect the proportion estimated to be situated in the colon.
Mortality due to colorectal cancer
We assume that mortality due to CRC depends on the following:
l Dukes’ stage at diagnosis
l years since diagnosis
l age at diagnosis
l LS status (see Mortality due to colorectal cancer for patients with Lynch syndrome).
We did not consider the effect of the following on mortality due to CRC:
l patient’s sex
l site of CRC
l surgery for CRC.
The baseline annual rate of mortality due to CRC was derived from data provided by the NCIN170 by
extracting 1-, 2-, 3-, 4- and 5-year relative survival from survival curves and assuming constant rates of
mortality within each year (Table 63 and Figure 28). It was assumed that the mortality rate for 4–5 years
since diagnosis also applies after 5 years (Table 64).
TABLE 62 Probability that incident CRC is situated in the colon
Previous surgery With LS
Without LS
Male Female
None 0.94 0.58 0.61
Segmental resection 0.94 0.58 0.61
Subtotal colectomy 0.00 0.00 0.00
Anterior resection 1.00 1.00 1.00
Proctocolectomy N/A N/A N/A
N/A, not applicable.
N/A as zero CRC incidence following proctocolectomy.
TABLE 63 Relative survival of patients with CRC by Dukes’ stage across all ages
Years since diagnosis Dukes’ A Dukes’ B Dukes’ C Dukes’ D
1 0.969 0.917 0.815 0.380
2 0.965 0.872 0.681 0.193
3 0.957 0.831 0.583 0.116
4 0.945 0.799 0.522 0.083
5 0.932 0.770 0.477 0.066
Source: NCIN.170
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The assumption that the mortality rate after 5 years is equal to the mortality rate for 4–5 years is likely to
be a slight overestimate of CRC mortality (Table 65). The result of a slight overestimate of CRC mortality in
the model would be a slight improvement in the cost-effectiveness of strategies with high yield of
LS mutations.
The HRs for CRC mortality by age, compared with CRC mortality across all ages, were estimated
using net survival statistics from the ONS,147 and are shown in Table 66. Details of calculations are given
in Appendix 6.
Mortality due to metachronous colorectal cancer
Mortality due to metachronous CRC was modelled by adding together the mortality rates for both the
index and metachronous CRC as calculated above, assuming that mortality from the metachronous cancer
would be no different from mortality from the index cancer for the same Dukes’ stage [as assumed by, for
example, Mvundura and colleagues (2010)54 and Dinh and colleagues (2011)55]. The same approach is
used independent of the LS status of the patient. As the mortality rates are dependent on the time since
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FIGURE 28 Colorectal cancer survival in model.
TABLE 64 Mortality rate from CRC (per 100,000 person-years) by Dukes’ stage
Years since diagnosis Dukes’ A Dukes’ B Dukes’ C Dukes’ D
0–1 3102 8709 20,460 96,729
1–2 419 5000 17,971 67,733
2–3 843 4761 15,465 51,116
3–4 1279 4000 11,060 32,857
> 4 1400 3667 9068 23,375
TABLE 65 One-, 5- and 10-year survival of CRC
Years
since diagnosis
Male
colon cancer
Female
colon cancer
Male
rectal cancer
Female
rectal cancer
Model
CRC
1 0.730 0.722 0.788 0.788 0.764
5 0.544 0.551 0.546 0.575 0.544
10 0.501 0.508 0.473 0.521 0.436
Source: Bowel cancer survival statistics, Cancer Research UK.171 Copyright © 2013, Cancer Research UK.
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diagnosis in the model, we keep track of time since diagnosis of the index cancer and the
metachronous cancer.
Although the data informing mortality due to CRC for people without LS will include additional mortality
due to metachronous CRC, the incidence of metachronous CRC in the data is likely to be very small so
would have a negligible effect on observed survival rates. Similarly, it is possible that mortality due to CRC
for patients with LS (see Mortality due to colorectal cancer for patients with Lynch syndrome, below)
would also include additional mortality due to metachronous CRC. However, we believe that this is
unlikely to have a significant impact, and indeed our estimate is that mortality due to CRC is lower for
some patients with LS.
Mortality due to colorectal cancer for patients with Lynch syndrome
Although it has long been believed that CRC patients with LS have better survival than those with sporadic
CRC, recent evidence is not unanimous in support of this.172 In a previous model of the cost-effectiveness
of testing for LS, Mvundura and colleagues54 cite a systematic review by Popat and colleagues (2005)173 to
make adjustments to survival for individuals with CRC and LS. Popat and colleagues173 derive HRs for
survival according to the MSI phenotype, which is observed in most LS CRCs and around 15% of all CRCs
(these correspond to the sensitivity and specificity of MSI). In another model of the cost-effectiveness of
testing for LS, Dinh and colleagues (2011)55 perform a meta-analysis and estimate a HR of 0.53 for
mortality due to CRC between individuals with and without LS.
There are a number of considerations to make when estimating such a HR. Firstly, many of the studies
cited investigate patients with tumours showing the MSI phenotype, rather than LS. Whereas most LS
CRCs show the MSI phenotype, it is not the case that most tumours showing the MSI phenotype are
LS CRCs.174 Secondly, survival may be reported as being better in LS CRC patients because of other
predictive factors such as age and stage at diagnosis, as LS CRCs are characterised by early onset and
surveillance may be in place to identify CRCs at an earlier stage. These factors should be accounted for
when estimating a HR for mortality due to CRC between individuals with and without LS. Thirdly, as LS
CRC patients are more likely to develop metachronous CRC, there may be differences in how these are
treated statistically; for example, if patients are not censored when they develop metachronous CRC, then
mortality would be confounded by additional mortality from the metachronous CRC. Additionally, if
patients are retrospectively recruited to studies on the basis of FH, it is more likely that less penetrant
alleles will be included.175
As Popat and colleagues (2005)173 investigate the HR for the MSI phenotype and not for LS, we do not use
these results. We followed citations from Coate and colleagues (2010)172 and summarise results in Appendix 7.
Of the studies we identified, only one [Barnetson and colleagues (2006)175] was in a similar setting to that
in our model. In this study, 870 patients diagnosed with CRC in Scotland under the age of 55 years were
tested for mutations in MLH1, MSH2 and MSH6 and were subsequently followed up to investigate the
effect of LS on CRC survival. This is a similar setting to that in our model as patients were selected by age
alone, and not according to FH, and were genotyped. The conclusion of this study is that after adjusting
for tumour stage [split by localised (stages I–II)/metastatic (stages III–IV)] there is no significant effect on
TABLE 66 Hazard ratios for CRC mortality by age at diagnosis, compared with CRC mortality across all ages
Age group
HR for CRC mortality
First year Following 4 years Thereafter
< 70 years 0.599 0.972 1
70–79 years 0.956 0.966 1
≥ 80 years 1.797 1.116 1
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survival of LS status. The Kaplan–Meier curves for survival in metastatic cancer seem relatively convincing of
the argument that there is no effect, but those for survival in localised cancer are less convincing; it seems
that a lack of statistical power may have led to the conclusion that there is no survival benefit, and
certainly there is not enough evidence to suggest that there is no survival benefit in localised disease from
having LS.
To obtain an alternative estimate of the effect of LS status on survival for localised CRC, we use results
from Lin and colleagues (1998).176 Lin and colleagues176 retrospectively identified 75 CRC cases with
confirmed MLH1/MSH2 mutations and compared their survival to 820 CRC cases believed to be from the
general population. Although Lin and colleagues recruited LS families in a different way from that
proposed in our model, we believed that this was the next most appropriate study as it includes a large
number of CRC cases with proven MMR mutations and does not include non-genotyped cases, adjusts for
the CRC stage and reports a HR from a Cox regression. Lin and colleagues do not censor at the time
of metachronous CRC incidence, which could lead to a HR estimate biased towards 1, but the rate of
metachronous cancer was relatively low (around 2% annually) so we believe that this would not have a
significant impact. It is also notable that the data in Lin and colleagues’ study are quite old, with LS CRC
diagnosed between 1945 and 1991. The comparator cohort included patients diagnosed between 1965
and 1996. The control cohort could therefore be expected to have slightly improved survival due to
improved medical and surgical techniques; this would also bias the HR estimate towards 1, although this
would likely have a minor effect as patients deemed to have suffered from postoperative mortality
were excluded.
In our model we assume that the HR for survival for LS carriers is 0.57 for Dukes’ stages A and B and 1 for
Dukes’ stages C and D (Figure 29). We perform two scenario analyses in which these HRs are altered.
In the first we use a HR of 1 for all Dukes’ stages and in the second we use a HR of 0.57 for all
Dukes’ stages.
Gynaecological cancers
Endometrial cancer
Endometrial cancer incidence
We assume that the incidence of EC is zero for women without LS, because it is much lower than the
incidence rate for women with LS, which is given below. In particular, given that the lifetime risk of uterine
cancer for women in the UK is 2.4%,8 and that EC accounts for most cases of uterine cancer, the lifetime
risk of EC for women in the UK is nearly 2.4%. This compares with the estimate of 1.7% obtained by
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FIGURE 29 Survival for patients with CRC according to LS status and Dukes’ stage.
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
Ladabaum and colleagues (2011)48 from the US SEER database.177 By contrast, we estimate a lifetime risk
of about 34% for women with LS.
As explained previously (see Surgery for endometrial cancer), we also assume that prophylactic surgery for
EC completely eliminates the risk of this cancer. Henceforth, we discuss the incidence of EC for women
with LS who have not had prophylactic surgery for EC. This applies to both female probands who are
diagnosed with CRC and their female relatives who have LS.
Of the seven analyses that incorporate EC,48,55–57,75,76,85 only three [Chen and colleagues (2007),85 Kwon
and colleagues (2008)75 and Yang and colleagues (2011)76] model the specific stage (I to IV) of cancer, and
Yang and colleagues (2011)76 is an extension of Chen and colleagues (2007)85 (see Table 89). The stage of
EC is not incorporated in the PenTAG model. Instead, individuals are deemed to either have the cancer or
not. Indeed, given that we assume no screening for EC (see Screening for endometrial cancer), we believe
that there is no reason to model the stage of the disease.
A recent study by Bonadona and colleagues2 of 10,283 individuals from several French clinics investigated
the risks of various cancers for individuals with LS. All these participants were from 537 families in which
MMR mutations were confirmed. In total, 2662 people were genotyped and, of these, 1633 were found
to have mutations. Most families had the MSH1 or MSH2 mutation, and a small number had the MSH6
mutation. For EC and OC, women were censored at the time of gynaecological surgery. The estimated
cumulative risk of EC by the age of 70 years was 34% and for OC 9%. The estimated cumulative risk of
EC was 0% by age 30 years, 2% by age 40 years, 8% by age 50 years, 23% by age 60 years, 34% by
age 70 years and 35% by age 80 years.
We use the rates of incidence of EC from the study by Bonadona and colleagues (2011)2 in our model
because (1) the study was large; (2) as far as we can tell, it appears methodologically sound; (3) it was
conducted recently; (4) a statistical technique was used to correct for ascertainment bias due to
recruitment of families with multiple cases of cancer; and (5) the rates are consistent with those found in
other studies, particularly as explained in the literature review of Palomaki and colleagues (2009),65 as
discussed below. However, as acknowledged by the authors, the cumulative risk of EC becomes rather
uncertain above about 55 years of age.
In their cost-effectiveness model, Ladabaum and colleagues (2011)48 assumed that the cumulative
incidence of EC by age 70 years is 37%, which is similar to our estimate of 34%. Ladabaum and
colleagues (2011) cite Palomaki and colleagues (2009)65 and Horner and colleagues (2009)177 as the
sources for their estimate. In their review of the literature, Palomaki and colleagues (2009)65 found that
estimates are variable, ranging from 31% to 64% across five studies. They suspect that some of the
higher estimates may be subject to FH bias.
In a study of 147 US families with LS, Stoffel and colleagues (2009)106 used a statistical method to control
for ascertainment bias to estimate a risk of EC of 39% by age 70 years. This estimate is also similar to our
estimate of 34%.
Mortality due to endometrial cancer
For women with EC, the rate of mortality due to EC was assumed to vary according to time since
diagnosis. As the stage of EC is not modelled, the rate of mortality was assumed to be the same for all
affected patients. In addition, mortality was assumed to be equal for women with and without LS.55,178
Data sources Three sources of EC survival data were identified for women in the general population of
England.148–150 The Cancer Research UK data150 included ONS data148 and unpublished research
commissioned by Cancer Research UK (Table 67). Cancer Research UK and ONS data are both reported as
age-standardised relative survival, which is calculated by weighting age-specific relative survival estimates
by the age distribution of uterine cancer in England and Wales in 1996–9. ONS data also report relative
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survival according to age groups and overall relative survival not age standardised (see Table 67).148 Survival
in the NCIN UK cancer e-Atlas149 is reported at 1, 3 and 5 years after diagnosis without age
standardisation (Table 68).
Peninsula Technology Assessment Group modelling approach We assumed that survival data for
uterine cancer were appropriate to use for EC on the basis that EC comprises the vast majority of uterine
cancer cases. For example, in 2010, of 6834 registrations of uterine cancer (ICD-10 codes C54–C55), 6409
(93.8%) were EC, while only 44 (0.6%) had a specified location other than the endometrium and 381
(5.6%) were of an unspecified location in the uterus.119
A piecewise constant hazard rate was assumed for death from EC which was fitted to survival data points
at 1, 3, 5 and 10 years (Tables 69 and 70). Age-standardised survival data were used when available (1, 5
and 10 years). For 3-year survival, non-standardised relative survival was used because age-standardised
relative survival was not available and because the effect of age standardisation appears to be small at 1
and 5 years. For survival beyond 10 years, a hazard rate of zero was assumed for death from EC. Figure 30
shows the result of our modelling.
TABLE 67 Relative survival for uterine cancera
Years since diagnosis Age-standardised relative survival (%) Non-standardised relative survival (%)
1 90.1 91.0
5 77.3 79.2
10 74.5 NR
NR, not reported.
a ICD-10 codes C54, C55.
Sources: Cancer Research UK150 and ONS.148
TABLE 68 Relative survival from uterine cancer in England, 2000–8 (not age standardised)
Years since diagnosis Relative survival (%)
1 90.5
3 81.4
5 77.9
Source: NCIN UK Cancer e-Atlas.149
TABLE 69 Selected EC relative survival data points for model
Years since diagnosis Relative survival (%) Source
1 90.1 ONS148
3 81.4 NCIN UK Cancer e-Atlas149
5 77.3 ONS148
10 74.5 Cancer Research UK150
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135
Mortality due to other causes
Death from other causes was modelled using separate mortality rates for men and women, provided in life
tables for England and Wales (2008–10),179 adjusted to remove the proportion of mortality due to CRC.
The proportion of mortality caused by CRC was estimated by dividing the number of deaths from CRC in
each age group by the total number of deaths in that age group, using mortality data for England in
2010.143 We did not adjust for mortality from EC as this accounted for < 1% of deaths in the general
population (whereas CRC accounted for 2.8%), and we did not adjust for mortality from other
LS-associated cancers as these are not included in our model.
Effectiveness parameters and assumptions
Diagnostic effectiveness parameters and assumptions
Diagnostic effectiveness is made up of the following three key components, which we discuss below:
l test accuracy
l adherence to testing
l numbers of probands and relatives per year in England, and proportion of probands and relatives
with LS.
TABLE 70 Endometrial cancer survival parameters used in the PenTAG model
Years since diagnosis Hazard of death from EC (deaths per 1000 EC patients per year)
0–1 104.25
1–3 50.77
3–5 25.84
5–10 7.38
10+ 0.00
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FIGURE 30 Relative survival of women with EC in the UK.
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These are important to both short- and long-term outcomes. For instance, adherence can affect the
accuracy of a strategy; a higher adherence to genetic testing will make a strategy more accurate as
genetic testing has a higher accuracy than diagnosing a patient using FH. Diagnostic accuracy and the
proportion of patients diagnosed with (and without) LS have important implications for the long-term
cost-effectiveness of a strategy.
Test accuracy
Estimates of test accuracy (sensitivity and specificity) were taken from the available literature (Table 71).
Accuracies of tests (e.g. IHC, MSI) are almost always available only for tests in isolation. One exception is
the BRAF test, for which we have accuracy information after an IHC test with abnormal MLH1 staining
[Palomaki and colleagues (2009)65] and after an MSI test [Domingo and colleagues (2005)183]. Given that
information on the accuracy of tests in sequence is generally lacking, the accuracy of such tests is assumed
as if it were applied in isolation.
Some test accuracies refer to specific genes; the EGAPP supplementary evidence review reports a different
sensitivity for genetic testing of PMS2 compared with MLH1, MSH2 and MSH6, and there are different
sensitivities for each of MLH1, MSH2 and MSH6 for MSI. The sensitivity for PMS2 is not reported owing to
lack of evidence, but the indication is that it is lower than those for MLH1 and MSH2. Therefore, as in
Palomaki’s review,65 we assume it is the same as for MSH6. BRAF has a sensitivity specifically reported for
abnormal MLH1 IHC results. For tests and accuracies where genes are not specified, we have assumed that
the accuracies are the same for every gene and therefore can refer to LS as a whole, rather than to
individual genes. In some cases, where accuracies are not available for all genes, there may be evidence
that this can be extrapolated to all LS genes. One example concerns the accuracy of a BRAF test after MSI
testing. A study by Domingo and colleagues (2004)84 on BRAF after MSI only considered MLH1 and MSH2;
their follow-up [Domingo and colleagues (2005)183] additionally considered MSH6 and suspected LS cases
where a genetic mutation had not been identified. Domingo’s study indicates that V600E is only found in
sporadic tumours, and so a BRAF test will not behave differently for the various LS genes. We therefore
extrapolated the sensitivity and specificity of BRAF after MSI to PMS2.
As already stated, the assumed accuracy of FH is that attributed to the AC II (as our probands already fulfil
the Revised Bethesda criteria), which has sensitivity 39% and specificity 98% according to sources
TABLE 71 Accuracies of diagnostic tests for LS
Test Sensitivity Specificity Source
MSI
MLH1 and MSH2 0.89 0.902 Palomaki et al. 200965
AssumedMSH6 0.77
PMS2 0.77
IHC 0.770 0.888 Palomaki et al. 200965
BRAF after IHC MLH1 abnormal 1.00 0.69 Palomaki et al. 200965
BRAF after MSI 1.00 0.40 Domingo et al. 200484
AC II 0.39 0.98 Hampel et al. 2005,103 Salovaara et al. 2000,180
Green et al. 2009,181 Barnetson et al. 2006,175
Balmana et al. 2008182
Genetic test MLH1, MSH2 and MSH6
(for probands)
0.90 0.9997 Dinh et al. 2011,55 Palomaki et al. 200965
Genetic test PMS2 (for probands) 0.62 0.9997 Dinh et al. 2011,55 Palomaki et al. 200965
Targeted genetic test (for relatives) 1 1 Assumed
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identified by Ladabaum.48 This value is taken from the original sources: Hampel and colleagues (2005),103
Salovaara and colleagues (2000),180 Green and colleagues (2009),181 Barnetson and colleagues (2006)175
and Balmana and colleagues (2008).182 These papers compare the AC II to genetic testing as a gold
standard, where a variety of genes (at least MLH1 and MSH2) are assessed. Furthermore, they are from a
variety of populations: one US, one Canadian and three European, of which one was UK-based. The
sensitivity and specificity of the AC II does not seem to be related to population or number of genes, with
mixed values coming from each individual study. The specificity estimates are more consistent than the
estimates of sensitivity; however, the UK study, which seems to be most relevant and looks at all genes
except PMS2, has a sensitivity of 42% and a specificity of 98%, suggesting that the average values of
sensitivity and specificity from Ladabaum48 (39% and 98%, respectively) are acceptable.
For simplicity, and in common with other cost-effectiveness models [Mvundura and colleagues (2010),54
Ladabaum and colleagues (2011)48], we assume that the test accuracies apply to all qualities of tumour
sample and that all tests are available and always successfully produce a result. In reality, some tests may
not be available, depending on the laboratory or provision of usable tumour tissue, and some tests
may ‘fail’. There is one exception made in the model: the failure rate is specifically included in the
sensitivity of the IHC test [Palomaki and colleagues (2009)65] because it is the only test to state it explicitly.
The sensitivity of diagnostic genetic testing for genes MLH1, MSH2 and MSH6 in probands is
conservatively set to 90% as it was in Dinh and colleagues’ report in 2011.55 This is to reflect genetic
variants of uncertain significance and other such factors. We consider targeted genetic testing in relatives
to be 100% accurate.
The sensitivities and specificities of these individual tests for probands are plotted in Figure 31. This shows
that BRAF has the highest sensitivity for any individual test, regardless of which test it is conducted after,
ACII
GT M126
GT PMS2
MSI M12
MSI M6P2
BRAF |MSIBRAF |IHC
MLH1 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0
Se
n
si
ti
vi
ty
1-specificity
IHC
0.70.1 0.2 0.3 0.4 0.5 0.6
FIGURE 31 Receiver operating characteristic plot of individual tests. Here ‘|’ means ‘given’ or ‘after’, for example
‘BRAF|MSI’ means ‘BRAF given MSI’ or ‘BRAF after MSI’. GT, genetic testing; GT M126, combined diagnostic
mutation testing for genes MLH1, MSH2 and MSH6; GT PMS2, diagnostic mutation testing for PMS2 gene; MSI
M12, MSI test in individuals with MLH1 or MSH2 constitutional mutations; MSI M6P2, MSI test in individuals with
MSH6 or PMS2 constitutional mutations.
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though this does affect the specificity. Genetic testing has the highest specificity, but different sensitivity
depending upon whether testing for PMS2 or MLH1, MSH2 and MSH6. In this figure, MSI’s difference in
accuracy for genes MLH1 and MSH2 compared with MSH6 and PMS2 is illustrated, rather than the overall
values of sensitivity and specificity for MSI. It is important to remember that in this instance MSI is one test,
influenced by the proband’s characteristics, not two separate tests as is the case for genetic testing. As is
typical, there appears to be a general pattern that those tests that are more sensitive are less specific and
vice versa.
Acceptance of testing and surveillance
Given that there is little published information on acceptance of testing, and that what evidence there is
seems variable, we have made several assumptions:
l The rate of acceptance of a test is independent of any previous tests the patient has taken.
l Acceptance of one genetic test implies acceptance of all.
l The rate of acceptance of IHC and BRAF is assumed equal to that of MSI (100%49) as they are all
preliminary tumour tests. Some clinicians might consider the results of the BRAF test enough of an
indicator for familial cancer that genetic counselling should be carried out prior to the test. If so, this
might influence acceptance of the BRAF test.
l Genetic counselling includes an investigation into FH and therefore, for strategies using genetic
counselling, the rate of acceptance of FH screening is included in the rate of acceptance of genetic
counselling. For patients who decline genetic counselling and for strategies where genetic testing is not
offered, there is a separate rate of acceptance of FH screening, initially set to 1.
Assumed acceptance rates are given in Table 72. Where possible, and if applicable, we checked the
original sources, and if necessary, recalculated the values.
Initial adherence to the surveillance strategy for CRC offered to the probands and relatives who test LS
mutation positive or LS assumed are given in Table 73. Of these adherence estimates, there was
substantial evidence only for relatives who test mutation positive. Probands who test mutation positive are
assumed to have a similar level of adherence given lack of evidence to the contrary. The rates of
TABLE 72 Rates of acceptance of diagnostic tests and genetic counselling
Test Proband/relative
Acceptance
rate (%) Source
MSI Proband 100 Ramsey et al. 200349 confirmed by expert
Ian Frayling (2012, personal communication)
IHC Proband 100 Assumed, see text
BRAF Proband 100 Assumed, see text
First genetic test (proband) Proband 90 Ladabaum et al. 201148
Second genetic test (proband) Proband 100 Assumed
Genetic counselling (proband) Proband 92.5 Clinical experts (IMF) gave range 90–95%
FH assessment after genetic
test (proband)
Proband 100 Assumed (as included in counselling)
FH assessment when genetic
counselling or test declined
(proband)
Proband 100 Assumed
Genetic test (relative) Relative 96a Calculated from Palomaki et al. 200965
Genetic counselling (relative) Relative 45a Calculated from Palomaki et al. 200965
a Numbers recalculated by PenTAG.
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adherence for probands and relatives assumed to have LS are taken from Ladabaum and colleagues
(2011)48 and based on expert opinion.
Numbers of probands and relatives with and without Lynch syndrome
Numbers of probands
The total number of probands aged < 50 years in England, 1699, was extracted from the latest edition
of the ONS cancer registration statistics.119 As the number of familial adenomatous polyposis (FAP) patients
in this group will be minimal (current practice indicates that nearly all FAP patients would now be
identified and managed before developing CRC), we believed it appropriate to assume that this value was
0, and that all probands would therefore have CRC as a result of sporadic cancer or due to LS. Other
hereditary CRCs are possible, but are not well defined and make up a small proportion of those diagnosed
with CRC, and as such are not considered here.
The number of TP LS probands is calculated using the prevalence of LS among CRC patients under age 50
years (taken from Hampel and colleagues120) of 8.4%. These are then subdivided into the number of each
gene using the breakdown from the supplementary evidence in the EGAPP review, which states that for all
true LS-positive patients, 32% will have a MLH1 mutation, 39% a MSH2 mutation, 14% a MSH6
mutation and 15% a PMS2 mutation.65 These values are consistent with those reported currently by UK
genetics centres, where there is currently no systematic testing for LS. Countries where systematic testing
already occurs appear to have a different distribution of genes, for instance Sjursen and colleagues184
report 18% MLH1, 50% MSH2, 26% MSH6 and 6% PMS2 mutations in Norway. We use these values in
a sensitivity analysis.
In strategy 3, outcomes of the IHC test need to correspond to the relevant genes, so the false-positive
IHC results are also split by gene, using values from Mvundura and colleagues54 (90% MLH1, 6% MSH2,
2% MSH6, 2% PMS2).
Numbers of relatives
Published data Many published studies of LS contain data regarding the number of probands identified,
the number of relatives identified (and, of these, how many are FDRs of the proband), the number of
relatives counselled, the number of relatives receiving predictive testing for LS and the number of relatives
testing positive for the family mutation (although in many cases not all of these are reported).
We collected a number of studies which provide these data and noticed substantial heterogeneity, which
suggested a meta-analysis would not be appropriate. We therefore attempted to identify studies with
particular relevance to the NHS.
TABLE 73 Initial rates of adherence to LS surveillance for CRC
Patient characteristic
Initial adherence to
surveillance (%) Source
Proband tested LS mutation positive 80 Ladabaum et al. 201148
Proband LS assumed 70 Expert opinion from Ladabaum et al. 201148
Relative tested LS mutation positive 80 Ladabaum et al. 201148
Relative LS assumed 50 Expert opinion from Ladabaum et al. 201148
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Barrow and colleagues (2009) Barrow and colleagues (2009)121 recruited LS patients referred to
the Manchester Regional Genetics Service and performed statistical analyses to estimate the risk of
extracolonic cancers in mutation carriers (in a previous study81 they estimated the risk of CRC). Although
their methodology for risk estimation has been criticised by Bonadona and colleagues (2011),2 their
recruitment statistics are not questioned and are valuable in this setting. The authors report that there
were 121 families on the database, which means there were up to 121 probands referred (some probands
may have been discovered to be from the same family, but this is not reported). The total number of
family members on the database was 1420, which means that at least 1299 relatives were identified. This
gives an estimate that an expected 1299/121= 10.7 relatives would be identified for each proband. Of the
1420 family members, 249 were proven mutation carriers. If we assume that 121 probands are accounted
for in the 249, this leaves 128 relatives testing positive. If we assume that 0.45 of those tested are found
to be carriers, this suggests that 284 of the 1299 relatives identified would be tested. This corresponds to
0.218 of the relatives identified. We estimate that the ratio of relatives tested to probands identified from
this study is 284/121= 2.35.
As in this study a FDR of a proven mutation carrier with a LS-associated cancer is labelled a ‘putative
carrier’ (n= 331) and a number of relatives were obligate carriers (n= 90), it is possible that the number of
relatives being recommended for testing would be lower.
Hampel and colleagues (2008) Hampel and colleagues (2008)120 attempted to identify LS in 1566 CRC
patients (unselected for age or FH) and identified 44 patients with deleterious mutations. They
subsequently attempted to identify, counsel and test relatives appropriately, and tested 249 relatives. This
gives a ratio of 5.66 relatives tested to each proband. If we assume that 46% of relatives identified would
be counselled, of which 95% would be tested,65 then this suggests that around 582 relatives would have
been identified, with a ratio of 13.24 relatives identified to each proband.
Palomaki and colleagues (2009) Palomaki and colleagues (2009)65 identified seven studies (none of
them from the UK) to estimate what proportion of relatives would be counselled and tested. They
performed a meta-analysis on these two proportions and eliminated one study from the meta-analysis for
the proportion counselled as it was a significant outlier. They concluded that the proportion of relatives
who would be counselled was 0.46 (95% CI 0.41 to 0.50) and the proportion of those counselled who
would be tested was 0.95 (95% CI 0.93 to 0.97). The authors did not suggest a figure for how many
relatives would be identified for each proband, but they did note that two studies focused on large
families and that after excluding these the range of ratios was 2.1–12 relatives identified per proband.
Unpublished data Data from Ian Frayling suggest that within 5 years of a proband receiving a positive
diagnosis with a specific mutation, on average just over three relatives will have been tested for the family
mutation (see Appendix 8). We assume that the rate of acceptance of testing in this instance will equal
Pr(agrees to counselling) × Pr(agrees to testing|accepted counselling)= 0.45 × 0.96= 0.436. Therefore, if
0.436 of the total number of relatives identified are tested, 0.436 × number of relatives identified= 3.04,
i.e. the number of relatives identified= 6.98.
Number of relatives in Peninsula Technology Assessment Group model We assume a base-case
value of five relatives being identified per proband. This was chosen to balance between the values of 2.35
estimated from Barrow and colleagues (2009)121 and 6.98 estimated from unpublished data supplied by
Ian Frayling. Given a total of 1699 probands aged < 50 years per year in England, this implies 8495
relatives per year in England. There is uncertainty in both of these estimates, but both are from UK
sources. We conducted a univariate sensitivity analysis on this parameter, varying it from 0 to 12, which
includes the range of values suggested by Palomaki and colleagues (2009).65
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Number of first-degree relatives
When probands are diagnosed LS assumed, their relatives cannot be offered genetic testing. Instead, LS
surveillance colonoscopies are offered to their FDRs. As such, it is important to know how many relatives
this is likely to affect.
Published data As described above (see Numbers of relatives) we identified a number of published
studies reporting the number of relatives identified by strategies to identify LS. The significant level of
heterogeneity led us to look for studies which were most relevant to the NHS.
Jenkins and colleagues (2006) Jenkins and colleagues114 studied the risk of CRC and other LS-associated
cancers in people with LS. They recruited 131 men and women diagnosed with CRC under the age of
45 years in the Melbourne metropolitan area, Australia, performed mutation testing on 59 (all with MSI-H
or MSI-L tumours, all with protein expression lacking on IHC and all from families meeting the AC, and a
random sample of 23 with MSS tumours and full protein expression on IHC), and identified 18 as carriers
of germline MMR gene mutations.39 One proband was discovered to have a de novo mutation. Jenkins
and colleagues sought FDRs and second-degree relatives (SDRs) aged > 18 years for all 131 initially
recruited patients (Table 74).
Of the 79 FDRs of mutation carriers, 51 (65%) received predictive testing, whereas among the 100 SDRs of
mutation carriers only 18 (18%) received predictive testing. However, as it seems the predictive tests were
not done to inform the relatives but solely for research purposes, it is not clear whether or not the rate of
predictive testing is informative for our analysis. We may, however, choose to use the result that 79 (44%)
of 179 relatives identified (by the proband during interview) were FDRs.
Hampel and colleagues (2008) Hampel and colleagues120 tested 249 relatives of 44 probands identified
from an unselected series of CRC patients. Of the 249 relatives, 99 were first degree, which corresponds
to 39.8% (95% CI 33.8% to 45.9%) of relatives tested being first degree.
Unpublished data Data from Ian Frayling show that 33 of 70 relatives tested (whose relationship to the
proband was known) were first degree. This corresponds to 47.1% (95% CI 35.8% to 58.8%) of relatives
tested being first degree.
Number of first-degree relatives in Peninsula Technology Assessment Group model We assume a
base-case value of 42% of relatives being first degree as an approximate midpoint between the results
from the studies by Jenkins and colleagues114 and Hampel and colleagues.120 We conducted a univariate
sensitivity analysis of this proportion, varying it between 35% and 55%. Figure 32 shows published and
unpublished estimates of the proportion, our base-case value and sensitivity analysis range for comparison.
Given our base case of five relatives identified per proband, a proportion of 42% being FDRs leads to an
estimate of 2.1 FDRs per proband.
TABLE 74 First- and second-degree relatives identified in the Victorian Colorectal Cancer Family Study39,114,185
Relatives
Number of relatives identified
Mutation carriers (n= 17)114 All early-onset CRC (n= 131)185
FDRs 79a 672
SDRs 100a 1333
Total 179a 2005
a Only relatives of mutation carrier on side of family with mutation are included.
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Proportion of relatives testing positive
Although theoretically it would be expected that the probability that the FDR of a known carrier of a gene
is also a carrier is 50% (unless the relative is an obligate carrier or non-carrier), in practice there are a
number of reasons why the observed probability is lower:
l de novo mutations can occur, which mean that no relatives of the index case will have the mutation
[in the study by Jenkins and colleagues (2006),114 1 of 18 probands had a de novo mutation]
l non-paternity can occur
l mortality bias can occur, meaning that mutation carriers are more likely to have died before being able
to receive predictive testing.
Previous models of cost-effectiveness Almost all previous studies of cost-effectiveness which model
diagnosis and management assume that 50% of FDRs of mutation carriers will also be carriers when
tested (Table 75). Mvundura and colleagues54 are the only exception, assuming 45%.
Published data Jenkins and colleagues114 tested blood samples from 179 relatives, which resulted in
79 mutation carriers (44.1%; 95% CI 37.0% to 51.5%). Hampel and colleagues120 tested 249 relatives,
which resulted in 109 mutation carriers (43.8%; 95% CI 37.7% to 50.0%).
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FIGURE 32 Proportion of relatives who are first degree.
TABLE 75 Proportion of relatives testing positive in previous models of cost-effectiveness
Study Probability that a FDR of a LS mutation carrier is also a carrier
Ramsey et al. 200123 0.50
Ramsey et al. 200349 0.50
Kievit et al. 200550 0.50
Breheny et al. 200651 0.50
Olsen et al. 200753 0.50
Mvundura et al. 201054 0.45
VW Wang et al. 201258 0.50
Ladabaum et al. 201148 and G Wang et al. 201257 0.50
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Unpublished data Unpublished data provided by Ian Frayling (see Appendix 8) showed that 44 of
109 relatives tested were mutation carriers (40.4%; 95% CI 31.5% to 49.7%). Unpublished data provided
by Munaza Ahmed (Wessex Clinical Genetics Service, 2013) (see Appendix 9) showed that 145 of
319 relatives tested were mutation carriers (45.5%; 95% CI 40.1% to 50.9%).
Proportion of relatives testing positive in the Peninsula Technology Assessment Group model
A simple random-effects meta-analysis of the proportion of relatives testing positive was conducted. This
gave a base-case estimate of 44.0% (Table 76). We conducted a sensitivity analysis varying the proportion
from 40% to 48% (slightly larger than the 95% CI from the meta-analysis to include the proportion in
data from Ian Frayling).
Lynch syndrome surveillance colonoscopy
Effect of colonoscopy on index colorectal cancer incidence rates
Colonoscopies (and accompanying polypectomies) reduce the incidence of CRC by removing premalignant
lesions from the bowel. Colonoscopies also allow asymptomatic CRCs to be detected, which improves the
Dukes’ stage distribution when CRC is diagnosed. Dukes’ stage at diagnosis affects survival (as described in
Mortality due to colorectal cancer), meaning that colonoscopies will also reduce the mortality from CRC
in the screened group. These factors are included in our model.
It is also documented by Jarvinen and colleagues (2009)107 that some patients will have colorectal surgery
upon discovery of large adenomas (this has been confirmed by one of our clinical experts). This occurred
in 7 out of 242 (2.9%) of participants undergoing surveillance. Additionally, three patients opted for
prophylactic surgery because surveillance was too painful. Neither of these factors is included in our model.
The reduction in index CRC incidence due to polypectomies is estimated from results from Jarvinen and
colleagues (2000),94 and is implemented as a HR applied when a person accepts colonoscopic surveillance.
This study was chosen as it reported a HR for CRC incidence and was identified by Palomaki and
colleagues (2009)65 as the key study on the effectiveness of colonoscopic surveillance.
The HR was estimated by extracting CRC incidence events from figure 1 (p. 831) of Jarvinen and
colleagues (2000)94 and conducting a Cox proportional hazards regression (see Appendix 10). This gave an
estimate of the HR of 0.387 (95% CI 0.169 to 0.885). As this is a very important parameter, sensitivity
analyses at one standard error above (0.590) and below (0.254) the central estimate were conducted.
A ‘back of the envelope’ calculation based on the 15-year CRC-free survival reported in figure 1 of the
study by Jarvinen and colleagues (0.817 in screening group, 0.578 in control group) gives a HR of
ln(0.817)/ln(0.578)= 0.369, which validates our base case of 0.387 from the Cox proportional
hazards regression.
The interval between colonoscopies in the study was 5 years between 1982 and 1986 and 3 years from
1986 onwards (the results are based on follow-up to the end of 1998). This is less frequent than the
2 years which we model for intensive surveillance, and it is therefore likely that the estimated HR is an
TABLE 76 Meta-analysis of proportion of relatives testing positive
Study Proportion (%) 95% CI (%)
Jenkins et al. 2006114 44.1 37.0 to 51.5
Hampel et al. 2008120 43.8 37.7 to 50.0
Ian Frayling (unpublished) 40.4 31.5 to 49.7
Munaza Ahmed (unpublished) 45.5 40.1 to 50.9
Random-effects meta-analysis 44.0 40.7 to 47.4
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underestimate of the effectiveness of biennial colonoscopy. In our base-case analysis, we allow for this by
adjusting the cost of colonoscopies (see Costs of Lynch syndrome surveillance colonoscopies). The authors
also acknowledge that there may be selection bias as the study and control groups were self-selecting.
Effect of colonoscopy on metachronous colorectal cancer incidence
The effectiveness of biennial colonoscopy in reducing the incidence of metachronous CRC is not well
established. Parry and colleagues (2011)168 showed no statistically significant difference in the surveillance
of patients initially affected by colon cancer who were subsequently affected by metachronous CRC and
those who were not affected, a finding also made by Win and colleagues (2013)186 in relation to patients
initially affected by rectal cancer. Cirillo and colleagues (2012)187 found that biennial colonoscopy was not
associated with a significant reduction in metachronous CRC in patients meeting the AC.
Most existing models of cost-effectiveness do not model metachronous CRC or do not report how it is
modelled in sufficient detail for reproducibility (Table 77). The two studies in which the methodology for
modelling the effectiveness in reducing metachronous CRC incidence is reported or was made available to
us [Dinh and colleagues (2011)55 and Mvundura and colleagues (2010)54] differ completely in their
implementation. Dinh and colleagues (2011)55 assume the same effectiveness in reducing metachronous
CRC incidence as for index CRC, whereas Mvundura and colleagues (2010)54 assume no reduction in
metachronous CRC incidence.
In the PenTAG model, we estimated effectiveness from Cirillo and colleagues,187 making a proportional
hazards assumption and assuming that there was similar follow-up for the patients receiving ‘appropriate’
(up to 24 months between colonoscopies) and ‘inappropriate’ (> 24 months between colonoscopies)
surveillance. Ten of 46 patients receiving appropriate surveillance and 7 of 19 patients receiving
inappropriate surveillance developed metachronous CRC.187 We accordingly estimated the HR as 0.533, as
(12/19)0.533= (36/46). Note that in our base case surveillance is effective at reducing metachronous CRC
incidence, albeit less effective than at reducing index CRC incidence. We also performed a sensitivity
analysis in which the HR was 1 (i.e. no reduction in metachronous CRC incidence due to LS surveillance).
TABLE 77 Effectiveness of LS surveillance in reducing metachronous CRC incidence in existing
cost-effectiveness models
Study Effectiveness of LS surveillance in reducing metachronous CRC incidence
Vasen et al. 199873 Metachronous CRC not modelled
Ramsey et al. 200123 NR
Dunlop 200274 Metachronous CRC not modelled
Ramsey et al. 200349 NR
Kievit et al. 200550 Metachronous CRC not modelled
Breheny et al. 200651 Metachronous CRC not modelled
Olsen et al. 200753 NR
Mvundura et al. 201054 NR in paper; no effectiveness (Scott Grosse, Centers for Disease Control and
Prevention, 2012, personal communication)
Dinh et al. 201155 Equally effective as for index CRC
VW Wang et al. 201258 Metachronous CRC not modelled
Ladabaum et al. 201148 and
G Wang et al. 201257
NR
NR, not reported.
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Effect of colonoscopy on Dukes’ stage of incident colorectal cancers
We assumed that a Dukes’ stage distribution different to that observed in the general population would
apply to CRC diagnoses in individuals undergoing LS surveillance colonoscopies, independent of LS status,
age, sex and any other variable. Mecklin and colleagues188 reported that between 1982 and 2005 (during
which time colonoscopic surveillance was 5-yearly between 1982 and 1989, 3-yearly between 1989 and
1994 and, from 1994 onwards, 3-yearly up to age 35 years then 2-yearly) 41 carcinomas were detected,
with the distribution 29 × Dukes’ A, 4 × Dukes’ B, 5 × Dukes’ C and 3 × Dukes’ D. We chose this as an
appropriate study as it has surveillance intervals matching those in Jarvinen and colleagues (2000),94 from
which the effect of colonoscopy on index CRC incidence is drawn, and there were no CRC cases of
unknown Dukes’ stage. The Dukes’ stage distribution in our model is the expected proportion from the
Dirichlet posterior distribution where a Jeffreys prior is used, and is shown in Table 78 and compared with
the distribution when patients do not receive surveillance in Figure 33.
Adherence to Lynch syndrome surveillance colonoscopy
The initial acceptance of LS surveillance is detailed above (see Acceptance of testing and surveillance).
In the model it is assumed that patients who initially accept LS surveillance continue to receive biennial
colonoscopies as recommended. It is also assumed that patients who initially decline LS surveillance do not
subsequently take up surveillance.
Effectiveness of surveillance colonoscopy in preventing index CRC in the model is based on the study by
Jarvinen and colleagues (2000),94 in which long-term adherence was reported as 93% (although 3%
deemed not to adhere long term had negative gene test results, so 95% is an alternative estimate of
TABLE 78 Stage distribution of CRCs for individuals undergoing colonoscopic surveillance, from Mecklin and
colleagues (2007)188
Dukes’
stage
Number of carcinomas
(simple proportion)
Dirichlet posterior hyperparameters
(prior distribution of Jeffreys prior)
Expected proportion
used in model
A 29 (0.707) 29.5 0.686
B 4 (0.098) 4.5 0.105
C 5 (0.122) 5.5 0.128
D 3 (0.073) 3.5 0.081
Source: Mecklin and colleagues.188
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FIGURE 33 Stage distribution of CRCs for people with and without LS surveillance.
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adherence). Additionally, in this study 63% of patients who initially declined surveillance colonoscopy were
participating in surveillance by the end of the study. The effectiveness of surveillance colonoscopy in this
study is based on an intention-to-treat analysis, which means it may be biased to appear less effective than
it really is (as there was greater crossover into the surveillance programme than out of it).
There are issues with applying the results of Jarvinen and colleagues directly to the UK setting. It is
proposed that surveillance would consist of 2-yearly colonoscopy, rather than the 3-yearly colonoscopy
described by Jarvinen and colleagues (note that for consistency we adjust the cost of colonoscopy in our
model to reflect this; see Costs of Lynch syndrome surveillance colonoscopies). Our clinical expert advice
suggests that decreasing the interval between colonoscopies can lead to better or worse adherence due
to the competing factors of putting patients off (as colonoscopies are uncomfortable procedures) and
giving the impression that intensive surveillance is needed (if surveillance is infrequent patients may assume
it is not important). It may also be the case that cultural differences mean that Finnish patients are more
likely to accept and adhere to surveillance than UK patients.
As we did not find data relating to long-term adherence of UK patients to biennial colonoscopy, we
judged that assuming no crossover was reasonable and as consistent as possible with the effectiveness
estimates from Jarvinen and colleagues.94 It may be that adherence falls off for patients, but this may be
balanced by delayed uptake of surveillance by patients initially declining surveillance.
Morbidity and mortality of Lynch syndrome surveillance colonoscopy
In our model we consider morbidity from colonoscopy in the form of bleeding requiring admission (mild,
moderate and severe) and perforation. These events incur treatment costs but are assumed not to impact
on QALYs as they are acute events from which a full recovery should be possible. Mortality from
colonoscopy is also included, with an associated cost. Table 79 gives the probabilities of these events in
the model.
Our estimates of the proportion of colonoscopies resulting in morbidity come from the UK National
Colonoscopy Audit of 2011 as reported by Gavin and colleagues.189 In this audit, 0.26% (95% CI 0.20%
to 0.36%) of colonoscopies led to bleeding, with 21% (95% CI 12.2% to 34.0%) of these requiring
admission. Of those requiring admission, 18% (95% CI 5.1% to 47.7%) suffered moderate bleeding and
9% (95% CI 1.6% to 37.7%) suffered severe bleeding. These estimates are from very small populations,
which accounts for the large CIs.
Perforations occurred in 0.04% (95% CI 0.02% to 0.08%) of colonoscopies in the study by Gavin and
colleagues,189 with all of them requiring admission.
Cairns and colleagues9 report that the mortality rate of colonoscopy is 0.83 per 10,000 procedures.
Colonoscopy mortality is assumed to occur at the beginning of the cycle.
TABLE 79 Morbidity and mortality of colonoscopy
Event Probability (per colonoscopy)
Mortality 0.83 per 10,000
Perforation 4 per 10,000
Bleeding 26 per 10,000
Of which required admission 21%
Of which were mild 73%
Of which were moderate 18%
Of which were severe 9%
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Effectiveness of colorectal cancer surgery
Effectiveness of CRC surgery is incorporated by applying a HR to the CRC incidence rate according to the
surgery type. Segmental resection was assumed to have no effect on the incidence of CRC (HR of 1).
Proctocolectomy was assumed to completely eliminate the risk of CRC (HR of 0). The HR for subtotal
colectomy on CRC incidence was estimated as 0.06 as that is the result of subtracting the relevant
proportion of incident CRCs in patients with LS (see Colorectal cancer incident site) from 1 (1 – 0.94= 0.06).
Similarly, the HR for anterior resection was estimated as 0.94.
The effectiveness was assumed to be independent of whether the person has LS or not. If additional
complexity were introduced to include a dependency on LS status, then subtotal colectomy would be
modelled as less effective for persons without LS than for those with LS and anterior resection would
be modelled as more effective. As very few people without LS develop CRC in the model, we judged that
this was unlikely to have an impact on cost-effectiveness.
Morbidity and mortality due to colorectal cancer surgery
We assumed that mortality of CRC surgery was already included in the 1-year survival of CRC and hence
did not model it separately. We assumed that any long-term morbidity of CRC surgery would be included
in our estimates for HRQoL for CRC and did not include any acute morbidity of CRC surgery.
More aggressive colorectal cancer surgery for individuals diagnosed with
Lynch syndrome
As previously described (see Colorectal cancer surgical management pathways), we include a parameter
representing the probability that a CRC patient receives more aggressive surgery than they otherwise
would because they have LS. When this parameter is set to 0 there is no difference between the surgery
choice for LS patients and that for general population patients.
There is a difference of opinion between surgical guidelines, for example BSG/ACPGBI guidelines9 (which
appear to recommend aggressive surgery for patients with known LS mutations), and our clinical expert
opinion, which is that the surgery would not be affected by the presence of a LS mutation.
For our base case we set the parameter to 0, for the following reasons:
l The BSG/ACPGBI recommendations are not based on high-quality evidence.
l In our base case we do not assume any disutility from different surgery types (see Impact of colorectal
cancer surgery on quality of life), even though this is a major consideration when deciding which
surgery to perform. If we set the parameter to anything other than 0 we would introduce a bias, as the
reduction in metachronous CRC incidence (see Effectiveness of colorectal cancer surgery) would not be
matched by a disutility for more aggressive surgery.
l We do not include different surgical mortality for different surgery types (see Morbidity and mortality
due to colorectal cancer surgery), even though 30-day surgical mortality following total/subtotal
colectomy is significantly greater than mortality following right hemicolectomy (a typical segmental
resection procedure) [odds ratio 1.52 (95% CI 1.15 to 2.01)].135 If we set the parameter to anything
other than 0 we would introduce a bias.
We vary the parameter in the sensitivity analyses.
Screening for endometrial cancer
Of the seven analyses that include EC, six assume screening for EC (see Table 89). It is not clear whether or
not the seventh analysis, by Kwon (2011),56 models screening. However, screening is assumed to yield
clinical benefits in only three of the six analyses: Chen and colleagues (2007),85 Kwon and colleagues
(2008)75 and Yang and colleagues (2011).76 No benefit is assumed in the remaining analyses: Dinh and
colleagues (2011),55 Ladabaum and colleagues (2011)48 and Wang and colleagues (2012).57
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Gynaecological cancer surveillance in the Peninsula Technology Assessment
Group model
We assume no costs or benefits related to surveillance for EC in our model. This is because we found
insufficient evidence to suggest that gynaecological cancer surveillance reduces the incidence of
gynaecological cancers or improves survival when individuals are affected (see Literature review of the
effectiveness of surveillance for endometrial cancer), and because it seems unreasonable to include
the substantial cost of surveillance with no benefit. In this sense, our approach differs from the three US
analyses that assumed costs, but no clinical benefit of surveillance.48,55,57
However, we note that our clinical advisors suggest that some surveillance occurs in clinical practice and
the Northern Genetic Service audit of LS carriers suggests that 28 out of 69 (41%) of women without
previous cancer and with intervention recorded were referred to or offered surveillance (Lorraine Cowley,
personal communication).
Literature review of the effectiveness of surveillance for endometrial cancer
We searched the literature for evidence of the effectiveness of gynaecological surveillance for patients with
LS (see Appendix 11). We identified three primary studies107,190,191 and four reviews65,167,192,193 which were
critically appraised in relation to the UK context and the decision problem.
None of the three primary studies was a randomised controlled trial (RCT). Two of the studies107,190 were
not intended to have a control group, but a selection of patients did not undergo the recommended
surveillance and we considered them a ‘control group’ in each case. Renkonen-Sinisalo and colleagues191
describe two cohorts, one comprising 83 women identified retrospectively with LS who had a previous EC,
and the other 175 women with LS in a surveillance programme.
As detailed in Appendix 11, we performed statistical analyses on the three primary studies to determine
the relative risk of gynaecological cancer and prophylactic hysterectomy for those receiving gynaecological
surveillance, and we did not find statistically significant results. We also performed statistical analysis to
determine the effect of surveillance on the surgical stage of gynaecological cancers and again did not find
statistically significant results.
Existing reviews
Auranen and Joutsiniemi (2011)192 conducted a systematic review of gynaecological cancer screening in
women belonging to LS families, which had five included studies.190,191,194–196 In our review, the study by
Lécuru and colleagues (2008)195 was excluded because the abstract suggested that there was no
comparator for the surveillance strategy. Auranen and Joutsiniemi (2011) conclude that the studies they
included do not allow for evidence-based decision-making.
Koornstra and colleagues (2009)193 conducted a review of extracolonic cancers, including gynaecological
cancer screening, and included three studies relevant to gynaecological cancer screening.190,191,196 They
conclude that the only evidence of surveillance benefit is that TVU and endometrial sampling detect
endometrial tumours in early stages based on the study by Renkonen-Sinisalo and colleagues (2007),191
despite this study not reporting a statistical difference by the Pearson chi-squared method.
Lindor and colleagues167 included two studies190,196 and concluded that there was insufficient evidence to
argue for or against endometrial sampling or TVU.
Palomaki and colleagues (2009)65 included three studies190,191,196 and concluded that TVU is not highly
effective at identifying ECs in women with LS, but that endometrial biopsy is effective at identifying both
premalignant and malignant lesions, according to the study by Renkonen-Sinisalo and colleagues (2007).191
Palomaki and colleagues recommend surveillance for women with LS but say that ‘Inadequate data are
available to document that transvaginal ultrasound and endometrial biopsy can reduce the incidence of
endometrial cancer.’65
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Surgery for endometrial cancer
We assume that TAHBSO completely eliminates the risk of EC, for the following reason. In a retrospective
study of prophylactic surgery to reduce the risk of gynaecological cancer,146 0 out of 61 women with LS
who underwent either prophylactic hysterectomy or TAHBSO developed EC, whereas 69 out of 210, i.e.
33% of women who did not undergo either surgery developed EC. Each woman who had undergone
hysterectomy or TAHBSO was matched (by age, treated at the same institution) with one or more control
women. The median age at surgery was 41 years, and at diagnosis of EC, 46 years. All women were
followed until the occurrence of gynaecological cancer, death or censorship. Although a randomised trial
would be preferable to a retrospective study, the study appears to give compelling evidence that
prophylactic surgery eliminates the risk of EC.
Prophylactic total abdominal hysterectomy with bilateral
salpingo-oophorectomy for women diagnosed with Lynch syndrome
Acceptance of prophylactic total abdominal hysterectomy with bilateral
salpingo-oophorectomy
The acceptance rate for TAHBSO for both probands and relatives is assumed to be 55%, i.e. 21 out of
38 women over 45 years of age without previous cancer, based on data provided by Lorraine Cowley
(personal communication) from the Northern Genetics Service audit of LS carriers in the UK (see Table 56).
By comparison, Dinh and colleagues55 assumed similar rates at the appropriate age: for relatives with LS
without CRC, acceptance was assumed to be 0% at age 30 years, 40% at age 40 years, 60% at age
50 years and 75% at age 80 years. Slightly higher rates were assumed for probands with CRC. By
contrast, Ladabaum and colleagues48 assumed substantially lower acceptance rates: 19% and 18%
for probands and relatives, respectively, citing a US study.146 Given that our estimate was taken from
a small sample size of 38 women, that there is substantial variability in this parameter in previous
cost-effectiveness analyses, and that this is an important parameter, we assumed wide variation
(20% and 90%) in acceptance rates for both probands and relatives in sensitivity analyses.
Utility parameters and assumptions
In this section, we follow the principles for the identification, review and synthesis of health state utility
values from the literature, as recommended recently by the NICE Decision Support Unit in the UK.197
There are no agreed reporting standards for studies of utilities, but the following information is key to
understanding the nature and the quantity and quality of evidence:197
l the population describing the health state (e.g. age, sex, disease severity)
l the approach used to describe the health state
l utility value elicitation technique, for example time trade-off, standard gamble, visual analogue score
l sample size
l respondent selection and recruitment, inclusion and exclusion criteria
l survey response rates, numbers lost to follow-up (and reasons), methods of handling missing data.
Clearly, the relevance of the data to the decision model, and to the agency to which the model will be
submitted, is important. In the current project, the NICE reference case is used.198 Modification of utility
values from the literature for use in economic models, and sensitivity analyses using less relevant
utility values, should be considered.197
A systematic search for studies reporting utilities should be undertaken.197 For the current project, the
search method is given in Appendix 4. In addition, sources of utility values were obtained from published
models on the cost-effectiveness of testing for LS.
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If disutilities are included in the model for CRC, then strategies which prevent the greatest numbers of
CRCs will experience a relative improvement in cost-effectiveness (likewise for EC). In addition, if greater
disutilities are included for later CRC stages then strategies with the most surveillance will experience a
relative improvement in cost-effectiveness, as surveillance reduces the proportion of CRCs diagnosed in
later stages. If disutilities are included for people undergoing colonoscopy surveillance (e.g. as this can be
painful and uncomfortable), this would result in a worsening of cost-effectiveness for strategies with more
surveillance. Therefore, there could be a balance between disutility of CRC and surveillance, in which
strategies with the fewest diagnostic errors would fare better. Similar considerations apply to risk-reducing
surgery. If disutilities are included for the psychological impact of LS germline testing (and separately
according to the results), this could worsen the cost-effectiveness of strategies involving extensive LS
testing, particularly strategy 8, in which all CRC patients are offered LS testing.
Utilities in cost-effectiveness models particularly for testing for
Lynch syndrome
In Table 80, we outline approaches taken to incorporate utilities in previous models of the
cost-effectiveness of testing for LS. Only a few analyses – Kwon and colleagues (2008),75 Wang and
colleagues (2012),57 Dinh and colleagues (2011),55 Mvundura and colleagues (2010)54 and Yang and
colleagues (2011)76 – considered utilities.
Owing to limitations of empirical data identified in an earlier review,213 the authors chose to use European
Quality of Life-5 Dimensions (EQ-5D) values from the Health Survey for England, using the absolute utility
decrement for individuals with cancer versus individuals of a similar age without cancer.214,215 It should be
noted that the cancer population subgroup included individuals with benign lumps and cysts and was not
specifically limited to CRC.215 Their estimates were taken simply as the utilities for age-matched individuals
in England without cancer (0.80) and individuals with cancer in general (0.70). Although we appreciate the
effort to find some method to allow for disutility due to CRC, we believe that it is unreasonable to use a
figure based on all cancers.
Baseline quality of life
Baseline quality of life (assumed to apply to patients without CRC, EC or other events which might have an
impact on HRQoL) was modelled as a function of age and sex, using the model for calculating EQ-5D
utility values described by Ara and Brazier:216
EQ-5D ¼ 0:9508566þ 0:0212126male− 0:0002587 age− 0:0000332 age2 (6)
We used the age at the beginning of each cycle to determine the baseline utility for that year.
Impact of colorectal cancer on quality of life
Impact of colorectal cancer on quality of life according to Dukes’ stage
A systematic review was recently undertaken for the NIHR to identify utility values for CRC by a group mostly
based at the University of Sheffield, UK.213 This review identified six relevant studies (Table 81).200,217,219–222
Cooper and colleagues (2010)213 concluded that these studies do not demonstrate a clear relationship
between HRQoL and stage of cancer, treatment, phase of disease or time since diagnosis. They further
concluded that, at the time of their review, only two studies, Ness and colleagues (1999)200 and Ramsey and
colleagues (2000),217 had attempted to estimate utilities for patients according to stage of CRC. They noted
that Ness and colleagues (1999)200 estimated that utility decreased substantially with more advanced cancer,
from 0.74 at stage I to 0.24 at stage IV (see Table 81). They noted that this contrasted with the results from
Ramsey and colleagues (2000),217 which estimated that utility is approximately independent of CRC stage
(utility= 0.84 at stage I and stage IV), and also contrasted with the results from the MABEL study,222 which
estimated a utility of 0.73 for individuals with metastatic CRC who had failed one prior line of chemotherapy.
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TABLE 81 Summary of characteristics of utility studies for CRC
Study Study population Preference elicitation Results Criticisms of study
aNess et al.
1999200
81 participants from
the USA who had
previously undergone
removal of
colorectal adenoma
Seven health states
describing various
stages of colon and
rectal cancer.
Preferences elicited
using standard gamble
Stage I rectal or stage I/II
colon cancer (mean
0.74); stage III colon
cancer (mean 0.67);
stage II/III rectal cancer
without ostomy (mean
0.59); stage II/III rectal
cancer with ostomy
(mean 0.50); stage IV
rectal or colon cancer
(mean 0.25)
Although health states
rated by individuals who
had previously
undergone removal of
colorectal adenoma,
health states described
were not experienced
by these individuals
A standard quality of
life questionnaire, such
as the EQ-5D or SF-36,
was not used
Standard gamble is not
preferred
Valuation performed by
81 participants, not by
large sample of general
public
Sample size of 81
people is very small
aRamsey et al.
2000217
173 long-term
survivors of CRC,
mean age 70 years,
sampled from US
SEER database
HUI3 questionnaire Stage I= 0.84, stage II=
0.86, stage III= 0.85,
stage IV= 0.84
Although a recognised
quality of life
questionnaire, the HUI3,
was used, the EQ-5D is
preferred
Small sample size
Possible response bias in
favour of healthier
subjects
Ramsey et al.
2002218
227 individuals at
least 5 years from
diagnosis of CRC,
sampled from US
SEER database,
average age 74 years
HUI3 questionnaire Stage I= 0.83, stage II=
0.86, stage III= 0.87,
stage IV= 0.81
Although a recognised
quality of life
questionnaire, the HUI3,
was used, the EQ-5D is
preferred
Possible response bias in
favour of healthier
subjects
Biased sample of
individuals who survived
at least 5 years from
diagnosis
aKo et al.
2003219
169 patients from
USA with colon
cancer
The Health and
Activities Limitation
Index was mapped on
to a utility scale
Mean utility shortly after
diagnosis 0.67 (n= 32),
not divided by disease
stage, mean utility after
5 years 0.71 (n= 80)
CRC stage not measured
The Health and Activities
Limitation Index is not
preferred by NICE198
Small sample sizes
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Cooper and colleagues (2010)213 based their estimates of utilities by stage of CRC on those from Ness and
colleagues (1999).200 Their reasoning was as follows:213
the study by Ness and colleagues involved eliciting preferences for hypothetical health states from
individuals who had previously undergone polypectomy, while the other studies involved eliciting
preferences from patients currently experiencing the health state. As NICE recommend that utilities
should be based upon public preferences, the study by Ness was used to estimate utilities associated
with CRC.
Cooper and colleagues (2010)213 adjusted the utilities from Ness and colleagues (1999)200 to allow for the
age-related utilities of the general population of England. They estimated the ratio of the utility of
TABLE 81 Summary of characteristics of utility studies for CRC (continued )
Study Study population Preference elicitation Results Criticisms of study
aPetrou and
Campbell
1997220
30 nurses experienced
in oncology careb
Utilities for six
chemotherapy-specific
scenarios elicited using
standard gambleb
CRC stage not
measured
Health states not
experienced by
population
Extremely small sample
sizes of patients
Standard gamble is
not preferred
aMRC FOCUS
trial, Seymour
et al. 2007221
2135 patients with
inoperable metastatic
or locoregional
disease
EORTC QLQ-C30 Utilities not obtained Utilities not derived, as
quality of life assessed
by EORTC QLQ-C30
cancer-specific
questionnaire
aMABEL trial,
Wilke et al.
2008222
Utilities for
125 patients taking
cetuximab (Erbitux®,
Merck Serono)+
irinotecan with
metastatic CRC
EQ-5D questionnaire Mean utility= 0.75223 Utilities for cetuximab
treatment not relevant,
as cetuximab not
recommended by NICE
in UK
Jonker et al.
2007224
260 patients receiving
BSC in RCT of
cetuximab vs. BSC for
metastatic CRC
HUI3 questionnaire,
valued by Canadian
general population
For BSC arm, mean
utility= 0.71 (n= 260) at
baseline, 0.68 (n= 184)
at week 4, 0.66 (n= 149)
at week 8, 0.63 (n= 72)
at week 16, 0.70 (n= 36)
at week 24225
Although a recognised
quality of life
questionnaire, the HUI3,
was used, the EQ-5D
is preferred
Best et al.
2010226
Convenience samples
of 49 CRC patients
Seven health states
described, reflecting
stage III CRC
EQ-5D questionnaire
Adjusted utility values
ranged from remission
0.83 to metastatic
progressive 0.37
Although individuals
who rated health states
had CRC, health states
described were not
experienced by these
people
Small sample size
BSC, best supportive care; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-C30; FOCUS, Fluorouracil, Oxaliplatin and CPT11 (irinotecan) – Use and Sequencing; HUI3, Health Utilities
Index Mark 3; MABEL, Monoclonal Antibody Erbitux in a European License study; MRC, Medical Research Council;
SF-36, Short Form questionnaire-36 items.
a Included in Cooper et al. (2010).213
b As reported by Cooper et al. (2010)213 review.
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
someone with CRC to the utility of a member of the general population, independent of age, as follows:
0.88 Dukes’ A, 0.70 Dukes’ B, 0.70 Dukes’ C, 0.30 Dukes’ D. For example, their utility estimates for
someone with CRC aged 60 years, given that the utility of a member of the general population of England
at this age is approximately 0.83,216 are: 0.73 Dukes’ A, 0.58 Dukes’ B, 0.58 Dukes’ C, 0.25 Dukes’ D.
We find five serious criticisms with the study by Ness and colleagues (1999).200 In all cases, the methods used
are not preferred by NICE.198 First, although health states were rated by individuals who had previously
undergone removal of colorectal adenoma, the health states described were not experienced by these
individuals. Second, a standard quality of life questionnaire, such as the EQ-5D or SF-36 (Short Form
questionnaire-36 items), was not used. Third, the standard gamble technique was used to value health states,
rather than the preferred time trade-off method. Fourth, valuation was performed by the participants, not by
a large sample of the general public. Fifth, the sample size of 81 participants is very small.
In a study of 173 long-term survivors of CRC, sampled from US SEER database, Ramsey and colleagues
(2000)217 found almost no difference in mean utilities by disease stage at diagnosis (see Table 81). This is in
contrast to the findings of Ness and colleagues (1999).200 For any given disease stage at diagnosis, Ramsey
and colleagues (2000)217 found much variability in utilities in the first 4 or so years after diagnosis, and much
less variability thereafter. The mean utility increased over time for some stages at diagnosis, and decreased
for others. Individuals who were in the terminal phase of their illness had much lower quality of life.
The findings of a study of long-term survivors of CRC by Ramsey and colleagues (2002)218 agree with those
of Ramsey and colleagues (2000).217 Two hundred and twenty-seven individuals, mostly diagnosed with
stages I, II and III CRC, who were at least 5 years from diagnosis were sampled from the US SEER database.
As in the study by Ramsey and colleagues (2000),217 mean utilities were high and similar across disease
stage. However, we consider the study by Ramsey and colleagues (2000)217 in preference to that of Ramsey
and colleagues (2002),218 because in the latter study, patients were a biased sample of long-term survivors.
Although we find criticisms with the study by Ramsey and colleagues (2000),217 unlike Cooper and
colleagues (2010),213 we believe that this is the most reliable and useful of all studies for our purposes
because (a) it is one of only two studies that estimated utilities as a function of CRC stage [the other being
Ness and colleagues (1999)200]; (b) unlike Ness and colleagues (1999),200 a standard quality of life
questionnaire, the Health Utilities Index Mark 3 (HUI3), was used, as required by NICE;198 (c) unlike
Ness and colleagues (1999),200 the individuals scoring the health states were those actually experiencing
the health state, as required by NICE; and (d) unlike Ness and colleagues (1999),200 valuation was
performed by a large sample of the general public, not by those scoring the health states, as required by
NICE. Criticisms of the study by Ramsey and colleagues (2000)217 are as follows. First, the sample size of
173 patients, though twice that of Ness and colleagues (1999),200 is still small, especially to detect
differences in utilities between disease stages. Second, Ramsey and colleagues (2000)217 admit that there
may have been response bias in favour of healthier subjects, as less than half of all individuals contacted
completed the questionnaire. Third, although the HUI3 is a recognised preference-based generic quality
of life questionnaire, the EQ-5D is preferred by NICE.198
Like Cooper and colleagues (2010),213 we consider the study by Ko and colleagues (2003)219 to be of limited
relevance, mostly because CRC stage was not reported, but also because the Health and Activities Limitation
Index used in the study is not preferred by NICE,198 and because of the small sample size (see Table 81).
We are unable to source the full text of the study by Petrou and Campbell (1997).220 However, Cooper
and colleagues (2010)213 say they did not consider the results of this study for their purposes because the
study does not provide utilities by disease stage. Further, Cooper and colleagues (2010)213 state that
the study population consisted of an extremely small sample of 30 nurses experienced in oncology care.
In addition, the health states were not experienced by the population. For all these reasons, we do not
consider this study further.
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We do not consider in any detail the results of the Medical Research Council FOCUS [Fluorouracil,
Oxaliplatin and CPT11 (irinotecan) – Use and Sequencing] trial221 for patients with inoperable metastatic or
locoregional CRC because utilities were not estimated, although HRQoL was measured using the European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
cancer-specific questionnaire.
Utilities were assessed by the HUI3 questionnaire estimated in a RCT of cetuximab versus best supportive
care for patients with advanced CRC who had typically had three or four previous lines of drug
treatment.224 Detailed utilities by time from randomisation are given in Table 81, with an average value,
weighted by the number of observations, of 0.68. We attach importance to this value because it is derived
from a large sample of patients using a recognised HRQoL questionnaire.
As noted by Cooper and colleagues (2010),213 the results from the Monoclonal Antibody Erbitux in a
European License (MABEL) study by Wilke and colleagues (2008)222 of patients taking cetuximab plus
irinotecan with metastatic CRC are more consistent with those of Ramsey and colleagues (2000)217 than
Ness and colleagues (1999).200 The mean utility for 125 of these patients was estimated as 0.75.223
Unfortunately, although this study used the EQ-5D questionnaire, which is preferred, the relevance of the
study is limited by the fact that patients took cetuximab plus irinotecan, which is not recommended by NICE.
Best and colleagues (2010)226 elicited utilities from a convenience sample of 49 CRC patients in the USA.
Patients completed the EQ-5D questionnaire for seven different health state descriptions consistent with
stage III CRC. Estimated utilities varied greatly, ranging from 0.83 for remission to 0.48–0.67 for individuals
taking adjuvant chemotherapy (according to the degree of neuropathy), to 0.37 for metastatic progressive
disease. Although it is interesting to note the great variability in utilities, we do not consider the results
further because of the very small sample size and because the health states described were not
experienced by the participants (although they had CRC).
Peninsula Technology Assessment Group estimated utilities by stage of
colorectal cancer
A highly detailed model for individuals with CRC would allow for increased HRQoL during remission, when
patients can lead a reasonably normal life, and decreased quality of life while taking chemotherapy, when
individuals may experience a range of problems such as fatigue, anxiety and reduced social activity.226
However, given the lack of high-quality relevant data, we simply apply a disutility from the normal utility of
the general population, unique for each Dukes’ stage (Table 82).
We base our estimated disutility for Dukes’ stages A, B and C on the study by Ramsey and colleagues
(2000)217 because, as we note above, we judge this study to be the most relevant. In this study, the mean
age of respondents was 71 years. The mean utilities for members of the general population of England
and Wales at this age are approximately 0.79 and 0.77 for men and women, respectively.216 Ramsey and
colleagues estimated utilities slightly in excess of these values for individuals with CRC of all stages
TABLE 82 Colorectal cancer stage-related disutilities in PenTAG model
CRC stage
Base case Sensitivity analysis
Disutility Based on study
Utility for
60-year-old
male
Utility for
60-year-old
female Disutility Based on study
Dukes’ A 0.00 Ramsey et al. 2000217 0.84 0.82 0.11 Ness et al. 1999200
Dukes’ B 0.00 Ramsey et al. 2000 0.84 0.82 0.23 Ness et al. 1999
Dukes’ C 0.00 Ramsey et al. 2000 0.84 0.82 0.26 Ness et al. 1999
Dukes’ D 0.13 Mittmann et al. 2009225 0.71 0.69 0.60 Ness et al. 1999
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(see Table 81). Therefore, in our base-case analysis, we estimate no disutility for individuals with stages A,
B and C CRC.
For Dukes’ stage D, we estimate a disutility of 0.13 as follows. In the RCT of cetuximab versus BSC,224
the mean utility for patients in the BSC arm was 0.68,225 and the median age of patients in this arm at
baseline was 64 years. Given that the utility for males (constituting 64% of patients in the trial) in the
general population at this age is 0.82216 and that for females is 0.80, this implies a disutility
of 0.81 – 0.68= 0.13.
We also perform a sensitivity analysis, in which we base estimates of utilities on the study by Ness and
colleagues (1999),200 because this is the only other study which reports utilities for all Dukes’ stages
and because it has been used in the cost-effectiveness analyses by Dinh and colleagues (2011)55 and
Cooper and colleagues (2010).213 The mean age of participants in Ness and colleagues (1999)200 was 54
years, with approximately 50% male and 50% female. The utility for a general member of the population
of England and Wales at this age is 0.85.216 We estimate the disutility for Dukes’ A as 0.85 – 0.74 (stage I
rectal or stage I/II colon cancer)= 0.11; the disutility for Dukes’ B as 0.85 – 0.62= 0.23, where 0.62 is the
average of 0.74 for stage I rectal or stage I/II colon cancer and 0.50 for stage II/III rectal cancer with
ostomy; the disutility for Dukes’ C as 0.85 – 0.59= 0.26, where 0.59 is the average of 0.67 for stage III
colon cancer and 0.50 for stage II/III rectal cancer with ostomy; and the disutility for Dukes’ D as
0.85 – 0.25 (stage IV rectal or colon cancer)= 0.60.
Impact of colorectal cancer surgery on quality of life
In the base-case analysis, no additional disutility for surgery that reduces the risk of CRC was assumed.
Our base-case disutilities for Dukes’ stages A, B and C are taken from Ramsey and colleagues (2000)217
(see Table 82), a study of 173 long-term survivors of CRC, sampled from the US SEER database. Although
not explicitly stated, we assume that a substantial proportion of the patients had undergone surgery for
CRC. Next, our base-case disutility for Dukes’ stage D is taken from a RCT of cetuximab versus best
supportive care for patients with metastatic CRC.224 Although the nature of previous surgery in patients
included in this trial is not stated,224 it is likely that a large proportion had undergone surgery for CRC
given that patients were heavily pre-treated. Finally, in a sensitivity analysis, we estimate disutilities for all
Dukes’ stages from Ness and colleagues (1999).200 In this study, descriptions of health states for various
stages of colon and rectal cancer included resection and use of ostomy (see Table 82). Given this, it could
be argued that any disutilities related to surgery for CRC are already incorporated in our chosen disutilities
according to Dukes’ stage. Nonetheless, we now present an overview of the relevant literature on the
HRQoL related to surgery for CRC, summarised in Table 83.
The only study on the cost-effectiveness of genetic testing for LS that has incorporated disutilities after
surgery for CRC is that of Dinh and colleagues (2011).55 First, a utility of 0.84 was assumed for total
colectomy with ileorectal anastomosis (IRA) or proctocolectomy and IPAA for individuals with advanced
adenoma, which Dinh and colleagues (2011) cite from van Duijvendijk and colleagues (2000).201
This study compared the HRQoL, as measured by the SF-36 questionnaire, of 183 patients with FAP in
the Netherlands who underwent colectomy and IRA with 140 patients, also with FAP, who underwent
proctocolectomy and IPAA, and with 279 people from the general Dutch population (see Table 83). HRQoL
was found to be similar for participants after the two types of surgery, but significantly poorer than for
people in the general population. However, we find no utilities reported in the study by van Duijvendijk
and colleagues (2000);201 in particular, the value of 0.84 used by Dinh and colleagues (2011)55 is not cited.
If we assume that none of the patients with FAP in the study had CRC, the study suggests a disutility
from having either of the operations; however, this is not quantified. The study by van Duijvendijk and
colleagues does report mean scores and standard deviations in the eight main SF-36 categories (plus mean
scores for the health transition category), and following the methodology of Ara and Brazier (2008)228 we
were able to map these mean scores to a set of mean EQ-5D preference-based scores [a different score for
each model in the study by Ara and Brazier (2008)] and compute a disutility of 0.208–0.290 for subtotal
colectomy with IRA and 0.214–0.299 for proctocolectomy with IPAA (see Appendix 12 for results and
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TABLE 83 Summary of characteristics of utility studies for CRC surgery
Study Study population Preference elicitation Results Criticisms of study
van
Duijvendijk
et al. 2000201
183 patients with FAP in
the Netherlands with
colectomy and IRA,
140 patients with FAP
with proctocolectomy and
IPAA, 279 individuals
from general Dutch
population. Mean age
40 years
SF-36 questionnaire HRQoL similar for
individuals after two
types of surgery, but
significantly poorer
than for individuals in
general population
No utilities quoted
Fazio et al.
1999202
Patients with
proctocolectomy with
stapled anastomosis
mostly for colitis. Median
age 37 years at surgery
Cleveland Global Quality
of Life instrument.
Also SF-36 questionnaire
in subgroup of
163 patients
Postoperative quality
of life as measured by
the SF-36 was
excellent and
compared well with
norms for the general
US population. Quality
of life increased in the
2 years after surgery,
and did not
deteriorate thereafter
Although a recognised
quality of life
questionnaire, the
SF-36, was used, the
EQ-5D is preferred
Kuppermann
et al. 2013212
71 highly educated
individuals based in USA
‘with a range of
understanding about
and experience with
Lynch Syndrome’
Health state vignettes Mean utility 0.68 for
probands tested
positive for LS who
undergo colectomy,
0.65 for probands
tested positive who
decline colectomy,
0.66 for probands
who decline testing
(see Table 84)
Health states not
experienced by
population
Health state
questionnaires,
especially EQ-5D, are
preferred to health
state vignettes
Kalady et al.
2011227
95 patients, aged
approximately 55 years,
meeting AC for LS
50 patients total
proctocolectomy and
45 partial colectomy
SF-36 questionnaire 1 year after surgery,
no significant
difference in any of
the eight domains of
the SF-36 between
two types of surgery
Although a recognised
quality of life
questionnaire, the
SF-36, was used, the
EQ-5D is preferred
Study published in
abstract form only
No utilities quoted
Syngal et al.
199883
Seven gastroenterologists
and three genetic
counsellors
Standard gamble Utilities of 0.95 for
patients with subtotal
colectomy, 0.89
for proctocolectomy
Very small sample size
Patients not scoring
questionnaire
Time trade-off
preferred to
standard gamble
IRA, ileorectal anastomosis.
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details of the calculation method). These do not correspond to the disutility of 0.16 implied in the study by
Dinh and colleagues (2011),55 although Dinh and colleagues cite Ara and Brazier (2008).228
Second, in their cost-effectiveness analysis, Dinh and colleagues (2011)55 estimated a utility of 0.83 after
proctocolectomy, which they cite from Fazio and colleagues (1999).202 Patients who underwent
proctocolectomy with stapled anastomosis, mostly for colitis, were included in the study (see Table 83).
HRQoL was measured using the Cleveland Global Quality of Life instrument, and in a subgroup of
163 patients, with the SF-36 form. Postoperative quality of life as measured by the SF-36 was excellent
and compared well with norms for the general US population. Quality of life increased in the 2 years
after surgery, and did not deteriorate thereafter.
In summary, in one study201 HRQoL was found to be substantially lower for FAP patients who underwent
colectomy and IRA or proctocolectomy and IPAA compared with individuals from the general Dutch
population, although the difference in utilities was not reported. Conversely, in the other study202 HRQoL
was found to be similar in colitis patients who underwent proctocolectomy with stapled anastomosis as in
individuals from the general US population. Therefore, it seems reasonable to assume no additional
disutility after proctocolectomy, given that (a) as mentioned above, arguably any disutilities related to
surgery for CRC are already incorporated in our chosen disutilities according to Dukes’ stage, (b) one study
found no disutility compared with a general population, and (c) another study found an unquantified
disutility compared with a general population.
The only study of which we are aware that measured the psychological impact of risk-reducing surgery for
CRC is by Kuppermann and colleagues (2013).212 In this study, based on health state descriptions assessed
by individuals with a range of familiarity with LS, the mean utility was 0.68 for probands tested positive
for LS who undergo colectomy, 0.65 for probands tested positive who decline colectomy and 0.66 for
probands who decline testing (see Table 84). Given that these utilities are similar, this suggests no
substantial impact or psychological impact of colectomy on HRQoL.
Kalady and colleagues (2011)227 used the SF-36 questionnaire to measure the HRQoL of 95 patients who
underwent surgery for colon cancer meeting the AC for LS at a single institution. One year after surgery,
there was no significant difference in any of the eight domains of the questionnaire between the
50 patients who underwent a total proctocolectomy and the 45 who underwent a partial colectomy.
In another study,83 a panel of 10 experts (seven gastroenterologists and three genetic counsellors) used the
standard gamble approach to estimate the utility of patients with subtotal colectomy as 0.95 and that of
those with proctocolectomy as 0.89. Although this is low-quality evidence (very small sample size, patients
not scoring questionnaire, time trade-off not used), it suggests little disutility after these surgeries.
Given this additional evidence, and that (a) arguably any disutilities related to surgery for CRC are already
incorporated in our chosen disutilities according to Dukes’ stage and (b) we assume no additional disutility
after proctocolectomy (which is the most substantial of all the risk-reducing surgeries for CRC), we also
assume no additional disutility for patients who have had any CRC risk-reducing surgery, including partial
colectomy, rectal excision and subtotal colectomy.
We performed a sensitivity analysis in which a disutility of 0.1 was applied to all surgeries except segmental
resection, on the basis that they could conceivably have an impact on quality of life.
Impact of endometrial cancer on quality of life
There are contradictory results in the literature regarding the impact of EC and its treatment on HRQoL.229
Some studies report that most women are cured but that treatment may induce alterations in functional
status, activity and family relationships and cause much psychological distress, whereas other studies report
good quality of life despite physical symptoms and effects of treatment.229
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In their cost-effectiveness model, Kwon and colleagues (2008)75 assume a utility of 0.83 for women with
EC, citing five references.203–207 Unfortunately, the authors provide no detail as to how they derived their
estimate from these sources. In their cost-effectiveness models, both Dinh and colleagues (2011)55 and
Yang and colleagues (2011)76 also assume a utility of 0.83 for women with EC, both citing Kwon (2008).75
Wang and colleagues (2012)57 assume a utility of 0.73 for women with EC, citing Kuppermann and
colleagues (2013).212 However, as explained below (see Psychological impacts of Lynch syndrome testing
and management on quality of life), we believe the methodology of this source study to be flawed, and
we therefore disregard this value.
There appears to be scant literature on the long-term quality of life of women with EC. Our systematic
search for HRQoL for women living with EC revealed only the following two studies of interest.
A study of 79 Norwegian women 3–4 years after radiotherapy for cancer of the endometrium and cervix
used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C36
(EORTC QLQ-C36) to measure HRQoL.229 Of these women, 57% had undergone surgery prior to
radiotherapy. Although the nature of surgery is not specified, we assumed that it included hysterectomy.
The stages of the cancers were I and II. These women suffered few treatment and/or disease-related side
effects. Compared to the general Norwegian population, the women scored lower on role functioning and
experienced more diarrhoea. Scores on the social functioning and global health status were similar to
those in the general population.229
A study of 264 Dutch, 5- to 10-year survivors of stage I–II EC found that the HRQoL of women treated
with surgery alone or surgery plus radiotherapy was similar to that of an age-matched general
population.230 The authors therefore concluded that the HRQoL of women with stage I–II EC is
generally good.
In our base case, we assume no disutility for EC. This is because (1) we can find no high-quality data on
relevant HRQoL, (2) the two studies discussed above of women with stages I and II EC found that the
HRQoL of women with EC was similar to that of age-matched general populations,229,230 and (3) although
there is likely to be a disutility for women with advanced EC, we assume that only a small proportion of
women have advanced cancer at diagnosis (73% stage I, 18% stages II and III, 9% stage IV). However, in
a sensitivity analysis, we assume a lifetime disutility of 0.10 for all women with EC.
Impact of prophylactic total abdominal hysterectomy with bilateral
salpingo-oophorectomy on quality of life
In our model, we assume that a large proportion of female probands and relatives who test positive for LS
will have prophylactic TAHBSO at a minimum age of 45 years. It seems plausible to include a long-term
disutility after TAHBSO for the following reasons. Hysterectomy is a major operation from which it takes
about 6 to 8 weeks to fully recover.231 Depression may be triggered, there may be some changes to
bowel and bladder function and some women develop urinary tract infection or constipation.231 After
oophorectomy, severe menopausal symptoms are likely, which may be treated with hormone
replacement therapy.231
In their cost-effectiveness model, Kwon 200875 assumed a utility of 0.86 for premenopausal women who
have prophylactic surgery, citing Grann and colleagues (2002)208 and van Roosmalen and colleagues
(2002).211 Grann and colleagues (2002)208 cite a utility of 0.82 for women who have had prophylactic
oophorectomy. However, we are unable to trace this value from their source references. Next, van
Roosmalen and colleagues (2002)211 do not give the utility for women who have had just prophylactic
oophorectomy or hysterectomy or both.
In their cost-effectiveness model, Dinh and colleagues (2011)55 also assumed a utility of 0.86 for women
after TAHBSO, citing Kwon (2008).75 No other existing models explicitly allowed for a disutility for
prophylactic TAHBSO.
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We assume no disutility after TAHBSO for the following reasons: (1) we can find no high-quality data on
relevant HRQoL; (2) the two studies of women with stages I and II EC (which we discuss in the next
section), most of whom had undergone surgery (which we presume included hysterectomy), found that
women suffer few treatment and/or disease-related side effects;229 and (3) we assume prophylactic surgery
at a minimum age of 45 years, coinciding with the end of childbearing. However, given that long-term
disutility after TAHBSO seems plausible, we assume a lifetime disutility of 0.10 in a sensitivity analysis.
In Chapter 6, Utilities associated with endometrial cancer, we demonstrate that overall cost-effectiveness is
very sensitive to this assumption.
Impact of Lynch syndrome surveillance colonoscopies on quality of life
In the cost-effectiveness model that underpins the current UK NHS Bowel Cancer Screening Programme,214
no disutilities are assumed for having screening (including flexible sigmoidoscopy). The authors justify their
decision by reasoning that any reduction in QALYs would be negligible because the time period over
which any disutility would apply would be very small. We also assume no disutility for colonoscopy for the
same reason.
Psychological impacts of Lynch syndrome testing and management on
quality of life
Background
Although diagnosis of LS can lead to interventions to reduce the chance of developing colorectal,
gynaecological and other cancers, it can also lead to anxiety about developing these cancers and the need
to make difficult decisions about whether or not to undergo risk-reducing surgeries. Furthermore, those
diagnosed with LS must decide whether or not and how to inform relatives about their test results so that
these relatives can consider whether or not they wish to be tested themselves. Given that anxiety is one
aspect of HRQoL, such effects should be considered in the estimation of health-state utilities of probands
and relatives.
We identified just a single study of the cost-effectiveness of strategies for testing for LS [Wang and
colleagues (2012)57] that incorporates disutilities associated with the psychological impact of testing.
In this study it was assumed that such disutilities are transient, lasting 1 year in the base-case analysis.
This assumption was based on several empirical studies.12,199,232–238 Disutilities due to testing itself and the
test results were taken from the empirical study by Kuppermann and colleagues (2013).212
Kuppermann and colleagues (2013)
Based on our survey of the literature, we agree with Kuppermann and colleagues (2013)212 that their study
is the first to measure disutilities associated with genetic testing for LS. They elicited utilities using the time
trade-off method, which is recommended by NICE in the UK.198 Seventy-one highly educated individuals
based in the USA, ‘with a range of understanding about and experience with LS’, were given a range of
health-state vignettes to value. Most of this sample (n= 49) were neither knowledgeable about nor at high
risk of LS. Health-state vignettes covered a range of possible testing scenarios, where participants had to
imagine first that their sibling had CRC and was to be tested for LS, and second, that they themselves had
CRC that was suspected to be related to LS. Scenarios included whether or not testing for LS was accepted
and whether or not risk-reducing surgery was undertaken.
Unfortunately, we question the reliability of the utilities from this study for several reasons. First, NICE’s
preferred method of obtaining utilities in the UK is for patients (in this case probands and their relatives) to
complete the EQ-5D questionnaire, and then for these responses to be valued by a representative sample
of the population of the UK.198 However, in the study by Kuppermann and colleagues (2013),212 utilities
were elicited not by probands and their relatives, but by individuals ‘with a range of understanding about
and experience with LS’, and not using the EQ-5D questionnaire, but using health-state vignettes. Next,
the sample was from the USA, not the UK, as preferred in our case. Furthermore, the sample of individuals
ASSESSMENT OF COST-EFFECTIVENESS: DESCRIPTION OF THE ECONOMIC MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
valuing the vignettes was biased as they were highly educated. For these reasons, we believe that the
utilities from Kuppermann and colleagues (2013)212 should be considered only as indicative. The results
were as shown in Table 84.
As expected, for relatives there is a disutility associated with testing positive for LS compared with testing
negative, with utilities of 0.74, 0.70 and 0.67 for testing positive versus 0.76 for testing negative. In our
model, we assume that relatives who accept testing and who are tested negative suffer no disutility
compared with members of the general population of England and Wales (see Table 85). As explained
below, in our base-case analysis we assume that all test-related disutilities apply for only 4 months, as the
literature suggests that the psychological impact of testing is transient. Next, in our model we assume that
relatives who decline testing incur a disutility over 4 months of 0.04, equal to the utility of 0.76 (siblings
who undergo testing, and test negative) minus 0.72 (siblings who decline testing). This disutility reflects
anxiety the relative may feel in not knowing whether or not he or she has LS, with the corresponding
substantial risk of developing cancer. Next, we assume a disutility of 0.02 for male relatives who are
diagnosed with LS, equal to 0.76 for siblings who undergo testing and test negative, minus 0.74 for males
who are tested positive for LS. Similarly, we assume a disutility of 0.06 for women who test positive and
undergo TAHBSO, equal to 0.76 minus 0.70, and a disutility of 0.09 for women who test positive and
decline TAHBSO, equal to 0.76 minus 0.67. The disutility is greater for women who decline TAHBSO
presumably because they know that there remains a chance that they will develop gynaecological cancers.
For women who test positive but are not offered TAHBSO as they are not at the appropriate age, we
assume that the disutility of testing positive will be the same as for men who test positive, i.e. 0.02.
Although women are at risk of more cancers than men (i.e. the additional risks of EC and OC), women are
at lower risk of CRC,65 and so we assumed that their anxiety related to future cancer risk should not differ
greatly from that of men.
TABLE 84 Summary of utilities associated with effects of genetic testing for LS
States Mean (SE)a
Siblings
Undergo testing, LS negative 0.76 (0.03)
Undergo testing, LS positive, no surgery offered (men) 0.74 (0.03)
Undergo testing, LS positive, undergo TAHBSO (women) 0.70 (0.03)
Undergo testing, LS positive, decline TAHBSO (women) 0.67 (0.03)
Decline testing 0.72 (0.03)
Probands
Undergo testing, LS positive, accept surgery
Colectomy (men) 0.68 (0.03)
TAHBSO (women) 0.67 (0.03)
Undergo testing, LS positive, decline surgery
Colectomy (men) 0.65 (0.03)
TAHBSO (women) 0.61 (0.03)
Decline testing 0.66 (0.03)
SE, standard error.
a Rounded to two decimal places. Standard error assuming all 70 participants completed all questions.
Adapted from Kuppermann et al.212
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With regard to the disutilities for probands, unfortunately Kuppermann and colleagues212 did not measure
the utility for probands who accepted testing and were diagnosed as LS negative. In the absence of this
information, we assume that these individuals have no associated disutility due to genetic testing
(Table 85). Next, we estimate the disutility for probands of declining testing as 0.04, equal to the
corresponding value for relatives. In our analysis, risk-reducing colorectal surgery is not offered to probands
because the surgical treatment of their CRC is assumed to be completed before genetic testing takes place
and our clinical experts advised that colectomy solely for prophylaxis would not be offered. Kuppermann
and colleagues212 do not measure the utility for probands who accepted testing and were diagnosed with
LS but were not offered any risk-reducing surgery, so we assume that the disutility for testing positive for
male probands is the same as the disutility for male relatives, i.e. 0.02. For female probands who test
positive and are not offered any risk-reducing surgery, we again assume the same disutility as for males,
i.e. 0.02. For female probands who test positive and are offered prophylactic TAHBSO, we assume
disutilities of 0.03 for those accepting surgery and 0.09 for those declining it. These disutilities are
estimated by subtracting the utilities of 0.67 and 0.61 reported in Kuppermann and colleagues212 from the
imagined utility of probands testing negative, which we estimate as the utility of probands declining
testing (0.66) plus a utility of 0.04 for not declining testing taken from the relatives, to give a utility for
probands testing negative for LS of 0.70. If a proband or relative declines testing but is still diagnosed with
LS (by FH for probands or on account of being a FDR of a known carrier for relatives) and offered TAHBSO,
we assume a disutility of 0.01 for probands and 0.04 for relatives (i.e. the same disutility as for probands
or relatives testing positive), with an additional disutility of 0.06 for probands declining TAHBSO and 0.03
for relatives declining TAHBSO. For example, the total disutility for a proband declining testing and
accepting TAHBSO would be 0.04 (declined testing)+ 0.01 (offered TAHBSO)= 0.05, while the total
disutility for a relative declining testing and declining TAHBSO would be 0.04 (declined testing)+ 0.04
(offered TAHBSO)+ 0.03 (declined TAHBSO)= 0.11.
TABLE 85 Summary of disutilities applied over 4 months associated with effects of genetic testing for LS in
PenTAG model
Result of genetic testing
Disutility
Males Females
Proband
Test declined, surgery not offered 0.04 0.04
Test declined, accept TAHBSO N/A 0.05
Test declined, decline TAHBSO N/A 0.11
Test accepted, LS negative 0.00 0.00
Test accepted, LS positive, surgery not offered 0.02 0.02
Test accepted, LS positive, accept TAHBSO N/A 0.03
Test accepted, LS positive, decline TAHBSO N/A 0.09
Relative
Test declined, surgery not offered 0.04 0.04
Test declined, accept TAHBSO N/A 0.08
Test declined, decline TAHBSO N/A 0.11
Test accepted, LS negative 0.00 0.00
Test accepted, LS positive, surgery not offered 0.02 0.02
Test accepted, LS positive, accept TAHBSO N/A 0.06
Test accepted, LS positive, decline TAHBSO N/A 0.09
N/A, not applicable.
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Other empirical studies
Heshka and colleagues (2008)239 performed a systematic review of studies that measured the psychological
impact of genetic testing on a range of hereditary conditions. Twelve of these studies concerned LS. Most
psychological outcomes were measured in one of the following four domains: general distress, specific
distress, anxiety and depression. In summary, most studies reported negative effects on those diagnosed
with LS, but these were short-lived, typically lasting up to 4 months. In our base-case analysis, we assume
that any disutilities concerning the psychological impact of genetic testing last only 4 months. Detailed
findings for each of the four domains are as follows:
1. Most studies found no effect of genetic testing on general distress for either those diagnosed LS
positive or those diagnosed negative, and most studies found no difference in general distress between
those diagnosed positive or negative after disclosure of test results.
2. Studies found either that genetic testing had no effect on cancer-specific distress, or that distress
increased for about 2 weeks and then returned to baseline levels. For individuals tested negative,
cancer-specific distress either decreased after test result disclosure or did not change. Those tested
negative generally had lower cancer-specific distress than carriers.
3. Anxiety generally increased in those tested positive at results disclosure and 2 weeks later, but had
returned to baseline levels or lower after 1 year. Anxiety in those tested negative decreased at results
disclosure or 1 month after the test, but also returned to baseline levels or lower by 1 year. Those
tested positive generally had higher anxiety than those tested negative at test result disclosure, but later
anxiety was similar.
4. Most studies reported no effect of genetic testing on depression in either those tested positive or those
tested negative.
Heshka and colleagues (2008)239 noted that most studies in the review acknowledged several limitations.
Most study populations were small and self-selected, not representative of individuals eligible for testing.
Participants were typically white and highly educated. Additionally, most studies included extensive
pre- and post-test counselling and education, which may not always generalise to the routine clinical
setting, although in our model we assume that individuals must receive genetic counselling if they are to
have genetic testing.
Four other studies not considered in the review by Heshka and colleagues (2008)239 also found no
long-term psychological impact of testing for LS:
l In a study of 92 individuals in the Netherlands,240 cancer distress and worry increased slightly in those
diagnosed LS positive after test disclosure and decreased at the next time point measured (6 months
after disclosure). Those tested negative remained at the same level of distress shortly after disclosure,
but distress had decreased by the 6-month reporting time.
l In a study of 116 individuals in the Netherlands,241 4 years after genetic counselling for LS only a small
minority of participants reported significant levels of distress, or significant family or social problems.
l A Canadian study242 found that 49 individuals diagnosed with LS who did not have CRC had adapted
psychologically to their test result at the mean follow-up time of approximately 6 years.
l An Australian study232 of 19 individuals diagnosed with LS and 54 without LS also found no long-term
evidence (at 1 and 3 years after testing) of undue psychological distress in those diagnosed with LS.
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Cost parameters and assumptions
Many of the published models use cost data from countries other than the UK. However, it was important
to choose values relevant to a UK and NHS perspective.
Adjustments to 2013–14 prices
All costs and prices in the model are inflated to 2011–12 prices using the Hospital and Community Health
Services (HCHS) Pay and Prices index,243 and then further inflated by 3.46% per annum for 2 years to
2013–14 prices, where 3.46% is the average (geometric mean) inflation of the index between 2000–1
and 2011–12.
Costs of tumour testing
Costs of the preliminary tumour tests have been obtained directly from laboratories in the UK (see
Table 86). Where possible, we also included the additional costs of administration, additional wear and
tear on machinery, training time and repeat tests.
Cost of genetic testing
Costs for genetic tests (for probands and relatives) are taken directly from genetic testing laboratories,
identified from the UKGTN.244 Only costs applicable to the NHS are collected (we were careful to exclude
private fees) and overall values for each cost are calculated across the laboratories that supply each given
test. Available genetic tests are individual sequencing tests for probands for MLH1, MSH2, MSH6 and
PMS2, with PMS2 testing currently only available in one UK laboratory in Leeds; individual targeted tests
for MLH1, MSH2, MSH6 and PMS2 for relatives; a combined MLH1, MSH2 sequencing test for probands;
and a combined MLH1, MSH2 and MSH6 sequencing test for probands. We decided to model using the
combined MLH1, MSH2 and MSH6 test for probands, because it is cheaper than doing all three individual
tests. This is followed by an individual sequencing test for PMS2. Relevant individual targeted tests are
conducted for relatives. The cost for PMS2 tests (for probands or relatives) was taken from the laboratory
in Leeds, as this is the only laboratory that provides this test. The cost for the combined M126 test was
taken as the mean cost from the four laboratories that offer this test and provide costs on their websites
(Yorkshire Regional Genetics Service,126 East Anglian Medical Genetics Laboratories,125 All Wales Molecular
Genetics Laboratory123 and Oxford Medical Genetics Laboratories122). Similarly, the cost of the individual
targeted genetic tests for relatives is calculated as the mean cost across laboratories. The listed costs of
genetic tests are currently all-inclusive for the NHS; that is, there are no additional charges for laboratory,
processing or transportation costs as they are accounted for through core funding.
Genetic testing costs reduce as technology enables greater efficiency, hence the laboratory costs are
expected to decrease. We performed a sensitivity analysis with reduced costs to reflect this.
Cost of genetic counselling
Genetic counselling is assumed to occur after initial tumour testing and before genetic testing. Genetic
counselling also includes taking a FH (according to our experts), so for all strategies that include genetic
testing, the cost of taking a FH is included in the cost of genetic counselling. A separate cost is given for
FH assessment in strategy 1 and for those who decline genetic counselling (Table 86 and Figure 34).
Genetic counselling was a parameter without a standard unit cost. As such, it was calculated using
estimates of time, staff involved and associated unit costs.
We found no standardised approach to genetic counselling (some places may provide two or three times
more counselling per patient than others) and, as such, the estimates we detail may not reflect the practice
of all genetics centres. To calculate the time and staff involved in genetic counselling we corresponded
with Professor Mary Porteous of the South East Scotland Genetic Service, based at the Western General
Hospital in Edinburgh (2013, personal communication).
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TABLE 86 Costs of diagnostic tests and genetic counselling
Test Patient Base-case cost Base-case source
MSI Proband £202 Average of £221 (Oxford Medical Genetics Laboratories),122 £150
(All Wales Molecular Genetics Laboratory),123 £215 (West Midlands
Regional Genetics Laboratory, via the UKGTN),244 2012 costs updated to
2013–14 costs
IHC Proband £238 Dr Mark Arends (Department of Pathology, University of Cambridge,
2012, personal communication) and Dr Ian Frayling (All Wales Genetics
Service, 2012, personal communication) £220–240, 2012 costs updated
to 2013–14 costs
BRAF Proband £118 Average of £140 [Mr Michael Gandy, University College London
(UCL)-Advanced Diagnostics, 2012, personal communication], £117
(East of Scotland Regional Genetic Service),124 £85 (All Wales Molecular
Genetics Laboratory),123 2012 costs updated to 2013–14 costs
Proband genetic
test (M126)
Proband £812 Average of £860 (Oxford Medical Genetics Laboratories),122 £900
(All Wales Molecular Genetics Laboratory),123 £850 (East Anglian Medical
Genetics Laboratories),125 £530 (Yorkshire Regional Genetics Service),126
2012 costs updated to 2013–14 costs
Proband genetic
test (PMS2)
Proband £735 £710 (Yorkshire Regional Genetics Service),126 2012 costs updated to
2013–14 costs
Proband genetic
test (MLH1)
Proband £464 Average of £400 (All Wales Molecular Genetics Laboratory),123 £390
(East of Scotland Regional Genetic Service),124 £475 (East Anglian
Medical Genetics Laboratories),125 £530 (Yorkshire Regional Genetics
Service),126 2012 costs updated to 2013–14 costs
Proband
genetic
counselling
Proband £67 PSSRU243 and personal communication with Professor Mary Porteous
(South East Scotland Genetic Service) updated to 2013–14 costs
Taking FH Proband £22 PSSRU243 and personal communication with Professor Mary Porteous
(South East Scotland Genetic Service) updated to 2013–14 costs
Targeted
genetic test for
relatives (MLH1)
Relative £169 Average of £170 (Oxford Medical Genetics Laboratories),122 £160
(All Wales Molecular Genetics Laboratory),123 £143 (East of Scotland
Regional Genetic Service),124 £175 (East Anglian Medical Genetics
Laboratories),125 £170 (Yorkshire Regional Genetics Service),126 2012
costs updated to 2013–14 costs
Targeted
genetic test for
relatives (MSH2)
Relative £172 Average of £170 (Oxford Medical Genetics Laboratories),122 £160
(All Wales Molecular Genetics Laboratory),123 £170 (Yorkshire Regional
Genetics Service),126 2012 costs updated to 2013–14 costs
Targeted
genetic test for
relatives (MSH6)
Relative £172 Average of £170 (Oxford Medical Genetics Laboratories),122 £160
(All Wales Molecular Genetics Laboratory),123 £170 (Yorkshire Regional
Genetics Service),126 2012 costs updated to 2013–14 costs
Targeted
genetic test for
relatives (PMS2)
Relative £176 £170 (Yorkshire Regional Genetics Service),126 2012 costs updated to
2013–14 costs
Relative genetic
counselling
Relative £67 PSSRU243 and personal communication with Professor Mary Porteous
(South East Scotland Genetic Service)
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In this centre genetic counselling occurred, where applicable, after the tumour tests (IHC and/or MSI) for
the proband. Generally, probands received a maximum of a single 45-minute session with a band 7
counsellor before gene testing, and a 30-minute session to discuss the results. The same was also true of
the relatives, though in practice the total 75 minutes could be split in various ways (for example,
sometimes relatives would have a group session then return for a shorter individual session before they
were tested). In this centre the cost of genetic counselling incurred for a relative of a proband was
therefore the same as that for the proband.
Using the costs from the Personal Social Services Research Unit (PSSRU) 2012,243 we could only find costs
for counselling services in primary medical care, which seemed more applicable to band 7 mental health
counsellors. However, no specific costs for genetic counsellors were stated and it seemed plausible that the
staff and overhead costs would be similar, so we concluded that this cost would be appropriate. The cost
therefore worked out to be £50 per hour (which included wages; salary oncosts; overheads including
management, administration and estates staff and non-staff; and capital overheads); £65 per hour of client
contact (including wages; salary oncosts; overheads including management, administration and estates staff
and non-staff; and capital overheads); or £59 per consultation. We chose to use the ‘per hour’ cost, which
resulted in a cost of £62.50 per patient for 75 minutes of counselling. We updated this to 2013 costs, by
inflating at 3.46% per annum over 2 years, from 2011–12 to 2013–14. This increased the cost to £67.
The South East Scotland Genetic Service was, at the time of writing, moving towards ward staff being
responsible for taking FH, a role for which a band 5 clinic nurse would be deemed appropriate. In this
setting the intention was to reduce the time spent with the counsellor. Again, this does not reflect all
practice across UK genetics services; some centres have, for example, clinical pedigree support workers at
similar banding levels, who are neither nurses nor counsellors. Owing to a paucity of alternative
information, we considered that this could also be used to cost for patients who do not visit a genetic
counsellor. The amount of the nurses’ time this was expected to take was 30 minutes.
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FIGURE 34 Costs of genetic counselling and FH assessment in strategies to identify LS in probands and
their relatives.
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Again using the PSSRU 2012, we found that the costs for a band 5 staff nurse were £35 (£41) per hour,
and £85 (£100) per hour of patient contact, where the costs in brackets included qualifications. Assuming
that training for taking FH could be included in the qualifications, we took the hourly cost of £41, which
worked out at £20.50 per patient. Using the same approach as before we updated this cost to 2013–14
costs, giving £22.
Given that different genetic centres have different approaches to genetic counselling, we performed a
sensitivity analysis on the cost of counselling, halving and doubling the time spent on each patient.
Figure 35 shows the costs of each test for probands and relatives. The cost of gene testing for relatives appears
much reduced compared with that for probands, as ‘predictive testing’ is less costly than full gene sequencing.
As the predictive gene testing only occurs as a result of finding a particular gene mutation in probands, gene
testing in relatives only ever tests for one gene, hence relatives cannot have a combined gene test (such as
M126). As MSI, IHC and BRAF are tumour tests, they are not conducted on asymptomatic relatives.
Costs of Lynch syndrome surveillance colonoscopies
We estimated the cost of colonoscopy from Department of Health reference costs 2011–12151 using
Healthcare Resource Groups (HRGs) FZ51Z (diagnostic colonoscopy, 19 years and over), FZ52Z (diagnostic
colonoscopy with biopsy, 19 years and over) and FZ53Z (therapeutic colonoscopy, 19 years and over). The
reference costs for these HRGs are shown in Table 87, as well as the average cost weighted by activity
(£553 in 2011–12 prices). We uprated this to 2013–14 prices as described in Adjustments to 2013–14
prices to obtain a cost of £592.
Finally, the cost of colonoscopy was adjusted to reflect the fact that the estimate of the effectiveness of
colonoscopy comes from a population in which colonoscopies were performed 3-yearly rather than
2-yearly.94 We could adjust for this by only including 3-yearly colonoscopies in the model, but given that
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FIGURE 35 Costs of individual tests to identify LS in probands and relatives.
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the number of additional colonoscopies required for each strategy was an outcome of interest, we
preferred instead to adjust the cost of colonoscopy. Jarvinen and colleagues (2000)94 report that over
600 colonoscopies were performed in the study group, with a total follow up of 1854 person-years. This
means that the average number of colonoscopies per person-year was at least 0.324, or a rate of at least
one colonoscopy per 3.09 years. As the surveillance protocol dictated 3-yearly colonoscopies and the
observed rate is very similar to this, we assumed a rate of one colonoscopy per 3 years. The cost of
colonoscopy was adjusted from £592 to £395.
Costs of morbidity and mortality due to Lynch syndrome
surveillance colonoscopies
Table 88 summarises the unit costs included for morbidity and mortality due to LS
surveillance colonoscopies.
We assumed that bleeding not requiring admission would incur no cost. We estimated the cost of mild
bleeding requiring admission by uprating the cost of this item, reported by Whyte and colleagues214 as £278
in 2008–9 prices, using the HCHS Pay and Prices inflation index, to £318 in 2013–14 prices (as described in
Adjustments to 2013–14 prices). We estimated the cost of moderate bleeding by using the Department of
Health reference costs 2011–12,151 using HRG FZ38F (gastrointestinal bleed with length of stay 1 day or
less) and including only non-elective inpatient activity, resulting in a cost of £458 in 2011–12 prices, which
we uprated to £490 in 2013–14 prices. We estimated the cost of severe bleeding by using HRGs FZ38D and
FZ38E (gastrointestinal bleed with length of stay 2 days or more) and including only non-elective inpatient
activity, resulting in a cost of £1853 in 2011–12 prices, which we uprated to £1984 in 2013–14 prices.
We estimated the cost of treating perforation from colonoscopy from Department of Health reference
costs 2011–12,151 using HRG FZ77 (major large intestine procedures, 19 years and over) and including only
non-elective inpatient activity, resulting in a cost of £4797 in 2011–12 prices, which was uprated to £5134
in 2013–14 prices.
TABLE 88 Summary of costs relating to morbidity and mortality due to colonoscopies
Event Cost (£) Source
Mortality 5134 Assumed same as perforation following Whyte et al. 2012214
Perforation 5134 Department of Health reference costs,151 FZ77 (Major large
intestine procedure)
Mild bleeding not
requiring admission
0 Assumption
Mild bleeding
requiring admission
318 Whyte et al. 2012214
Moderate bleeding 490 Department of Health reference costs,151 FZ38F (Gastrointestinal bleed with
length of stay 1 day or less)
Severe bleeding 1984 Department of Health reference costs,151 FZ38D/FZ38E (Gastrointestinal bleed
with length of stay 2 days or more)
TABLE 87 Reference costs for colonoscopies
HRG Description Number of colonoscopies Unit cost (£) Total cost (£)
FZ51Z Diagnostic colonoscopy, 19 years and over 143,080 528 75,555,599
FZ52Z Diagnostic colonoscopy with biopsy,
19 years and over
129,405 572 73,975,538
FZ53Z Therapeutic colonoscopy, 19 years and over 90,181 567 51,164,816
Weighted average 362,666 553 200,695,953
ASSESSMENT OF COST-EFFECTIVENESS: DESCRIPTION OF THE ECONOMIC MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
We estimated that the cost of colonoscopy mortality would be the same as for perforation, i.e. £5134 in
2013–14 prices, following the assumption of Whyte and colleagues214 that mortality only follows
perforation and does not include any additional costs.
Costs of colorectal cancer treatment
Costs of colorectal cancer treatment in published models of cost-effectiveness
of testing for Lynch syndrome
There is much variability in the assumed nature and magnitude of costs for treating CRC across studies of
the cost-effectiveness of testing for LS (Table 89). Approaches are:
TABLE 89 Costs of treatment for CRC in published models of the cost-effectiveness of testing for LS
Cost-effectiveness
analysis Chemotherapy for CRC
Medical
management
for CRC End of life for CRC
Breheny et al. 200651 AU$18,358 in 2001–2 prices for total cost over lifetime to treat CRC. Evidence appears lacking
Brown and
Kessler 199622
$40,000 in mid-1990s prices for total cost over lifetime to treat CRC, citing a US study published
in 1994244
DACEHTA 200752 Not clear from publication
Dinh et al. 201155 Stage I $27,221 initially, $2166 continuing Stage I $48,791
Stage II $37,563 initially, $2024 continuing Stage II $48,662
Stage III $45,804 initially, $2883 continuing Stage III $51,276
Stage IV $59,812 initially, $8945 continuing Stage IV $68,809
aAll from US Medicare 1998–2003246 All from US Medicare 1998–2003
Kievit et al. 200550 €1634 for follow-up for 3 years after subtotal colectomy in 2002 prices
Kwon et al. 200875 None
Kwon et al. 201156 $35,000 in 2010 prices for total cost over lifetime to treat CRC, citing US studies247–249
Ladabaum et al.
201148
$34,000–44,000 initially, decreasing from
$2500–3500 in year 1 to $2400–2800 in year 5,
depending on whether LS positive or negative and
whether or not screened. In 2010 US$, from
US data source246
$49,000–52,000, depending on whether
LS positive or negative and whether or
not screened. In 2010 US$, from US
data source
Mvundura et al.
201054
See Ramsey et al. 200123
Olsen et al. 200753 €12,320 for Dukes’ C and D
based on Danish practice
in 2004
None None
Ramsey et al. 200123 First CRC diagnosis: stage I $25,516, stage II $28,166, stage III $31,907, stage IV $45,393
Second CRC diagnosis: stage I $27,794, stage II $28,872, stage III $33,658, stage IV $49,352b
1999 prices; source: US Medicare249
Ramsey et al. 200349 See Ramsey et al. 200123
Reyes et al. 200259 None
Wang et al. 201257 See Ladabaum et al. 201148
Yang et al. 201176 None
DACEHTA, Danish Centre for Evaluation and Health Technology Assessment.
a The definition of ‘continuing’ cost is not clear, but we assume it refers to annual cost.
b We assume that costs are lifetime.
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l no costs59,75,76
l a single total lifetime cost over all Dukes’ stages22,50,51,56
l a single lifetime cost specific to each disease stage, separately for a first and second CRC23,49,54
l costs according to whether incurred initially, regularly or at end of life48,57
l costs split by stage, whether incurred initially, regularly or at end of life55
l cost for chemotherapy only.53
Costs of colorectal cancer treatment in the Peninsula Technology Assessment
Group model
There are many stages in the management of patients with CRC from the time of diagnosis [see Trueman
and colleagues (2007),134 pp. 28–9, for detailed diagrams showing treatment pathways for colon and
rectal cancer]. Furthermore, there is substantial variation across England in the management of CRC
patients.133,134,251 For these reasons, costing the treatment of patients with CRC from the time of diagnosis
is a very substantial project in its own right.
The data sources used in previous models of LS to inform the cost of treatment for CRC (see Table 89)
were not used because they are not UK based and are rather old. However, fortunately, two UK-based
studies have recently done just this.
The UK NHS Bowel Cancer Screening Programme, which started in 2006, and which currently
recommends biennial screening with the guaiac faecal occult blood test for individuals aged 60–74 years,
was informed by a cost-effectiveness analysis that currently assumes the following lifetime costs for
treating CRC: £12,455 for Dukes’ A, £17,137 for Dukes’ B, £23,502 for Dukes’ C and £25,703 for Dukes’
D.214 These estimates were taken from a 2009 UK study that quantified the activities, costs and outcomes
associated with the treatment of bowel cancer,251 and inflated to the year 2010. Unfortunately, though
the source publication251 gives some of the parameter values that underlie these figures, it contains
insufficient data to allow the reader to recreate these lifetime costs.
Another study was published in 2007 on the costs and benefits of bowel cancer services in England.134
Numerous parameters were used to estimate the costs of treating CRC patients. Sources for resource use
included the Hospital Episode Statistics, ONS, nationally published audits, locally published data, published
literature and expert opinion.134 Unit cost data were taken from NHS reference costs published by the
Department of Health, the PSSRU at the University of Kent, published literature, and local sources and
expert opinion.134 The costs associated with treatment of patients with CRC are shown in Table 90. All
costs relate to those patients who incur the particular cost item. For example, the cost of £11,209 for
primary chemotherapy and radiotherapy for patients with colon cancer relates only to those patients who
receive either chemotherapy or radiotherapy. Some patients diagnosed with colon cancer may receive
neither chemotherapy nor radiotherapy. All values are in 2004–5 prices.
With the exception of primary surgery (the costs of which are estimated in Colorectal cancer surgery costs),
we based the costs for CRC treatment in the PenTAG model on the costs in Table 90, and our adapted
costs are shown in Table 91.
In our model we distinguish between colon and rectal cancer only in the year of diagnosis (as it is used in
the logic to decide which surgery is appropriate). Therefore, costs incurred in the year of diagnosis
(diagnosis costs, surgery costs, primary chemotherapy and radiotherapy) have costs dependent on both the
stage at diagnosis and the site of the CRC (colon or rectum). Costs incurred later (surveillance, treatment
for recurrence, stoma care and palliative care) have costs dependent on the stage at diagnosis and
whether or not the patient has LS, on the basis that 94% of LS CRC patients have colon cancer55
and 65% of sporadic CRC patients have colon cancer.119
All costs were inflated over 9 years, to 2013–14 prices, as described in Adjustments to 2013–14 prices.
Next, these unit costs were adjusted for the proportions of patients receiving the cost item according to
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TABLE 90 Per patient costs of treatment for CRC (2004–5 prices)
Cost Components
Cost per patient
with colon
cancer (£)
Cost per patient
with rectal
cancer (£)
Diagnosis Referral and diagnosis. Presenting via GP, A&E or
elsewhere in secondary care. Diagnostic tests include
colonoscopy, flexible sigmoidoscopy, double contrast
barium enema
379 379
Primary surgery MRI and pathology, stoma, stoma closure,
complications and stenting
4616 5980
Primary
chemotherapy
and radiotherapy
Pre- and postoperative chemoradiation,
adjuvant chemotherapy
11,209 7726
Chemotherapy is a mix of capecitabine and oxaliplatin
plus 5-FU/leucovorin (folinic acid) (FOLFOX)
Follow-up
surveillance (mean
annual cost)
CEA test, CT scan, colonoscopy, consultation.
Assumed for 5 years following primary treatment
204 195
Recurrence surgery
and chemotherapy
Almost all due to metastatic recurrence. Assumed to
occur within 5 years of primary treatment
9554 9279
Stoma care
(annual cost)
Assumed mix of ileostomy and colostomy 1279 1279
Palliative care Interventions (almost all chemotherapy, mix of 5-FU
followed by 5-FU and irinotecan and FOLFIRI/FOLFOX),
and end-of-life care (symptom management, hospital
and hospice stays)
7703 7016
A&E, accident and emergency; FOLFIRI, FOLinic acid, Fluorouracil, IRInotecan; FOLFOX, FOLinic acid, Fluorouracil,
OXaliplatin; GP, general practitioner; MRI, magnetic resonance imaging.
Source: Trueman et al. (2007).134
TABLE 91 Per patient costs of treatment for CRC (2013–14 prices) assumed in the PenTAG model
Cost When incurred
Colon cancer (by Dukes’ stage
at diagnosis)
Rectal cancer (by Dukes’ stage
at diagnosis)
A B C D A B C D
Diagnosis Diagnosis £499 all Dukes’ £499 all Dukes’
Primary
chemotherapy
and radiotherapy
Diagnosis £0 £5755 £13,133 £13,133 £0 £2848 £7628 £7628
Follow-up surveillance
(mean annual cost)
Maximum 5 years
from index CRC
£269 all Dukes’ £256 all Dukes’
Recurrence surgery
and chemotherapy
In last year of life if
patient dies of CRC
within 5 years
of diagnosis
£12,578 all Dukes’ £12,216 all Dukes’
Stoma care
(annual cost)
Every year
after surgery
£1684 all Dukes’ for 11%
of patients
£1684 all Dukes’ for 49%
of patients
Palliative care In last year of life if
patient dies of CRC
£10,141 all Dukes’ £9236 all Dukes’
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
Dukes’ stage at diagnosis. The resulting cost of £499 for diagnosis clearly applies regardless of Dukes’
stage at diagnosis.
The proportions of patients who receive chemotherapy and radiotherapy according to Dukes’ stage at
diagnosis were estimated for colon cancer patients as 0% Dukes’ A, 39% Dukes’ B, 89% Dukes’ C and 89%
Dukes’ D. The corresponding proportions for rectal cancer patients were estimated as 0% Dukes’ A, 28%
Dukes’ B, 75% Dukes’ C and 75% Dukes’ D. The values for Dukes’ A, B and C are taken from Trueman and
colleagues (2007).134 We assumed that the proportions for Dukes’ D equal the proportions for Dukes’ C.
These assumptions appear consistent with the recent NICE clinical guidelines for the treatment of CRC.133
In common with Trueman and colleagues (2007),134 follow-up surveillance was assumed to occur up to a
maximum of 5 years after diagnosis of the index CRC. Further, the same resource use was assumed
regardless of cancer stage. Although this may be unlikely, this simplifying assumption is unimportant given
the relatively small costs.
The York Health Economics Consortium (YHEC) estimates of the cost of treatment for CRC recurrence
were assumed to be due almost totally to metastatic recurrence.134 Unfortunately, YHEC do not report the
proportion of patients who experience metastatic recurrence. However, given that recurrence was assumed
to occur within the first 5 years after primary treatment,134 and given that life expectancy for patients who
have metastatic CRC is short, in the PenTAG model it is assumed that a patient who dies from CRC
(i.e. not general mortality or EC) within 5 years from diagnosis of the index CRC does so owing to
metastatic recurrence, thus incurring the cost of treatment for metastatic recurrence. The effect of this
assumption is that this cost is more likely to be incurred for those patients diagnosed with a more
advanced CRC, because these patients are more likely to die within 5 years of diagnosis.
In common with Trueman and colleagues (2007),134 the annual cost of stoma care of £1684 in 2013–14
prices was assumed to be incurred in each year after surgery for those patients who received a stoma and
for whom the stoma was not subsequently closed. The YHEC study estimated that 67.0% of rectal cancer
patients require a stoma, with 26.6% of these subsequently closed, and that 14.5% of colon cancer
patients require a stoma, again with 26.6% of these subsequently closed. Together this implies that 49%
of rectal cancer patients and 11% of colon cancer patients require a stoma which is not subsequently
closed. Resource use was assumed independent of cancer stage at diagnosis.
The cost of palliative care is assumed to be incurred in the last year of life only if the patient dies of CRC
(as opposed to other causes, including EC). Although resource use was assumed independent of cancer
stage at diagnosis, the cost of palliative care is more likely to be incurred for patients diagnosed with more
advanced disease, because they are more likely to die of CRC.
No biological agents are assumed for treating CRC as NICE has not recommended first-line treatment with
bevacizumab in combination with oxaliplatin and either 5-FU plus folinic acid or capecitabine for the
treatment of metastatic CRC (www.nice.org.uk/nicemedia/live/13291/52091/52091.pdf), nor has it
recommended treatment with bevacizumab (Avastin®, Roche) in combination with fluoropyrimidine-based
chemotherapy, cetuximab chemotherapy or monotherapy, and panitumumab (Vectibix®, Amgen)
monotherapy for metastatic CRC that has progressed following first-line treatment with chemotherapy.133
NICE was also unable to recommend panitumumab in combination with FOLFIRI (FOLinic acid, Fluorouracil,
IRInotecan) for the treatment of metastatic CRC that has progressed following first-line treatment with
chemotherapy,133 and second-line use of bevacizumab, panitumumab or cetuximab (http://guidance.nice.
org.uk/TA/WaveR/102/Consultation/EvaluationReport/AssessmentReport/pdf/English).
Colorectal cancer surgery costs
We assumed that the cost of surgery would depend on the nature of surgery, independent of the Dukes’
stage of the CRC. As LS CRCs have a greater tendency to be proximal than sporadic,55 we estimated costs
separately for LS CRCs and sporadic CRCs (although there is only a difference for segmental resections).
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To estimate the cost of colorectal surgery we chose the most relevant Office of Population, Censuses and
Surveys Classification of Surgical Operations and Procedures (4th revision) (OPCS-4.6) codes for the
procedures and used the Healthcare Resource Groups 4 (HRG4) 2011/12 Reference Costs Grouper Code to
Group workbook252 to map these to the appropriate HRGs, which were then located in reference costs to
obtain 2011–12 costs for the procedures (see Appendix 13). All costs were then uprated to 2013–14 prices
as described in Adjustments to 2013–14 prices. The cost of stoma reversal was then added for the
appropriate proportion of patients, and for segmental resections the proportion of proximal/distal
procedures was based on LS status.
The estimated costs of surgery for CRC are summarised in Table 92.
Cost of endometrial cancer prevention
The cost of prophylactic hysterectomy and bilateral salpingo-oophorectomy was estimated as £3322 in
2013–14 prices (inflated from £3104 in 2011–12 prices). This estimate is based on Department of Health
reference costs 2011–12151 and the HRGs MA07 (major open upper genital tract procedures) and MA08
(major laparoscopic or endoscopic, upper genital tract procedures), weighted by activity recorded in the
reference costs (Table 93). These HRGs were determined by mapping the relevant OPCS-4.6 codes for
the procedures253 using the HRG4 Code to Group workbook distributed with the Department of Health
HRG4 2011/12 Reference Cost Grouper,252 as shown in Table 94.
TABLE 92 Summary of estimated costs (2013–14 prices) of surgery for CRC
Surgery LS CRC (£) Sporadic CRC (£)
Segmental resection 6154 6104
Subtotal colectomy IRA 7331 7331
Anterior resection 7399 7399
Proctocolectomy IPAA 7441 7441
TABLE 94 Mapping OPCS codes for procedures to HRGs for reference costs
Procedure OPCS codes HRG
TAHBSO Q07.4+Q22.1 MA07
TLHBSO Q07.4+Q22.1+Y75.2 MA08
LAVHBSO Q08.9+Q22.1+Y75.1 MA08
LAVHBSO, LAVH with bilateral salpingo-oophorectomy; TLHBSO, TLH with bilateral salpingo-oophorectomy.
TABLE 93 Department of Health reference costs 2011–12 related to prophylactic hysterectomy and bilateral
salpingo-oophorectomy
HRG Number of procedures Unit cost (£) Total cost (£)
MA07C Major open upper genital tract procedures
with major CC
1381 4535 6,262,304
MA07D Major open upper genital tract procedures
without major CC
33,863 3269 110,692,366
MA08Z Major laparoscopic or endoscopic, upper
genital tract procedures
15,225 2606 39,680,196
Weighted average 50,469 3104 156,634,867
CC, comorbidities or complications.
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Cost of endometrial cancer treatment
Cost of surgery for endometrial cancer
The cost of hysterectomy and bilateral salpingo-oophorectomy as a treatment for EC was estimated as
£3877 in 2013–14 prices (inflated from £3622 in 2011–12 prices). This estimate is based on Department
of Health reference costs 2011–12151 HRG MA06Z (major open or laparoscopic, upper or lower genital
tract procedures for malignancy). As before, we confirmed that this was the correct HRG using the HRG4
Code to Group workbook distributed with the Department of Health HRG4 2011/12 Reference
Cost Grouper.252
Cost of radiotherapy for endometrial cancer
We estimate the cost of radiotherapy per patient as £5856. We base our estimate on the value of $7895
from the study by Havrilesky and colleagues (2009),152 which is similar to the estimate of $8418 used in
the model of Yang and colleagues (2011).76 First, the $7895 is adjusted from US dollars to pounds sterling
by purchasing power parities and from year 2009 to 2011,254 to yield £5520. Next, this is inflated by
2 years, from 2011 to 2013–14 prices (see Adjustments to 2013–14 prices) to give £5909.
Given the estimated split of stages of EC at diagnosis and the proportions of patients at each stage who
receive radiotherapy, this implies that 47%= (73%× 33%)+ (18%× 100%)+ (9%× 50%) of patients
diagnosed with EC will receive radiotherapy. Therefore, the cost of radiotherapy per EC patient is
47%× £5909= £2753. In our model, this cost is assumed to occur immediately on diagnosis of EC.
Cost of chemotherapy for endometrial cancer
There is no general agreement as to what currently constitutes the best chemotherapy for EC, as very few
phase III studies have been done comparing different chemotherapy regimens.255 Treatments include:255
l single-agent therapy
¢ cisplatin
¢ carboplatin
¢ paclitaxel
¢ doxorubicin
¢ liposomal doxorubicin
l combination therapy
¢ doxorubicin 60mg/m2 intravenous (IV) plus cisplatin 50mg/m2
¢ doxorubicin 45mg/m2 IV plus cisplatin 50mg/m2 plus paclitaxel 160mg/m2
¢ cisplatin 50mg/m2 IV plus doxorubicin 50mg/m2 or
¢ doxorubicin 45mg/m2 IV plus cisplatin 50mg/m2 IV plus paclitaxel 160mg/m2 IV plus filgrastim
(Neupogen®, Amgen) 5 µg/kg subcutaneous
¢ carboplatin area under the curve 5–7 plus paclitaxel 175mg/m2.
Next, we assume the treatment regime above of doxorubicin 45mg/m2 IV plus cisplatin 50mg/m2 IV on
day 1, plus paclitaxel 160mg/m2 on day 2, repeated every 21 days, as it is representative of the above
treatments and it has been used in a RCT.256 Unlike the RCT,256 we do not include the acquisition and
administration costs of filgrastim, because this drug appears to be given rarely and because it is given on
10 days in each treatment cycle, hence incurring a very high administration cost, as it is given
subcutaneously. The costs of doxorubicin, cisplatin and paclitaxel were taken from the electronic Market
Information Tool (eMit) database.153 These data include an estimate of the average prices paid for generic
drugs in the UK in the 4 months up to May 2012.
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Given the prices doxorubicin 50mg/25ml injection £6.38, cisplatin 50mg/50ml injection £7.60 and
paclitaxel 300mg/50ml injection £21.00 from the eMit database,153 this implies a total drug cost over
six cycles of £272, assuming a mean body surface area of 1.85m2 and weight of 70 kg.
Next, the estimated total cost of 12 days of administration of chemotherapy (over six cycles) is £2732,
given a cost per administration of £228. The cost per administration is calculated as £206 in 2010–11
prices, corresponding to the HRG SB15Z ‘Deliver subsequent elements of a chemotherapy cycle’ in the
sheet ‘Chemotherapy delivery: outpatients’ from the NHS reference costs 2010–11,257 inflated over 3 years
to 2013–14 prices as described in Adjustments to 2013–14 prices.
Together, the cost of drugs and administration for a course of six cycles is £272+ £2732= £3005.
Given the estimated split of stages of EC at diagnosis described above and the proportions of patients
at each stage who receive chemotherapy, this implies that 18%= (73%× 0%)+ (18%× 50%)+
(9% × 100%) of patients diagnosed with EC will receive chemotherapy. Therefore, the cost of
chemotherapy per patient is 18%× £3005= £541. In our model, this cost is assumed to occur immediately
on diagnosis of EC.
To acknowledge the lack of agreement as to what constitutes best chemotherapy, we perform two
sensitivity analyses, in which the total cost of chemotherapy of £3005 is halved and doubled, respectively.
Cost of follow-up management of endometrial cancer
A review of the routine follow-up management of patients after treatment for EC identified
11 studies258–268 from a range of countries, including one study from England263 and one from Scotland,262
covering the period 1977–97.269 The management was designed to identify recurrence of EC and included
clinical examination, smear of the vaginal vault, chest X-ray, ultrasound and CT scans, although the study
from England reported only occasional clinical examinations and the study from Scotland only occasional
clinical examinations and occasional smear. In our model, we do not include the costs for any such
follow-up management, because of the very low cost relative to other costs, such as the cost of
hysterectomy, radiotherapy and chemotherapy.
Assessing convergence of the Peninsula Technology
Assessment Group model
As the PenTAG model is a patient-level simulation, it reflects patient-level variability (sometimes termed
first order or stochastic uncertainty) and heterogeneity.270,271 The uncertainty due to these factors
(sometimes termed variability) is generally not of interest in a national decision-making framework, where
there is more interest in the exploration of the parameter uncertainty and perhaps structural uncertainty.
Nevertheless, such uncertainty does result from the PenTAG model, so it is necessary to quantify the
amount of uncertainty in the decision problem and how this relates to the number of patients simulated
using the model.
Given an infinite number of iterations, the results of the model would converge to a stable estimate of
cost-effectiveness for all strategies, but time and computer power are limited and it is important to assess
the effect of parameter uncertainty on key outcomes of the model.
For each patient group we simulated n patients and calculated the sample means of the costs, life-years
and QALYs (all discounted and undiscounted) along with the standard errors of those sample means. The
sample means of the disaggregated costs across several cost groups (discounted and undiscounted) were
also calculated. This allowed estimation of the incremental effect of a correct diagnosis of LS and
acceptance of LS surveillance on costs and benefits, i.e. the incremental effect of moving a patient from
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the FN group to the TP with surveillance group. It also allowed estimation of the incremental effects of
other changes in patient diagnosis.
The overall decision problem is to find which strategy (if any) for diagnosing LS in CRC patients under
50 years of age is cost-effective, so it is important to assess how the uncertainty due to patient variability
affects the uncertainty in the decision problem.
The net health benefit (NHB) framework270 is very useful in this context, and Appendix 14 details how the
uncertainty in the outcomes for the patient groups is carried through into the uncertainty in the
incremental net health benefit (INHB) of each strategy (relative to a reference strategy).
We judged that the PenTAG model had converged when the 95% CI for the INHB of the seemingly
optimal strategy versus strategy 1(1) (no testing) did not cross 0 (i.e. we are confident that the optimal
strategy would give a positive INHB). We were also able to assess the level of confidence that the
seemingly optimal strategy would have a positive INHB versus other strategies which may be employed
through the same methodology.
This convergence criterion would adequately ensure that the basic decision problem was answered, but
would not necessarily allow for an exploration of parameter uncertainty, which is dealt with in Exploring
parameter uncertainty in the Peninsula Technology Assessment Group model.
Checking the Peninsula Technology Assessment Group model
for wiring errors
The PenTAG model was checked for wiring errors in the following ways:
l All model formulae written by one modeller were checked by a different modeller.
l The reasonableness of outputs given extreme input values was checked. For example, no deaths due to
CRC when the mortality rate from CRC was set to zero.
l Base-case model results were checked for reasonableness using numerous graphs.
l Model results were checked for reasonableness given numerous univariate sensitivity analyses.
Exploring parameter uncertainty in the Peninsula Technology
Assessment Group model
Some parameters in the PenTAG model could be explored without simulating a new set of patients.
Simulating a new set of patients is undesirable because of the added time taken for simulation and because
different simulated sets of patients would lead to different results unless an extremely large number of
simulations was run.
Parameters relating to the diagnostic section of the model are easily explored without simulating a new set
of patients.
Cost parameters for the long-term management component of the model can be explored where they are
included in the disaggregated costs. For example, the cost of colonoscopies is estimated for each strategy
and the effect of changing the cost of an individual colonoscopy can therefore be very simply incorporated
into the total cost for each strategy. Some costs are bundled together in disaggregated costs, for example
the total cost of colonoscopy complications is estimated for each strategy, but not the total cost of mild
bleeding complications requiring admission. We judged that the level of cost disaggregation was
appropriate for exploring parameter uncertainty, and hence all explorations of cost parameter uncertainty
were conducted without simulating new sets of patients.
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Chapter 6 Assessment of cost-effectiveness:
results of the cost-effectiveness model
Summary of Peninsula Technology Assessment Group
cost-effectiveness results
Here we present a summary of our findings, details of which are provided later in the chapter.
Base-case results
Diagnostic results
The sensitivity and specificity of each strategy are lower for the relatives than they are for the probands
except where no testing occurs. As there are more relatives than probands, relatives have a greater weight
on the test accuracy for probands and relatives combined, and therefore the overall test accuracies are
more similar to those of the relatives.
Diagnostic results for probands
l The specificity of all strategies for probands is > 98%.
l Sensitivities are far lower than specificities for all strategies. Sensitivities vary considerably across
strategies, from 39% based on AC alone to 78% when all probands are initially offered
genetic testing.
l The sensitivity and specificity of strategies 2 and 3 are virtually identical as the strategies are very
similar. The same is true of strategies 4, 5 and 6, though they have higher sensitivities than strategies 2
and 3 (67% compared with 60%).
l The overall test accuracies of strategies are influenced by the test accuracies of the individual tests
within the strategies and the orders of the tests in the strategies.
l Additional tests in a strategy appear to either improve the overall sensitivity and worsen the specificity,
or vice versa.
l The prevalence of LS in the proband population is assumed to be 8.4%. Strategies using genetic
testing diagnose around 5–7% of probands correctly as LS positive (TP). Around 0.1–0.3% are
diagnosed incorrectly as LS positive (FP) when tumour-based tests are included in the strategies,
increasing to 1.6% for the strategy that uses only genetic testing. In all testing strategies, 90–92% of
probands are diagnosed correctly as LS negative; 1.9–3.4% of probands are incorrectly diagnosed as LS
negative if genetic testing is used, increasing to 5.1% without gene testing.
Diagnostic results for relatives
l The test accuracies for relatives are similar to, but slightly lower than, those for probands.
l The specificity of all strategies for relatives is > 97%.
l The sensitivity varies considerably across strategies, from 16% based on AC alone to 71% where all
probands are initially offered genetic testing.
l The prevalence of LS in relatives of probands with LS is roughly 44%, resulting in an overall prevalence
in the relatives’ population (relatives of all probands) of 3.7%. For all strategies, there is a greater
proportion of TNs for relatives than probands because of the lower prevalence of LS in relatives (3.7%
vs. 8.4%).
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Costs of diagnostic test for probands
l The total costs per proband of testing comprise the initial test in a strategy (e.g. IHC in strategy 2) and
the subsequent tests in a strategy (e.g. genetic tests, genetic counselling/FH) multiplied by the
proportion of probands undergoing these tests.
l The total cost of testing per proband varies across the testing strategies in the range £300–800.
l The largest component costs are in respect of IHC, MSI and the genetic test M126. The contributions
to total costs are far smaller for BRAF, genetic counselling and FH, and PMS2 and MLH1
genetic testing.
l The most expensive strategy for probands is direct genetic testing and the least expensive are the no
testing strategies.
Costs of diagnostic test for relatives
l The great majority (approximately 92–95%) of probands are diagnosed LS negative, and the relatives
of these probands incur no testing costs. Instead, only those relatives of probands who are diagnosed
with LS incur testing costs. For these relatives, there are just two component costs: counselling and
predictive genetic tests for individual gene mutations. Hence, the average cost of diagnosis per relative
of a CRC proband (£5–7) is significantly less than for probands (£300–800).
l The costs of testing per relative for those relatives with probands who test positive are much higher,
at about £80–90.
l Total costs per annum in England of diagnostic tests for probands and relatives combined are in the
range £600,000–1,400,000.
l The great majority of the costs are in respect of diagnosis of probands, rather than relatives. This is
because, even though we assume five relatives per proband, the average cost of diagnosis per relative
of a CRC proband (£5–7) is far less than for probands (£300–800).
Life expectancy
l Life expectancy for probands is similar across the strategies, with females having a higher life
expectancy than males. The same is true for relatives.
l Despite the fact that relatives are assumed to be slightly older than probands when probands are
diagnosed with CRC (e.g. mean age of male LS-negative relatives is 44 years compared with 41 years
for probands), the life expectancy of relatives is much greater than for probands (approximately 37 vs.
14 years). This is because all probands, but very few relatives, have CRC.
l The life expectancy of probands without LS is 13.9 years for all strategies, whereas the life expectancy
of probands with LS increases from 12.9 years with no testing to 14.5 years for strategy 8 (all probands
offered genetic testing), an improvement of 1.6 years.
l For relatives without LS, life expectancy is 37.5 years in all strategies, and for relatives with LS, life
expectancy increases from 34.0 years for no testing to 35.6 years in strategy 8, also an improvement of
1.6 years.
l For female probands, life expectancy is lowest for patients diagnosed FN (12.9 years) and highest for
patients diagnosed TP with surveillance (15.8 years), a difference of 2.9 years. For female relatives, life
expectancy is lowest for patients diagnosed FN (34.4 years) and highest for patients diagnosed FP with
surveillance (38.7 years), a difference of 4.3 years. The results for males follow a similar pattern.
Costs of treating cancers
l The long-term costs are substantially greater than the diagnostic costs.
l Strategies 1(2) (AC only) and 8 (direct genetic testing) have the highest long-term costs. Strategy 8 has
a higher cost of colonoscopies. Strategy 1(2) has higher CRC treatment costs.
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l Treatment costs are substantially greater for probands than for relatives because all probands have
CRC, and thus incur the substantial costs of treatment for CRC, whereas only some relatives
develop CRC.
l Costs are higher for patients who are LS positive rather than LS negative because of the greater chance
of primary and metachronous CRC.
l Patients diagnosed FN have the highest costs owing to the increased risks of CRC and EC from having
LS without any treatment to improve survival.
l Prevention costs are greater for relatives than for probands.
l The cost of CRC treatment is far greater than the cost of EC treatment because a much greater
proportion of patients are diagnosed with CRC. The cost of CRC prevention is higher than the cost of
EC prevention because a greater proportion of the cohort undergo colonoscopies than TAHBSO.
Cost-effectiveness
l The ICERs of all strategies compared with no testing are < £10,000 per QALY, which is considerably
lower than the £20,000-per-QALY threshold routinely used by NICE in England and Wales.
l As the cost of LS testing increases across testing strategies, the additional costs of CRC and EC
prevention are not all recouped by reduced costs of treatment.
l The main components of the savings in the costs of treatment are in respect of chemotherapy and
radiotherapy for primary CRC, chemotherapy and radiotherapy for recurrence CRC, palliative care for
CRC and surgery for CRC. Savings in the remaining components of treatment are much smaller: CRC
diagnosis, CRC stoma care, CRC follow-up surveillance, TAHBSO on diagnosis of EC, chemotherapy
and radiotherapy for EC.
l Most, but not all, of the additional costs of surveillance for CRC are offset by savings in treatment for
CRC. Some of the costs of prophylactic TAHBSO are offset by savings in treatment for EC, though
increased costs of prophylactic TAHBSO are far greater than the decreased costs of treatment for EC.
l The differences in QALYs across testing strategies related to the psychological impact of diagnosis are
far smaller than all other sources of QALYs (i.e. life expectancy adjusted for disutility of Dukes’ D CRC
and age-related quality of life) because it is assumed that the disutilities due to the psychological
impact of testing have an effect only in the very short term (4 months), whereas all other sources of
QALYs are accrued over the future life expectancy of probands and relatives.
l Total QALYs increase with the sensitivity of the testing strategy because as the sensitivity increases, the
number of LS-positive people who are treated increases, and such treatment can substantially improve
life expectancy.
l All ICERs versus no testing are similar, varying from £5491 per QALY for strategy 5 to £9571 per QALY
for strategy 8.
l The testing strategies on the efficiency frontier are strategies 1(1), 5, 7 and 8. The remaining strategies
are either dominated (less effective and more expensive than at least one other strategy) (strategies 2,
4 and 6) or extended dominated (less effective and more expensive than some combination of two
other strategies) (strategies 1(2) and 3). On the efficiency frontier, the ICER of strategy 5 versus no
testing is £5491 per QALY. The ICER of strategy 7 versus strategy 5 is £25,106 and therefore
marginally greater than NICE’s cost-effectiveness threshold. The ICER of strategy 8 versus strategy 7 is
£82,962 per QALY, and therefore far greater than the threshold.
l At a willingness-to-pay threshold of £20,000 per QALY, strategies 4, 5, 6 and 7 offer the best value for
money, and the cost-effectiveness of these strategies is similar. These strategies are predicted to result
in an additional 130 discounted QALYs per year in England compared with no testing. This equates to
the total discounted QALYs accrued over the lives of approximately five people.
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Numbers of colonoscopies, colorectal cancers and endometrial cancers
l The number of colonoscopies per patient is greater for those testing strategies that diagnose a larger
proportion of patients with LS, because these patients are offered enhanced surveillance.
l For probands with LS, the number of colonoscopies increases from 2.1 given no testing to 5.6 in
strategy 8 (direct genetic testing), as a greater proportion of probands with LS are diagnosed as such
under genetic testing, and hence a greater proportion receive enhanced surveillance. The number of
colonoscopies per relative with LS increases from 0.3 given no testing to 7.0 in strategy 8, for the
same reason.
l The expected total number of colonoscopies performed related to probands aged < 50 years and their
relatives in England per year increases from approximately 4200 given no testing to 8600 in strategy 8.
l Among male relatives and probands, the proportion developing CRC is significantly higher than among
their female counterparts and a higher proportion of relatives develop index CRC compared with
metachronous CRC in probands.
l The expected number of new cases of CRC for the entire cohort of 1699 probands (metachronous
CRCs) and 8495 relatives (primary and metachronous CRCs), in England per year, is approximately 665
given no testing, reducing to a minimum of 633 in strategy 8 (a difference of 32).
l Given no testing, 79 metachronous cancers are expected in the proband population and 586 index and
metachronous cancers in the relative population. Given direct genetic testing, 72 metachronous CRCs
are expected in the probands and 561 index and metachronous CRCs in the relatives.
l The greater the sensitivity of the test strategy, the lower the probability that probands and relatives
develop CRC. For example, the probability of metachronous CRC among probands with LS falls from
40% (no testing) to 35% (direct genetic testing), and the probability of primary and metachronous
CRC among relatives with LS falls from 30.2% (no testing) to 24.1% (direct genetic testing).
l The lifetime risk of EC decreases as more LS-positive relatives and probands are identified by a strategy
because these people receive prophylactic TAHBSOs. For example, the probability of EC among
probands with LS falls from 11.2% (no testing) to 7.4% (direct genetic testing), and the probability of
EC among relatives with LS falls from 23.7% (no testing) to 15.5% (direct genetic testing).
l The expected annual number of ECs related to probands aged < 50 years and their relatives in England in
the no testing strategy is 54, with 46 occurring in female relatives and 8 in female probands. This reduces
to a minimum of 35 given direct genetic testing, with 30 in female relatives and 5 in the probands.
Increasing the maximum age of probands
l In an extension of the scope of our work, we examine the consequences of extending the testing of LS
to a wider population. We raise the age limit of proband testing from 50 years in our base case to age
60 years, and then to age 70 years.
l When the age limit of probands is raised, the prevalence of LS in probands falls from 8.4% at a
maximum age of 50 years (base case) to 5.7% at an age limit of 60 years and 3.8% at an age limit of
70 years. This is because the incidence of CRC in the general population rises more rapidly than the
incidence of CRC in people with LS.
l The total annual incidence of cases of CRC in England increases from 1699 at maximum proband age
50 years, to 5018 at maximum age 60 years and 13,900 at maximum age 70 years. The corresponding
number of relatives increases from 8495 in the base case to 25,090 when the age limit of the
probands is raised to 60 years and 69,500 when the age limit is raised to 70 years.
l Some other parameters are also changed when the maximum age for probands is increased.
Increasing the maximum age of probands from 50 to 60 years
l The life expectancy of relatives remains fairly similar to the base case, regardless of LS status, as the
relatives remain mostly unaffected by the change in the proband age limit. The life expectancy of
probands, however, falls regardless of LS status, owing to the higher mean age of probands and
consequently shorter life expectancy.
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l As expected, total costs increase dramatically and approximately in proportion to the increase in the
number of probands and relatives. The distribution of these costs across strategies is very similar to
those in the base case.
l Similar to the costs, the overall number of colonoscopies increases as the number of patients increases.
But the proportional increase in the number of colonoscopies is lower than the proportional increase in
the number of probands and relatives because a smaller proportion of probands are LS positive.
l The proportion of relatives developing a CRC remains similar to the base case and the proportion of
probands reduces because their life expectancy reduces.
l The lifetime risk of EC remains similar to that in the base case for both probands and relatives.
l All test strategies are now slightly worse value for money versus no testing compared with the base
case. However, the ICERs are all well below the £20,000-per-QALY threshold. The lowest ICER is
approximately £7700 per QALY, again for strategy 5.
l Despite a slight deterioration in cost-effectiveness, the INHB at the population level compared with no
testing increases in all strategies except universal genetic testing, compared with the base case. This
increase is expected, as the diagnostic testing now benefits a larger group of patients. Strategy 5 again
gives the greatest INHB at a willingness to pay of £20,000 per QALY of 193 discounted QALYs for the
population of England per year. This compares with 130 discounted QALYs for this strategy in the
base-case analysis.
Increasing the maximum age of probands from 50 to 70 years
l As with the 60-years age limit, we find a marked increase in the incremental diagnostic costs for all
strategies compared with no testing. Furthermore, the proportional increase in these costs is greater
than the proportional changes in the other costs (CRC prevention and treatment, and EC prevention
and treatment). Again, this is because of an increase in the proband population and a reduction in the
prevalence of LS. In all genetic testing strategies, the incremental cost of LS diagnosis is now higher
than the incremental cost of CRC prevention.
l As with the age limit of 60 years, the ICERs of each strategy compared with no testing are larger than
in the base case. All ICERs are now > £10,000 per QALY gained. Strategy 5 again has the lowest
ICER, at £10,800 per QALY, and the ICER for strategy 8, universal genetic testing, is now above the
£20,000-per-QALY threshold, which implies that it is no longer cost-effective versus no testing.
l The INHB compared with no testing for all probands and relatives in England per year increases from
the base case for all strategies except strategies 7 and 8. Strategy 5 again gives the maximum INHB,
now at approximately 271 discounted QALYs. This compares with 130 discounted QALYs for this
strategy in the base-case analysis.
Endometrial cancer excluded
l In this scenario, we remove EC from the model. First, this allows us to examine the impact of EC on
our base-case analysis. Additionally, it could be argued that it would be more appropriate to exclude
EC from our base-case analysis, given that we do not model OC. This is because the genetic testing
strategies incur substantial costs for prophylactic TAHBSO in our base case, but we do not allow for the
associated reduction in incidence of OC.
l The life expectancies of all patient groups change only very slightly when EC is removed, which shows
that there is little mortality from EC.
l For female relatives there is a slight increase in life expectancy, but most noticeably for those diagnosed
TP and FN, as mortality due to EC for females with LS is removed. This pattern is repeated for female
probands, though the effect is less pronounced.
l As expected, total costs are reduced when EC is excluded, as there are no longer costs for the
prevention or treatment of EC.
l Costs for females diagnosed as having LS (TP, FP) are reduced because the substantial costs of
prophylactic TAHBSO are avoided. Costs for females with LS (FN, TP) are also reduced given that
treatment for EC (TAHBSO, chemotherapy and radiotherapy) is avoided.
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l Given the reduced costs and slight increase in life expectancy, plus no disutility from EC, the costs for
all strategies are reduced from the base case and the QALYs increased. The incremental QALY gains
compared with no testing are lower for all testing strategies than in the base case, but given the much
larger reductions in costs due to the lack of prophylactic TAHBSO, the ICERs compared with no testing
are reduced compared with the base case, i.e. all strategies become more cost-effective compared with
no testing. This may seem counter-intuitive, as one might expect the cost-effectiveness of testing to
improve as more people with LS are correctly identified. In a sense, the result is more a reflection of the
cost-effectiveness of treatment for EC. It is important to reiterate that our base-case analysis does not
account for the benefit gained from prophylactic TAHBSO in the prevention of OC.
l The ranking of cost-effectiveness among strategies remains the same, with strategy 5 still giving the
largest net health benefit.
BRAF replaced by methylation testing
l In this scenario BRAF testing is replaced by methylation testing in strategies 3, 5, 6 and 7.
l Methylation testing was assumed to have sensitivity 93% and specificity 80% (compared with
sensitivity 100% and specificity 40% or 69% for BRAF testing following MSI or IHC, respectively).
l Methylation testing was assumed to cost £166 (compared with £118 for BRAF testing).
l Sensitivities of strategies 3, 5, 6 and 7 were reduced slightly and specificities were increased marginally.
l Diagnostic costs of strategies 3, 5, 6 and 7 were reduced slightly because fewer patients received
further testing (in particular genetic testing).
l Long-term costs and QALYs were reduced, which appears to be because fewer patients test positive
(with more patients falsely testing negative).
l The cost-effectiveness of strategies 3, 5, 6 and 7 changed marginally, with the INHB of all four
strategies decreasing versus no testing at a threshold of £20,000 per QALY.
l The scenario analysis suggests that based on current evidence, BRAF testing is more cost-effective than
methylation testing, but the difference is small.
Univariate sensitivity analyses
l Several univariate sensitivity analyses were conducted to investigate the impact of various parameters
on the cost-effectiveness results.
l In the majority of cases, the values used in the sensitivity analyses were not meant to represent
plausible alternative values, but were chosen to demonstrate the impact on cost-effectiveness of
changing the parameter value.
l The disutility after prophylactic TAHBSO was the only parameter which was found to result in the ICER
of any testing versus no testing exceeding the £20,000-per-QALY threshold, as described below
(see Utilities associated with endometrial cancer).
l Table 95 lists parameters with a minimal impact on cost-effectiveness.
l Table 96 lists parameters with a moderate impact on cost-effectiveness.
l Table 97 lists parameters with a substantial impact on cost-effectiveness.
l The incidence of CRC for individuals with LS has a substantial impact on cost-effectiveness for the values
chosen, which are the 95% confidence limits from Bonadona and colleagues (2011),2 which is the study
used in our base-case analysis. The confidence limits are wide because individuals with LS become
uninformative for incidence estimates once they receive surveillance and surveillance is widespread.
In reality, we may have greater confidence in the incidence of CRC for individuals with LS because other
studies have been conducted with appropriate methodology and have obtained central estimates within
these confidence limits. It was expected that incidence of CRC would have a significant impact on
cost-effectiveness because the greater the incidence of CRC, the more potential there is to prevent
CRCs and achieve QALY gains. It is notable that all strategies still remain cost-effective at a threshold of
£20,000 per QALY.
l The mean number of relatives identified per proband has a substantial impact on cost-effectiveness,
although it is notable that even when we assume that no relatives would be identified, all strategies
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TABLE 95 Parameters with minimal impact on the cost-effectiveness of genetic testing
Parameter How varied
Diagnosis
Relative prevalence of four MMR genes Published data from Norway184
Adherence of probands to genetic counselling Non-adherence halved
Adherence of probands and relatives to genetic testing Non-adherence halved
Probability that a relative of a LS-positive proband has LS Alternative source: All Wales Medical Genetics Service
(Ian Frayling, 2013, personal communication)
Proportion of relatives identified who are first degree Varied from 35% to 55%
Effectiveness
Probability of aggressive surgery for LS Set to 1 (subtotal colectomy always used instead of
segmental resection; proctocolectomy always used instead
of anterior resection)
Colonoscopy mortality rate Set to rate for polypectomies
Costs
Cost of BRAF tumour testing Halved and doubled
Cost of applying FH Halved and doubled
Cost of genetic counselling Halved and doubled
Cost of predictive genetic testing (for relatives) Halved and doubled
Cost of colonoscopy complications Halved and doubled
Cost of CRC diagnosis Halved and doubled
Cost of CRC surgery Halved and doubled
Cost of CRC stoma care Halved and doubled
Cost of CRC follow-up surveillance Halved and doubled
Cost of CRC recurrence Halved and doubled
Cost of CRC palliative care Halved and doubled
Cost of EC surgery Halved and doubled
Cost of EC radiotherapy Halved and doubled
Cost of EC chemotherapy Halved and doubled
HRQoL
EC disutility Set to 0.1 (base case 0)
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TABLE 96 Parameters with moderate impact on the cost-effectiveness of genetic testing
Parameter How varied
CRC natural history
HR of LS CRC survival HR 0.57
HR 1
EC natural history
EC incidence given LS positive Halved and doubled
Diagnosis
Prevalence of LS in probands Halved and doubled
Adherence to genetic counselling and testing (separately for
probands and relatives)
Adherence halved
100% adherence
Adherence to genetic counselling for relatives Non-adherence halved
Effectiveness
HR for colonoscopy for preventing index CRC 1 SE above and below base case
Acceptance of prophylactic TAHBSO Set to 20% and 90%
Initial adherence to LS surveillance colonoscopy Adherence halved
Non-adherence halved
100% adherence
Costs
Cost of IHC tumour testing Halved and doubled
Cost of MSI tumour testing Halved and doubled
Cost of diagnostic genetic testing (for probands) Halved and doubled
Cost of CRC chemotherapy and radiation Halved and doubled
Cost of prophylactic TAHBSO Halved and doubled
HRQoL
CRC disutilities Based on Ness et al. (1999)200
CRC surgery disutility Set to 0.1 except for segmental resection (base case 0)
Psychological disutilities relating to genetic testing and offering
prophylactic TAHBSO
Set to 0
Doubled
SE, standard error.
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still remain cost-effective at a threshold of £20,000 per QALY. It was anticipated that cost-effectiveness
would improve as more relatives are identified, as there should be a greater potential for QALY gains in
relatives with LS without CRC, and as predictive genetic testing is less costly than diagnostic testing.
However, we do not find that increasing the number of relatives results in cost savings.
l In the base-case analysis, the HR for colonoscopy in the prevention of CRC is assumed to be 0.533. We find
that the effectiveness of colonoscopy in preventing metachronous CRC has a substantial impact on
cost-effectiveness, although it is notable that when no benefit is assumed (HR= 1), all strategies still
remain cost-effective at a threshold of £20,000 per QALY. Metachronous CRC results in additional costs
for treatment of CRC and reduces life expectancy. Therefore, it is to be expected that reducing the
effectiveness of a measure to prevent metachronous CRC would result in a worsening of cost-effectiveness.
l The cost of colonoscopy has a substantial impact on cost-effectiveness, although it is notable that even
when the cost is doubled, all strategies remain cost-effective at a threshold of £20,000 per QALY. As
colonoscopy is the principal intervention for reducing CRC incidence, it is not surprising that the cost
of colonoscopy has a substantial impact on cost-effectiveness. The base-case estimate of cost of
colonoscopy is likely to be accurate, as it is based on a weighted average of 360,000 colonoscopies. In
our base case, however, we did reduce the cost of colonoscopy to balance the efficacy of colonoscopy,
taken from Jarvinen and colleagues (2000),94 in which colonoscopies were 3 yearly. Reversing this
adjustment would scale the cost of colonoscopy by a factor of 1.5, i.e. less than the doubling which is
examined in our univariate sensitivity analysis.
l The disutility from prophylactic TAHBSO has a very significant impact on cost-effectiveness. When a
disutility of 0.1, which is an arbitrary value, is assumed, all strategies become dominated by no testing,
i.e. testing results in greater costs and reduced QALYs. This is a very important result, and results from
55% of women diagnosed with LS accepting prophylactic TAHBSO and incurring a substantial lifetime
disutility. This is the only univariate sensitivity analysis in which any strategy becomes not cost-effective
versus no testing. Were such a disutility to be considered reasonable, our model would suggest that
prophylactic TAHBSO should not be offered as the health benefits from preventing EC are outweighed
by the loss in HRQoL owing to the prophylactic surgery. It is also worth noting that even when no
disutility is assumed for prophylactic TAHBSO, increasing the acceptance of prophylactic TAHBSO
worsens cost-effectiveness.
l The length of time for which psychological disutilities are applied has a substantial impact on
cost-effectiveness. In the base case, psychological disutilities relating to genetic testing are assumed to
apply for 4 months. In our sensitivity analysis we assume they apply for 1 year (i.e. three times as long),
which is an arbitrary value. This worsens the cost-effectiveness of all strategies but they all remain
cost-effective at a threshold of £20,000 per QALY.
TABLE 97 Parameters with substantial impact on the cost-effectiveness of genetic testing
Parameter How varied
CRC natural history
CRC incidence for individuals with LS Set to 95% confidence limits from Bonadona et al. (2011)2
Diagnosis
Mean number of relatives per proband Set to 0 and 12 (base case 5)
Effectiveness
HR for colonoscopy for preventing metachronous CRC Set to 1 (no effectiveness) (0.533 in base case)
Costs
Cost of colonoscopy Halved and doubled
HRQoL
Prophylactic TAHBSO disutility Set to 0.1 (0 in base case)
Length of psychological disutility Set to 1 year (base case 4 months)
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Peninsula Technology Assessment Group cost-effectiveness results
We first present the base-case cost-effectiveness results. In our base case, the maximum age of probands is
50 years, EC is modelled and our best estimates are used for parameters in the model. Next we present
the cost-effectiveness results under a number of scenarios, in which we either change parameters or
change the model structure from the base case. Finally, we present a number of sensitivity analyses in
which one or two parameters are individually varied.
Throughout this section we use diagnostic strategy identifiers as shown in Table 98, and as shown
graphically in Chapter 5, Diagnostic strategies for probands (see Figures 4–11).
Base-case results
Details of the base-case inputs are given in Chapter 5. In summary, the base case models the estimated
1699 probands with newly diagnosed CRC under 50 years old per year in England, and their
8495 relatives between 18 and 75 years old. Both CRC and EC are modelled for proband and relative
populations. The base-case results are presented in the following order: short-term diagnostic outcomes,
long-term survival outcomes and, finally, cost-effectiveness.
Diagnostic results (base case)
The base-case diagnostic results are shown in Table 99.
To assess the impact of the testing strategies in the short term, we examined the results each strategy had,
firstly on diagnosing the probands, then the relatives and, finally, the combined results. We present the
total cost of diagnosis per person and across the expected annual population of probands and relatives
in England.
We first present the sensitivities and specificities of the strategies in identifying the probands, shown in
Figure 36 and the associated ROC plot in Figure 37. These figures demonstrate that specificity is
consistently higher than sensitivity across the strategies. This occurs because the sensitivities of the
individual tests are generally lower than the specificities and because conducting further tests on only the
proportion of the cohort that test positive (as is the case in most of the strategies) can only lead to an
increase in specificity. This phenomenon is discussed in greater detail later in this section. We now attempt
to account for the differences in sensitivities and specificities across the strategies.
The sensitivity of strategy 1(2) is particularly low as it is based purely on FH, which has a much lower
sensitivity than tumour-based tests and gene tests. The sensitivities and specificities of strategies 2 and 3
are virtually identical as the strategies themselves are very similar. Specifically, in both, probands all
undertake IHC testing, and further down the testing sequence some are offered gene testing. Strategy 3
separates out the probands who are found to have MLH1 missing on their IHC result and performs a BRAF
test before the offer of a gene test. As these represent a small proportion of probands, this causes the two
strategies to be very similar in sensitivity and specificity, and the slightly higher specificity of strategy 3 is
related to the additional BRAF test. The sensitivities and specificities of strategies 4 and 5 are virtually
identical for the same reason; the strategies are fairly similar, with all probands undergoing MSI and the
addition of BRAF in strategy 5. Again, the specificity of strategy 5 is slightly higher as a consequence of
the additional BRAF test. The sensitivities of strategies 4 and 5 are higher than those of strategies 2 and 3
because the overall sensitivity of the MSI test is higher than the sensitivity of IHC.
These results also demonstrate that the sensitivity of some strategies is lower than that of an individual test
in the sequence. In the case of strategy 2, where the overall sensitivity for probands is 60% but the
sensitivity for IHC testing is 77%, this occurs mainly because the diagnosis of some probands who decline
genetic testing is based upon the FH, which has a much lower sensitivity than IHC. Additionally, when a
test which does not have 100% sensitivity is followed by another test which also does not have 100%
sensitivity, the overall sensitivity of the sequence will be reduced. This happens for all strategies that
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TABLE 99 Base-case diagnostic results
Population
Strategy
1(1) 1(2) 2 3 4 5 6 7 8
Probands, na (%)b
Total 1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
1699
(100.0)
Without LS 1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
1556
(91.6)
Correctly diagnosed
as not LS
1556
(91.6)
1530
(90.1)
1553
(91.4)
1555
(91.5)
1554
(91.5)
1555
(91.5)
1555
(91.5)
1552
(91.3)
1529
(90.0)
Incorrectly diagnosed
as LS
0 (0.0) 27 (1.6) 3 (0.2) 1 (0.1) 3 (0.2) 2 (0.1) 2 (0.1) 4 (0.2) 27 (1.6)
Declined surveillance 0 (0.0) 8 (0.5) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1) 8 (0.5)
Accepted surveillance 0 (0.0) 19 (1.1) 2 (0.1) 1 (0.1) 2 (0.1) 1 (0.1) 1 (0.1) 3 (0.2) 19 (1.1)
With LS 143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
143
(8.4)
Incorrectly diagnosed
as not LS
143
(8.4)
87
(5.1)
57
(3.4)
57
(3.4)
47
(2.8)
47
(2.8)
47
(2.8)
35
(2.1)
32
(1.9)
Correctly diagnosed as LS 0
(0.0)
56
(3.3)
86
(5.1)
86
(5.1)
96
(5.7)
96
(5.7)
96
(5.7)
108
(6.4)
111
(6.5)
Declined surveillance 0 (0.0) 17 (1.0) 18 (1.1) 18 (1.1) 21 (1.2) 21 (1.2) 21 (1.2) 23 (1.4) 24 (1.4)
Accepted surveillance 0 (0.0) 39 (2.3) 67 (3.9) 67 (3.9) 75 (4.4) 75 (4.4) 75 (4.4) 85 (5.0) 87 (5.1)
Relatives, na (%)b
Total 8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
8495
(100.0)
Without LS 8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
8181
(96.3)
Correctly diagnosed
as not LS
8181
(96.3)
8060
(94.9)
8044
(94.7)
8048
(94.7)
8029
(94.5)
8032
(94.5)
8032
(94.5)
8008
(94.3)
7955
(93.6)
Incorrectly diagnosed
as LS
0
(0.0)
122
(1.4)
137
(1.6)
133
(1.6)
152
(1.8)
149
(1.8)
149
(1.8)
173
(2.0)
226
(2.7)
Declined surveillance 0
(0.0)
61
(0.7)
68
(0.8)
66
(0.8)
76
(0.9)
75
(0.9)
75
(0.9)
87
(1.0)
113
(1.3)
Accepted surveillance 0
(0.0)
61
(0.7)
68
(0.8)
66
(0.8)
76
(0.9)
75
(0.9)
75
(0.9)
87
(1.0)
113
(1.3)
With LS 314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
314
(3.7)
Incorrectly diagnosed
as not LS
314
(3.7)
262
(3.1)
141
(1.7)
141
(1.7)
120
(1.4)
120
(1.4)
120
(1.4)
97
(1.1)
90
(1.1)
Correctly diagnosed as LS 0
(0.0)
51
(0.6)
173
(2.0)
173
(2.0)
194
(2.3)
194
(2.3)
194
(2.3)
217
(2.6)
224
(2.6)
Declined surveillance 0 (0.0) 26 (0.3) 65 (0.8) 65 (0.8) 73 (0.9) 73 (0.9) 73 (0.9) 82 (1.0) 85 (1.0)
Accepted surveillance 0
(0.0)
26
(0.3)
107
(1.3)
107
(1.3)
121
(1.4)
121
(1.4)
121
(1.4)
135
(1.6)
139
(1.6)
a Rounded to nearest whole number.
b Rounded to one decimal place.
As a result of the above, numbers and percentages may not add correctly.
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FIGURE 37 Receiver operating characteristic plot of the diagnostic strategies (probands only).
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FIGURE 36 Sensitivities and specificities of the proband diagnostic strategies (probands only).
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include both tumour testing and gene testing, as gene testing does not have 100% sensitivity
(90% sensitivity for MLH1, MSH2 and MSH6 mutations, and 60% for PMS2 mutations). The same
pattern occurs in strategy 8, where the overall sensitivity is lower than the sensitivity for M126 gene
testing. Again, this is partly due to the sensitivity of PMS2 testing being lower than that of M126, and also
because approximately 17% of people decline genetic testing and are assessed by their FH, which has a
much lower sensitivity (39%).
The accuracy of test strategies is also altered by both the number of tests and the order in which they
were conducted. Strategies 3 and 5 demonstrate that a BRAF test, either after an IHC MLH1 abnormal or a
MSI result, can improve the specificity of a strategy; however, this improvement is less noticeable when
conducted on a MSI cohort with IHC-normal results, as in strategy 7. In general, adding tests to a strategy
whose previous test result was indicative of LS increases the specificity of the strategy, as demonstrated by
the fact that the specificity of strategy 3 is slightly higher than that of strategy 2, and the specificity of
strategy 5 is slightly higher than that of strategy 4; and the result of lower specificity in strategy 8 (which
uses only gene testing) compared with all other testing strategies which include not only gene testing but
also tumour-based tests.
Strategy 8 has the lowest specificity (98.3%), mostly because it relies on only one type of test (gene
testing, plus some decisions based on FH), and partly because a larger proportion of probands decline
genetic testing and subsequently undergo FH screening. The probands that decline genetic testing are
therefore assessed only by their FH, so that the maximum specificity for them is equal to that of the FH
assessment: 98%. The overall effect of adding tests in this manner is to enrich the cohort by eliminating
more FPs from further testing. Depending on the characteristics of the additional tests, it may also lessen
the sensitivity; but this does not happen in strategies 3 and 5 (compared with strategies 2 and 4,
respectively) as BRAF has a sensitivity of 100%, the impact of which was previously discussed.
Additional tests in a strategy appear to either improve the overall sensitivity and worsen the specificity, or
vice versa. Additional tests on those probands who test negative by a previous test appear to increase the
overall sensitivity, but slightly reduce the specificity of the strategy. For example, strategy 7 has a higher
sensitivity than strategy 2 because the IHC-normal probands are not ruled out immediately; instead, further
tests (MSI followed by BRAF and gene testing if appropriate) are undertaken. Additionally, strategy 7 has a
higher sensitivity than strategy 5 because the use of MSI and BRAF after IHC normal gives a higher
sensitivity than MSI and BRAF alone, as the additional TPs identified in the IHC-normal cohort combined
with the TPs identified by the IHC-abnormal result mean that a higher proportion of TPs are identified,
compared with either IHC or MSI and BRAF alone.
The test accuracies for relatives are similar to those for probands because the approach to diagnosing
relatives is the same across all strategies: genetic testing is offered to relatives of probands who test
positive for LS; of those relatives who decline testing, FDRs are assumed to have LS if probands are
assumed to have LS (so-called ‘LS assumed’), and all other relatives are assumed not to have LS.
Differences in test accuracies between probands and relatives across the testing strategies are driven by
differences in the proportions of probands diagnosed LS mutation positive, LS assumed and LS negative.
In general, the sensitivity and specificity of each strategy are lower for relatives than for probands as, aside
from the proportion who undergo genetic testing, the relatives cannot be allocated a diagnosis based on a
testing procedure. As such, the methods used are less accurate for relatives than for probands. The
exceptions to this are the two no-testing strategies. Strategy 1(1) has the same sensitivity (0%) and
specificity (100%) for relatives as for probands, as both assume that no one has LS. Strategy 1(2) has a
much lower sensitivity for relatives than for probands, because LS relatives are misdiagnosed as LS negative
when the proband is also misdiagnosed as LS negative, and when the higher-degree relatives of probands
assumed to have LS are treated as LS negative. The higher-degree relatives of probands assumed to have
LS who are treated as LS negative are also related to the slight increase in specificity for relatives in
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strategy 1(2), as there will be probands in the group who were misdiagnosed as LS assumed, for whom
the majority of relatives will be treated as LS negative, therefore lowering the false positivity rate. This
occurs because the majority of probands’ relatives are not FDRs; out of the specified five relatives per
proband, roughly 2.1 are FDRs. The sensitivities and specificities of the strategies for relatives are shown in
Figure 38; Figure 39 presents the associated ROC plot.
The test accuracy results for all probands and relatives combined are a weighted average of the test
accuracies for probands and relatives. The weighting is greater for relatives as there are more relatives than
probands (Figure 40). Here, all strategies that identify some patients as LS positive have a specificity of
97% or above, with a sensitivity ranging from 23% to 74%.
To improve our understanding of the test accuracy results, we now discuss the numbers of TPs, FPs, TNs
and FNs for all strategies.
The prevalence of LS in the proband population is assumed to be 8.4%. In general, strategies using
genetic testing diagnose around 5–7% of the probands correctly as LS positive (TP), with 79% of these
accepting colonoscopic surveillance (Figures 41 and 42). Around 0.1–0.3% are diagnosed incorrectly as LS
positive (FP) when tumour-based tests are included in the strategies (with similar levels of acceptance of
surveillance), increasing to 1.6% for strategy 8, which uses only genetic testing. In strategies 2–8 where
testing is done, 90–92% of probands are diagnosed TN and 1.9–3.4% are diagnosed FN if genetic testing
is used, increasing to 5.1% without genetic testing.
The prevalence of LS in relatives of probands with LS is roughly 44%, resulting in an overall prevalence in
the relatives’ population (relatives of all probands) of 3.7%. Strategies that use gene testing identify
2.0–2.6% of relatives as LS positive correctly (1.3–1.6% accepting surveillance), and this drops to 0.6% in
strategy 1(2) (0.3% accepting surveillance), which is based on FH assessment of the probands only
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FIGURE 38 Sensitivities and specificities of the proband diagnostic strategies (relatives only).
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FIGURE 39 Receiver operating characteristic plot of the diagnostic strategies (relatives only).
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FIGURE 40 Receiver operating characteristic plot of the diagnostic strategies (probands and relatives combined).
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FIGURE 41 Proportions of probands diagnosed TP, FP, TN and FN, by strategy.
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FIGURE 42 Proportions of probands diagnosed TP, FP, TN and FN, by strategy, rescaled to 10%.
Note, total TN exceed bar limits.
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(Figures 43 and 44). Between 1.4% and 2.7% of relatives are incorrectly diagnosed LS positive, with half
of these (0.7–1.3%) accepting unnecessary surveillance. Most probands and their relatives fall into the
category of TN. There is a greater proportion of TNs for all strategies for relatives, as shown in Figure 43,
than for probands (see Figure 41) because of the lower prevalence of LS in relatives (3.7% vs. 8.4%).
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FIGURE 43 Proportions of relatives diagnosed TP, FP, TN and FN, by strategy.
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FIGURE 44 Proportions of relatives diagnosed TP, FP, TN and FN, by strategy, rescaled to 5%.
Note, total TN exceed bar limits.
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Furthermore, any relatives of FP probands will be correctly diagnosed as TN as the predictive genetic test
for relatives has specificity 100%. The lower prevalence of LS in the relatives’ population also results in a
smaller proportion of TPs for relatives, as well as a smaller proportion of FN relatives than FN probands.
There is a greater proportion of FPs for all strategies for relatives compared with probands, as relatives who
decline testing are assumed to have LS (over half of whom are actually LS negative).
We now investigate the proportions of probands and relatives diagnosed with LS, by test result and true LS
status (Figures 45 and 46). Most probands judged to be LS positive are tested mutation positive, with a
smaller proportion correctly assumed LS positive. The strategies always identify fewer than the true
proportion of probands who are LS positive, even including FPs (see Figure 45). By contrast, most strategies
identify more relatives as LS positive than there actually are (see Figure 46). The main driver appears to be
the greater proportion of relatives assumed to have LS, mostly incorrectly. The proportion of probands
assumed to have LS incorrectly is much smaller as it is based on strict family criteria rules, rather than
assumptions as for relatives.
Costs of diagnostic tests (base case)
Here we examine the costs of the diagnostic strategies. The total cost per proband for all strategies is
roughly £300–800 (Figure 47). Costs comprise the initial test in a strategy (e.g. IHC in strategy 2) and the
subsequent tests in a strategy (e.g. genetic tests, genetic counselling/FH) multiplied by the proportion of
probands undergoing these tests. The largest component costs are in respect of IHC, MSI and the genetic
test M126. The contributions to total costs are far smaller for BRAF, genetic counselling and FH, and PMS2
and MLH1 genetic testing. We now account for the differences in the costs across strategies.
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The most expensive strategy for probands is strategy 8 and the least expensive are the no testing strategies.
Strategy 8 is particularly expensive because genetic testing is the first test in the strategy, and genetic testing
is far more expensive than IHC and MSI testing, both of which are initial tests in other strategies.
There is no set relationship between the number of tumour tests and the cost of the strategy. In strategies
with an additional component test (e.g. strategies 3 and 5 additionally include BRAF testing compared
with strategies 2 and 4, respectively), the overall strategy cost is lowered, as the additional test reduces the
proportion of probands undergoing genetic testing, which is relatively expensive. In strategies where an
additional test occurs in a proportion of probands who received a previous test result that was not
indicative of LS (e.g. the MSI test in strategy 7 but not in strategy 2), total costs are greatly increased as
more of the cohort are exposed to further testing, both tumour based and genetic.
Note that the cost of strategy 6 is the same as that of strategy 5, with the addition of a cost for IHC. This
is because IHC in strategy 6 is assumed not to alter the proportion of probands undergoing further tests.
This IHC does, however, represent the additional cost if genetics centres request an IHC result in order to
understand the results of the genetic tests. Indeed, our expert advisor, Ian Frayling, suggests that the IHC is
routinely performed, although the cost of additional tests is generally borne by genetics centres.
The total cost of M126 gene testing is lower in strategy 3 than in strategy 2, because a large proportion
of the abnormal IHC results are abnormal for MLH1 and these probands proceed to BRAF and then
genetic testing for MLH1, rather than testing for M126.
Despite the high cost of the PMS2 test (£735), the total cost of PMS2 testing per proband is very small in
all strategies as very few probands undergo this test. This is because most probands are either ruled out
for LS (or have been given a diagnosis for one of the other mutations and are thus ruled out from further
testing) before the test for PMS2 occurs; patients who are negative on the M126 genetic test must still
have a positive FH before they are offered PMS2 testing.
In strategy 7, the cost of MSI is only slightly lower than in strategy 6 (resource use of MSI is 86% of that in
strategy 6), whereas the cost of BRAF is much lower (resource use of MSI is 60% of that in strategy 6).
Here the cost of MSI is only slightly lower in strategy 7 because the majority of the cohort (83%) are
previously tested as IHC normal and therefore proceed to a MSI test. However, in this new cohort, the
prevalence of LS is reduced from 8% to 2%, which means that fewer people test positive after MSI (a
reduction from 16% to 10% of the total cohort) and so proceed to BRAF testing. Strategy 7 has a much
higher cost of M126 than strategies 1–5. As previously explained, in strategy 7, IHC alone is not used to
rule out LS, but probands who do test IHC abnormal proceed directly to M126 testing (if they accept). The
remaining probands continue to further testing, being excluded by MSI or BRAF. Therefore, the proportion
of patients undergoing M126 is the same as in strategy 2, plus those who are MSI positive and BRAF
V600E negative and who accept genetic testing.
The per-proband costs of genetic counselling and FH are lower than testing costs in all strategies because
the unit costs are lower.
We now turn to the costs of diagnosis for relatives. First, the great majority (approximately 92–95%) of
probands are diagnosed LS negative, and the relatives of these probands incur no testing costs. Instead,
only those relatives of probands who are diagnosed with LS incur testing costs. For these relatives, there
are just two component costs: counselling and predictive genetic tests for individual gene mutations.
Hence, the average cost of diagnosis per relative of a CRC proband (£5–7) (Figure 48) is significantly lower
than the cost per proband (£300–800). The cost for relatives appears to be primarily driven by the cost of
counselling; there is a greater variation in the cost of counselling across strategies that offer it than in the
cost of any single gene test. This is because counselling is given to most relatives of CRC probands who
test either LS mutation positive or LS assumed. Therefore, the cost of counselling for relatives in strategies
that identify more probands as LS mutation positive or LS assumed will consequently be higher. The cost
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for relatives is highest in strategy 8 because this has the highest proportion of probands diagnosed LS
positive, and therefore the highest proportion of relatives offered testing or counselling.
For those relatives with probands who test positive, the costs of testing per relative are much higher, at about
£80–90 (Figure 49). The counselling costs are now very similar, as these are no longer affected by differences
in the proportions of probands diagnosed LS positive across strategies. The cost per relative of a LS-diagnosed
proband is lowest for strategy 8 among the strategies that include genetic testing. This is because strategy
8 has the highest proportion of probands testing LS mutation positive or LS assumed. The larger proportion of
LS-assumed probands (in comparison with the mutation positives) compared with the other strategies reduces
the cost per relative of a LS-diagnosed proband, as proportionally less genetic testing is undertaken.
Total costs per annum in England of diagnostic tests for probands and relatives combined are in the range
£600,000–1,400,000 (Figure 50). The great majority of the costs are in respect of diagnosis of probands,
rather than relatives. This is because, even though we assume five relatives per proband, the average cost of
diagnosis per relative of a CRC proband (£5–7) is far lower than that for probands (£300–800). The pattern
of differences in total cost across strategies is therefore similar to the pattern for probands alone (see Figure 47).
Life expectancy (base case)
Here we present the life expectancies for probands and relatives according to sex, LS status, test result and
testing strategy.
Firstly, life expectancy for probands is similar across the strategies, with females having a higher life
expectancy than males (Figure 51). The same is true for relatives (Figure 52). This is expected as general
population data demonstrate a greater life expectancy for females than males.179 Despite the fact that
relatives are assumed to be slightly older than probands when probands are diagnosed with CRC
(e.g. mean age of male LS-negative relatives is 44 years compared with 41 years for probands), the life
expectancy of relatives is much greater than that of probands (approximately 37 vs. 14 years). This is
because all probands, but very few relatives, have CRC.
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FIGURE 48 Total strategy costs per relative of a CRC proband.
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We now consider the impact of testing on people with and without LS. The life expectancy of probands
without LS is 13.9 years for all strategies, whereas the life expectancy of probands with LS increases from
12.9 years with no testing to 14.5 years for strategy 8 (all probands offered genetic testing), an improvement
of 1.6 years (Figure 53). For relatives without LS, life expectancy is 37.5 years in all strategies, and for relatives
with LS, life expectancy increases from 34.0 years for no testing to 35.6 years in strategy 8, also an
improvement of 1.6 years (Figure 54). This demonstrates that the impact on life expectancy of testing for LS
may be similar for both probands and relatives (this has not been investigated in previous models). Life
expectancy for probands and relatives improves under genetic testing as more patients are identified as LS
positive and hence proceed to enhanced colonoscopic surveillance and prophylactic TAHBSO. Both of these
reduce mortality, as surveillance colonoscopies reduce the risk and stage of CRC, and TAHBSO eliminates the
risk of EC.
The life expectancies of patients who are TP, FP, FN and TN with/without surveillance help to explain the
results above (see Figures 55 and 56).
For female probands, life expectancy is lowest for patients diagnosed FN (12.9 years) and highest for
patients diagnosed TP with surveillance (15.8 years), a difference of 2.9 years (Figure 57). For female
relatives, life expectancy is lowest for patients diagnosed FN (34.4 years) and highest for patients
diagnosed FP with surveillance (38.7 years), a difference of 4.3 years (Figure 58). Here we note that
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FIGURE 54 Life expectancy of relatives, by LS status and testing strategy.
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FIGURE 56 Life expectancy of male relatives by test result and surveillance.
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females (probands and relatives) benefit from LS diagnosis in reducing both CRC and EC mortality,
whereas males benefit from reduced CRC mortality only.
Probands can benefit from LS diagnosis by reducing the incidence of metachronous CRC. As such,
TP probands who undergo surveillance have the highest life expectancy, as the surveillance reduces CRC
risk (and, in general, the CRC is caught at an earlier stage than in probands not undergoing surveillance
who develop a metachronous CRC). They also have a higher life expectancy than FP probands with
surveillance, because CRC mortality rates are generally lower for people with LS. For probands and
relatives, regardless of sex, life expectancy is lowest for patients who are LS positive and receive no
surveillance, i.e. those who are diagnosed FN or TP with no surveillance. Therefore, testing strategies which
result in larger numbers in these categories will have lower life expectancies overall.
Life expectancies of relatives who are TN, FP or FP with surveillance and those who are TP are very similar.
Relatives benefit from LS diagnosis by avoiding primary CRC. Relatives who undergo surveillance but are FP
have a slightly higher survival than TN and FP relatives, as there is some additional benefit from the
colonoscopic surveillance. For male relatives, those who are TP with surveillance have the highest life
expectancy, as a result of the improved survival from surveillance, plus the lower CRC mortality associated
with LS. Given that only female relatives with LS benefit from EC prevention and that all female relatives
have a lower risk of CRC than male relatives, the female relatives with LS who undergo surveillance (TP
with surveillance) have a lower life expectancy than the TN, FP and FP-with-surveillance female relatives.
The small 95% error bars on Figures 55–58 demonstrate that the results are not subject to significant
Monte Carlo variation.
Cost results (base case)
We have previously presented the costs of diagnostic testing [see Costs of diagnostic tests (base case)].
Total diagnostic costs are far smaller than total long-term costs of treating CRC and EC across all strategies
(Figure 59). However, as we will explain below (see Incremental costs), the differences in diagnostic costs
between strategies constitute a substantial proportion of the differences in total costs, and hence strongly
influence cost-effectiveness. Discounting does not affect diagnostic costs, as they are assumed to be
incurred at time zero, but reduces total costs by about 33%, as it reduces long-term costs (Figure 60).
Total long-term costs are similar across strategies (Figure 61); however, the differences between strategies
are large enough to strongly influence their cost-effectiveness (see Incremental costs). Strategy 8, direct
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FIGURE 59 Undiscounted long-term and diagnostic costs by test strategy.
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genetic testing, has the greatest total long-term cost, due to particularly high costs of colonoscopies and
prophylactic TAHSBO, which in turn are due to the large number of patients tested positive.
Examining Figure 61, we see that the largest cost items in all strategies are the costs for CRC palliative
care, CRC recurrence chemotherapy and surgery, and CRC stoma care. This is a result of both the large
unit costs for each of these items, plus the fact that they are accrued over time. The endometrial
prevention and management costs are far smaller than the equivalent costs for CRC, as they affect a much
smaller proportion of the total cohort; only female patients with LS can get EC and only female patients
identified as LS are offered prophylactic surgery for EC (and not all adhere to this offer).
In Figures 62–65, it is shown that treatment costs are higher for probands than for relatives. This is
because all probands have CRC, and thus incur the substantial costs of treatment for CRC, whereas only
some relatives develop CRC. Costs are higher for patients who are LS positive rather than LS negative
because of the greater chance of primary and metachronous CRC (see Expected number of colorectal
cancers). Costs are lowest for patients who are TN and FP with no surveillance, as these subgroups do not
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FIGURE 62 Undiscounted treatment and prevention costs for male probands.
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incur the cost of surveillance and have general population risk of CRC. For female patients, there is a slight
increase in costs for FP with no surveillance over TN, as patients who are FP with no surveillance are
offered prophylactic TAHBSO, whereas TN patients are not. The cost for probands and relatives diagnosed
FP with surveillance is higher owing to the substantial cost of colonoscopies. Patients diagnosed FN have
the highest costs owing to the increased risks of CRC and EC from having LS without any treatment to
improve survival. TP patients who do not undergo surveillance incur similar costs to FN patients, as they
both have LS and do not undergo surveillance. However, the costs for male relatives are slightly lower as
they may still benefit from the more aggressive colorectal surgery given to patients with LS, reducing
further instances of CRC and therefore costs. For female relatives and probands, patients diagnosed TP
with no surveillance incur higher costs than patients diagnosed FN, as some will undergo prophylactic
TAHBSO. For all subgroups, patients diagnosed TP with surveillance incur the third highest costs, as they
incur surveillance costs but reduced CRC treatment costs, owing to the enhanced surveillance.
Figures 62–65 also demonstrate that the finding that the costs of EC prevention and management are
lower than the equivalent CRC costs is replicated when the cohort is divided into the subgroups
represented by the figures. Once again, the cost of CRC treatment is higher than the cost of treatment for
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EC as a much greater proportion of patients are diagnosed with CRC. The cost of CRC prevention is higher
than the cost of EC prevention because a greater proportion of the cohort undergo colonoscopies than
TAHBSO. In general, prevention costs are higher for relatives than for probands when the colonoscopies
are based on LS diagnosis (there are CRC prevention costs for all probands as they receive colonoscopies
as standard follow-up to their CRC, though these are not as frequent as in the case of LS).
Cost-effectiveness results (base case)
In order to understand the cost-effectiveness of the various testing strategies, we first examine the
disaggregated incremental costs and QALYs.
Incremental costs
We consider five main groups of costs: LS testing, CRC prevention, CRC treatment, EC prevention and EC
treatment (Figure 66). These are related as follows: as the cost of LS testing increases across testing
strategies, the costs of CRC and EC prevention also tend to increase. As these in turn increase, the costs of
CRC and EC treatment decrease. However, the net effect is that as the total cost of prevention increases,
so too does the total cost of prevention and treatment, i.e. the additional costs of prevention are not all
recouped by reduced costs of treatment.
The main components of the savings in the costs of treatment are in respect of chemotherapy and
radiotherapy for primary CRC, chemotherapy and radiotherapy for recurrence CRC, palliative care for CRC
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and surgery for CRC (Figure 67). Savings are much smaller in the remaining components of treatment:
CRC diagnosis, CRC stoma care, CRC follow-up surveillance, TAHBSO on diagnosis of EC, and
chemotherapy and radiotherapy for EC.
Most, but not all of the additional costs of surveillance for CRC are offset by savings in treatment for CRC
(see Figure 66), though the additional costs are approximately £100,000 greater than the savings. Strategy
3 has the smallest difference in these costs (£80,760) and strategy 8 has the largest difference (£217,000).
Similarly, some of the costs of prophylactic TAHBSO are offset by savings in treatment for EC (see Figure 66),
though increased costs of prophylactic TAHBSO are far greater than the decreased costs of treatment for EC;
the net cost rises from a minimum of £188,682 in strategy 1(2) (AC only) to a maximum of £420,948 in
strategy 8 (direct genetic testing). As the sensitivity of the strategies increases, the net cost also increases.
When sensitivities are similar between strategies, the net cost increases with specificity. As an individual
prophylactic TAHBSO is less expensive than treatment for EC (£3322 compared with £7171), the higher
cost of EC prevention compared with the savings from EC treatment avoided must be due to the smaller
number of ECs compared with prophylactic TAHBSOs.
Incremental quality-adjusted life-years
The differences in total QALYs across testing strategies related to the psychological impact of diagnosis are
far smaller than all other sources of QALYs (i.e. life expectancy, adjusted for disutility of Dukes’ D CRC,
and age-related quality of life) (Figure 68). This is because it is assumed that the disutilities due to the
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FIGURE 68 Incremental discounted QALYs vs. strategy 1(1), by diagnostic and long-term outcomes.
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psychological impact of testing have an effect only in the very short term (4 months), whereas all other
sources of QALYs are accrued over the future life expectancy of probands and relatives.
Total QALYs increase with the sensitivity of the testing strategy because as the sensitivity increases, the
number of LS-positive people who are treated increases, and such treatment can substantially improve life
expectancy [see Life expectancy (base case)]. Total QALYs are far less sensitive to the number of FPs
because increased surveillance for these people has little benefit for life expectancy.
Incremental cost-effectiveness ratios
Total discounted costs and QALYs, per strategy, over all probands and relatives per annum in England are
given in Figures 69 and 70. Figure 69 demonstrates that the difference in costs and QALYs across the
strategies is not large but, in general, as Table 100 demonstrates, as the QALYs increase so do the costs.
Discounted QALYs increase from 151,793 given no testing to 152,000 in strategy 8 (direct genetic testing).
The total discounted cost increases from £36,224,000 given no testing to £38,198,000 in strategy 8. Total
discounted QALYs are the same for strategies 2 and 3, as are those for strategies 4, 5 and 6. Strategies 5
and 6 are expected to have the same total QALYs, as the addition of IHC in strategy 6 is assumed to affect
only costs. In strategies 3 and 5, the addition of BRAF appears only to reduce the cost of the strategy
compared with strategies 2 and 4, respectively, with no effect on QALYs. Taking strategies 4 and 5 as an
example, we see that they have identical sensitivities, with only a slight improvement in specificity.
The decrease in FPs does not significantly improve the results, other than reducing the costs by reducing
the number of colonoscopies.
Accounting for both the discounted costs and QALYs, we investigate the ICERs of the strategies compared
with both no testing and each other. The ICERs of all strategies compared with no testing are < £10,000
per QALY (see Table 100), which is considerably less than the £20,000-per-QALY threshold routinely used
by NICE in England and Wales132 (Figure 71). All ICERs versus no testing are similar, varying from £5491
per QALY for strategy 5 to £9571 per QALY for strategy 8.
The testing strategies on the efficiency frontier are strategies 1(1), 5, 7 and 8 (see Table 97). The remaining
strategies are either dominated (less effective and more expensive than at least one other strategy)
(strategies 2, 4 and 6) or extended dominated (less effective and more expensive than some combination
of two other strategies) [strategies 1(2) and 3].
On the efficiency frontier, the ICER of strategy 5 versus no testing is £5491 per QALY. The ICER of strategy 7
versus strategy 5 is £25,106, and therefore marginally greater than NICE’s cost-effectiveness threshold.
The ICER of strategy 8 versus strategy 7 is £82,962 per QALY, and therefore far greater than the threshold.
Strategy 6 is always dominated by strategy 5 because they have the same test accuracies, but strategy 6
additionally includes the cost of IHC testing.
We now consider NHBs, defined as total QALYs minus (total costs divided by the willingness-to-pay
threshold) of each strategy. Strategy 5 has the highest NHB at a willingness-to-pay threshold of £20,000
per QALY (Figures 72 and 73). In Figures 72 and 73, error bars represent the 95% CI over the 32,000
simulated patients. In Figure 72, the 95% CIs overlap, particularly for strategies 4, 5 and 6. This suggests
that there is uncertainty about which strategy is the most cost-effective at a willingness to pay of £20,000
per QALY. However, in Figure 73 these error bars are much smaller as they compare the INHB of each
strategy with strategy 5, rather than with strategy 1(1). This demonstrates that strategy 5 is the most
cost-effective at a willingness to pay of £20,000 per QALY. In summary, at a willingness-to-pay threshold
of £20,000 per QALY, strategies 4, 5, 6 and 7 offer the best value for money, and the cost-effectiveness
of these strategies is similar. These strategies are predicted to result in an additional 130 discounted QALYs
per year in England compared with no testing. By comparison, the total discounted QALYs for a man who
lives to age 80 years, allowing for age-related quality of life, is approximately 25. The 130 discounted
QALYs therefore equate to the total discounted QALYs accrued over the lives of approximately five people.
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Additional results (base case)
We now present the following important results for each testing strategy from our cost-effectiveness
analysis: expected number of colonoscopies per annum in England, expected number of CRCs per annum
in England and expected number of ECs per annum in England.
Expected number of colonoscopies
Here we investigate the total number of colonoscopies, because the total cost of colonoscopies strongly
influences the cost-effectiveness of testing strategies. As expected, the number of colonoscopies increases
with the proportion of patients who are diagnosed with LS, because these patients are offered enhanced
surveillance. Individuals diagnosed with LS, who adhere to surveillance, receive one colonoscopy every
2 years. Patients with CRC who are diagnosed LS negative or who decline LS surveillance receive one
colonoscopy every 5 years. This explains why all patients receive some colonoscopies, even in strategy 1(1),
where no testing occurs. This is the minimum number of colonoscopies per patient across the strategies.
The average number of colonoscopies per proband without LS increases from approximately 2.33 under no
testing to 2.39 for strategy 8 (Figure 74). The 2.33 colonoscopies represent standard CRC follow-up, with
the increase occurring in other strategies due to probands identified incorrectly as LS positive. It therefore
follows that strategies with higher false positivity rates (lower specificity) have a higher number of
colonoscopies. The number of colonoscopies per LS-negative relative increases from 0.02 to 0.23 across
testing strategies. These are similarly all due to FPs. For patients with LS, the number of colonoscopies per
proband increases from 2.11 in the no testing strategy to 5.58 in strategy 8 as a greater proportion of
probands with LS are diagnosed as such under genetic testing, and hence a greater proportion receive
enhanced surveillance. The number of colonoscopies per relative with LS increases from 0.30 given no
testing, to 7.0 in strategy 8, for the same reason. The number of colonoscopies per proband with LS is
lower than for those without LS in the no testing strategy, as probands with LS have a shorter life
expectancy. Furthermore, the risk of metachronous cancer in probands with LS is much higher than that in
probands without; the surgery for this is likely to be more aggressive, resulting in the inability to use
follow-up colonoscopies. The increase in colonoscopies for relatives with LS between strategies 1(2) and 2
is most likely due to a higher uptake in LS-positive relatives owing to a correct diagnosis by genetic testing,
plus the longer life expectancy of these relatives increasing the number of colonoscopies.
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FIGURE 73 Incremental net health benefit compared with strategy 5 at a willingness to pay of £20,000 per QALY.
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The expected total number of colonoscopies performed in England per annual cohort increases from
approximately 4200 given no testing to 8600 in strategy 8 (Figure 75), suggesting that diagnostic
strategies for LS may increase the number of colonoscopies twofold.
Expected number of colorectal cancers
The number of CRCs in probands clearly does not include the index cancer, as all probands present with
this, and its incidence is unaffected by the diagnostic process. Furthermore, relatives are assumed not to
have had CRC previously.
The risk of CRC is higher for males than females among probands and relatives (Figure 76), in accordance
with our knowledge of CRC risk. The proportion of relatives who develop primary CRC is greater than
the proportion of probands who develop metachronous CRC. The probabilities of developing CRC are
slightly lower given genetic testing because there is a greater chance that LS is identified.
The expected number of new CRCs for the entire cohort of 1699 probands (metachronous CRCs) and
8495 relatives (primary and metachronous CRCs), in England per year, is approximately 665 in the no
testing strategy, reducing to a minimum of 633 in strategy 8 (a difference of 32). Given no testing, 79 are
metachronous cancers in the proband population and 586 are index and metachronous cancers in the
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FIGURE 75 Total number of colonoscopies conducted in England per cohort in each testing strategy.
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relative population. In strategy 8, 72 metachronous CRCs are expected in the probands and 561 index and
metachronous CRCs in the relatives.
The lifetime probabilities of developing metachronous CRC for probands without LS (approximately 1.4%)
and primary and metachronous CRC for relatives (approximately 5.5%) remain roughly constant across
strategies (Figures 77 and 78). A very small proportion of this group test as FP and consequently undergo
enhanced surveillance, accounting for very small differences in the probabilities of having CRC across
strategies. As expected, the lifetime probability of developing CRC for patients with LS (24–30% for
relatives, 35–40% for probands, depending upon the strategy) is far higher than for those without LS. The
probabilities that probands and relatives with LS develop CRC are lower under genetic testing strategies, as
these correctly identify many such people as having LS. These patients then receive enhanced surveillance,
which acts to reduce the probability of developing CRC. The greater the sensitivity of the test strategy,
the lower the probability that probands and relatives develop CRC. For example, the probability of
metachronous CRC among probands with LS falls from 40.0% (no testing) to 35.0% (direct genetic
testing), and the probability of primary and metachronous CRC among relatives with LS falls from 30.2%
(no testing) to 24.1% (direct genetic testing).
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Expected number of endometrial cancers
No women who are LS negative are assumed to develop EC. Further, all probands and relatives are
assumed not to have previously developed EC.
The lifetime risk of EC decreases as more LS-positive relatives and probands are identified by a strategy
because these people receive prophylactic TAHBSOs (Figure 79). For example, the probability of EC among
probands with LS falls from 11.2% (no testing) to 7.4% (direct genetic testing), and the probability of EC
among relatives with LS falls from 23.7% (no testing) to 15.5% (direct genetic testing).
The expected annual number of ECs related to probands aged < 50 years and their relatives in England
in the no testing strategy is 54, with 46 occurring in female relatives and 8 in female probands. This
reduces to a minimum of 35 in strategy 8 (direct genetic testing), with 30 in female relatives and 5 in the
probands. The probability of developing EC is greater for relatives than probands (approximately 17% vs.
8% for genetic strategies) because life expectancy is greater for relatives, which gives a greater time frame
in which to develop EC.
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Scenario analysis 1 (endometrial cancer excluded) results
In this scenario, we remove EC from the model. In so doing, we exclude the incidence and treatment of
EC, as well as the associated mortality rates, costs and QALYs. We also exclude the preventative measures
associated with EC, so that there are no longer costs, QALYs or mortality rates for prophylactic TAHBSOs
within the model. This allows us to examine the impact of EC on our base-case analysis, as well as
providing a scenario that is comparable with previous models of LS, where EC is not accounted for.
Additionally, it could be argued that it would be more appropriate to exclude EC from our base-case
analysis, given that we do not include OC. This is because the genetic testing strategies incur substantial
costs for prophylactic TAHBSO in our base case, but we do not allow for the associated reduction in
incidence of OC.
One would imagine that the results for males in this scenario would be as in the base-case analysis, given
that males do not get EC. To a very high level of accuracy, this is true. However, there are very slight
differences because the model simulates individual patients, and allows for chance in estimating the times
of events, such as incidence of CRC and EC.
As expected, the diagnostic results are unaffected by the exclusion of EC.
Life expectancy
The life expectancies of all groups of patients change only very slightly when EC is removed (Figures 80
and 81), which shows that there is little mortality from EC. The life expectancy of male probands remains
very similar between the base case and scenario 1. This is expected as the exclusion of EC should not have
an impact on the male population. However, the uncertainty inherent in the model due to the individual
patient simulations does alter the life expectancy of the male relatives, with a slight increase across all
strategies. There are counter-intuitive results for other groups: female probands appear to have a
very slightly reduced life expectancy when EC is removed, but female relatives appear to have a very
slight increase.
This can be partly explained using the results of the cohort’s LS status, as demonstrated in Table 101.
Here, as expected, probands and relatives with LS have an increase in life expectancy when EC is removed.
Relatives without LS also appear to have an increase in life expectancy, which results from the inherent
uncertainty in the model due to the individual patient simulations. Probands without LS appear to have a
slightly reduced life expectancy as a result of very small change in the males’ life expectancy and a reduced
life expectancy in the female probands. To understand these results more clearly it is important to break
down the female subgroups into their relevant diagnoses.
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When the patients are split according to TP/FP/FN/TN (± surveillance), the causes of differences in
life expectancy versus the base case become clearer. For female relatives there is a slight increase in life
expectancy (Figure 82; compare with Figure 57), but most noticeably for those diagnosed TP and FN,
as mortality due to EC for females with LS is removed. This pattern is repeated for female probands
(Figure 83), though the effect is less pronounced.
Cost results
As expected, total costs are reduced when EC is excluded, as there are no longer costs for the prevention
or treatment of EC. Given the slightly increased life expectancy of female relatives and probands with LS,
we expect a slight increase in costs of colonoscopies and CRC treatment, as there are further opportunities
for this to occur. Indeed, the undiscounted costs of these increase by between £400,000 and £1,800,000
depending on the strategy (Figure 84; compare with Figure 61).
TABLE 101 Change in life expectancy between base case and scenario 1, by LS status
Output parameter Scenario
Strategy
1(1) 1(2) 2 3 4 5 6 7 8
Life expectancy
(years): probands
With LS Base case 12.93 13.65 14.17 14.17 14.32 14.32 14.32 14.49 14.54
Scenario 1
(no EC)
13.12 13.82 14.33 14.33 14.48 14.48 14.48 14.64 14.69
Without
LS
Base case 13.90 13.90 13.90 13.90 13.90 13.90 13.90 13.90 13.90
Scenario 1
(no EC)
13.86 13.86 13.86 13.86 13.86 13.86 13.86 13.86 13.86
Life expectancy
(years): relatives
With LS Base case 33.97 34.28 35.20 35.20 35.36 35.36 35.36 35.52 35.57
Scenario 1
(no EC)
34.76 35.03 35.86 35.86 35.99 35.99 35.99 36.14 36.18
Without
LS
Base case 37.51 37.52 37.52 37.52 37.52 37.52 37.52 37.52 37.52
Scenario 1
(no EC)
37.55 37.55 37.55 37.55 37.55 37.55 37.55 37.55 37.55
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Costs for females diagnosed as having LS (TP, FP) are reduced because the substantial costs of prophylactic
TAHBSO are avoided (Figures 85 and 86). Costs for females with LS (FN, TP) are also reduced given that
treatment for EC (TAHBSO, chemotherapy and radiotherapy) is avoided.
Costs for males and females are now similar, though slightly lower for female relatives, most likely given that
they have a reduced risk of CRC compared with male relatives. Similar results occur for female probands.
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Additional results
The number of colonoscopies in this scenario is generally very slightly higher than the number of
colonoscopies in the base case (Figure 87). This is primarily due to the slightly increased life expectancy for
females with LS, who no longer die from EC.
The proportion of female relatives and probands developing CRCs also increases very slightly, for the same
reason (Figure 88).
Cost-effectiveness results
Given the reduced costs and slight increase in life expectancy, plus no disutility from EC, the costs for all
strategies are reduced from the base case and the QALYs increased. The incremental QALY gains compared
with strategy 1(1) are lower for all testing strategies than in the base case (Figure 89), but given the much
larger reductions in costs due to the lack of prophylactic TAHBSO (Figures 90 and 91), the ICERs compared
with strategy 1(1) are reduced compared with the base case, i.e. all strategies become more cost-effective
compared with no testing. This may seem counter-intuitive, as one might expect the cost-effectiveness of
testing to improve as more people with LS are correctly identified. In a sense, the result is more a reflection
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FIGURE 86 Undiscounted treatment and prevention costs for female relatives, excluding EC.
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of the cost-effectiveness of treatment for EC. It is important to reiterate that our base-case analysis does not
account for the benefit gained from prophylactic TAHBSO in the prevention of OC.
The ranking of cost-effectiveness among strategies remains the same, with strategy 5 still giving the largest
net health benefit (Table 102).
Scenario analysis 2 (BRAF replaced by methylation testing) results
There is currently one further test used in the diagnostic process for LS diagnosis: a methylation test to
check for hypermethylation. It is used in a similar manner to BRAF, after MSI or an abnormal MLH1 IHC
result to rule out sporadic cancers. As such, we considered it important to conduct a scenario analysis
where methylation was used in place of BRAF. Details of this scenario, including in-depth results, can be
found in Appendix 15, as we only present the main cost-effectiveness findings here.
Using methylation testing in the place of BRAF only alters the results of the strategies that use BRAF.
Table 103 therefore demonstrates little change from the base case, with the ICERs versus strategy 1(1)
remaining < £10,000 per QALY. However, the strategies that use methylation now gain fewer QALYs
than the similar strategies that do not use methylation (compare strategies 3 and 2, or 5 and 4), thereby
altering the order of effectiveness of the strategies. Strategy 5 still has the smallest ICER compared with no
testing, but strategy 4 now has the greatest INHB compared with strategy 1(1) at a willingness to pay of
£20,000 per QALY.
Comparing strategies simultaneously, strategies 1(2), 2, 3 and 6 are still dominated by other strategies.
The ICER for strategy 5 is slightly reduced to £5436 per QALY gained over strategy 1(1), but strategy 4 is
no longer extended dominated, instead having an ICER versus strategy 5 of £7965 per QALY gained. The
ICERs for strategies 7 and 8 remain above £25,000 per QALY. Observing these results together, it would
appear that strategy 4 (MSI followed by genetic testing) is now the most cost-effective strategy at a
willingness to pay of £20,000 per QALY.
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We conclude that using methylation in place of BRAF can still be cost-effective at a willingness to pay of
£20,000 per QALY compared with no testing, but that compared with other strategies (and the results
from BRAF), it may not be most cost-effective.
Scenario analysis 3 (changing the age limit for probands)
In an extension of the scope of our work, we examine the consequences of extending the testing for LS to
a wider population. We raise the age limit for testing probands from 50 years in our base case to age
60 years, and then to age 70 years.
When the age limit of the probands is raised, the prevalence of LS in probands falls (Table 104) because
the incidence of CRC in the general population rises more rapidly than the incidence of CRC in people
with LS. Using the study by Hampel and colleagues120 again as our source of LS prevalence in a newly
diagnosed population, we find that the prevalence falls from 8.4% at maximum age of 50 years to 5.7%
at an age limit of 60 years and 3.8% at an age limit of 70 years. The total annual incidence of cases of
CRC in England increases from 1699 at maximum age 50 years, to 5018 at maximum age 60 years, to
13,900 at maximum age 70 years. In addition, the following parameters are affected by the increase in
maximum proband age: the proportion of probands who are male, and the proportion of general
population patients with colon cancer versus rectal cancer.
The number of relatives increases from 8495 in the base case to 25,090 when the age limit of the
probands is raised to 60 years and 69,500 when the age limit is raised to 70 years. As in the base case,
the age and other characteristics of relatives are not linked to the age of the probands. Therefore,
although the age distribution of the probands alters, the age distribution of the relatives does not.
Maximum age of probands at diagnosis 60 years
Diagnostic results
The change in prevalence of LS in the probands has a surprising effect on the diagnostic results. One
might expect that altering the prevalence of a condition in a population should not affect the sensitivity
or specificity of a test (or testing strategy), yet our results demonstrate a slight improvement in overall
specificity compared with the base case (Figure 92). This is driven by the ratio of the number of false
mutation-positive probands to false LS-assumed probands (which significantly alters the diagnoses of the
relatives), and occurs as a result of having separate genetic tests for M126 and PMS2.
TABLE 104 Parameters affected by maximum age of probands at diagnosis
Input parameter
Maximum proband age (years)
Source
< 50
(base case) < 60 < 70
Prevalence of LS in probands 8.4% 5.7% 3.8% Hampel et al. 2008120
Number of probands per annum in England 1699 5018 13,900 ONS Cancer Registration Statistics,
England 2010119
Proportion of probands male 54.8% 56.0% 59.5% ONS Cancer Registration Statistics,
England 2006–10119,136–139
Proportion of general population male
probands with colon (not rectal) cancer
58.4% 54.4% 56.9% ONS Cancer Registration Statistics,
England 2010119
Proportion of general population female
probands with colon (not rectal) cancer
60.9% 61.3% 65.0% ONS Cancer Registration Statistics,
England 2010119
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When probands undergo the M126 genetic test, those who are positive for a PMS2 mutation cannot test
positive for any other mutation. Therefore, they are part of the test-negative cohort and must make up a
section of the cohort who truly test negative on the M126 genetic test. When the prevalence in the
probands changes, the ratio is altered between those testing negative because they are LS negative and
those testing negative because they are PMS2 positive. As the probands who test negative for M126 go
on to further testing (and, if they are not ruled out by FH, become either mutation positive on PMS2 or
LS assumed), this alters the ratio between the TN, the FP-assumed and the false mutation-positive
probands. The larger number of relatives, whose diagnoses depend on the diagnoses of the probands,
exacerbates the results of this difference, resulting in the change in specificity. Sensitivity is unchanged as
the FNs and TPs are unaffected.
Life expectancy
The life expectancy of relatives remains fairly similar to the base case, regardless of LS status, owing to
the relatives remaining mostly unaffected by the change in the proband age limit (Figure 93). The life
expectancy of probands, however, falls regardless of LS status (Figure 94, compared with Figure 53),
owing to the higher mean age of probands and consequently shorter life expectancy. The average age
of probands in the base case is 41.1 years compared with 49.4 years when the age limit is increased
to 60 years.
Cost results
As expected, total costs increase dramatically and approximately in proportion to the increase in the
number of probands and relatives (Figure 95). The distribution of these costs across strategies is very similar
to that in the base case. For example, strategy 5 testing costs are lower than those for strategies 4 or 6
(Figure 96). Differences in long-term costs are also similar across strategies (Figure 97) compared with the
base case.
Additional results
Similar to the costs results, the overall number of colonoscopies increases purely on the basis of the
number of patients increasing (Figure 98). The proportional increase in the number of colonoscopies is
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FIGURE 92 Receiver operating characteristic plot for all patients (probands and relatives) when age limit of
probands is raised to 60 years.
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lower than the proportional increase in the number of probands and relatives because a smaller proportion
of probands are LS positive. The average number of colonoscopies per patient identified as not having LS
decreases for the probands from an average of 2.3–2.7, depending on the strategy, to 1.8–2.0, primarily
because of their reduced life expectancy. The number of colonoscopies per relative remains similar to
the number in the base case, as their age distribution is assumed unchanged. Figure 99 shows the average
number of colonoscopies for individuals with newly diagnosed CRC aged < 60 years and their relatives.
Similarly, the proportion of relatives developing a CRC remains similar to that in the base case, and the
proportion of probands developing metachronous CRC reduces (Figure 100). This occurs as the lifetime
probability of metachronous CRC reduces for probands, because their life expectancy also reduces
(as their mean age at diagnosis increases) (Figure 101; compare with Figure 77).
The lifetime risk of EC appears to remain similar to that in the base case for both probands and relatives
within the LS population (Figure 102), but there is a reduction in risk for the entire cohort, as there is a
smaller proportion of probands and relatives with LS and the probands have a shorter life expectancy.
Cost-effectiveness results
The increase in the proband age limit to 60 years increases not only the overall cost per strategy, but
also the incremental cost compared with no testing (Figures 103 and 104). The incremental cost of LS
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FIGURE 98 Total number of colonoscopies conducted in England per annum, when proband age limit is increased
to 60 years.
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FIGURE 99 Average number of colonoscopies per patient, when proband age limit is increased to 60 years.
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diagnosis is now much increased compared with the base case. Indeed, the proportional increase is greater
than the proportional increase in the other cost components: CRC prevention and treatment, and EC
prevention and treatment. This is due to the lower prevalence of LS within this population compared with
the base-case population and, consequently, the smaller proportion offered surveillance colonoscopy for
CRC prevention and TAHBSO for EC prevention. In all other respects, despite obvious increases in the costs
and cost savings due to the larger population, the pattern of incremental costs across testing strategies
remains similar to that seen in the base case.
The incremental QALY gains for each strategy compared with strategy 1(1) are also larger than in the base
case, though not as pronounced as the increases in costs (Figure 105). The net result is that all test
strategies are now slightly worse value for money versus no testing (Table 105). The impact of the QALY
loss due to the psychological impact of genetic testing is proportionally larger than in the base case,
reflecting the extra numbers undergoing the diagnostic strategies.
Despite a slight deterioration in cost-effectiveness, the INHB at the population level compared with no
testing increases in all strategies except universal genetic testing, compared with the base case. This
increase is expected, as the diagnostic testing now benefits a larger group of patients. Universal genetic
testing is the exception given that testing costs increase substantially.
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FIGURE 104 Incremental discounted testing, prevention and treatment costs when the proband age limit is
increased to 60 years.
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All strategies are still cost-effective compared with no testing at a threshold of £20,000 per QALY gained,
as demonstrated by Figure 106. Strategy 5 gives the greatest INHB of 193 discounted QALYs, and hence
is the most cost-effective, at a willingness to pay of £20,000 per QALY. This compares with 130 discounted
QALYs for this strategy in the base-case analysis.
Maximum age of probands at diagnosis 70 years
The changes in the life expectancy and costs described in the previous section, given a maximum proband
age at diagnosis of 60 years, follow a pattern similar to that given a maximum proband age of 70 years
(Figure 107). Therefore, we present only the main cost-effectiveness results.
Cost-effectiveness results
As with the 60-year age limit, we find a marked increase in the incremental diagnostic costs for all
strategies compared with no testing. Furthermore, the proportional increase in these costs is greater than
the proportional changes in the other costs: CRC prevention and treatment, and EC prevention and
treatment (Figure 108). Again, this is because of an increase in the proband population and a reduction in
the prevalence of LS. In all genetic testing strategies, the incremental cost of LS diagnosis is now higher
than the incremental cost of CRC prevention.
Incremental QALYs versus no testing also increase for all strategies (Figure 109). As with the age limit of
60 years, the QALY loss from LS diagnosis contributes proportionally more compared with the base case,
because the ratio of the number of people tested to total health gain increases.
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FIGURE 106 Total discounted costs and QALYs for all probands and relatives per annum in England by testing
strategy, when proband age limit is increased to 60 years.
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As with the age limit of 60 years, the ICERs of each strategy compared with no testing are larger
than in the base case. All ICERs are now > £10,000 per QALY gained. Strategy 5 again has the lowest
ICER, at £10,800 per QALY, and the ICER for strategy 8, universal genetic testing, is now above the
£20,000-per-QALY threshold (Figure 110 and Table 106), which implies that it is no longer cost-effective
versus no testing.
The INHB compared with no testing for all probands and relatives in England per year increases from the
base case for all strategies, except strategies 7 and 8. Strategy 5 again gives the maximum INHB, now at
approximately 271 discounted QALYs. This compares with 130 discounted QALYs for this strategy in the
base-case analysis.
No discounting
In the base case and all scenarios, the costs and benefits of the strategies are discounted over time at a
rate of 3.5% per annum, in line with NICE guidance. In this section we present undiscounted results.
The majority of results presented in the base case, for cost and survival, are presented in undiscounted
form, with discounts applying only when directly assessing cost-effectiveness. As such, we present only the
main cost-effectiveness results (Table 107). The cost-effectiveness of all testing strategies versus no testing
improves compared with the base case.
As Table 107 shows, not including the discount rate increased both the costs and QALYs of each strategy.
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FIGURE 110 Total discounted costs and QALYs for all probands and relatives per annum in England by testing
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Univariate sensitivity analyses
We conducted several univariate sensitivity analyses to investigate the impact of various parameters
on the model results. In the majority of cases, the values used in the sensitivity analyses were not meant
to represent the true parameter value, but were chosen to demonstrate the impact of changing the
parameter value on the cost-effectiveness of testing for LS.
Cost of tumour testing
For each tumour-based test, we assessed the impact of halving and doubling the cost and present the
ICERs compared with strategy 1(1) (no testing), and the INHB at a £20,000 threshold compared with
strategy 1(1). As not all tests are used in each strategy, not all strategies change ICER or INHB when the
cost of one tumour-based test changes. As expected from the results of the base case, it is the tests which
are run first, or on a large proportion of the cohort, that have the greatest impact on the cost-effectiveness
of a strategy. As the results in Table 108 (see also Table 109) demonstrate, all strategies are cost-effective
at a threshold of £20,000 per QALY compared with no testing, regardless of change in tumour-based test
cost. An example of the change in diagnostic costs is given in Figures 111 and 112, which show the
change in total diagnostic costs under IHC sensitivity analyses.
TABLE 107 Cost-effectiveness results when discount rate is not applied
Strategy Total undiscounted QALYs Total undiscounted cost (£) ICER vs. strategy 1(1) (£/QALY)
1(1) 275,654 54,336,327 –
1(2) 275,825 54,852,971 3029
2 276,101 55,428,502 2448
3 276,100 55,325,673 2219
4 276,155 55,410,000 2145
5 276,155 55,385,965 2098
6 276,155 55,436,784 2199
7 276,216 55,944,392 2864
8 276,238 56,459,582 3641
TABLE 108 Cost of tumour-based tests sensitivity analysis, ICERs compared with no testing
Parameter
name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1 (1) 1 (2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
Cost of
IHC (£)
238 119 – 6021 5178 4566 5610 5491 5633 6595 9571
476 – 6021 8975 8361 5610 5491 6058 9614 9571
Cost of
MSI (£)
202 101 – 6021 6444 5831 4652 4533 4817 6890 9571
404 – 6021 6444 5831 7525 7406 7690 9024 9571
Cost of
BRAF (£)
118 59 – 6021 6444 5760 5610 5401 5684 7553 9571
236 – 6021 6444 5972 5610 5672 5955 7697 9571
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FIGURE 111 Diagnostic costs when the cost of IHC is halved.
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Cost of genetic testing and counselling
In this section, we analyse the impact of costs surrounding genetic testing, counselling and FH assessment
by halving and doubling the various costs. The ICERs compared with no testing are given in Table 109.
Changing the cost of FH assessment affects probands only. This parameter has little effect on the ICERs
versus no testing for each strategy, compared with the base case.
Changing the cost of genetic counselling for relatives also changes the cost of counselling for relatives of
probands assumed to have LS (and therefore relatives with no possibility of genetic testing), so the change
in this cost also affects strategies that do not include genetic testing, i.e. strategy 1(2). Despite this,
there is still little change in the ICERs versus strategy 1(1) in the base case. Changing the cost of genetic
counselling in probands only affected the strategies that included genetic testing, but again had little
impact on the cost-effectiveness of each strategy compared with the base case.
As the cost of genetic counselling for probands and relatives was the same in our base case, we also
examined the case when the counselling costs were changed for both at the same time; again there was
little change from the base case. The same was true when the cost of genetic testing in relatives
was altered.
Changing the cost of diagnostic genetic testing in probands, particularly halving the cost, had a much
greater impact on the cost-effectiveness of each strategy, with strategy 8 having lower total costs than
strategy 7 (Figure 113). This reduces the ICERs versus no testing for all strategies compared with the base
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FIGURE 112 Diagnostic costs when the cost of IHC is doubled.
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TABLE 109 Incremental cost-effectiveness ratios vs. strategy 1(1) for sensitivity analyses of the cost of FH
assessment, genetic counselling and genetic testing
Parameter
name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1(1) 1(2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
Cost of taking
FH (£)
22 11 – 5729 6443 5830 5608 5490 5773 7600 9565
44 – 6604 6447 5833 5612 5493 5776 7604 9585
Cost of genetic
counselling
(probands
only) (£)
67 33 – 6021 6389 5797 5562 5454 5738 7541 9317
134 – 6021 6554 5899 5704 5565 5848 7722 10,081
Cost of genetic
counselling
(relatives
only) (£)
67 33 – 5930 6404 5792 5570 5452 5735 7561 9523
134 – 6202 6524 5910 5689 5570 5853 7682 9668
Cost of genetic
counselling
(probands and
relatives) (£)
67 33 – 5930 6349 5758 5522 5415 5698 7500 9268
134 – 6202 6635 5978 5784 5643 5927 7803 10,178
Cost of
diagnostic
genetic testing
(probands) (£)
MLH1, 464 MLH1, 232 – 6021 5818 5517 5069 5068 5351 6913 6728
PMS2, 735 PMS2, 367
M126, 812 M126, 406
MLH1, 929 – 6021 7697 6459 6690 6338 6621 8977 15,258
PMS2, 1469
M126, 1624
Cost of
predictive
genetic testing
(relatives) (£)
MLH1, 169
MSH2, 172
MSH6, 172
PMS2, 176
MLH1, 85 – 6021 6358 5745 5524 5405 5689 7515 9485
MSH2, 86
MSH6, 86
PMS2, 88
MLH1, 339 – 6021 6616 6002 5781 5663 5946 7773 9745
MSH2, 345
MSH6, 345
PMS2, 352
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case, except strategy 1(2), which does not include genetic testing. The ICER most altered is that for
strategy 8 versus strategy 1(1); strategy 8 in fact becomes the most cost-effective strategy at a
cost-effectiveness threshold of £20,000 per QALY. Similar results occur when the cost of genetic testing in
probands is doubled (Figure 114), except that the ICERs compared with strategy 1(1) increase compared
with the base case.
Acceptance of genetic testing
The sensitivity analyses of parameters that influenced the acceptance of genetic testing were conducted
by halving the acceptance rate of each parameter and then halving the non-acceptance rate. Results
are presented in Table 110. Unlike the costs, relatives’ acceptance of genetic counselling only applies
to genetic counselling of relatives with mutation-positive probands, leaving the ICER of strategy 1(2)
unaffected.
Unusually, the change in acceptance of genetic counselling and testing does not appear to have a
particularly large impact on the ICERs versus no testing in the base case, with all ICERs compared with no
testing remaining < £11,000 per QALY gained in all cases.
Our final sensitivity analysis of the acceptance of genetic testing and counselling is to set the acceptance of
both for probands and relatives to 100%. Like the majority of our sensitivity analyses, this was done to
demonstrate the importance of acceptance of genetic counselling and testing as parameters in the model,
not as a probable real-life scenario. When acceptance was raised to 100% for both counselling and
genetic testing in probands and relatives, the ICERs compared with no testing reduced significantly
compared with the base case, and strategy 7 had the greatest NHB.
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FIGURE 113 Total diagnostic costs when the cost of genetic testing in probands is halved.
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FIGURE 114 Total diagnostic costs when the cost of genetic testing in probands is doubled.
TABLE 110 Incremental cost-effectiveness ratios vs. no testing for sensitivity analysis of the acceptance of genetic
counselling and testing
Parameter name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1(1) 1(2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
Proband adherence
to genetic counselling
92.5% 46.3% – 6021 7760 7269 6592 6581 7024 9488 9503
96.3% – 6021 6378 5758 5560 5436 5711 7507 9575
Relative adherence to
genetic counselling
45% 23% – 6021 7395 6750 6521 6396 6693 8609 10686
73% – 6021 5416 4837 4624 4513 4781 6511 8366
Proband adherence
to genetic testing
90% 45% – 6021 7818 7305 6642 6620 7063 9552 9788
95% – 6021 6350 5730 5539 5414 5686 7468 9558
Relative adherence
to genetic testing
96% 48% – 6021 7395 6750 6521 6396 6693 8609 10,686
98% – 6021 6405 5793 5572 5453 5736 7559 9525
All patients comply
with genetic
counselling and
testing
100%
for all
6021 3994 3426 3318 3192 3411 4906 7025
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Prevalence of Lynch syndrome in the proband population
As one of the parameters altered in the age-limit-of-probands scenarios, there is already an assumption
that the prevalence plays an important role in the cost-effectiveness of strategies to diagnose LS. To assess
this this theory we halve, then double, the prevalence.
Halving the prevalence of Lynch syndrome in the proband population (to 4.2%)
As demonstrated in the diagnostic results for the age limit scenarios, reducing the prevalence to 4.2% in
the proband population has no effect on the sensitivity, but increases the specificity of the strategies
(Figure 115). This appears to be particularly true of the strategies that employ tumour testing, which have
higher specificities to begin with.
The total costs of LS diagnosis decrease for all strategies except strategy 1(1), because fewer probands test
positive in early tests and proceed to diagnostic germline testing (Figure 116). The total costs of CRC
prevention decrease substantially for all strategies because surveillance is offered to significantly fewer
patients; indeed, in this sensitivity analysis the total cost of CRC prevention is lower than the total cost of
LS diagnosis in all strategies that use genetic testing. Given that this sensitivity analysis follows a similar
pattern to the results of scenario 3, it is unsurprising that a reduction in prevalence equates to a reduction
in the cost-effectiveness of strategies testing for LS.
The incremental QALYs for strategies versus strategy 1(1) are approximately halved from the base case
(Figure 117).
As expected, the results demonstrate a worsening in cost-effectiveness when the prevalence is halved,
with ICERs increasing for all strategies compared with strategy 1(1) and the INHB reducing in all cases
(Figure 118 and Table 111). However, all strategies are still cost-effective compared with no testing at a
threshold of £20,000 per QALY, and at this threshold strategy 5 again has the largest INHB compared with
no testing.
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FIGURE 115 Receiver operating characteristic plot for all patients, when prevalence of LS in probands
is halved to 4.2%.
ASSESSMENT OF COST-EFFECTIVENESS: RESULTS OF THE COST-EFFECTIVENESS MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
254
–0.6
–0.4
–0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1(1) 1(2) 2 3 4 5 6 7 8
In
cr
em
en
ta
l d
is
co
u
n
te
d
 c
o
st
 v
s.
 s
tr
at
eg
y 
1(
1)
 (
£M
)
Diagnostic strategy
LS diagnosis
CRC prevention
CRC treatment
EC prevention
EC treatment
FIGURE 116 Incremental discounted costs for prevalence 4.2%.
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Doubling the prevalence of Lynch syndrome in probands (to 16.8%)
Doubling the prevalence of LS in probands to 16.8% reduces the specificity of all the strategies and
reduces the specificity of those strategies that use tumour-based tests enough that they become less
specific than strategy 1(2), which uses only FH to identify LS patients (Figure 119). The incremental costs
and QALYs for each strategy are shown in Figures 120 and 121, respectively.
Increasing the prevalence has the expected impact of reducing the ICERs compared with strategy 1(1)
and increasing the INHB of each strategy versus strategy 1(1) in the base case; as expected, this is a
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FIGURE 118 Incremental cost-effectiveness ratios compared with strategy 1(1) when the prevalence of LS in the
probands is 4.2%.
TABLE 111 Summary results when the proband LS prevalence is 4.2%
Strategy
Total
discounted
QALYs
Total
discounted
cost (£)
Incremental
discounted
QALYs vs.
strategy 1(1)
Incremental
discounted
cost vs.
strategy 1(1) (£)
ICER vs.
strategy 1(1)
(£/QALY)
INHB at
£20,000 per
QALY vs.
strategy 1(1)
1(1) 151,939 35,018,577 – – – –
1(2) 151,972 35,333,268 33 314,691 9516 17.3
2 152,019 35,818,538 80 799,960 10,027 39.8
3 152,019 35,720,435 80 701,857 8787 44.8
4 152,029 35,765,766 90 747,188 8344 52.2
5 152,029 35,735,984 90 717,407 8007 53.7
6 152,029 35,773,280 90 754,703 8423 51.9
7 152,040 36,267,428 100 1,248,851 12,447 37.9
8 152,042 36,748,683 102 1,730,106 16,891 15.9
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FIGURE 119 Receiver operating characteristic plot of all patients when the prevalence of LS in patients is 16.8%.
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reversal of the results of halving the prevalence (Figure 122 and Table 112). In this sensitivity analysis,
strategy 7 has the greatest NHB.
Distribution of genes
As genetic testing for LS becomes more commonplace, the distribution of gene mutations identified will
alter, given that the mutation distribution is based on the mutations currently identified and the additional
ones that may be identified by different diagnostic strategies. In this sensitivity analysis, the gene mutation
distribution is taken from Norway, where testing for LS is now routine (Table 113).184
The change in distribution, particularly the reduction in the prevalence of PMS2 mutations, alters the
sensitivity and specificity of those strategies that use genetic testing (Figure 123). For these strategies,
the sensitivity increases and specificity decreases. This is because the sensitivity is higher for the M126
genes than for PMS2, but when more probands are identified correctly, there will also be a larger
proportion of relatives identified incorrectly, thereby increasing the overall FP rate.
As the type of gene mutation does not affect the long-term outcomes of a patient in our model – only
whether or not they have LS and whether or not LS is identified – the only impact on the long-term
outcomes occurs as a result of the change in proportions of FNs and FPs. The overall impact on
cost-effectiveness is not large, as demonstrated in Table 114; there is an increase in both costs and
QALYs gained, but the ICERs remain < £20,000 per QALY for all strategies compared with no testing and
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FIGURE 121 Incremental discounted QALYs for prevalence 16.8%.
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TABLE 112 Summary results when the proband LS prevalence is 16.8%
Strategy
Total
discounted
QALYs
Total
discounted
cost (£)
Incremental
discounted
QALYs vs.
strategy 1(1)
Incremental
discounted
cost vs.
strategy 1(1) (£)
ICER vs.
strategy 1(1)
(£/QALY)
INHB at
£20,000 per
QALY vs.
strategy 1(1)
1(1) 151,502 38,634,207 – – – –
1(2) 151,627 39,159,480 126 525,274 4181 99.4
2 151,821 40,121,977 320 1,487,770 4655 245.2
3 151,821 40,026,009 320 1,391,802 4354 250.1
4 151,860 40,156,099 359 1,521,892 4244 282.5
5 151,860 40,152,774 359 1,518,568 4234 282.7
6 151,860 40,230,640 359 1,596,433 4451 278.8
7 151,904 40,717,796 402 2,083,589 5183 297.9
8 151,916 41,097,605 414 2,463,398 5950 290.9
TABLE 113 Change in distribution of gene mutations
Gene mutation Base case (%) Sensitivity analysis (%)
MLH1 32 18
MSH2 39 50
MSH6 14 26
PMS2 15 6
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decrease slightly in the strategies that use genetic testing. There is also an increase in INHB in these
strategies compared with no testing at a threshold of £20,000 per QALY. These results occur primarily
because the gain (QALYs gained) resulting from fewer FNs is greater than the loss incurred (costs) by the
greater number of FPs.
Probability a relative of a Lynch syndrome-positive proband is affected by
Lynch syndrome
In our base case, the proportion of relatives of LS-positive probands who are also affected by LS is 44.0%.
Using data direct from Ian Frayling, we examine the case when the proportion reduces to 42.6%. The
summary results are given in Table 115; these demonstrate that as the probability decreases, the ICERs
compared with no testing increase and the INHB at a £20,000-per-QALY threshold compared with no
testing decrease, suggesting a reduction in cost-effectiveness. However, all strategies have a positive INHB
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FIGURE 123 Receiver operating characteristic plot for alternative gene mutation distribution.
TABLE 114 Summary of results for alternate gene mutation distribution
Strategy
Total
discounted
QALYs
Total
discounted
cost (£)
Incremental
discounted
QALYs vs.
strategy 1(1)
Incremental
discounted
cost vs.
strategy 1(1) (£)
ICER vs.
strategy 1(1)
(£/QALY)
INHB at
£20,000 per
QALY vs.
strategy 1(1)
1(1) 151,793 36,223,787 – – – –
1(2) 151,857 36,608,672 64 384,885 6021 44.7
2 151,963 37,273,808 169 1,050,021 6201 116.8
3 151,963 37,179,463 169 955,676 5641 121.6
4 151,982 37,247,811 188 1,024,023 5445 136.9
5 151,982 37,226,792 188 1,003,005 5332 138.0
6 151,982 37,277,498 188 1,053,710 5601 135.4
7 152,006 37,775,940 213 1,552,153 7303 134.9
8 152,012 38,225,325 219 2,001,538 9149 118.7
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and an ICER compared with no testing < £20,000, suggesting they are still cost-effective at a threshold of
£20,000 per QALY gained, for this proportion of relatives.
Number of relatives, proportion first-degree relatives
Another important parameter considered was the number of relatives per proband. As the evidence base
for this parameter varied quite widely, we used the extreme values of 0 and 12 relatives to assess the
impact of this parameter.
All strategies remain cost-effective compared with no testing at a threshold of £20,000 per QALY when
the number of relatives is reduced to 0, suggesting that testing for LS is cost-effective even when it is only
conducted on probands. However, ICERs reduce in almost all strategies when the number of relatives
increases and therefore the cost-effectiveness improves (Table 116). Figure 124 gives an example of the
effect of the number of relatives tested per proband on cost-effectiveness. The only exception to this is
strategy 1(2), whose ICER compared with strategy 1(1) increases when the number of relatives increases
and reduces when there are no relatives included in the analysis. Presumably, this is due to the larger
proportion of incorrectly diagnosed relatives which results when the probands are identified purely on the
basis of the FH. There are also fewer probands identified in strategy 1(2) compared with all other testing
strategies, resulting in much lower costs.
TABLE 115 Summary results when the probability that a relative of a LS-positive proband is also affected by LS
is 42.6%
Strategy
Total
discounted
QALYs
Total
discounted
cost (£)
Incremental
discounted
QALYs vs.
strategy 1(1)
Incremental
discounted
cost vs.
strategy 1(1) (£)
ICER vs.
strategy 1(1)
(£/QALY)
INHB at
£20,000 per
QALY vs.
strategy 1(1)
1(1) 151,802 36,169,556 – – – –
1(2) 151,865 36,557,650 63 388,095 6142 43.8
2 151,958 37,203,902 157 1,034,346 6602 105.0
3 151,958 37,106,511 157 936,955 5977 109.9
4 151,978 37,180,712 176 1,011,156 5751 125.3
5 151,978 37,159,749 176 990,193 5630 126.4
6 151,978 37,210,568 176 1,041,012 5919 123.8
7 151,999 37,703,087 197 1,533,532 7781 120.4
8 152,004 38,150,737 202 1,981,181 9791 103.3
TABLE 116 Incremental cost-effectiveness ratios compared with no testing when the number of relatives and
proportion of relatives who are FDRs are altered
Parameter
name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1(1) 1(2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
Number of
relatives
5 0 – 907 9166 7659 6966 6725 7494 12,274 16,413
12 – 8432 5700 5329 5239 5153 5303 6325 7770
Proportion of
relatives who
are FDRs (%)
42 35 – 5514 6421 5814 5585 5470 5756 7583 9478
55 – 6784 6487 5863 5655 5528 5809 7635 9741
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Though an increase in the number of relatives generally appears to improve the cost-effectiveness, an
increase in the proportion of FDRs increases the ICERs (i.e. cost-effectiveness worsens). This occurs because
the proportion of relatives incorrectly assumed to have LS increases, leading to an increase in unnecessary
colonoscopies and prophylactic TAHBSO.
Univariate sensitivity analysis on colorectal cancer
To assess the parameters related to CRC we conduct univariate sensitivity analyses on parameters
related to CRC management and CRC prevention. The ICERs compared with no testing for each strategy
are presented in Table 117, except the results for changes in the effectiveness and adherence to LS
surveillance colonoscopies, which are presented below (see Tables 119 and 120). Where certain analyses
represented more than one parameter change, the disaggregation of those parameter groups are given in
Table 118, as referenced in Table 117.
Costs were altered using the disaggregated results of the base case, halving and then doubling the costs
where appropriate, but all other parameters related to CRC required further runs of the model. Owing to
time constraints, these runs were reduced from 32,000 to 4000 simulations, and therefore there is greater
uncertainty in them than in the base case. Despite the extra uncertainty, the results are still informative
regarding the impact of the parameters upon the model.
Costs associated with colorectal cancer
The general finding of univariate sensitivity analysis on the costs incurred in relation to CRC is that
increasing the cost of CRC treatment (diagnosis, surgery, follow-up, etc.) reduces the ICERs for all
strategies compared with no testing, thus improving the cost-effectiveness. This is to be expected as the
cost savings from preventing CRCs would be greater. In contrast, increasing the cost of CRC prevention
(colonoscopies and their complications) increases the ICERs of all strategies compared with no testing. In
no circumstance does halving or doubling the cost of prevention or treatment of CRC cause the ICER of
any strategy to increase above the £20,000-per-QALY threshold.
The two largest cost drivers appear to be the cost of colonoscopies and the cost of chemotherapy and
radiotherapy. This is unsurprising as the cost of chemotherapy and radiotherapy is the single largest
treatment cost for CRC, and the cost of colonoscopy, while not incurring a large unit cost, has a large
overall cost due to the total number of colonoscopies undertaken in each strategy.
Halving and doubling the cost of colonoscopy complications also demonstrates the effect of halving and
doubling the number of adverse events incurred during colonoscopy (except colonoscopy mortality).
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FIGURE 124 Impact of number of relatives tested per proband on the cost-effectiveness of strategy 5 vs.
strategy 1(1).
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This is because in the model the only effect of these adverse events is the costs associated with them;
there is no additional utility decrement.
Utilities associated with colorectal cancer
In the case of utility decrement associated with CRC stage, we examined a scenario of different plausible
values from the study by Ness and colleagues.200 Under these values, the utility of patients was worse in all
of the Dukes’ stages compared with the base case. As such, the cost-effectiveness of all strategies testing
for LS is improved, with all ICERs compared with no testing reducing compared with the base case, as
identifying patients with LS and preventing CRC, or diagnosing it at an earlier stage through colonoscopy,
has a greater benefit than in the base case.
In our base case, the disutility associated with CRC is at its most optimistic, being set at 0 for all types of
CRC surgery. In our sensitivity analysis we increase the disutility associated with the more aggressive forms
of surgery (subtotal colectomy IRA, rectal excision, proctocolectomy) to 0.1. As with the change in utility
associated with CRC stages, this improves the cost-effectiveness of all strategies compared with no testing,
compared with the base case. This disutility appears to have a greater impact upon cost-effectiveness than
an increase in the disutility of the stages of CRC, with the ICERs reducing by a greater amount compared
with the base case under CRC surgery disutility compared with stages disutility.
As both changes to utility increase the cost-effectiveness of the strategies, all strategies have an ICER
compared with no testing below the £20,000-per-QALY threshold.
TABLE 118 Breakdown of cost parameters for each group assessed in univariate sensitivity analysis
Cost parameter
group altered
Individual
parameter altered Base cost (£) Half (£) Double (£)
Cost of colonoscopy
complication
Cost of bleeding (mild) 318 159 637
Cost of bleeding
(moderate)
490 245 980
Cost of bleeding (severe) 1984 992 3967
Cost of perforation 5134 2567 10,269
Cost of mortality 5134 2567 10,269
Cost of CRC surgery Segmental resection GP, 6104 GP, 3052 GP, 12,209
LS, 6154 LS, 3077 LS, 12,308
Subtotal colectomy IRA GP and LS, 7331 GP and LS, 3666 GP and LS, 14,662
Rectal excision GP and LS, 7399 GP and LS, 3699 GP and LS, 14,797
Proctocolectomy GP and LS, 7441 GP and LS, 3720 GP and LS, 14,882
Cost of CRC chemotherapy
and radiotherapy
Dukes’ A Colon, 0 Colon, 0 Colon, 0
Rectal, 0 Rectal, 0 Rectal, 0
Dukes’ B Colon, 5755 Colon, 2878 Colon, 11,510
Rectal, 2848 Rectal, 1424 Rectal, 5696
Dukes’ C Colon, 13,133 Colon, 6567 Colon, 26,266
Rectal, 7628 Rectal, 3814 Rectal, 15,257
Dukes’ D Colon, 13,133 Colon, 6567 Colon, 26,266
Rectal, 7628 Rectal, 3814 Rectal, 15,257
GP, general population.
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Effectiveness of Lynch syndrome surveillance colonoscopies
The effectiveness of LS surveillance colonoscopies is potentially a very important parameter. We would
expect that improving the effectiveness of surveillance colonoscopies would improve the cost-effectiveness
of strategies in which individuals are offered surveillance.
To get the best estimate of the impact of the effectiveness of surveillance at preventing index CRC on
cost-effectiveness, we held the costs and QALYs for individuals not receiving surveillance and for all
probands (as they face no index CRC risk) constant across the sensitivity analyses using the results from the
base case (i.e. only the costs and QALYs for relatives receiving surveillance are simulated). We also used
32,000 simulated individuals for each patient group (the same number as in the base case).
We estimated the impact of the effectiveness of surveillance at preventing metachronous CRC by running
the whole model with 4000 patients simulated per group.
As expected, when the effectiveness of LS surveillance colonoscopies is increased, the cost-effectiveness of
testing increases (Table 119).
Adherence to Lynch syndrome surveillance to prevent colorectal cancer
Adherence is an important factor for both patients and clinicians. With regards to preventing CRC, we
examined both adherence to colonoscopies for patients and the possibility of clinicians conducting a more
aggressive colorectal surgery on CRC patients with LS (Table 120).
Changes in adherence to LS surveillance colonoscopy demonstrate that, for most strategies, a reduction in
adherence results in deterioration in cost-effectiveness compared with the base case, with increased ICERs
compared with no testing relative to the base case, and that an increase in adherence improves the
cost-effectiveness. This is a result of the benefit gained from the additional colonoscopies being greater
than the extra cost. Once again it is strategy 1(2) which appears to have a few anomalous results. In the
case of strategy 1(2), there is no difference in ICER compared with no testing for patients with confirmed
LS mutations (as it does not use genetic testing, there are none in this strategy). For relatives with assumed
LS, the cost-effectiveness of strategy 1(2) increases as the adherence to colonoscopies decreases. Though
this seems counter-intuitive, especially given both the results of the other strategies and the result of the
decreasing adherence for probands in strategy 1(2), this actually reflects reduction in benefit and higher
costs from the lower number of TP relatives identified by strategy 1(2) compared with the other strategies.
In short, the benefit of identifying some TP patients in strategy 1(2) is outweighed by the costs of not
identifying a larger number.
TABLE 119 Sensitivity analyses for effectiveness of LS surveillance colonoscopies
Parameter name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1(1) 1(2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
HR for colonoscopy
for preventing
index CRC
0.387 0.254 – 5644 5856 5272 5060 4948 5218 6959 8827
0.590 – 6514 7247 6602 6371 6246 6543 8462 10,540
HR for colonoscopy
for preventing
metachronous CRC
0.533 1 – 11,402 9830 8974 8687 8515 8898 11,407 14,443
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We also looked at the scenario where all patients identified as LS assumed or LS mutation positive are
offered and accept LS surveillance colonoscopies. In this instance the cost-effectiveness of all
strategies improves.
Colonoscopy mortality
Increasing the probability of mortality due to colonoscopy from 8.3 to 39.0 per 100,000 colonoscopies had
a very small impact on cost-effectiveness. The ICERs appear to increase slightly for all strategies versus no
testing, except for strategy 1(2). All ICERs compared with no testing remained < £10,000 per QALY.
Aggressive surgery for colorectal cancer patients diagnosed with Lynch syndrome
With regards to the use of aggressive CRC surgery for patients diagnosed with LS (mutation positive or
assumed), the values from different sources made it clear that this value could lie anywhere between 0%
and 100%. As such, we conduct our sensitivity analysis at 100%, as 0% was used as our base case. As
previously stated, a change in surgery is not accounted for in the case of the proband’s index cancer, as
we assume that a LS diagnosis will not be achieved until after a proband has been treated. One important
aspect of this to consider is that under our other base-case parameters, the disutility for all surgeries is 0,
regardless of the extent or functional consequences of surgery. As such, this is a best-case scenario for the
use of aggressive surgery.
Again the results for strategy 1(2) differed from the other strategies, owing to the weighting of FPs versus
TPs for that strategy. For all the strategies that used genetic testing, an improvement in cost-effectiveness
is demonstrated in lower ICERs compared with no testing than in the base case. This is a result of the
reduction in CRCs for true LS patients as a result of the more aggressive surgery (as well as a
slight reduction in CRCs in the incorrectly diagnosed members of the general population).
Colorectal cancer incidence and survival
The final area that we examined in our sensitivity analysis for CRC was surrounding parameters associated
with CRC incidence and survival.
Our results in Table 117 suggest that CRC incidence in LS patients is an important driver of the model.
When the incidence was increased, the ICERs of every strategy compared with no testing decreased
compared with the base case, implying that when the incidence of CRC is higher it is more beneficial
to identify patients with LS. This makes sense as more benefit will be gained from the colonoscopic
surveillance of patients with LS. When CRC incidence was reduced, the ICERs greatly increased
compared with the base case, with ICERs of all strategies > £10,000 per QALY gained and the ICER
of strategy 8 > £17,000.
In our base case, LS patients have an improved survival from CRC in Dukes’ A or B compared with general
population patients (with a HR of 0.57) and the same survival for Dukes’ C and D (HR of 1). In our
sensitivity analysis of CRC survival based on Dukes’ stage, we examine the case when LS patients have the
same survival for all Dukes’ stages as the general population (HR of 1 for all Dukes’ stages) and when LS
patients have improved survival for all Dukes’ stages compared with the general population (HR of 0.57 for
all Dukes’ stages). As expected, an improvement in survival increases the QALY gain for all LS patients,
regardless of strategy, with additional QALYs gained for each strategy compared with their base case [even
strategy 1(1)]. There was also a reduction in costs for each strategy compared with the base case. Overall,
the strategies that tested for LS had greater benefits compared with the base case than strategy 1(1),
resulting in lower ICERs compared with strategy 1(1) than in the base case. Conversely, setting the survival
of LS patients to be the same as that of the general population resulted in higher ICERs compared with no
testing than in the base case, as the additional benefit of testing for LS (that LS-related CRCs caught earlier
would have an increased survival over general population patients in the earlier Dukes’ stages of CRC in
the base case) was no longer apparent. However, in both sensitivity analyses all the strategies’ ICERs
compared with no testing remained < £11,000 per QALY gained.
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Univariate sensitivity analysis on endometrial cancer
As with the parameters influencing CRC, we also conducted univariate sensitivity analyses on the
parameters related to both EC treatment and EC prevention. The ICERs compared with no testing for each
strategy are presented in Table 121. Changes to EC parameters once again only influence long-term
outcomes, with diagnostic results the same as those of the base case.
As with the CRC sensitivity analyses, costs related to the prevention and treatment of EC were again
altered using the disaggregated results of the base case, halving and then doubling the costs where
appropriate. All other parameters related to CRC required further runs of the model of 4000 simulations,
once again resulting in greater uncertainty in them than in the base case, but demonstrating with enough
certainty the general pattern of the results.
Costs associated with endometrial cancer
As with the CRC sensitivity analyses, decreasing the cost of EC prevention (prophylactic TAHBSO) resulted
in lower ICERs compared with no testing than in the base case, and increasing the cost of prophylactic
TAHBSO resulted in higher ICERs compared with no testing than in the base case. However, despite the
implications of scenario analysis 1, where EC was not included in the analysis, increasing the cost of
prophylactic surgery does not greatly reduce the cost-effectiveness of the strategies, with all of the ICERs
remaining < £12,000 per QALY gained. It does, however, have a larger impact on the ICERs than any
other single cost parameter related to EC.
Increasing the cost of EC treatment (TAHBSO, radiotherapy or chemotherapy) improves the
cost-effectiveness of all the testing strategies compared with the base case; the ICERs compared with no
testing are lower than in the base case. Conversely, decreasing the cost of EC treatment reduces the
cost-effectiveness of all strategies.
Strategy 5 has the lowest ICER compared with no testing for nearly all EC cost univariate sensitivity
analyses, the exception being when the cost of prophylactic TAHBSO is halved.
Utilities associated with endometrial cancer
In the base case there are few disutilities associated with EC. A few relate to psychological disutility
associated with being offered a prophylactic TAHBSO, but these are discussed separately in Psychological
disutility. The two utility decrements which we evaluate in this section are the impact of a utility decrement
associated with undergoing a TAHBSO (either prophylactically or for EC) and a utility decrement associated
with having EC. In the sensitivity analyses we consider adjusting these to 0.1.
As Table 121 demonstrates, the addition of a utility decrement for EC improves the cost-effectiveness of
strategies that test for LS, with their ICERs compared with no testing reducing from the base case. In this
instance, strategy 1(2) had the lowest ICER compared with no testing of £5404 per QALY gained, though
several other strategies had very similar ICERs, particularly strategy 5, which had an ICER compared with
no testing of £5545 per QALY gained. Strategy 5 had the highest INHB at a threshold of £20,000
compared with no testing.
The single parameter change with the greatest impact upon the cost-effectiveness of testing for LS is the
disutility associated with undergoing a TAHBSO, which applies to individuals opting for prophylactic
TAHBSO and to EC patients. In our base case this is assumed to be 0, for reasons discussed in Chapter 5,
Impact of prophylactic total abdominal hysterectomy with bilateral salpingo-oophorectomy on quality of
life, and when it was increased to 0.1 in our sensitivity analysis (chosen arbitrarily), this resulted in all
strategies of testing for LS being dominated by no testing, such that they were both more expensive
(as in the base case) and had fewer QALYs than strategy 1(1). As Figure 125 shows, some strategies did
maintain an incremental QALY gain in the long term compared with strategy 1(1), but when this occurred
it was outweighed by the psychological disutility accrued from diagnosing LS. As such, there was no
overall incremental QALY gain in any of the strategies. This is a significant change to the outcome of the
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model, which is not achieved by any other change in parameter value. Given the significant impact of this
change, when both EC and TAHBSO disutility are included in the model, the strategies remain dominated
by no testing.
Adherence to Lynch syndrome management to prevent endometrial cancer
Unlike the utility values for prophylactic TAHBSO, the adherence to this prophylactic surgery does not have
such a significant impact on the results. It does, however, have an impact on those strategies which
identify fewer patients as LS positive, with strategy 1(2) having a greater change in ICER compared with no
testing from the base case than any other strategy, particularly when the adherence rate increases to 90%.
In general, the ICERs increase with an increase in adherence to prophylactic TAHBSOs, reflecting the
additional cost, which is not offset by a particularly significant increase in QALYs.
Psychological disutility
Changing the parameters for the psychological disutility of being tested for LS does not have an impact on
the cost of each strategy, though there is some variation from the base case due to having a different set
of fewer simulations. The impact of changes to psychological disutility is seen in the change in QALYs
gained by each of the LS testing strategies (Table 122). By removing any psychological disutility, we see
that the ICERs compared with no testing reduce for all strategies compared with the base case, owing to
the reduction of any QALY loss gained from testing for LS, both in the short term with regards to diagnosis
and in the long term with regards to being offered a TAHBSO. By doubling the disutility from the base
case, we find that the ICERs compared with no testing increase, in accordance with the additional QALY
loss accrued in the testing strategies.
In our base case the time for which the psychological disutilities apply is 4 months. When this is increased
to 1 year, the ICERs compared with no testing increase from the base case, particularly in the case of
strategy 8, owing to the larger proportion of probands offered genetic testing.
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FIGURE 125 Incremental discounted QALYs vs. strategy 1(1) when disutility of prophylactic TAHBSO is set to 0.1.
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TABLE 122 Incremental cost-effectiveness ratios vs. no testing for sensitivity analysis of psychological disutility
Parameter
name
Base
parameter
Sensitivity
analysis
parameter
ICER of each strategy vs. strategy 1(1) (£/QALY)
1(1) 1(2) 2 3 4 5 6 7 8
Base case – – – 6021 6444 5831 5610 5491 5774 7601 9571
Psychological
disutility
GT declined,
0.04
Testing LS
positive,
0.02
Being
offered
TAHBSO:
proband,
0.01;
relative, 0.04
Declining
TAHBSO:
proband,
0.06;
relative, 0.03
0 – 4562 4899 4432 4256 4168 4387 5792 7214
Double – 6045 6749 6113 5889 5765 6056 7941 10,068
Length of
psychological
disutility
4 months 1 year – 13,109 9676 8660 8397 8172 8590 11,433 16,181
GT, genetic testing.
ASSESSMENT OF COST-EFFECTIVENESS: RESULTS OF THE COST-EFFECTIVENESS MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
274
Chapter 7 Discussion
Aim
The question addressed by this project is ‘what is the diagnostic utility and cost-effectiveness of genetic
testing for HNPCC in all newly diagnosed persons with CRC under 50 years of age, and of strategies to
test their close relatives?’.
This question was addressed by a systematic review of clinical effectiveness and cost-effectiveness studies,
and by a de novo economic analysis.
Main findings
Clinical effectiveness
Ten published papers were included in the review, one on MSI only, three on MSI and IHC, four on IHC
and one TA commissioned by the US Department of Health and Human Services. The TA, which this
review continues from, found minimal published information on the analytical validity of laboratory testing
for LS, along with some concern regarding variability between testing facilities. Genomic rearrangements
and large deletions were missed when only sequencing and gene screening was performed. Very few
studies focused on unselected patients with CRC and many had small sample sizes. Results ranged from
18% to 100% for sensitivity and 25% to 100% for specificity. CIs were very wide.
The majority of studies included in this review were single gate, where only one sample of individuals was
assessed by the index test and reference standard. Two studies (which appear to be using the same
population) were two gate, recruiting a group of patients with known mutation status and a control group
with no known mutation status. All studies were assessed for quality against the QUADAS-2 tool and
many were found to be at risk of bias as, owing to cost, the reference standard was only performed on
patients with a likely mutation or MSI. Other concerns were small sample size and minimal details on
robustness of testing. Some studies recruited from preselected patients (e.g. from registries), whereas
others recruited from the general population. This means that a population including patients with
sporadic CRC may recruit a higher proportion of patients with methylation of MLH1 (meMLH1). This has
consequences for both IHC and MSI testing which will identify meMLH1 as MSI, whereas constitutional
genetic testing would identify the sample as negative, thereby leading to FP results.
Owing to the range of study designs – for example a wide range and number of markers of MSI, and
targeting different proteins for IHC – pooling of data was not possible. As such, a summary of individual
results is displayed in Table 123. The sensitivities and specificities for IHC are wide ranging (from 73.3% to
100% and 12.5% to 100%, respectively), although not all studies searched for all proteins and some of
the results were combined. Clearly, specificity is the greatest concern, as a high number of FPs means that
individuals may be told they have LS when they do not. Furthermore, those studies recruiting from a
population that had no prior testing may include an increased number of FPs due to MLH1 methylation
found in sporadic CRC. The sensitivity for MSI ranged from 88% to 100%, and specificity ranged
from 68% to 84%. However, no two studies included in this review have used the same panel of markers,
and therefore a comparison is difficult and results vary. As with IHC, not all patients received the
reference standard.
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
275
Cost-effectiveness model
The results of the cost-effectiveness model are summarised in the scientific summary and in Chapter 6,
Summary of Peninsula Technology Assessment Group cost-effectiveness results. Here, we present a section
of the results in this summary.
Testing strategies
When testing for LS in probands, specificity is consistently higher than sensitivity across the strategies; all
strategies that identify some patients as LS positive have a specificity of ≥ 98%, whereas sensitivity ranges
from 39% to 78%. The specificities of all genetic testing strategies are similar and all > 99.8%. Strategy 8
(universal genetic testing) has the highest sensitivity (77.9%). In general, additional tests for a cohort
TABLE 123 Summary of test accuracy results
IHC
First
author Patients (n) Reference standard Protein
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Barrow
201042
68 Germline testing performed
before recruitment
MLH1 100 (84 to 100) 91.5 (79.6 to 97.6)
PMS2 95.2 (76.2 to 99.9) 91.5 (79.6 to 97.6)
MSH2 87.5 (61.7 to 98.4) 88.5 (76.5 to 95.6)
MSH6 81.3 (54.4 to 96.0) 80.8 (67.5 to 90.4)
Barrow
201120
42 Germline testing performed
before recruitment
MLH1 89.5 (66.9 to 98.7) 78.3 (56.3 to 92.5)
MSH2 86.7 (59.5 to 98.3) 77.8 (57.7 to 91.4)
Becouarn
200543
197 Direct sequencing with
search for large mutations
if point mutation not
identified
MLH1, MSH2 73.3 (44.9 to 92.2) 28.6 (3.7 to 71.0)
Limburg
201144
195 Direct sequencing with
Southern blot and MLPA
MLH1,
MSH2, MSH6
85.7 (42.1 to 99.6) 91.9 (86.3 to 95.7)
Niessen
200621
281 Direct sequencing
and MLPA
MLH1 80 (38 to 96) 89 (84 to 93)
MSH2 100 (57 to 100) 96 (92 to 98)
MSH6 86 (46 to 97) 93 (88 to 96)
Shia
200511
110 Direct sequencing and
large deletion analysis
MLH1,
MSH2, MSH6
80.8 (60.6 to 93.4) 89.5 (75.2 to 97.1)
Southey
200539
131 Direct sequencing
and MLPA
MLH1,
MSH2, MSH6
100 (82 to 100) 91 (83 to 96)
Stomorken
200545
250 Direct sequencing and
large rearrangement
analysis
MLH1,
MSH2, MSH6
100 (75.3 to 100) 12.5 (0.3 to 52.7)
MSI testing
First
author Patients (n) Reference standard
Panel
of markers
Sensitivity, %
(95% CI, %)
Specificity, %
(95% CI, %)
Niessen
200621
281 Direct sequencing
and MLPA
Five markers 88.0 (68.8 to 97.5) 68.1 (61.7 to 74.0)
Shia
200511
110 Direct sequencing and
large deletion analysis
Seven markers 100 (85.8 to 100) 84.0 (68.0 to 93.8)
Southey
200539
131 Direct sequencing
and MLPA
10 markers 94 (73 to 100) 80 (71 to 88)
Wolf
200646
55 Sequence analysis Five markers 100 (71.7 to 100) 78.6 (62.8 to 89.2)
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
276
whose previous test result was indicative of LS increases specificity, as each additional test can only reduce
the number of FPs. One side effect of this is that it is also likely to reduce the sensitivity; if the tests have
< 100% sensitivity then the number of FNs also increases (and the number of TPs decreases) with each
additional test. This explains why, in most strategies, the sensitivity of the strategy is lower than the
sensitivity of the first test in the sequence, even in strategy 8, where all probands are offered genetic
testing, as it includes at least two tests for gene testing plus guidance from the probands’ FH.
For probands, the strategies always identify less than the true proportion of LS-positive probands, but most
strategies identify more relatives as LS positive than there actually are. The main driver appears to be the
proportion of relatives assumed to have LS, with the majority of these incorrectly assumed to have LS.
The data on test accuracy are limited. It is accepted that gene testing does not have 100% sensitivity or
100% specificity, but often these are used as the ‘gold standard’ for assessing other tests, though some
studies use a much broader view including mutation positive and FH indicative of LS as their ‘gold
standard’. There is also little evidence regarding the distribution of identified mutations in the FPs from
tumour tests such as IHC. By rarely using IHC to identify the testing sequence of genes, this problem is
mostly eliminated, though a similar problem then occurs for the distribution of FPs post gene testing.
Little is currently known about the effect of running tests sequentially on the sensitivity and specificity of
each component test, particularly tumour-based testing. Only BRAF is currently modelled with values given
explicitly after MSI or IHC with MLH1 abnormal. It is unclear whether or not the values for sensitivity and
specificity of genetic testing in the literature relate to an enriched group of patients. However, given that it
is unlikely that genetic testing in probands would be run on an unselected cohort, the assumed sensitivity
and specificity of genetic testing in strategy 8 may not be entirely accurate.
The cost of tests varies substantially across the various genetics centres. Therefore, we varied these
parameters widely in our sensitivity analyses.
Evidence for the rates of acceptance of diagnostic tests and genetic counselling is quite varied, though the
results from our sensitivity analyses indicate that, even at low rates, LS testing is cost-effective compared
with no testing.
Similarly, despite varying the number of relatives per proband widely, all strategies remain cost-effective
compared with no testing at a willingness to pay of £20,000 per QALY. This holds even when assuming
no relatives, although the net health benefit is greatly reduced.
Clinical outcomes
Life expectancy for probands is similar across the strategies, with females having a higher life expectancy
than males. The same is true for relatives, though they have a much higher life expectancy.
Life expectancy is heavily influenced by LS diagnosis and true LS status. Patients who are diagnosed FN or
TP with no surveillance have the lowest life expectancy. TP probands who undergo surveillance have the
highest life expectancy, as surveillance reduces CRC risk (and CRC is caught at an earlier stage). They also
have a higher life expectancy than FP probands with surveillance because, in general, mortality rates for
the type of CRC specific to people with LS is lower. Relatives who are TN, FP, FP with surveillance and TP
with surveillance have very similar high life expectancies. Relatives who undergo surveillance but are FP
have a slightly higher life expectancy than TN and FP relatives, as there is some additional benefit from the
colonoscopic surveillance. For male relatives, those who are TP with surveillance have the highest life
expectancy. For female relatives, for whom CRC risk is lower in general and the benefit from diagnosis is
split between CRC and EC prevention, those who are TP with surveillance have a lower life expectancy
than the TN, FP and FP-with-surveillance female relatives. These results suggest that strategies with lower
numbers of FN patients will have higher life expectancies overall, which does appear to occur.
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When no testing for LS occurs, there are more colonoscopies per relative with LS than per relative without
LS, but the number of colonoscopies per proband with LS is lower than for those without LS. The total
number of colonoscopies depends on the correct diagnosis of a patient and compliance with surveillance.
Strategies that reduce the number of FNs and increase the number of FPs result in more colonoscopies
for patients both with and without LS. This is more noticeable in the relatives, as the probands receive
follow-up surveillance colonoscopy even if they are diagnosed LS negative.
For male relatives and probands, the proportion developing CRC is significantly higher than their female
counterparts, and a higher proportion of relatives develop CRC compared with probands. The expected
number of CRCs for the entire cohort of 1699 probands and 8495 relatives reduces as more patients are
identified as LS positive by the strategies, with the strategy that offers universal genetic testing (strategy 8)
having the lowest number of CRCs, in both the relative and proband populations. This is explained by the
impact of colonoscopy surveillance as a preventative measure for CRC.
The lifetime probability of developing CRC for probands (< 2%, where the CRC must be metachronous)
and relatives (< 6% develop at least one CRC, depending upon the strategy) without LS remains roughly
constant across all strategies. The lifetime probability of developing CRC for patients with LS is unfailingly
higher than for those without LS (24–30% of relatives develop index CRC; 35–40% of probands develop
metachronous CRC).
The lifetime risk of EC decreases as more LS-positive relatives and probands are identified by a strategy.
The expected number of ECs per year in England in the no testing strategy is approximately 54, with 46
for female relatives and 8 for female probands. This reduces to a minimum of 35 in strategy 8, with 30 for
female relatives and 5 for probands. This demonstrates that strategies that identify higher numbers of
patients as LS positive, and hence result in more prophylactic TAHBSOs, reduce the numbers of ECs.
Aside from correct diagnosis, compliance with preventative measures appears to have a strong influence
on clinical outcomes. Even in the base case, where compliance remains the same, the strategies with
higher numbers of surveillance colonoscopies appear to have benefits such as few CRCs and a higher life
expectancy, because more patients are identified by genetic testing rather than by assumption.
Health-related quality of life following TAHBSO strongly affects total QALYs by testing strategy. In a
sensitivity analysis where a disutility of 0.1 is assumed, all strategies result in lower total QALYs than under
no testing.
The incidence of CRC for people with LS and the effectiveness of surveillance colonoscopies in preventing
metachronous CRCs also strongly affect total QALYs.
Cost-effectiveness
The total diagnostic cost for the cohort demonstrates that the majority of the costs come from the cost of
diagnosing the probands, rather than the follow-up diagnostic costs for relatives. This is because the
majority of probands will not be diagnosed with LS and therefore the majority of relatives will not undergo
any form of testing. The costs are generally driven in each strategy by the tests undertaken by the highest
numbers of probands.
Diagnostic costs are small compared with long-term costs, but do influence the difference in costs
between strategies. In the long term, strategies 1(2) and 8 have the highest costs, presumably because
strategy 8 has a higher cost of colonoscopies and strategy 1(2) has higher CRC treatment costs.
Long-term costs are lowest for TN and FP-with-no-surveillance patients, as these subgroups do not incur
the cost of surveillance and have general population risk of CRC. For female patients there is a slight
increase in costs for FP with no surveillance over TN, as FP-with-no-surveillance patients are still offered
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prophylactic TAHBSO. FN and TP-with-no-surveillance patients have the highest costs due to the increased
risk of CRC without any measures to improve survival.
In general, across testing strategies, as total QALYs increase, so do total costs. This is expected as the
preventative measures used in the strategies increase both costs and QALYs. Discounted QALYs per year in
England accrued by both probands and relatives increase from 151,793 when no testing is performed to
152,000 in strategy 8. The total lifetime cost of no testing for the entire cohort is £36,223,787, increasing
to £38,198,324 in strategy 8.
The most influential costs in the long-term results are the preventative measures: colonoscopies and
prophylactic TAHBSO. Some of these costs are offset by savings in CRC and EC treatment compared with
the no testing strategy. In general, those strategies which identify a higher number of patients (probands
and relatives) as LS mutation positive or LS assumed have higher CRC and EC preventative costs, as well as
increased cost savings from CRC and EC treatment, although the preventative costs always outweigh the
savings in treatment. When univariate sensitivity analysis is conducted, the cost of colonoscopies is
particularly influential in terms of ICERs, reducing some by nearly half when the cost is halved and
increasing them to nearly double when the costs are doubled.
In all strategies that test for LS, there is an increase in QALYs, and those strategies that have a higher
sensitivity have the most QALYs. One impact this demonstrates is that the number of FPs is less important
to the QALYs than FNs. Long-term outcomes resulting from diagnosis have a much larger impact on the
overall QALY gain than the immediate QALY decrement associated with diagnosis.
All strategies compared with no testing have an ICER < £10,000 per QALY gained. The strategy with the
lowest ICER compared with no testing [strategy 1(1)] is strategy 5, with an ICER of £5491 per QALY
gained. When comparing the strategies with each other in order of most effective, strategy 5 again is
the most cost-effective and the ICER remains at £5491 per QALY. Strategy 5 has the largest NHB at the
£20,000 threshold, though all strategies that include some form of diagnostic testing have an increase in
NHB. The cost-effectiveness results directly reflect the importance of diagnosis in the short term and the
long-term cost and benefits that are applied as a result of that diagnosis.
One of the surprising results from the sensitivity analyses is the effect of adding a disutility following
TAHBSO. When this disutility was increased to 0.1, strategy 1(1) (no testing) was found to be the cheapest
and most effective strategy. As the number of prophylactic TAHBSOs includes those performed in patients
who did not need them (patients who tested FP for LS and who accepted prophylactic TAHBSO), and does
not eliminate the need for TAHBSOs as treatment for EC (patients who tested FN for LS and those who
tested positive but declined prophylactic TAHBSO, who go on to develop EC), it is not unreasonable that
there may be an overall QALY loss when comparing these specific groups (without accounting for the
effect of LS surveillance colonoscopies). However, the disutility is large enough to negate both the benefit
of EC reduction and the benefit from LS surveillance colonoscopies across the entire cohort. The disutility
for TAHBSO was not included in the base case for reasons discussed, partly because the quality of the
supporting data is poor. Furthermore, we do not account for all benefits of prophylactic TAHBSO, such as
preventing OC. It is interesting to note that the cost-effectiveness of the testing strategies is heavily
dependent on the cost-effectiveness of the subsequent medical management of CRC and EC. Indeed, this
effect has been noted in a previous model of CRC treatment by Pilgrim and colleagues (2009).251
Strengths and limitations of the systematic review of
test accuracy
The strengths of this systematic review are that it was conducted by an independent research team
using the latest evidence, to a pre-specified protocol. The search strategy did not restrict by study design
and also included forward chasing. The studies were independently screened by two reviewers,
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with data extraction and quality appraisal performed by one reviewer and checked by a second. Any
disagreements were resolved by consensus.
One limitation was the inability to compare or pool data due to variations in study design, for example
different selections of biomarkers or genes under observation. A second significant concern was the lack of
reference standard testing on individuals considered to be MSS. The reason for this given by many authors
was cost. The recruited population was often small, with unclear patient flow. Overall, all studies were
deemed to be at risk of bias, according to QUADAS-2.
Strengths and limitations of the systematic review of
cost-effectiveness
Again, the strengths of this systematic review are that it was conducted by an independent research team
using the latest evidence, to a pre-specified protocol. Abstracts were independently screened by four
reviewers and full papers were independently screened by two reviewers, with data extraction and quality
appraisal performed by two reviewers. Any disagreements were resolved by consensus.
The review was highly inclusive. This allowed for a wide selection of literature and a comprehensive
evidence base, and made us confident about the approach taken in our modelling. By including previous
cost-effectiveness reviews conducted in this area, we were confident that the right papers were being
identified by our review. The volume of cost-effectiveness evidence currently available did suggest that
much of the work in this area had been done before, but the evidence was not always consistent or
directly relevant to our study, and so our review indicated that a de novo model would be beneficial to our
specific set of circumstances.
Strengths and limitations of the Peninsula Technology
Assessment Group economic model
Strengths
l Our work was not sponsored by any manufacturers of tests for LS.
l Our economic analysis is the first specifically concerning the UK NHS.
l Our analysis considers both strategies to identify LS and the long-term consequences of diagnoses.
l Our model adheres to methodology recommended in the NICE reference case and has been checked
extensively. In addition to our four basic scenario analyses, we also present numerous one-way
deterministic sensitivity analyses, which we have chosen for plausibility, to reflect key areas of
uncertainty and for those parameters that substantially affect cost-effectiveness.
l The parameter values and structure of our model have been chosen in light of a detailed review of the
literature of the cost-effectiveness of testing for LS.
l Our model uses individual patient simulation, which enables more sophisticated analysis, such as the
modelling of competing risks of mortality from CRC and EC.
l Our analysis includes health state utilities. Only 4 of the 32 published cost-effectiveness analyses for LS
have explicitly done this. Furthermore, two of these only looked at long-term management options for
patients already diagnosed with LS who were asymptomatic. We also model disutilities due to the
psychological impacts of genetic testing.
l Our analysis includes EC as a long-term outcome. Only 5 of the 32 published cost-effectiveness
analyses for LS have done this. Again, two considered long-term management options for patients
already diagnosed with LS who were asymptomatic. Furthermore, one of the studies was an update of
an earlier study.
l Several experts in LS have informed the development of our model.
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Limitations
It is important to understand that the cost-effectiveness model relies on a considerable number of
structural and parametric assumptions, which have been sourced from expert clinical advice and from
evidence in the literature. As with any mathematical model which attempts to synthesise a large yet
incomplete evidence base, the results of the analysis are subject to considerable uncertainty.
l We did not model OC and other cancers associated with LS. However, as stated in Chapter 5,
Gynaecological cancers, if these cancers were included it is highly likely that the cost-effectiveness of
testing for LS would improve.
l The following parameters are uncertain and strongly influence cost-effectiveness:
¢ the effectiveness of LS colonoscopies in preventing metachronous CRC
¢ the impact of TAHBSO on HRQoL
¢ the psychological impact of LS testing on HRQoL.
l The model does not include chemoprevention (aspirin for CRC and other LS-associated cancers, oral
contraceptive pill for gynaecological cancers).
l We have not produced a probabilistic sensitivity analysis. Although we believe this approach to be
appropriate and have chosen to explore the many structural assumptions as thoroughly as possible
using deterministic sensitivity analysis, the absence of probabilistic sensitivity analyses might be viewed
as a limitation.
l We have not modelled the specific genes which are mutated. It is suggested in some guidelines
(but is not yet recommended by InSiGHT) that colonoscopic surveillance should begin later for carriers
of MSH6 and PMS2 mutations than for carriers of MLH1/MSH2 mutations.
l Compliance with colonoscopy is more complex than the initial acceptance or non-compliance
modelled. Some patients may leave excess time between colonoscopies or before starting them.
Currently, however, the evidence for how common this behaviour is, and for the impact of larger
delays between colonoscopies on the effectiveness of surveillance, is not available. In a Finnish study,
a large proportion of people initially declining surveillance subsequently entered the surveillance
programme.94 In this programme, long-term compliance was also good. Data were not available for the
UK relating to these behaviours.
l The psychological impact of genetic testing is poorly understood and utilities in the model are drawn
from a single study which has methodological flaws.
l We do not account for increasing morbidity and mortality from adverse events in colonoscopy with
age. The age limit of 75 years in the model reflects a consensus as to when the benefits of
colonoscopy are outweighed by the associated complications. Increasing morbidity and mortality could
be important, as our model assumes that all relatives and probands receive the same benefits from
colonoscopy, regardless of age. If we account for the increasing morbidity and mortality, the
cost-effectiveness of colonoscopies (and therefore the cost-effectiveness of diagnosing LS) may
decrease. However, given that in a sensitivity analysis where the rate of mortality following colonoscopy
was increased from 8.3 to 39 per 100,000 the cost-effectiveness of testing strategies was only
marginally worsened, it is likely that cost-effectiveness would not be affected greatly by such a
structural change. It might be reasonable to assume that clinicians would accurately balance risks and
benefits for patients such that 75 years is an average age of stopping colonoscopies rather than a fixed
age, and that morbidity and mortality are not allowed to rise significantly.
l The added benefits of certain tests are not accounted for. The probable use of IHC to understand results
from genetic testing, though discussed, is not modelled owing to a lack of evidence surrounding the
impact this has on the sensitivity of gene tests. Additionally, the benefit of MSI testing to determine the
chemotherapy regime of a patient is not accounted for.
l The proportion of de novo mutations is not well documented. Attempts to represent these in our
model may not reflect the true proportion.
l Individuals who decline genetic counselling or genetic testing may still choose to receive surveillance
colonoscopies; it is not clear to what extent these patients can give informed consent to this
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surveillance, as without genetic counselling and genetic testing it is difficult to assess the potential
benefits of surveillance. In the case where individuals decline genetic counselling it is not clear who
should obtain informed consent for surveillance, and even if individuals receive genetic counselling,
there is no set practice for obtaining informed consent when genetic testing is declined.
l It is assumed that informed consent is taken for tumour testing for LS and that this does not incur any
cost or have any psychological impact on HRQoL. The validity of these assumptions has not been
explored for tumour testing as it has been for constituent genetic testing.
l Relatives are assumed not to be screened for LS until age 18 years, but prenatal predictive screening is
already offered for LS. DNA collection methods could risk miscarriage, and the presence of mutations
may lead to abortions with an accompanying psychological impact which has not been explored in
our model.
l Limited UK data were identified regarding the feasibility of identifying relatives and cascading testing,
which led to uncertainty in the number of relatives that would be identified.
l Risks of CRC and other cancers in the absence of surveillance are not estimated with much precision
because it would be unethical to deny surveillance to individuals once they are diagnosed with LS.
Statistical methods to adjust for this have low power, although it may be possible to conduct a
meta-analysis of different studies using appropriate techniques to obtain more precise estimates. The
risks of CRC and other cancers in the presence of surveillance have not been evaluated in a UK setting.
l We understand that some clinicians would like to investigate the possibility of delaying initial surgical
management of CRC until LS status is known. This is not modelled. Although it may be practical to
delay surgical management for counselling and predictive genetic testing, i.e. for relatives of known
carriers (which can be conducted quickly), our clinical experts have advised that identifying LS in
probands can be a lengthy process.
l There is no high-quality evidence that including a risk-reducing component in surgery for known
carriers results in a clinical benefit when any HRQoL disutility is included.
l In our model, positive diagnostic genetic test results are assumed to be mutations with known or
clearly predicted pathogenicity, whereas negative results include results where no mutations are
identified and where variants of unknown significance are identified. Although there is a project
under way at present attempting to classify variants of unknown significance as pathogenic or
non-pathogenic,272 it is possible that variants of unknown significance would result in increased costs
as further tests are required which are not necessarily included in the cost of diagnostic testing in
the model.
l No psychological disutility is included for variants of unknown significance, as these are neither
explicitly modelled nor investigated in the trial from which psychological disutilities are drawn.
l The estimates of CRC incidence for individuals with LS are drawn from a study [Bonadona and
colleagues (2011)2] with a different distribution of gene mutations to the proportion assumed in the
diagnostic model [based on Palomaki and colleagues (2009)65], with the main difference being that
15% of mutations are in the PMS2 gene in the diagnostic model compared with 0% in Bonadona and
colleagues (2011).
l Mutations in other genes lead to familial early-onset CRC [POLE, POLD1; mutations in APC lead to FAP;
in MUTYH, MUTYH-associated polyposis; in STK11-LKB1, Peutz-Jeghers syndrome; in SMAD4 and
BMPR1A (and, rarely, GREM1 and SGNE1), juvenile polyposis].9 As a result, an indicative FH would
lead to further investigations in the event of no MMR mutation being found in a proband; such
investigations are not included in the model.
l Constitutional epimutations may not be detected by current methods,273,274 and though at present they
would be included in the model as negative diagnostic test results (with LS possibly being assumed
on the basis of FH), it is possible that in the future further testing may be recommended for such
mutations which could incur extra costs and affect cost-effectiveness. However, a doubling of the cost
of diagnostic genetic testing did not have a significant impact on cost-effectiveness, except for strategy 8
(universal genetic testing).
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Adaptation of the Peninsula Technology Assessment Group
economic model to other countries
Our economic model is written specifically for the UK NHS. However, we believe that it can be adapted
reasonably easily for use in other countries because we believe that the great majority of the structure of
the model applies to other countries. Examples of parameters that would change include:
l all unit costs, for example costs of genetic tests and colonoscopies
l discount rates for costs and benefits
l numbers of relatives per proband
l LS surveillance regimes
l incidences of CRC and EC
l mortality due to CRC and EC
l policy of offering prophylactic TAHBSO
l treatments for CRC and EC.
Examples of parameters that would probably either remain unchanged or change only slightly include:
l all utilities
l all test accuracies
l proband and relative age distributions.
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Chapter 8 Conclusions
Implications for service provision
In addition to cost impacts there would be other implications for service provision as a result of
implementing reflex testing for LS in CRC patients aged < 50 years.
Impact on colonoscopy services
Based on a cohort of 1599 CRC patients aged < 50 years per year (the 2010 figure for England), were
strategy 5 to be adopted (the strategy with the highest NHB) there would be approximately 3400 extra
colonoscopies performed over the lifetime of each annual cohort.
Further analysis of the model would be needed to estimate the growth in numbers of colonoscopies as
successive cohorts are identified.
Suggested research priorities
One of the attractions of modelling is that it serves to highlight those areas where further research would
be of value for future clinical and policy decision-making.
In theory, a formal value-of-information analysis could be performed to quantify the value of research into
various components of our cost-effectiveness model. However, this would require quantification of the
uncertainty in most of the parameters in this model, which we believe would be time poorly spent.
Instead, sensitivity analyses suggest that the following quantities would be worthy of further research.
The items are ranked in approximate order of priority.
Incorporate ovarian cancer into the cost-effectiveness model
Ovarian cancer is estimated to affect approximately 9% of women with LS by age 70 years in the absence
of preventative action.2 Prophylactic hysterectomy and bilateral salpingo-oophorectomy effectively removes
the risk of OC.146 Prophylactic hysterectomy and bilateral salpingo-oophorectomy is already incorporated
into the cost-effectiveness model for prevention of EC, and hence the costs and surgical mortality risks of
this procedure are already included; however, the clinical benefits with respect to OC are not included
as OC is not modelled. It is expected that the inclusion of OC would result in an improvement in
cost-effectiveness, but the scale of the impact is unknown. A rough estimate for strategy 5, based on a
lifetime cost of £25,000,254,275 5-year survival of 44%147 and an assumed 15-year life expectancy from
average age of OC, would suggest that 134 women would receive prophylactic surgery, of whom
approximately 12 (9%) would have developed OC. This results in undiscounted cost savings of £300,000.
Furthermore, we assume that 5.3 (44%) go on to live for 10 years (15 years minus 5 years of survival) at
utility 0.75, adding approximately 40 QALYs. The resulting total undiscounted costs are now £55.1M
(down from £55.4M, vs. £54.3M for no testing) and the total undiscounted QALYs are now 276,195 (up
from 276,155, vs. 275,654 for no testing). The estimated ICER versus no testing (based on undiscounted
costs and QALYs) is then only £1500 per QALY, down from £2100 per QALY.
Incorporate aspirin for colorectal cancer chemoprevention into the
cost-effectiveness model
There is evidence to suggest that aspirin reduces the risk of CRC for individuals with LS.17 Further research
is being conducted in this area to determine clinically optimum dosage. Incorporation of chemoprevention
into the cost-effectiveness model would also allow estimation of the most health-economically efficient
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dosage and allow estimation of the impact on cost-effectiveness of reflex testing for LS when
chemoprevention forms part of the potential management strategy.
It may be the case that acceptance of and adherence to aspirin medication is better than acceptance of
and adherence to surveillance colonoscopy.
Model the cost-effectiveness of reflex testing for Lynch syndrome in
alternative populations
It has been suggested by our clinical experts and in the literature [e.g. Kwon and colleagues (2011)56]
that it may be cost-effective to perform reflex testing for LS in alternative populations, particularly in the
incident EC population. An argument is made that identifying LS in women with newly diagnosed EC will
benefit them more than such diagnosis in individuals with newly diagnosed CRC as there is greater scope
for prevention of CRC (with 5-year survival of 54%), and that more probands will benefit as 5-year survival
from EC is high at 77%.
Testing in alternative populations was outside the scope of this project but could result in cost-effective
identification of additional LS families. Research is needed to identify the prevalence of LS in such
populations, the diagnostic test accuracy of strategies to identify LS in such populations and the
cost-effectiveness of such strategies.
Research into the natural history and impact on health-related quality of life
of colorectal cancer
We agree with Pilgrim and colleagues (2009)251 that research into the natural history of CRC and disutilities
for patients with CRC would be useful.
Impact of hysterectomy and bilateral salpingo-oophorectomy on
health-related quality of life
Univariate sensitivity analysis showed that the cost-effectiveness of all strategies to identify LS was very
sensitive to the disutility applied to women receiving hysterectomy and bilateral salpingo-oophorectomy,
which, when set to 0.1, resulted in all testing strategies being dominated by (i.e. more expensive and less
effective than) no testing.
Psychological impact of genetic testing for Lynch syndrome on
health-related quality of life
The current evidence for the psychological impact of genetic testing for LS on HRQoL is extremely weak. It
is important that the direction, magnitude and duration of this impact is ascertained through good-quality
UK studies, or at least by some form of modelling of the psychological impact of genetic testing
according to the characteristics of the condition and management options available.
Diagnostic accuracy of tests in combination
Estimates of test accuracy (sensitivity and specificity) were taken from the available literature. Accuracies of
tests (e.g. IHC, MSI) are almost always available only for tests in isolation. One exception is the BRAF test,
for which we have accuracy information after an IHC test with abnormal MLH1 staining [Palomaki and
colleagues (2009)65] and after a MSI test [Domingo and colleagues (2005)183].
Given that information on the accuracy of tests in sequence is generally lacking, the accuracy of such tests
was assumed to be the same as if they were applied in isolation. This likely leads to an overestimate of
the diagnostic accuracy of strategies in which tests are performed in sequence.
There may be accuracy studies in which tests are performed in sequence within the literature,
from which appropriate estimates may be derived. Additionally, it may be appropriate, given the absence
of high-quality diagnostic accuracy studies, for new primary research to be conducted in which multiple
tests are evaluated for all patients.
CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
286
We note that the strategy offering the greatest NHB at a willingness to pay of £20,000 per QALY
(strategy 5) does not combine IHC and MSI.
Adaptation of the cost-effectiveness model for use in other countries
This evaluation suggests that reflex testing for LS in early-onset CRC patients and their relatives may be
cost-effective in the NHS. This naturally suggests that reflex testing may also be cost-effective in other
settings. We note that a number of evaluations have already been performed in the USA,22,23,48,49,54,55,57,88
the Netherlands,50 Denmark,52,53 Australia51 and Singapore.58 We have noted shortcomings of many of
these evaluations and suggest that new evaluations could still be worthwhile even in countries where
evaluations have already taken place.
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Appendix 1 Literature search strategy for
test accuracy
There remain noted difficulties in searching for, and locating, diagnostic test accuracy studies[Doust et al. (2005);276 Leeflang et al. (2006);277 Bayliss and Davenport (2008)278]. With this advice in
mind, we have plotted the search for this review on only the population for this review.
The search strategy was reviewed by the research team and clinical experts prior to running the searches.
Database Hits
1. MEDLINE 4632
2. MEDLINE In-Process & Other Non-Indexed Citations 216
3. EMBASE 5172
4. PsycINFO 49
5. HMIC 15
6. CINAHL 56
7. ASSIA 11
8. Web of Science 5274
9. The Cochrane Library 75
10. BNI 12
Database Results 15,512
Deduplication 8361
Unique records to screen 7151
NRR 2
Current Controlled Trials 83
ClinicalTrials.gov 203
FDA website 35
EMEA website 0
BNI, British Nursing Index.
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1. MEDLINE
Host: Ovid.
Data parameters: 1946 to April week 3, 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 4626.
Search strategy
# Searches Results
1 (lynch$ adj3 syndrome).ti,ab. 895
2 (lynch$ adj3 famil$).ti,ab. 167
3 1 or 2 901
4 Colorectal Neoplasms, Hereditary Nonpolyposis/ 2994
5 (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer).tw. 2099
6 HNPCC.tw. 1884
7 ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab. 1682
8 ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab. 1037
9 ((hereditary adj3 (cancer or neoplasm)) and (colon$ or colorectal$)).ti,ab. 2074
10 ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab. 14
11 ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab. 17
12 or/4-11 4196
13 ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
2501
14 Amsterdam criteria.tw. 319
15 or/13-14 2627
16 3 or 12 or 15 5271
17 limit 16 to english language 4713
18 animals/ not humans/ 3,611,730
19 17 not 18 4632
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
314
2. MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: added on or before 27 April 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 216.
Search strategy
# Searches Results
1 (lynch$ adj3 syndrome).ti,ab. 96
2 (lynch$ adj3 famil$).ti,ab. 18
3 1 or 2 96
4 Colorectal Neoplasms, Hereditary Nonpolyposis/ 0
5 (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer).tw. 61
6 HNPCC.tw. 63
7 ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab. 40
8 ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab. 39
9 ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab. 70
10 ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab. 0
11 ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab. 0
12 or/4-11 115
13 ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
103
14 Amsterdam criteria.tw. 7
15 or/13-14 109
16 3 or 12 or 15 228
17 limit 16 to english language 216
18 animals/ not humans/ 1
19 17 not 18 216
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3. EMBASE
Host: Ovid.
Data parameters: 1980 to week 17, 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 1061.
Search strategy
# Searches Results
1 (lynch$ adj3 syndrome).ti,ab. 1537
2 (lynch$ adj3 famil$).ti,ab. 261
3 1 or 2 1545
4 hereditary nonpolyposis colorectal cancer/ 1202
5 (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer).tw. 2629
6 HNPCC.tw. 2469
7 ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab. 2056
8 ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab. 1344
9 ((hereditary adj3 (cancer or neoplasm)) and (colon$ or colorectal$)).ti,ab. 2687
10 ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab. 18
11 ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab. 21
12 or/4-11 4969
13 ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
3349
14 Amsterdam criteria.tw. 431
15 or/13-14 3531
16 3 or 12 or 15 6694
17 limit 16 to english language 5979
18 limit 17 to human 5172
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4. PsycINFO
Host: Ovid.
Data parameters: 1806 to April week 3, 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 49.
Search strategy
# Searches Results
1 (lynch$ adj3 syndrome).ti,ab. 10
2 (lynch$ adj3 famil$).ti,ab. 3
3 1 or 2 11
4 Colorectal Neoplasms, Hereditary Nonpolyposis/ 0
5 (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer).tw. 23
6 HNPCC.tw. 24
7 ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab. 15
8 ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab. 13
9 ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab. 36
10 ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab. 0
11 ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab. 0
12 or/4-11 45
13 ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
4
14 Amsterdam criteria.tw. 0
15 or/13-14 4
16 3 or 12 or 15 54
17 limit 16 to english language 49
18 animals/ not humans/ 5401
19 17 not 18 49
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5. Health Management Information Consortium
Host: Ovid.
Data parameters: 1979 to March 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 15.
Search strategy
# Searches Results
1 (lynch$ adj3 syndrome).ti,ab. 4
2 (lynch$ adj3 famil$).ti,ab. 0
3 1 or 2 4
4 Colorectal Neoplasms, Hereditary Nonpolyposis/ 0
5 (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer).tw. 5
6 HNPCC.tw. 4
7 ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab. 4
8 ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab. 2
9 ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab. 11
10 ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab. 0
11 ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab. 0
12 or/4-11 13
13 ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
3
14 Amsterdam criteria.tw. 2
15 or/13-14 4
16 3 or 12 or 15 15
17 limit 16 to english language [limit not valid; records were retained] 15
18 animals/ not humans/ 225
19 17 not 18 15
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6. Cumulative Index to Nursing and Allied Health Literature
Host: EBSCOhost.
Data parameters: 1946 to April week 3, 2012.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 4626.
Search strategy
S1. (lynch* N3 syndrome)
S2. (lynch* N3 famil*)
S3. S1 OR 2S
S4. (MM "Colorectal Neoplasms, Hereditary Nonpolyposis")
S5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer))
S6. HNPCC
S7. ((hereditary N3 nonpolyposis) and (colon* or colorectal*))
S8. ((hereditary N3 non-polyposis) and (colon* or colorectal*))
S9. ((hereditary N3 (cancer or neoplasm)) and (colon or colorectal))
S10. ((Familial N3 Nonpolyposis) and (colon* or colorectal*))
S11. ((Familial N3 Non-polyposis) and (colon* or colorectal*))
S12. S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon* or colorectal or lynch* or HNPCC or hereditary))
S14. (Amsterdam criteria)
S15. S13 OR S14
S16. S3 OR S12 OR S15
Notes: Server-side deduplication carried out to remove MEDLINE hits.
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7. Applied Social Sciences Index and Abstracts
Host: CSA.
Data parameters: None specified.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 11.
Search strategy
#1. (lynch* and syndrome)
#2. (lynch* and famil*)
#3. Or/1-2
#4. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer))
#5. HNPCC
#6. Or/4-5
#7. 3 or 6
8. Web of Science [SCI-EXPANDED, Social Sciences Citation
Index (SSCI), Arts & Humanities Citation Index (A&HCI),
Conference Proceedings Citation Index – Science (CPCI-S),
Conference Proceedings Citation Index – Social Science &
Humanities (CPCI-SSH)]
Host: ISI.
Data parameters: None specified.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 5274.
Search strategy
#1. Topic=(("Hereditary Nonpolyposis Colorectal Cancer"))
#2. Topic=(("Hereditary Non-polyposis Colorectal Cancer"))
#3. Topic=(((lynch* near/3 syndrome)))
#4. Topic=((((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or
(hMSH6) or (hMLH3) or (PMS1) or (PMS2)) and (colon* or colorectal or lynch* or HNPCC or hereditary)))
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#5. Topic=(("Amsterdam criteria"))
#6. #1 or #2 or #3 or #4 or #5
9. The Cochrane Library
Host: www.thecochranelibrary.com/view/0/index.html.
Data parameters: None specified.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: Cochrane Reviews (3); other reviews (5); trials (43); methods studies (1); TAs (8); economic evaluations
(15); Cochrane Groups (0).
Current search history
#1. (lynch* near/3 syndrome) (19)
#2. (lynch* near/3 famil*) :ti,ab,kw (0)
#3. MeSH descriptor Colorectal Neoplasms, Hereditary Nonpolyposis explode all trees (47)
#4. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer)):ti,ab,
kw (28)
#5. (HNPCC):ti,ab,kw (15)
#6. ((hereditary near/3 nonpolyposis) and (colon* or colorectal*)):ti,ab,kw (51)
#7. ((hereditary near/3 non-polyposis) and (colon* or colorectal*)):ti,ab,kw (9)
#8. ((Familial near/3 Nonpolyposis) and (colon* or colorectal*)):ti,ab,kw (0)
#9. ((Familial near/3 Non-polyposis) and (colon* or colorectal*)):ti,ab,kw (0)
#10. ((hereditary near/3 (cancer or neoplasm)) and (colon* or colorectal*)):ti,ab,kw (56)
#11. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon* or colorectal or lynch* or HNPCC or hereditary)):ti,ab,
kw (11)
#12. ("Amsterdam criteria"):ti,ab,kw (3)
#13. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12) (75)
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10. British Nursing Index
Host: ProQuest.
Data parameters: 1994 to current.
Date searched: Monday, 30 April 2012.
Searcher: Cooper.
Hits: 12.
Search strategy
#1. (lynch N/3 syndrome)
#2. (lynch syndrome)
#3. (Hereditary Nonpolyposis Colorectal Cancer or Hereditary Non-polyposis Colorectal Cancer)
#4. HNPCC
#5. ((MLH1 or MSH2 or MSH3 or MSH6 or hMSH2 or hMLH1 or hPMS1 or hPMS2 or hMSH6 or hMLH3 or
PMS1 or PMS2) and (colon$ or colorectal or lynch$ or HNPCC or hereditary))
#6. ("Amsterdam criteria")
#7. #1 or #2 or #3 or #4 or #5 or #6
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Appendix 2 Clinical effectiveness: blank
quality appraisal and data extraction form
Design Participants Tests Outcomes
Authors (date):
Related references:
Objective:
Basic design:
□ Single gate
□ Two gate
□ Systematic review
□ Other
Country:
Setting:
No. of centres:
Funding:
Sample description/
presentation:
No. recruited:
Selection:
□ Consecutive
□ Random
□ Other
□ Unclear
Prior testing:
Inclusion criteria:
Exclusion criteria:
Index tests included:
□ IHC
□ MSI
□ BRAF
□ Methylation
Index tests (technical
details):
Reference standard
(technical details):
Time intervals between
tests:
Outcome assessor:
Blinding:
Accuracy outcomes:
Other:
Test failures:
Data
Sample attrition/
dropout:
No. receiving index test
(reasons):
No. receiving reference
standard (reasons):
Data excluded
(and reasons):
Notes
Participant characteristics
Index test 1 Index test 2 Index test 3
Reference
standard
No. of patients
Median/mean age, yrs (range)
No. < 50 years
No. meeting AMS II
No. meeting Bethesda
Gender
l Men
l Women
Cancer location
l Rectum
l Left colon
l Right colon
l Transverse colon
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Design Participants Tests Outcomes
Results
MSI v reference standard: □ Applicable □ Not applicable
MSI
Reference standard
+ve –ve Total
+ve
–ve
Total
IHC v reference standard: □ Applicable □ Not applicable
IHC
Reference standard
+ve –ve Total
+ve
–ve
Total
BRAF v reference standard: □ Applicable □ Not applicable
BRAF
Reference standard
+ve –ve Total
+ve
–ve
Total
Methylation v reference standard: □ Applicable □ Not applicable
Not methylated
Reference standard
+ve –ve Total
+ve
–ve
Total
Other results:
Major methodological issues
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Design Participants Tests Outcomes
Quality appraisal – QUADAS-2
Flow diagram of primary study:
DOMAIN 1: PATIENT SELECTION
Was a consecutive or random sample of patients enrolled? (Y/N/U)
Was a case–control study design avoided? (Y/N/U)
Did the study avoid inappropriate exclusions? (Y/N/U)
Could the selection of patients have introduced bias? (H/L/U)
Is there concern that the included patients do not match the review question? (H/L/U)
DOMAIN 2: INDEX TESTS (complete for each index test)
Were the index test results interpreted without knowledge of the results of the
reference standard?
(Y/N/U)
If a threshold was used, was it pre-specified? (Y/N/U)
Could the conduct or interpretation of the index test have introduced bias? (H/L/U)
Is there concern that the index test, its conduct, or interpretation differ from the
review question?
(H/L/U)
DOMAIN 3: REFERENCE STANDARD
Is the reference standard likely to correctly classify the target condition? (Y/N/U)
Were the reference standard results interpreted without knowledge of the results of the
index test?
(Y/N/U)
Could the reference standard, its conduct, or its interpretation have introduced bias? (H/L/U)
Is there concern that the target condition as defined by the reference standard does not
match the review question?
(H/L/U)
DOMAIN 4: FLOW AND TIMING
Was there an appropriate interval between index test(s) and reference standard? (Y/N/U)
Did all patients receive a reference standard? (Y/N/U)
Did all patients receive the same reference standard? (Y/N/U)
Were all patients included in the analysis? (Y/N/U)
Could the patient flow have introduced bias? (H/L/U)
H, high; L, low; N, no; U, unclear; Y, yes.
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Appendix 3 Clinical effectiveness: excluded
studies
Reason for exclusion: population
Abbott DE, Cantor SB, Rodriguez-Bigas MA, Chang GJ, Lynch PM, Feig BW, et al. Detecting hereditary
nonpolyposis colorectal cancer syndrome (HNPCC) in colorectal cancer (CRC) patients: optimal strategies at
lower costs. Ann Surg Oncol. 65th Annual Cancer Symposium of the Society of Surgical Oncology,
Orlando, FL, 21–24 March 2012.
Alemayehu A, Tomkova K, Zavodna K, Ventusova K, Krivulcik T, Bujalkova M, et al. The role of clinical
criteria, genetic and epigenetic alterations in Lynch-syndrome diagnosis. Neoplasma 2007;54:391–401.
Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, et al. Detection of BRAF V600E mutation in
colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol
Diagn 2006;8:540–3.
Bessa X, Alenda C, Paya A, Alvarez C, Iglesias M, Seoane A, et al. Validation microsatellite path score in a
population-based cohort of patients with colorectal cancer. J Clin Oncol 2011;29:3374–80.
Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F, et al. A prospective, multicenter,
population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol
Hepatol 2008;6:206–14.
Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, et al. Distinction of
hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through
quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007;13:3221–8.
Bouzourene H, Taminelli L, Chaubert P, Monnerat C, Seelentag W, Sandmeier D, et al. A cost-effective
algorithm for hereditary nonpolyposis colorectal cancer detection. Am J Clin Pathol 2006;125:823–31.
Canard G, Lefevre JH, Colas C, Coulet F, Svrcek M, Lascols O, et al. Screening for Lynch syndrome in
colorectal cancer: are we doing enough? Ann Surg Oncol 2012;19:809–16.
Chen S, Watson P, Parmigiani G. Accuracy of MSI testing in predicting germline mutations of MSH2
and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard.
Biostatistics 2005;6:450–64.
Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment
and correlation of microsatellite instability and immunohistochemical markers among population- and
clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011;13:271–81.
Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, et al. Improved testing for microsatellite
instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol 2010;17:3370–78.
Ewald J, Rodrigue CM, Mourra N, Lefevre JH, Flejou JF, Tiret E, et al. Immunohistochemical staining for
mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer.
Br J Surg 2007;94:1020–7.
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Frankel WL, Hampel H, LaJeanesse J, Panescu J, Jones S, de la Chapelle A. Immunohistochemical staining
for MLH1, MSH2 and MSH6 identifies germline mutations in mismatch repair genes in colorectal and
endometrial cancers initially found to be microsatellite stable. Mod Pathol 2005;18:103A.
Glogowski E, Boyar S, Sarrel K, Le Blang C, Utay E, Shia J, et al. Unexplained immunohistochemical DNA
mismatch repair deficiency. Collaborative Group of the Americas on Inherited Colorectal Cancer, 15th
Annual Meeting, Montreal, QC, 10–11 October 2011.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch
syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783–8.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch
syndrome (hereditary nonpolyposis colorectal cancer). New Engl J Med 2005;352:1851–60.
Hayes, Inc. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic
Colorectal Cancer. Structured abstract. Lansdale, PA: Hayes, Inc.; 2010.
Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L. Microsatellite instability detection by
high-resolution melting analysis. Clin Chem 2010;56:1750–7.
Julie C, Beauchet A, Christophe T, Muti C, Coulet F, Brouquet A, et al. Evaluation of mspath score
compared to revised Bethesda guidelines for detecting Lynch syndrome in a consecutive series
of 225 colorectal carcinomas. Virchows Arch 2008;452:S30.
Julie C, Beauchet A, Tresallet C, Brouquet A, Muti C, Coulet F, et al. Evaluation of mspath score compared
to revised Bethesda guidelines for detecting Lynch syndrome in a consecutive series of 223 colorectal
carcinomas. Ann Oncol 2009;20:25.
Kadiyska TK, Konstantinova DV, Atanasov VR, Kremensky IA, Mitev VI. Frequency and application of the
hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for hereditary nonpolyposis colorectal
cancer. Cancer Detect Prev 2007;31:254–6.
Kang YN, Kwon SY, Kim SP, Kwon KY, Lee SS. Evaluation of microsatellite instability, hMLH1 expression
and hMLH1 promoter hypermethylation in 176 colorectal carcinomas. Lab Invest 2005;85:108A.
Kets CM, Van Krieken JHJM, Hebeda KM, Wezenberg SJ, Goossens M, Brunner HG, et al. Very low
prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients
with colorectal cancer without microsatellite instability. Br J Cancer 2006;95:1678–82.
Lee SC, Gou JY, Lim R, Soo R, Koay E, Salto-Tellez M, et al. Clinical and molecular characteristics of
hereditary non-polyposis colorectal cancer families in Southeast Asia. Clin Genet 2005;68:137–45.
Loughrey MB, Waring PM, Tan A, Trivett M, Kovalenko S, Beshay V, et al. Incorporation of somatic BRAF
mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Fam Cancer 2007;6:301–10.
Mangold E, Pagenstecher C, Friedl W, Fischer HP, Merkelbach-Bruse S, Ohlendorf M, et al. Tumours from
MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers
exhibit weak positive MLH1 staining. J Pathol 2005;207:385–95.
Marrupe D, Meizoso T, Lopez E, Mestre MJ, Garcia S, Cortes L, et al. Correlation between clinical and
pathologic criteria and immunohistochemical detection of mismatch repair gene proteins in patients with
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Appendix 4 Literature search strategy for
the cost-effectiveness systematic review
This initial search was filtered to capture cost-effectiveness and data on original models, as well asinformation on guidelines for the review population. With the cost data in mind, the searches were run
in the following databases: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE,
CINAHL, The Cochrane Library (all), Web of Science (including conference proceedings) and EconLit.279,280
The filters used were the NHS EED search filter supplemented by the NHS Quality Improvement
filter (brief).281
The above databases were also searched for guidelines information, as were the British Nursing Index (BNI)
and HMIC; however, the latter returned nil results.
Searches were run on Wednesday, 29 February 2012 and returned 2036 title and abstracts.
Database Hits
1. MEDLINE 1061
2. MEDLINE In-Process & Other Non-Indexed Citations 51
3. EMBASE 1493
4. CINAHL 38
5. The Cochrane Library (all) 102
6. Web of Science 634
7. EconLit 1
Total 3380
Duplicates removed −1344
Total to screen 2036
1. MEDLINE
Host: Ovid.
Data parameters: 1946 to February week 3, 2012.
Date searched: Wednesday, 29 February 2012.
Searcher: Cooper.
Hits: 1061.
Search strategy
1. (lynch$ adj3 syndrome).ti,ab.
2. ((lynch$ adj3 famil$) and (cancer$ or neoplasm$)).ti,ab.
3. Or/1-2
4. Colorectal Neoplasms, Hereditary Nonpolyposis/
5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer)).tw.
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6. HNPCC.tw.
7. ((hereditary or inherited) adj3 (colon or colorectal) and (cancer or neoplasm$)).ti,ab.
8. ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab.
9. ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab.
10. ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab.
11. ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab.
12. ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab.
13. (familial adj3 (colon$ or colorectal$)).ti,ab.
14. Or/4-13
15. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
16. (Amsterdam criteria).tw.
17. Or/15-16
18. 3 OR 14 OR 17
19. exp Economics/
20. ec.fs.
21. economics, medical/
22. economics, nursing/
23. economics, pharmaceutical/
24. exp "economics, hospital"/
25. exp pharmacoeconomics/
26. (economic$ or cost or costs or costly or costing or costed or price or prices or pricing or priced
or discount or discounts or discounted or discounting or ration$ or expenditure or expenditures or
budget$ or afford$ or pharmacoeconomic or pharmaco-economic$).ti,ab.
27. (cba or cea or cua).ti,ab.
28. exp "fees and charges"/
29. (fee or fees or charge$ or preference$).tw.
30. (fiscal or funding or financial or finance).tw.
31. exp "costs and cost analysis"/
32. exp Health Care Costs/
33. (cost$).ti,ab.
34. (cost$ adj1 (util$ or effective$ or efficac$ or benefit$ or consequence$ or analy$ or minimi$ or saving$
or breakdown or lowering or estimate$ or variable$ or allocation or control or illness or sharing or life
or lives or affordabl$ or instrument$ or technolog$ or day$ or fee or fees or charge or charges)).ti,ab.
35. ((value or values or valuation) adj3 (money or monetary or life or lives or costs or cost$)).ti,ab.
36. (unit cost or unit-cost or unit-costs or unit costs or drug cost or drug costs or hospital costs or
health-care costs or health care cost or medical cost or medical costs).ti,ab.
37. exp decision support techniques/
38. exp models, economic/
39. exp Statistical Model/
40. (markov$).ti,ab. or markov chains/
41. (monte carlo).ti,ab. or monte carlo method/
42. (decision adj2 (tree$ or analy$ or model$)).ti,ab. or decision tree/
43. (survival adj3 analys$).ti,ab.
44. "deductibles and coinsurance"/
45. exp Health expenditures/
46. (uncertain$).ti,ab. or uncertainty/
47. (quality adj3 life).ti,ab. or quality of life/
48. (value adj3 life).ti,ab. or value of life/
49. Quality-adjusted life years/
50. (qol$ or qoly or qolys or hrqol$ or qaly or qalys or qale or qales).ti,ab.
51. ((sensitivity analys$) or ("willingness to pay") or (quality-adjusted life year$) or (quality adjusted life
year$) or (quality-adjusted life expectanc$) or (quality adjusted life expectanc$)).ti,ab.
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52. utilit$.tw.
53. (valu$).tw.
54. exp hospitalization/
55. Or/19-54
56. Guidelines as Topic/
57. Health Planning Guidelines/
58. Practice Guidelines as Topic/
59. Clinical Protocols/
60. Guideline.pt.
61. Practice Guideline/
62. Practice Guideline.pt.
63. Consensus Development Conference.pt.
64. (guideline* or standards).ti.
65. (expert consensus or consensus statement or consensus conference* or practice parameter* or
position statement* or policy statement* or cpg or cpgs or best practice*).ti,ab
66. Or/56-65
67. 55 or 66
68. 18 and 67
69. Animals/ NOT Humans/
70. 69 NOT 70
71. limit 70 to english language
2. MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: added on or before 28 February 2012.
Date searched: Wednesday, 29 February 2012.
Searcher: Cooper.
Hits: 51.
Search strategy
1. (lynch$ adj3 syndrome).ti,ab.
2. ((lynch$ adj3 famil$) and (cancer$ or neoplasm$)).ti,ab.
3. Or/1-2
4. Colorectal Neoplasms, Hereditary Nonpolyposis/
5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer)).tw.
6. HNPCC.tw.
7. ((hereditary or inherited) adj3 (colon or colorectal) and (cancer or neoplasm$)).ti,ab.
8. ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab.
9. ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab.
10. ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab.
11. ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab.
12. ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab.
13. (familial adj3 (colon$ or colorectal$)).ti,ab.
14. Or/4-13
15. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
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16. (Amsterdam criteria).tw.
17. Or/15-16
18. 3 OR 14 OR 17
19. exp Economics/
20. ec.fs.
21. economics, medical/
22. economics, nursing/
23. economics, pharmaceutical/
24. exp "economics, hospital"/
25. exp pharmacoeconomics/
26. (economic$ or cost or costs or costly or costing or costed or price or prices or pricing or priced
or discount or discounts or discounted or discounting or ration$ or expenditure or expenditures or
budget$ or afford$ or pharmacoeconomic or pharmaco-economic$).ti,ab.
27. (cba or cea or cua).ti,ab.
28. exp "fees and charges"/
29. (fee or fees or charge$ or preference$).tw.
30. (fiscal or funding or financial or finance).tw.
31. exp "costs and cost analysis"/
32. exp Health Care Costs/
33. (cost$).ti,ab.
34. (cost$ adj1 (util$ or effective$ or efficac$ or benefit$ or consequence$ or analy$ or minimi$ or saving
$ or breakdown or lowering or estimate$ or variable$ or allocation or control or illness or sharing or
life or lives or affordabl$ or instrument$ or technolog$ or day$ or fee or fees or charge or
charges)).ti,ab.
35. ((value or values or valuation) adj3 (money or monetary or life or lives or costs or cost$)).ti,ab.
36. (unit cost or unit-cost or unit-costs or unit costs or drug cost or drug costs or hospital costs or
health-care costs or health care cost or medical cost or medical costs).ti,ab.
37. exp decision support techniques/
38. exp models, economic/
39. exp Statistical Model/
40. (markov$).ti,ab. or markov chains/
41. (monte carlo).ti,ab. or monte carlo method/
42. (decision adj2 (tree$ or analy$ or model$)).ti,ab. or decision tree/
43. (survival adj3 analys$).ti,ab.
44. "deductibles and coinsurance"/
45. exp Health expenditures/
46. (uncertain$).ti,ab. or uncertainty/
47. (quality adj3 life).ti,ab. or quality of life/
48. (value adj3 life).ti,ab. or value of life/
49. Quality-adjusted life years/
50. (qol$ or qoly or qolys or hrqol$ or qaly or qalys or qale or qales).ti,ab.
51. ((sensitivity analys$) or ("willingness to pay") or (quality-adjusted life year$) or (quality adjusted life
year$) or (quality-adjusted life expectanc$) or (quality adjusted life expectanc$)).ti,ab.
52. utilit$.tw.
53. (valu$).tw.
54. exp hospitalization/
55. Or/19-54
56. Guidelines as Topic/
57. Health Planning Guidelines/
58. Practice Guidelines as Topic/
59. Clinical Protocols/
60. Guideline.pt.
61. Practice Guideline/
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62. Practice Guideline.pt.
63. Consensus Development Conference.pt.
64. (guideline* or standards).ti.
65. (expert consensus or consensus statement or consensus conference* or practice parameter* or
position statement* or policy statement* or cpg or cpgs or best practice*).ti,ab
66. Or/56-65
67. 55 or 66
68. 18 and 67
69. Animals/ NOT Humans/
70. 69 NOT 70
71. limit 70 to english language
3. EMBASE
Host: Ovid.
Data parameters: 1980 to week 8, 2012.
Date searched: Wednesday, 29 February 2012.
Searcher: Cooper.
Hits: 1493.
Search strategy
1. limit 70 to engli(lynch$ adj3 syndrome).ti,ab.
2. ((lynch$ adj3 famil$) and (cancer$ or neoplasm$)).ti,ab.
3. Or/1-2
4. Colorectal Neoplasms, Hereditary Nonpolyposis/
5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer)).tw.
6. HNPCC.tw.
7. ((hereditary or inherited) adj3 (colon or colorectal) and (cancer or neoplasm$)).ti,ab.
8. ((hereditary adj3 nonpolyposis) and (colon$ or colorectal$)).ti,ab.
9. ((hereditary adj3 non-polyposis) and (colon$ or colorectal$)).ti,ab.
10. ((hereditary adj3 (cancer or neoplasm)) and (colon or colorectal)).ti,ab.
11. ((Familial adj3 Nonpolyposis) and (colon$ or colorectal$)).ti,ab.
12. ((Familial adj3 Non-polyposis) and (colon$ or colorectal$)).ti,ab.
13. (familial adj3 (colon$ or colorectal$)).ti,ab.
14. Or/4-13
15. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon$ or colorectal or lynch$ or HNPCC or hereditary)).ti,ab.
16. (Amsterdam criteria).tw.
17. Or/15-16
18. 3 OR 14 OR 17
19. exp Economics/
20. ec.fs.
21. economics, medical/
22. economics, nursing/
23. economics, pharmaceutical/
24. exp "economics, hospital"/
25. exp pharmacoeconomics/
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26. (economic$ or cost or costs or costly or costing or costed or price or prices or pricing or priced or
discount or discounts or discounted or discounting or ration$ or expenditure or expenditures or
budget$ or afford$ or pharmacoeconomic or pharmaco-economic$).ti,ab.
27. (cba or cea or cua).ti,ab.
28. exp "fees and charges"/
29. (fee or fees or charge$ or preference$).tw.
30. (fiscal or funding or financial or finance).tw.
31. exp "costs and cost analysis"/
32. exp Health Care Costs/
33. (cost$).ti,ab.
34. (cost$ adj1 (util$ or effective$ or efficac$ or benefit$ or consequence$ or analy$ or minimi$ or saving$
or breakdown or lowering or estimate$ or variable$ or allocation or control or illness or sharing or life
or lives or affordabl$ or instrument$ or technolog$ or day$ or fee or fees or charge or charges)).ti,ab.
35. ((value or values or valuation) adj3 (money or monetary or life or lives or costs or cost$)).ti,ab.
36. (unit cost or unit-cost or unit-costs or unit costs or drug cost or drug costs or hospital costs or
health-care costs or health care cost or medical cost or medical costs).ti,ab.
37. exp decision support techniques/
38. exp models, economic/
39. exp Statistical Model/
40. (markov$).ti,ab. or markov chains/
41. (monte carlo).ti,ab. or monte carlo method/
42. (decision adj2 (tree$ or analy$ or model$)).ti,ab. or decision tree/
43. (survival adj3 analys$).ti,ab.
44. "deductibles and coinsurance"/
45. exp Health expenditures/
46. (uncertain$).ti,ab. or uncertainty/
47. (quality adj3 life).ti,ab. or quality of life/
48. (value adj3 life).ti,ab. or value of life/
49. Quality-adjusted life years/
50. (qol$ or qoly or qolys or hrqol$ or qaly or qalys or qale or qales).ti,ab.
51. ((sensitivity analys$) or ("willingness to pay") or (quality-adjusted life year$) or (quality adjusted life
year$) or (quality-adjusted life expectanc$) or (quality adjusted life expectanc$)).ti,ab.
52. utilit$.tw.
53. (valu$).tw.
54. exp hospitalization/
55. Or/19-54
56. Guidelines as Topic/
57. Health Planning Guidelines/
58. Practice Guidelines as Topic/
59. Clinical Protocols/
60. Guideline.pt.
61. Practice Guideline/
62. Practice Guideline.pt.
63. Consensus Development Conference.pt.
64. (guideline* or standards).ti.
65. (expert consensus or consensus statement or consensus conference* or practice parameter* or
position statement* or policy statement* or cpg or cpgs or best practice*).ti,ab
66. Or/56-65
67. 55 or 66
68. 18 and 67
69. Animals/ NOT Humans/
70. 69 NOT 70
71. sh language
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4. Cumulative Index to Nursing and Allied Health Literature
Host: EBSCOhost.
Data parameters:
Date searched: 28 February 2012.
Searcher: Cooper.
Hits: 38.
Search strategy
S1. (lynch* N3 syndrome)
S2. ((lynch* N3 famil*) and (cancer* or neoplasm*))
S3. (S1 OR S2)
S4. (MH "Colorectal Neoplasms, Hereditary Nonpolyposis")
S5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer))
S6. (HNPCC)
S7. ((hereditary or inherited) N3 (colon or colorectal) and (cancer or neoplasm*))
S8. ((hereditary N3 nonpolyposis) and (colon* or colorectal*))
S9. ((hereditary N3 non-polyposis) and (colon* or colorectal*))
S10. ((hereditary N3 (cancer or neoplasm)) and (colon or colorectal))
S11. ((Familial N3 Nonpolyposis) and (colon* or colorectal*))
S12. ((Familial N3 Non-polyposis) and (colon* or colorectal*))
S13. (familial N3 (colon* or colorectal*))
S14. (S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13)
S15. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon* or colorectal or lynch* or HNPCC or hereditary))
S16. ((Amsterdam criteria) and (colon* or colorectal or lynch* or HNPCC or hereditary))
S17. (S15 OR S16)
S18. (S3 OR S14 OR S17)
S19. (MH "Economics+")
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S20. (economic* or cost or costs or costly or costing or costed or price or prices or pricing or priced or
discount or discounts or discounted or discounting or ration* or expenditure or expenditures or budget* or
afford* or pharmacoeconomic or pharmaco-economic*)
S21. (cba or cea or cua)
S22. (MH "Fees and Charges")
S23. (fee or fees or charge* or preference*)
S24. (fiscal or funding or financial or finance)
S25. (MH "Costs and Cost Analysis+")
S26. (cost*)
S27. (cost* N1 (util* or effective* or efficac* or benefit* or consequence* or analy* or minimi* or saving*
or breakdown or lowering or estimate* or variable* or allocation or control or illness or sharing or life or
lives or affordabl* or instrument* or technolog* or day* or fee or fees or charge or charges))
S28. ((value or values or valuation) N3 (money or monetary or life or lives or costs or cost*))
S29. (unit cost or unit-cost or unit-costs or unit costs or drug cost or drug costs or hospital costs or
health-care costs or health care cost or medical cost or medical costs)
S30. (MH "Decision Support Techniques+")
S31. (model*)
S32. (MM "Models, Statistical")
S33. (markov*)
S34. (monte carlo)
S35. (decision N2 (tree* or analy* or model*))
S36. (MH "Decision Trees")
S37. (survival N3 analys*)
S38. (uncertain*)
S39. (quality N3 life)
S40. (MH "Quality of Life")
S41. (value N3 life)
S42. (MM "Quality-Adjusted Life Years")
S43. (qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales)
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S44. ((sensitivity analys*) or ("willingness to pay") or (quality-adjusted life year*) or (quality adjusted life
year*) or (quality-adjusted life expectanc*) or (quality adjusted life expectanc*))
S45. utilit*
S46. (valu*)
S47. S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34
or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49
S48. (MM "Practice Guidelines")
S49. (guideline* or standards)
S50. (expert consensus or consensus statement or consensus conference* or practice parameter* or
position statement* or policy statement* or cpg or cpgs or best practice*)
S51. S51 or S52 or S53
S52. 55 or 66
5. The Cochrane Library
Host: www.thecochranelibrary.com/view/0/index.html
Data parameters:
Date searched: 28 February 2012.
Searcher: Cooper.
Hits: 102.
Search strategy
#1. (lynch* NEAR/3 syndrome):ti,ab,kw
#2. ((lynch* NEAR/3 famil*) and (cancer* or neoplasm*)):ti,ab,kw
#3. (#1 OR #2)
#4. MeSH descriptor Colorectal Neoplasms, Hereditary Nonpolyposis, this term only
#5. ((Hereditary Nonpolyposis Colorectal Cancer) or (Hereditary Non-polyposis Colorectal Cancer)):ti,ab,kw
#6. (HNPCC):ti,ab,kw
#7. ((hereditary or inherited) NEAR/3 (colon or colorectal) and (cancer or neoplasm*)):ti,ab,kw
#8. ((hereditary NEAR/3 nonpolyposis) and (colon* or colorectal*)):ti,ab,kw
#9. ((hereditary NEAR/3 non-polyposis) and (colon* or colorectal*)):ti,ab,kw
#10. ((hereditary NEAR/3 (cancer or neoplasm)) and (colon or colorectal)):ti,ab,kw
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#11. ((Familial NEAR/3 Nonpolyposis) and (colon* or colorectal*)):ti,ab,kw
#12. ((Familial NEAR/3 Non-polyposis) and (colon* or colorectal*)):ti,ab,kw
#13. (familial NEAR/3 (colon* or colorectal*)):ti,ab,kw
#14. (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15. (((MLH1) or (MSH2) or (MSH3) or (MSH6) or (hMSH2) or (hMLH1) or (hPMS1) or (hPMS2) or (hMSH6)
or (hMLH3) or (PMS1) or (PMS2)) and (colon* or colorectal or lynch* or HNPCC or hereditary)):ti,ab,kw
#16. ((Amsterdam criteria) and (colon* or colorectal or lynch* or HNPCC or hereditary)):ti,ab,kw
#17. (#15 OR #16)
#18. (#3 OR #14 OR #17)
Notes: line 16 was lost to specificity and so its sensitivity was tightened to the population for this review.
6. Web of Science
Host: ISI.
Data parameters: 1899 to current.
Date searched: Wednesday, 29 February 2012.
Searcher: Cooper.
Hits: 634.
Search strategy
1. Topic=("Hereditary Nonpolyposis Colorectal Cancer")
2. Topic=((lynch* near/3 syndrome))
3. #1 OR #2
4. (economic* or cost or costs or costly or costing or costed or price or prices or pricing or priced or
discount or discounts or discounted or discounting or ration* or expenditure or expenditures or
budget* or afford* or pharmacoeconomic or pharmaco-economic*)
5. (markov* or monte carlo)
6. (decision near/2 (tree* or analy* or model*))
7. (survival near/3 analys*)
8. (qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales)
9. ((sensitivity analys*) or ("willingness to pay") or (quality-adjusted life year*) or (quality adjusted life
year*) or (quality-adjusted life expectanc*) or (quality adjusted life expectanc*))
10. utilit*
11. (valu*)
12. (guideline* or standards)
13. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OT #11 OR #12
14. #3 AND 13
15. Refined by: Languages=( ENGLISH )
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7. EconLit
Host: CSA.
Data parameters:
Date searched: 28 February 2012.
Searcher: Cooper.
Hits: 1.
Search strategy
1. (KW=("Hereditary Nonpolyposis Colorectal Cancer"))
2. KW=(lynch* syndrome)
3. ((KW=(hereditary) or KW=(inherited)) and (KW=(colon) or KW=(colorectal)) and (KW=(cancer) or
KW=(neoplasm*)))
4. (((KW=(MLH1)) or (KW=(MSH2)) or (KW=(MSH3)) or (KW=(MSH6)) or (KW=(hMSH2)) or (KW=
(hMLH1)) or (KW=(hPMS1)) or (KW=(hPMS2)) or (KW=(hMSH6)) or (KW=(hMLH3)) or (KW=(PMS1)) or
(KW=(PMS2))) and (KW=(colon*) or KW=(colorectal) or KW=("lynch$") or KW=(HNPCC) or
KW=(hereditary)))
5. (KW=(Amsterdam criteria))
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Appendix 5 Published estimates of cumulative
risk of colorectal cancer for individuals with
Lynch syndrome
Study
Number of
families Selection
Correction
for selection/
ascertainment
bias
Adjustment for
interventions
MMR
genes
included
Cumulative
risk of CRC to
age 70 years,
% (95% CI)
Bonadona
et al. 20112
537 40 cancer
genetics clinics
Adjustment for
ascertainment
within
genotype-
restricted
likelihood
mechanism
Risks for CRC
censored on
first colonoscopy
MLH1
(n= 248),
MSH2
(n= 256),
MSH6
(n= 33)
MLH1/MSH2/
MSH6
M 38 (25 to 59)
F 31 (19 to 50)
P 35 (25 to 49)
MLH1
P 41 (25 to 70)
MSH2
P 48 (30 to 77)
MSH6
P 12 (8 to 22)
van Vliet
et al. 2011164
17 Population-based
prospective
recruitment via
early-onset
(< 45 years)
CRC cases
Adjustment for
ascertainment
(conditioned on
phenotype and
genotype
of proband)
Censored at
first cancer,
polypectomy
or hysterectomy
MLH1 (n= 9),
MSH2 (n= 4),
MSH6 (n= 3),
PMS2 (n= 1)
Paternal origin
M 41 (20 to 71)
F 42 (18 to 78)
Maternal
origin
M 81 (49 to 99)
F 34 (17 to 63)
Baglietto
et al. 2010166
113 Family cancer
clinics (n= 65)
Population-based
cancer registries
(n= 48)
Adjustment for
ascertainment
Censored at
polypectomy
or hysterectomy
MSH6
(n= 113)
M 22 (14 to 32)
F 10 (5 to 17)
Choi et al.
2009282
32 Population-based
cancer registry
[AC I (n= 27), FH
or early-onset
CRC (n= 5)]
(Via Bonadona
et al. 2011)
Incomplete
adjustment
(conditioned on
phenotype of
proband
and FDRs)
Not stated MLH1
(n= 14),
MSH2
(n= 17),
MSH6 (n= 1)
MLH1/MSH2/
MSH6
M 60 (35 to 73)
F 47 (27 to 60)
P 53 (37 to 64)
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Study
Number of
families Selection
Correction
for selection/
ascertainment
bias
Adjustment for
interventions
MMR
genes
included
Cumulative
risk of CRC to
age 70 years,
% (95% CI)
MLH1
M 67 (27 to 89)
F 35 (10 to 59)
P 44 (19 to 70)
MSH2
M 55 (2 to 75)
F 53 (2 to 70)
P 54 (3 to 69)
Stoffel et al.
2009106
147 Cancer genetics
clinic
Base analysis
Incomplete
adjustment
(conditioned on
genotype and
phenotype of
proband and
phenotype of
FDRs)
Most
conservative
analysisa
Adjustment for
ascertainment
(conditioned on
genotype and
phenotype of
proband and
phenotype of
all relatives)
Not censored
on polypectomy
MLH1
(n= 55),
MSH2
(n= 81),
MSH6
(n= 11)
Base analysis
MLH1/MSH2/
MSH6
M 66 (59 to 76)
F 43 (37 to 53)
MLH1
M 97
F 53
MSH2
M 52
F 39
Most
conservative
analysisa
MLH1/MSH2/
MSH6
M 34 (3 to 54)
F 32 (0 to 38)
Barrow et al.
200881
121 Cancer genetics
clinic
(Via Bonadona
et al. 2011)
Inappropriate
Base analysis
not censored
Sensitivity
analysis censored
on family
ascertainment
MLH1
(n= 51),
MSH2
(n= 59),
MSH6
(n= 11)
Base analysis
MLH1/MSH2/
MSH6
M 54 (51 to 58)
F 46 (43 to 50)
Sensitivity
analysis
MLH1/MSH2/
MSH6
M 56 (52 to 60)
F 44 (40 to 47)
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Study
Number of
families Selection
Correction
for selection/
ascertainment
bias
Adjustment for
interventions
MMR
genes
included
Cumulative
risk of CRC to
age 70 years,
% (95% CI)
Senter et al.
2008105
55 Cancer genetics
clinics
Adjustment for
ascertainment
(conditioned on
genotype and
phenotype of
proband and
phenotype of
all relatives)
NR PMS2 PMS2
M 20 (11 to 34)
F 15 (8 to 26)
Alarcon et al.
2007165
36 Cancer
genetics clinics
Adjustment
for
ascertainment
Not censored MLH1
(n= 22),
MSH2
(n= 14)
MLH1/MSH2
M 47 (12 to 98)
F 33 (24 to 54)
Jenkins et al.
2006114
17 Population-based
cancer registry
recruiting
families by
probands with
CRC < 45 years
Adjusted for
ascertainment
(conditioned on
genotype and
phenotype
of proband)
Censored on
polypectomy if
not affected by
CRC during
lifetime
MLH1 (n= 8),
MSH2 (n= 4),
MSH6 (n= 4),
PMS2 (n= 1)
Any MMR
M 45 (29 to 62)
F 38 (19 to 51)
MLH1/MSH2
M 56 (37 to 75)
F 48 (26 to 65)
Bermejo et al.
2005283
5098 Cancer registry,
families with four
generations
documented
and second
generation aged
up to 70 years
[AC I (n= 21),
AC II (n= 42),
Bethesda
(n= 5095)]
N/A? Not censored
on polypectomy
N/A (To age 75 years)
AC I
P 57 (46 to 69)
AC II
P 41 (33 to 50)
Bethesda
M 42 (39 to 44)
F 23 (22 to 24)
Hampel et al.
2005284
70 Cohort 1
(n= 45)
CRC between
1980 and 1994
with suggestive
clinical
characteristics
and FH
Cohort 2
(n= 25)
Population-based
recruitment
(CRC any age,
MSI positive)
Exclusion of
probands
(sufficient for
cohort 2 but not
cohort 1 or
combined
cohort; analysis
published is for
combined
cohort)
Not censored
on polypectomy
MLH1
(n= 65),
MSH2 (n= 5)
MLH1/MSH2
M 69
F 52
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Study
Number of
families Selection
Correction
for selection/
ascertainment
bias
Adjustment for
interventions
MMR
genes
included
Cumulative
risk of CRC to
age 70 years,
% (95% CI)
Quehenberger
et al. 2005102
84 HNPCC registry Adjustment for
ascertainment
(conditioned on
genotype of
proband and
phenotype
of relatives)
Censored on
polypectomy
MLH1
(n= 39),
MSH2
(n= 45)
MLH1/MSH2
M 27 (13 to 51)
F 22 (11 to 44)
MLH1
M 22 (7 to 61)
F 18 (5 to 42)
MSH2
M 30 (13 to 57)
F 25 (12 to 50)
Hendriks
et al. 200499
(Via Bonadona
et al. 2011)
20
(Via Bonadona
et al. 2011)
Multiple-case
families
(Via Bonadona
et al. 2011)
None
(Via Bonadona
et al. 2011)
None
MSH6 MSH6
M 69 (42 to 83)
F 30 (12 to 44)
Plaschke et al.
2004285
27 HNPCC registry
(AC I/II,
Bethesda),
selected MSI-H/L
and IHC normal
for MLH1
and MSH2
None None MSH6 (From figure 1)
MSH6
P ≈ 80
Green et al.
200297
12 Genetics clinic Inappropriate
exclusion
Censored at entry
to surveillance
programme
MSH2
founder
mutation
(943+ 3,
A> T)
Founder MSH2
M 81
F 59
Vasen et al.
2001286
74 HNPCC registry
(multiple-case
families)
None None MLH1
(n= 34),
MSH2
(n= 40)
(From figures 2
and 3)
MLH1
M 65
F 54
P 59
MSH2
M 73
F 54
P 64
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
348
Study
Number of
families Selection
Correction
for selection/
ascertainment
bias
Adjustment for
interventions
MMR
genes
included
Cumulative
risk of CRC to
age 70 years,
% (95% CI)
Wagner et al.
2001104
1 Referral to
clinical genetics
on FH
None None MSH6 MSH6
P 32
Aarnio et al.
1999118
50 Known mutation
carriers
None NR MLH1
(n= 47),
MSH2 (n= 3)
MLH1/MSH2
P 82
Dunlop et al.
1997101
6 Relatives of
early-onset
MSI-H CRC cases
(< 35 years)
Partial (exclusion
of index cases);
not conditioned
on phenotype
of proband
NR MLH1 (n= 1),
MSH2 (n= 5)
MLH1/MSH2
M 74
F 30
Vasen et al.
1996116
(Via abstract)
19
NR in abstract NR in abstract NR in abstract MLH1, MSH2 MLH1
P 80
MSH2
P 80
Aarnio et al.
199515
(Via abstract)
40
NR in abstract NR in abstract NR in abstract NR
in abstract
P 78
F, females; M, males; N/A, not applicable; NR, not reported; P, persons.
a Sensitivity analysis from Stoffel et al. (2009)106 no longer available online; results from Bonadona et al. (2011),2 e-table 5.
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Appendix 6 Effect of age at diagnosis on
colorectal cancer survival
T able 124 shows the net 1- and 5-year survival of CRC for various age groups.
We estimated HRs for CRC mortality during the first year since diagnosis by comparing the net survival
for the relevant age group with net survival across all ages. The HR for persons aged < 70 years was
therefore ln(83.4%)/ln(73.9%)= 0.599. Likewise, for persons aged 70–79 years the HR was ln(74.9%)/
ln(74.9%)= 0.956, and for persons aged ≥ 80 years the HR was ln(58.1%)/ln(74.9%)= 1.797.
We estimated HRs for CRC mortality during the subsequent 4 years by first calculating the conditional
survival to 5 years given survival to 1 year (Table 125), and then similarly calculating HRs by comparing
conditional survival for the relevant age group with conditional survival across all ages. The HR for persons
aged < 70 years was therefore ln(74.9%)/ln(74.3%)= 0.972. Likewise, for persons aged 70–79 years
the HR was ln(75.1%)/ln(74.3%)= 0.966, and for persons aged ≥ 80 years the HR was ln(71.8%)/
ln(74.3%)= 1.116.
TABLE 124 Net survival of CRC
Years since diagnosis
All ages
(%)
Aged < 70 years
(%)
Aged 70–79 years
(%)
Aged 80+ years
(%)
1 73.9 83.4 74.9 58.1
5 54.9 62.5 56.2 41.7
Source: ONS.147
TABLE 125 Conditional survival to 5 years
Age All ages Aged < 70 years Aged 70–79 years Aged 80+ years
Conditional survival to
5 years given survival to
1 year
54.9%/
73.9%= 74.3%
62.5%/
83.4%= 74.9%
56.2%/
74.9%= 75.1%
41.7%/
58.1%= 71.8%
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Appendix 7 Selected studies comparing survival
of individuals with Lynch syndrome colorectal cancer
with that of individuals with sporadic colorectal cancer
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
353
St
u
d
y
St
u
d
y
p
o
p
u
la
ti
o
n
s
A
d
ju
st
ed
fo
r
ag
e
A
d
ju
st
ed
fo
r
C
R
C
st
ag
e
Es
ti
m
at
io
n
m
et
h
o
d
C
en
so
ri
n
g
M
o
rt
al
it
y
ev
en
t
H
R
W
at
so
n
et
al
.
19
98
2
8
7
(p
rim
ar
y
an
al
ys
is
)
H
N
PC
C
co
h
o
rt
(n
=
27
4)
Re
tr
os
pe
ct
iv
el
y
id
en
tif
ie
d
th
ro
ug
h
H
N
PC
C
re
gi
st
rie
s,
m
ee
tin
g
cl
in
ic
al
cr
ite
ria
or
be
in
g
kn
ow
n
to
ca
rr
y
m
ut
at
io
n
(2
0
of
98
fa
m
ili
es
),
in
cl
ud
in
g
sy
nc
hr
on
ou
s
C
RC
s
an
d
m
et
ac
hr
on
ou
s
C
RC
s
if
in
de
x
C
RC
un
st
ag
ed
Tu
m
o
u
r
re
g
is
tr
y
co
h
o
rt
(n
=
82
0)
C
on
se
cu
tiv
e
C
RC
ca
se
s
at
a
si
ng
le
ho
sp
ita
l,
ex
cl
ud
in
g
m
et
ac
hr
on
ou
s
C
RC
s
Pa
rt
ia
l(
no
n-
C
RC
de
at
hs
ce
ns
or
ed
in
tu
m
ou
r
re
gi
st
ry
co
ho
rt
w
ho
ar
e
ge
ne
ra
lly
ol
de
r)
Y
es
C
ox
(p
ro
po
rt
io
na
l
ha
za
rd
s)
re
gr
es
si
on
H
N
PC
C
co
h
o
rt
C
en
so
re
d
at
da
te
of
la
st
fo
llo
w
-u
p
of
fa
m
ily
or
at
10
ye
ar
s
(w
hi
ch
ev
er
is
ea
rli
er
)
H
N
PC
C
co
h
o
rt
D
ea
th
fr
om
an
y
ca
us
e
be
fo
re
la
st
fo
llo
w
-u
p
of
fa
m
ily
0.
67
Tu
m
o
u
r
re
g
is
tr
y
co
h
o
rt
C
en
so
re
d
at
da
te
of
la
st
fo
llo
w
-u
p
if
al
iv
e
or
at
de
at
h
fr
om
no
n-
C
RC
ca
us
e
Tu
m
o
u
r
re
g
is
tr
y
co
h
o
rt
D
ea
th
fr
om
C
RC
W
at
so
n
et
al
.
19
98
2
8
7
(a
dd
iti
on
al
an
al
ys
is
)
A
s
in
pr
im
ar
y
an
al
ys
is
(r
ow
ab
ov
e)
Y
es
Y
es
C
ox
(p
ro
po
rt
io
na
l
ha
za
rd
s)
re
gr
es
si
on
H
N
PC
C
co
h
o
rt
C
en
so
re
d
at
da
te
of
la
st
fo
llo
w
-u
p
of
fa
m
ily
or
at
10
ye
ar
s
(w
hi
ch
ev
er
is
ea
rli
er
)
H
N
PC
C
co
h
o
rt
D
ea
th
fr
om
an
y
ca
us
e
be
fo
re
la
st
fo
llo
w
-u
p
of
fa
m
ily
0.
63
Tu
m
o
u
r
re
g
is
tr
y
co
h
o
rt
C
en
so
re
d
at
da
te
of
la
st
fo
llo
w
up
Tu
m
o
u
r
re
g
is
tr
y
co
h
o
rt
D
ea
th
fr
om
an
y
ca
us
e
Sa
nk
ila
et
al
.
19
96
2
8
8
(A
bs
tr
ac
t
re
vi
ew
ed
on
ly
)
H
N
PC
C
co
ho
rt
(n
=
17
5)
Sp
or
ad
ic
C
RC
co
ho
rt
(n
=
14
,0
00
)
Pa
rt
ia
lly
(s
po
ra
di
c
C
RC
co
ho
rt
lim
ite
d
to
ag
e
<
65
ye
ar
s)
?
Re
la
tiv
e
su
rv
iv
al
?
?
O
ve
ra
ll
5-
ye
ar
su
rv
iv
al
ra
te
65
%
vs
.
44
%
in
fa
vo
ur
of
H
N
PC
C
‘T
he
re
la
tiv
e
su
rv
iv
al
ra
te
s
of
pa
tie
nt
s
w
ith
H
N
PC
C
w
er
e
be
tt
er
in
ev
er
y
st
ra
ta
an
al
yz
ed
’
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
354
St
u
d
y
St
u
d
y
p
o
p
u
la
ti
o
n
s
A
d
ju
st
ed
fo
r
ag
e
A
d
ju
st
ed
fo
r
C
R
C
st
ag
e
Es
ti
m
at
io
n
m
et
h
o
d
C
en
so
ri
n
g
M
o
rt
al
it
y
ev
en
t
H
R
Be
rt
ar
io
et
al
.
19
99
2
8
9
H
N
PC
C
co
h
o
rt
(n
=
14
0)
Id
en
tif
ie
d
th
ro
ug
h
H
N
PC
C
re
gi
st
rie
s
by
A
C
Y
es
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
N
ot
st
at
ed
(p
re
su
m
ed
la
st
fo
llo
w
-u
p
ac
co
rd
in
g
to
de
fin
iti
on
of
‘o
bs
er
ve
d
su
rv
iv
al
’)
N
ot
st
at
ed
(p
re
su
m
ed
de
at
h
fr
om
an
y
ca
us
e
ac
co
rd
in
g
to
de
fin
iti
on
of
‘o
bs
er
ve
d
su
rv
iv
al
’)
1.
01
(9
5%
C
I0
.7
2
to
1.
32
)
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
20
35
)
C
on
se
cu
tiv
e
C
RC
ca
se
s
at
a
si
ng
le
ho
sp
ita
l,
ex
cl
ud
in
g
m
et
ac
hr
on
ou
s
C
RC
s
an
d
pa
tie
nt
s
w
ith
FH
of
ga
st
ro
in
te
st
in
al
ca
nc
er
Ba
rn
et
so
n
et
al
.
20
06
1
7
5
U
ns
el
ec
te
d
C
RC
pa
tie
nt
s
(n
=
87
0)
ag
ed
<
55
ye
ar
s.
G
er
m
lin
e
m
ut
at
io
n
te
st
in
g
w
as
us
ed
to
sp
lit
in
to
tw
o
co
ho
rt
s:
H
N
PC
C
co
ho
rt
(n
=
38
)
Sp
or
ad
ic
C
RC
co
ho
rt
(n
=
83
2)
N
o
(b
ut
al
ld
ia
gn
os
ed
<
55
ye
ar
s
so
un
lik
el
y
to
ha
ve
ef
fe
ct
)
Y
es
Lo
g-
ra
nk
te
st
En
d
of
st
ud
y
(n
on
e
lo
st
to
fo
llo
w
-u
p)
D
ea
th
fr
om
an
y
ca
us
e
N
ot
re
po
rt
ed
,
bu
t
no
si
gn
ifi
ca
nt
di
ff
er
en
ce
in
su
rv
iv
al
be
tw
ee
n
ca
rr
ie
rs
an
d
no
n-
ca
rr
ie
rs
w
he
n
st
ra
tif
ie
d
by
lo
ca
lis
ed
/
m
et
as
ta
tic
(p
=
0.
6)
A
ar
ni
o
et
al
.
19
98
1
4
(a
bs
tr
ac
t
re
vi
ew
ed
on
ly
)
H
N
PC
C
co
ho
rt
(n
=
43
)
Sp
or
ad
ic
C
RC
co
ho
rt
(n
=
12
2)
?
?
?
?
?
0.
41
(p
=
0.
02
)
El
sa
ko
v
an
d
K
ur
tin
ai
tis
20
06
2
9
0
H
N
PC
C
co
h
o
rt
(n
=
8)
C
RC
ca
se
s
fr
om
H
N
PC
C
fa
m
ili
es
w
ith
pr
ov
en
M
LH
1/
M
SH
2
m
ut
at
io
ns
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
26
3)
Re
tr
os
pe
ct
iv
el
y
id
en
tif
ie
d
co
ho
rt
,
ag
e
m
at
ch
ed
an
d
w
ith
st
ag
e
II
or
III
C
RC
Y
es
(a
ge
m
at
ch
ed
)
Pa
rt
ia
l(
lim
it
an
al
ys
is
to
st
ag
e
II/
III
bu
t
pr
op
or
tio
ns
di
ff
er
en
t)
K
ap
la
n–
M
ei
er
W
ilc
ox
on
En
d
of
st
ud
y
pe
rio
d
?
Im
pr
ov
ed
10
-y
ea
r
su
rv
iv
al
(8
7.
5%
vs
.
44
.8
%
)
(p
=
0.
03
)
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
355
St
u
d
y
St
u
d
y
p
o
p
u
la
ti
o
n
s
A
d
ju
st
ed
fo
r
ag
e
A
d
ju
st
ed
fo
r
C
R
C
st
ag
e
Es
ti
m
at
io
n
m
et
h
o
d
C
en
so
ri
n
g
M
o
rt
al
it
y
ev
en
t
H
R
Fu
jit
a
et
al
.
19
96
2
9
1
H
N
PC
C
co
ho
rt
(n
=
14
)
C
RC
ca
se
s
m
ee
tin
g
A
C
Sp
or
ad
ic
C
RC
co
ho
rt
(n
=
16
04
)
C
RC
ca
se
s
w
ith
ou
t
FH
of
ca
nc
er
N
o
N
o
K
ap
la
n–
M
ei
er
Lo
g-
ra
nk
te
st
?
?
Im
pr
ov
ed
5-
ye
ar
su
rv
iv
al
(9
2.
3%
vs
.
60
.0
%
)
(p
<
0.
05
)
H
ag
hi
gh
ie
t
al
.
20
09
2
9
2
H
N
PC
C
co
h
o
rt
(n
=
61
)
C
RC
pa
tie
nt
s
fr
om
H
N
PC
C
fa
m
ili
es
(B
et
he
sd
a
gu
id
el
in
es
)
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
60
)
C
on
se
cu
tiv
e
C
RC
ca
se
s
w
ith
ou
t
FH
Pa
rt
ly
(s
tr
at
ifi
ed
by
ag
e
ab
ov
e
or
be
lo
w
50
ye
ar
s)
N
o
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
?
?
0.
34
1
(9
5%
C
I0
.1
23
to
0.
94
3)
Li
n
et
al
.
19
98
1
7
6
H
N
PC
C
co
h
o
rt
(n
=
75
)
C
RC
ca
se
s
fr
om
H
N
PC
C
fa
m
ili
es
w
ith
M
LH
1/
M
SH
2
m
ut
at
io
ns
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
75
5)
Pr
es
um
ed
to
be
th
e
sa
m
e
gr
ou
p
as
W
at
so
n
et
al
.1
99
8
Pa
rt
ia
l(
no
n-
C
RC
de
at
hs
ce
ns
or
ed
in
tu
m
ou
r
re
gi
st
ry
co
ho
rt
w
ho
ar
e
ge
ne
ra
lly
ol
de
r)
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
N
on
-C
RC
de
at
h
H
N
PC
C
co
h
o
rt
D
ea
th
fr
om
an
y
ca
us
e
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
C
RC
de
at
h
0.
57
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
356
St
u
d
y
St
u
d
y
p
o
p
u
la
ti
o
n
s
A
d
ju
st
ed
fo
r
ag
e
A
d
ju
st
ed
fo
r
C
R
C
st
ag
e
Es
ti
m
at
io
n
m
et
h
o
d
C
en
so
ri
n
g
M
o
rt
al
it
y
ev
en
t
H
R
M
yr
hø
je
t
al
.
19
97
2
9
3
(a
bs
tr
ac
t
re
vi
ew
ed
on
ly
)
H
N
PC
C
co
ho
rt
(n
=
10
8)
Sp
or
ad
ic
C
RC
co
ho
rt
(n
=
87
0)
?
?
?
?
?
Im
pr
ov
ed
5-
ye
ar
su
rv
iv
al
(6
2%
vs
.
39
%
)
Pe
rc
es
ep
e
et
al
.
19
97
2
9
4
H
N
PC
C
co
h
o
rt
(n
=
85
)
C
RC
ca
se
s
fr
om
fa
m
ili
es
m
ee
tin
g
A
C
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
37
7)
C
on
se
cu
tiv
e
C
RC
ca
se
s
no
t
in
H
N
PC
C
co
ho
rt
Y
es
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
N
on
-C
RC
de
at
h
C
RC
de
at
h
0.
74
1
(9
5%
C
I0
.4
42
to
1.
26
6)
St
ig
lia
no
et
al
.
20
08
2
9
5
H
N
PC
C
co
h
o
rt
(n
=
40
)
Pa
tie
nt
s
m
ee
tin
g
A
C
I
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
57
3)
C
on
se
cu
tiv
e
C
RC
ca
se
s
w
ith
ou
t
FH
N
o
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
N
ot
st
at
ed
A
ny
de
at
h
H
N
PC
C
su
rv
iv
al
su
pe
rio
r
(p
<
0.
00
01
)
Y
ou
et
al
.
20
06
2
9
6
H
N
PC
C
co
h
o
rt
(n
=
56
)
C
RC
ca
se
s
m
ee
tin
g
A
C
Sp
o
ra
d
ic
C
R
C
co
h
o
rt
(n
=
14
7)
C
RC
ca
se
s
w
ith
ou
t
FH
,
ag
e-
,
se
x-
an
d
C
RC
-s
ite
m
at
ch
ed
to
H
N
PC
C
co
ho
rt
N
/A
(a
ge
m
at
ch
ed
)
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
Lo
ss
to
fo
llo
w
-u
p
N
on
-C
RC
de
at
h
C
RC
de
at
h
N
o
di
ff
er
en
ce
(p
=
0.
77
4)
DOI: 10.3310/hta18580 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 58
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
357
St
u
d
y
St
u
d
y
p
o
p
u
la
ti
o
n
s
A
d
ju
st
ed
fo
r
ag
e
A
d
ju
st
ed
fo
r
C
R
C
st
ag
e
Es
ti
m
at
io
n
m
et
h
o
d
C
en
so
ri
n
g
M
o
rt
al
it
y
ev
en
t
H
R
Ru
ss
o
et
al
.
20
09
2
9
7
C
RC
ca
se
s
(n
=
52
6)
fr
om
A
C
fa
m
ili
es
.
G
er
m
lin
e
m
ut
at
io
n
te
st
in
g
w
as
us
ed
to
sp
lit
in
to
tw
o
co
ho
rt
s:
M
ut
at
io
n
po
si
tiv
e
(M
LH
1/
M
SH
2)
(n
=
25
8)
M
ut
at
io
n
ne
ga
tiv
e
(n
=
26
8)
Y
es
Y
es
C
ox
pr
op
or
tio
na
l
ha
za
rd
s
re
gr
es
si
on
N
ot
re
po
rt
ed
N
ot
re
po
rt
ed
0.
71
(9
5%
C
I0
.5
1
to
0.
98
)
N
/A
,
no
t
ap
pl
ic
ab
le
.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
358
Appendix 8 Analysis of data from Ian Frayling
D r Ian Frayling MA PhD FRCPath FEBLM, Consultant in Genetic Pathology and Laboratory Director,All Wales Medical Genetics Service
Description of data
Anonymised data were provided by Ian Frayling from the All Wales Medical Genetics Service, including
details of predictive tests within 33 families with LS mutations. For each predictive test we were provided
with the date when the family mutation was first reported, the date when the predictive test result was
reported, the sex of the person receiving the predictive test and whether or not they were diagnosed as a
LS carrier. In some cases the data also contained the kinship of the predictive test, i.e. whether the person
was a FDR, SDR or more distant relation of the index case.
The data cover reports from October 2000 to November 2012 and include details of 109 predictive tests
on members of 33 families. The mean time between diagnostic test and predictive test was 747 days
(median 415 days, interquartile range 182–1206 days, range 0–3510 days).
Proportion of relatives who test positive
Of the 109 relatives who received predictive testing, 44 (40%, 95% CI 31% to 50%) tested positive for
the family mutation. There is significant evidence to suggest that the true proportion who would test
positive is < 0.5 (one-tailed binomial test, p= 0.027), and there are a number of factors which contribute
to this, including non-paternity, de novo mutations, mortality bias and offering testing to those at < 50%
genetic risk because it is not possible (e.g. owing to death or to testing being declined) or not appropriate
to test intervening relatives.
Proportion of relatives who are male
Of the 109 relatives who received predictive testing, 39 (36%, 95% CI 27% to 46%) were male. There is
significant evidence to suggest that the true proportion who would be male is not 0.5 (two-tailed binomial
test, p= 0.004). Ian Frayling also analysed the sex of the index cases (those receiving diagnostic tests) and
found that there were 17 female and 16 male index cases. It is his belief that men are less likely to take up
predictive testing than women and we cannot identify any alternative explanations.
Independence of test result and sex
We tested whether or not the test result and sex of the relative were dependent variables by constructing
a 2 × 2 table (Table 126) and using a Pearson’s chi-squared test. We found no evidence of dependency
(chi-squared= 0.262, degrees of freedom= 1, p= 0.61).
TABLE 126 2 × 2 table of test result and sex
Sex Mutation found (n) Mutation not found (n)
Male 17 22
Female 27 43
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Kinship of relatives to proband
For 70 (64%) of the 109 tests, we were provided with the kinship of the relative being tested to the
proband. These are summarised in Table 127, which shows that 47% of relatives tested are FDRs while
53% are more distantly related.
Expected number of relatives tested per proband over time
The data provided clearly indicated that relatives are not tested immediately after a positive diagnostic test.
It is important to know the expected number of relatives that would be tested for each proband over time
as this has an effect on workload and the overall effectiveness of testing (if all relatives waited decades
before being tested for the family mutation, most of the potential benefit of testing would have
been forgone).
We analysed the number of relatives tested per proband by using a Kaplan–Meier-style estimator. We
assumed that all families were censored at the date of the most recent database search (an effective ‘study
end’ date of 1 November 2012).
If di is the number of predictive tests at time ti and ni is the number of families still being observed at time
ti, our estimator is
K^(t) =∑
ti<t
di
ni
(7)
Results of applying this method are given in Tables 128 and 129 and Figure 126.
TABLE 128 Expected number of relatives tested over time
Time since proband diagnostic test (months) Expected number of relatives tested
3 0.52
6 0.85
12 1.53
18 2.06
24 2.28
36 2.45
48 2.95
60 3.16
120 4.33
TABLE 127 Kinship of relatives to probands
Kinship to proband Number of predictive tests
FDR 33
SDR 12
Third- or higher-degree relative 25
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Adjustment for families without predictive tests
The data provided do not include families without any predictive tests. Ian Frayling has advised that the
number of such families would be very low as the likelihood of identifying family members for testing is
considered during genetic counselling, and, as a result, people without relatives would be less likely to
be tested. Ian Frayling gave an estimate that 2% of probands, or fewer, would never identify relatives to
be tested. To investigate the effect of this on our analysis, we added a family which would be observed
throughout the experiment but would never lead to a predictive test. As there were originally 33 families,
this meant that 1 out of 34= 2.9% of probands would never identify relatives to be tested.
The results with the adjustment are given in Tables 130 and 131 and Figure 127. Figure 128 additionally
shows a comparison plot of the estimator with and without the adjustment.
TABLE 129 Expected time since proband diagnostic test to test a specified number of relatives
Number of relatives tested Expected time since proband diagnostic test (months)
1 6.6
2 16.9
3 52.8
4 97.5
0
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FIGURE 126 Expected number of relatives tested per proband (ticks indicate when families are censored).
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TABLE 130 Expected number of relatives tested over time after adjusting for probands never identifying relatives
for testing
Time since proband diagnostic test (months) Expected number of relatives tested
3 0.50
6 0.82
12 1.48
18 2.00
24 2.21
36 2.38
48 2.85
60 3.05
120 4.13
TABLE 131 Expected time since proband diagnostic test to test a specified number of relatives after adjusting for
probands never identifying relatives for testing
Number of relatives tested Expected time since proband diagnostic test (months)
1 7.1
2 18.1
3 54.1
4 99.9
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FIGURE 127 Expected number of relatives tested per proband, accounting for the possibility of probands never
identifying relatives for testing (ticks indicate when families are censored).
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FIGURE 128 Effect of adjusting for probands never identifying relatives for testing.
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Appendix 9 Data from the Wessex Clinical
Genetics Service
Anonymised data were kindly provided by Dr Munaza Ahmed relating to diagnostic and predictive testsfor LS performed by the Wessex Clinical Genetics Service. The data related to 208 families, and
consisted of 527 test results in total. For each test result, the sex of the subject was recorded, and for
443 results the age of the subject at testing or counselling was also recorded. The data unfortunately did
not specify whether the test result was for a diagnostic or a predictive test.
Data processing
We were advised by Dr Ahmed that only the first test record for each family could be a diagnostic test and
that it would not have been a diagnostic test if the result was ‘mutation absent’. This allowed us to
identify 355 tests as being predictive tests (319 tests were not the first test in the family and 36 were the
first test and had the result ‘mutation absent’).
We were further advised that all tests with the result ‘VUS’ (variants of unknown significance) would have
been diagnostic tests. This allowed us to identify 11 tests as being diagnostic tests.
Of the 319 predictive tests which were not the first test record for a family, 145 (45%) had the result
‘carrier’ and 174 (55%) had the result ‘mutation absent’ (Table 132). We estimated that 30 of the
161 tests with the result ‘carrier’ which were the first test record for a family but could not be definitely
classed as predictive or diagnostic would have been predictive, which gave us the same proportion of
carriers in the predictive tests which were the first records as for subsequent records.
Number of predictive tests for each proband identified
We estimated that in total there were 385 predictive tests and 142 diagnostic tests, which gives a ratio of
2.7 predictive tests for each proband identified.
Sex of relatives receiving predictive testing
We analysed the sex of relatives in predictive tests which were not the first test in a family (as these would
have been entirely non-carriers and might affect the sex distribution) (Table 133).
The data suggest that 38.6% of relatives receiving predictive testing are male (95% CI 33.2% to 44.1%).
Results of predictive testing
We analysed the results of predictive tests which were not the first test in a family (as these would have
been carried out entirely among non-carriers) (Table 134).
Relationship between sex and results of predictive testing
We analysed the relationship between sex and the results of predictive tests which were not the first test in
a family (Table 135).
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There is no statistically significant evidence of a relationship between sex and the results of predictive
testing (chi-squared p-value= 0.24; risk ratio male vs. female= 1.16, 95% CI 0.91 to 1.47).
Age at predictive testing
We analysed the age at testing or counselling in predictive tests which were not the first test in a family
(as these would have been carried out entirely among non-carriers, which might affect the age
distribution). The age distribution is shown in Figure 129. It can be seen clearly that there are very few
tests on relatives under the age of 20 years, which is to be expected because the test result would be
unlikely to have an impact on clinical management at this age. Likewise, testing is less likely to affect
clinical management for people aged > 70–75 years, as guidelines suggest that this is the maximum age at
which surveillance should be offered.
TABLE 132 Wessex Clinical Genetics Service record characteristics
Test result First test record (n) Subsequent test record (n) Total (n)
Carrier 30 145 175
Mutation absent 36 174 210
Total 66 319 385
TABLE 135 Tabulation of carrier status and sex
Sex Carrier (n) Mutation absent (n) Total (n)
Female 84 112 196
Male 61 62 123
Total 145 174 319
TABLE 133 Sex of relatives receiving predictive genetic testing
Sex Number of relatives (%)
Female 196 (61)
Male 123 (39)
Total 319 (100)
TABLE 134 Results of predictive genetic testing
Test result Number of relatives (%)
Carrier 145 (45)
Mutation absent 174 (55)
Total 319 (100)
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FIGURE 129 Age distribution of relatives receiving predictive testing.
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Appendix 10 Deriving the hazard ratio for
colorectal cancer incidence due to Lynch syndrome
surveillance colonoscopies from Jarvinen and
colleagues (2000)
We extracted CRC incidence events from the Kaplan–Meier curves given in figure 1 of Jarvinen andcolleagues94 for those with mutations. We estimated time of CRC incidence to 0.1-year accuracy as
the figure did not allow more accurate extraction. We confirmed that the number of incident CRCs
extracted matched the number described in the text (8/44 in the study group, 19/46 in the control group).
We then assumed one censored individual in each group within 15 years to match the reported 15-year
Kaplan–Meier survival. The remainder of each cohort was assumed to be censored at 15 years. We
believed that very few individuals would have been censored as the steps in the Kaplan–Meier curves were
of almost identical height on each curve. We assumed that one individual in the study group was censored
between 7.5 years and 11.5 years, and that one individual in the control group was censored at 1.3 years
(the minimum follow-up in the control group including non-carriers was 1 year 4 months). Our extracted
survival data are presented in Table 136 and Figure 130.
Using the extracted survival data we performed Cox proportional hazards regression and obtained a HR
for CRC incidence of 0.387 (95% CI 0.169 to 0.885) for those undergoing surveillance versus those not
undergoing surveillance. We tested the proportional hazards assumption using the command ‘estat phtest’
in Stata Version 12 (StataCorp LP, College Station, TX, USA) which gave a p-value of 0.246, indicating that
the proportional hazards assumption could not be rejected.
TABLE 136 Colorectal cancer-free survival data extracted from figure 1 of Jarvinen and colleagues94
Group Incident CRCs (years)
Censoring events
(years)
15-year CRC-free
survival
Study group
(with surveillance)
0.0, 0.0, 5.0, 5.1, 5.5, 7.5, 11.5, 11.8 10.0 0.817
Control group
(no surveillance)
2.7, 3.0, 3.5, 4.1, 4.6, 5.3, 5.5, 5.7, 5.8, 6.1, 6.2, 6.7,
7.7, 8.4, 9.1, 13.3, 14.1, 14.3, 14.5
1.3 0.578
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FIGURE 130 Reconstructed Kaplan–Meier curves from Jarvinen and colleagues (2000).94
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Appendix 11 Literature review of the
effectiveness of surveillance for endometrial cancer
We searched the literature for evidence of the effectiveness of gynaecological surveillance for patientswith LS. Titles and abstracts were screened by one reviewer (TS) for inclusion (Figure 131).
Thirteen references65,107,167,190–194,196,298–301 were included on the basis of title and abstract screening. Of
these, seven references107,190,191,194,196,298,299 were primary studies (two298,299 were conference abstracts and
the remaining five were peer-reviewed full papers), five references65,167,192,193,300 were papers including a
review of the literature and one301 was a letter in response to Dove-Edwin and colleagues.190
After reviewing full texts, we excluded four primary studies194,196,298,299 as they did not include an
appropriate comparator. We excluded the paper by Schorge and colleagues300 as it did not include any
relevant studies (all studies related to other hereditary causes of OC). We excluded the letter by Wood and
colleagues301 as it did not contain any study results and, as a letter, was not peer-reviewed.
Our final set of included references comprised three primary studies107,190,191 and four reviews.65,167,192,193
Primary studies
Dove-Edwin and colleagues190 describe the outcomes of surveillance for endometrial carcinoma in
292 patients recruited by the Imperial Cancer Research Fund (ICRF) Family Cancer Clinic at St. Mark’s Hospital,
London (n= 184) or the Netherlands Foundation for the Detection of Hereditary Tumours (n= 180). Patient
records were examined retrospectively and 269 were informative for the analysis, of which 171 were from
families meeting the AC and 98 were from families meeting other clinical criteria suggestive of LS and/or
having a LS mutation. Of the 269 women analysed, 222 had at least one scan, meaning that 47 had no TVU
scan and could be considered a control group. In the ‘intervention group’ (women receiving at least one
TVU scan) there were two endometrial carcinomas, both interval cancers detected following symptomatic
presentation and both stage I. In the ‘control group’ (women not receiving a TVU scan) there were no
endometrial carcinomas.
Jarvinen and colleagues107 evaluate the effectiveness of surveillance in 242 healthy patients with LS
mutations. Of these, 103 were women who were eligible for surveillance when they were recruited.
Three women declined surveillance and could be considered a control group. In the ‘intervention group’
(women complying with EC surveillance), 16 ECs were detected during screening (12 at stage I, two at
stage II and two at stage III) in addition to one EC at stage I being found following prophylactic
hysterectomy. One interval EC was detected at stage I. Three OCs were detected during screening
(two at stage I, one at stage II) and two interval OCs were discovered (one at stage I, one at stage III).
In the ‘control group’ (women not complying with EC surveillance), one stage I EC and one stage I OC
were discovered following symptomatic presentation.
Renkonen-Sinisalo and colleagues191 describe the results of EC screening in 385 women with LS mutations.
They also describe the characteristics of 83 women with LS mutations who were affected by EC before
surveillance was instituted. The two groups of women cannot be compared in terms of EC incidence as
the second group is recruited as 100% affected by EC, but it is possible to compare the stage distributions
of ECs in the two groups. The stage distributions for the two groups are shown in Table 137. EC survival
was not significantly different for the two groups.
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n = 175 titles and 
abstracts 
n = 13 included titles
and abstracts 
n = 2 duplicates excluded
n = 151 excluded by title/abstract
n = 9 could not be assessed
n = 6 included studies:
• n = 3 primary studies 
• n = 4 reviews 
n = 4 primary research studies 
excluded due to no comparator 
n = 1 review excluded due to no 
relevant included studies 
n = 1 letter to authors excluded 
(contained no study results) 
FIGURE 131 Included studies.
TABLE 137 Endometrial cancer stage in Renkonen-Sinisalo and colleagues191
FIGO stage Intervention group (n) Control group (n)
I 12 (6× IA, 6× IB) 67 (27× IA, 32× IB, 8× IC)
II 1 (1× IIB) 2 (1× IIA, 1× IIB)
III 1 (1× IIIA) 11 (4× IIIA, 7× IIIC)
IV 0 2 (2× IVB)
Unknown 0 1
FIGO, International Federation of Gynaecology and Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique).
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Analysis of primary studies
We expect surveillance to reduce the incidence of gynaecological cancers by the following mechanisms:
l detection and removal by operative hysteroscopy of pre-malignancies195,196
l detection of pre-malignancies leading to prophylactic hysterectomy (perhaps with bilateral
salpingo-oophorectomy)191,194
l FP screening leading to prophylactic hysterectomy.
We also expect surveillance to improve the stage distribution of gynaecological cancers by the
following mechanisms:
l screen-detected asymptomatic malignancies
l symptomatic malignancies detected during screening which would not have presented until later and
may not have been accurately diagnosed, for example in primary care.
It is also possible that surveillance could improve awareness and response to symptoms, but equally
surveillance could give false reassurance.
In our analysis, therefore, we look for reduction in incidence of gynaecological cancers and an improvement
in the stage distribution of cancers. We evaluate whether or not a reduction in incidence has been achieved
by examining the relative risk of gynaecological cancers individually and combined (Table 138), and evaluate
whether or not the stage distribution has been improved using ordered logistic regression (Table 139).
Note that in none of the analyses are we able to draw statistically significant conclusions.
Existing reviews
Auranen and Joutsiniemi192 conducted a systematic review of gynaecological cancer screening in women
belonging to LS families, which had five included studies.190,191,194–196 In our review, the study by Lécuru
and colleagues195 was excluded because the abstract suggested there was no comparator for the
surveillance strategy. Auranen and Joutsiniemi conclude that the studies they included do not allow for
evidence-based decision-making.
TABLE 138 Relative risks of gynaecological cancers and prophylactic hysterectomy for gynaecological surveillance
Study Intervention arm Control arm
Relative risk of
gynaecological
cancer (95% CI)
Relative risk of
prophylactic
hysterectomy (95% CI)
Dove-Edwin
et al. 2002190
222 patients, 2 EC 47 patients, 0 EC Not computed Not computed
Jarvinen et al.
2009107
100 patients: 17 EC,
5 OC, 47 prophylactic
hysterectomy
3 patients: 1 EC,
1 OC, 1 PH
EC 0.510
(0.097 to 2.677)
OC 0.150
(0.024 to 0.920)a
Gynaecological cancer
0.330 (0.137 to 0.797)a
1.410 (0.281 to 7.080)
a Fisher exact p-value> 0.1, i.e. CI approximation not good.
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Koornstra and colleagues193 conducted a review of extracolonic cancers, including gynaecological cancer
screening, and included three studies relevant to gynaecological cancer screening.190,191,196 They conclude
that the only evidence of surveillance benefit is that TVU and endometrial sampling detect endometrial
tumours in early stages from the study by Renkonen-Sinisalo and colleagues,191 despite this study not
reporting a statistical difference by the Pearson chi-squared method.
Lindor and colleagues167 included two studies190,196 and concluded that there was insufficient evidence to
argue for or against endometrial sampling or TVU.
Palomaki and colleagues65 included three studies190,191,196 and concluded that TVU is not highly effective at
identifying ECs in women with LS but that endometrial biopsy is effective at identifying both pre-malignant
and malignant lesions according to the study by Renkonen-Sinisalo and colleagues.191 Palomaki and
colleagues recommend surveillance for women with LS but say that ‘Inadequate data are available to
document that transvaginal ultrasound and endometrial biopsy can reduce the incidence of
endometrial cancer.’
We conclude that there is insufficient evidence to suggest that gynaecological cancer surveillance reduces
the incidence of gynaecological cancers or improves the survival of cancers when individuals are affected.
TABLE 139 Statistical analysis of gynaecological cancer stage
Study Intervention arm Control arm Statistical analysis
Dove-Edwin
et al. 2002190
EC
2× stage I
EC
None
Not done
Jarvinen et al.
2009107
EC
12× stage I,
2× stage II,
2× stage III
EC
1× stage I
Ordered logistic regression cannot be used without
more data in control arm
OC
3× stage I,
1× stage II,
1× stage III
OC
1× stage I
Renkonen-Sinisalo
et al. 2007191
EC
12× stage I,
1× stage II,
1× stage III
EC
67× stage I,
2× stage II,
11× stage III,
2× stage IV
Ordered logistic regression with four main
stages
Coefficient of surveillance not statistically
significant (z= –0.45, p= 0.651)
Predicted stage distribution:
Intervention: 0.864 stage I, 0.025 stage II,
0.095 stage III, 0.015 stage IV
Control: 0.815 stage I, 0.032 stage II, 0.130
stage III, 0.022 stage IV
Ordered logistic regression with 10 substages
Coefficient of surveillance not statistically
significant (z= –1.03, p= 0.302)
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Appendix 12 Calculating utility scores from
van Duijvendijk and colleagues
The study by van Duijvendijk and colleagues201 compares the HRQoL of colectomy and IRA versusproctocolectomy and IPAA in patients receiving major prophylactic surgery for FAP, as well as HRQoL in
patients from the general population. Quality of life was measured using the SF-36 questionnaire. The
authors report the number of patients in each group, their mean age (and the standard deviation of their
age), and the mean values and standard deviations in the eight main categories in the SF-36 questionnaire
(Table 140) and the health transition category.
Ara and Brazier228 describe a methodology to calculate utility scores from SF-36 category scores. Their
methodology is described by seven models, of which models 1–5 and 7 are special cases of model 6, the
most general model supplied, in which all eight categories have corresponding coefficients, as do age and
age squared and also the squared values of four categories (PF, SF, MH, BP). Models 4–7 require the
squared values of some variables.
The utility score for a single patient, denoted i, is calculated by
Ui = αþ β⋅xi (8)
where α is the intercept, xi is the vector of questionnaire results and patient characteristics,
xi = (PFi, SFi, RPi, REi,MHi,VT i, BPi,GHi,Agei,Age2i , PF
2
i , SF
2
i ,MH
2
i , BP
2
i )
T
(9)
and β is the set of coefficients derived and published in the paper.
TABLE 140 Short Form questionnaire-36 items categories
Abbreviation Category
PF Physical functioning
RP Role functioning: physical
BP Bodily pain
GH General health perceptions
VT Vitality
SF Social functioning
RE Role functioning: emotional
MH Mental health
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The mean utility for a set of patients is calculated by
U =
∑ni¼1Ui
n
(10)
where n is the number of patients. By linearity of expectation, this can be written as
U = αþ β⋅x (11)
where x is the vector of mean values across all patients. Note that the mean value of Age2 is not generally
equal to the square of the mean value of Age (this may explain the discrepancy between our calculated
values and those of Dinh and colleagues55), but as standard deviations and patient numbers are provided we
can calculate the appropriate mean values of these squared variables. If s is the sample standard deviation of
a variable x and we want to calculate E[x2]=∑(x2)/n we make use of the following formula for s:
s=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑(x2)−
(∑x)2
n
n−1
vuut
(12)
to calculate that
∑(x2)= s(n−1)þ (∑x)
2
n
(13)
and therefore
E½x2= ∑x
2
n
¼ s(n−1)þ
(∑x)
n
2
n
. (14)
Using this formula we calculated the additional information (Table 141) necessary to apply all the models
in the study by Ara and Brazier228 to calculate utility scores for the three groups.
With this information we computed the utility scores for the three groups using the seven different
models, and therefore the utility decrement for the two types of surgery using each model (Table 142).
TABLE 141 Additional calculations necessary for calculation of utility scores
Parameter
General population (n= 279) IRA (n= 161) IPAA (n= 118)
E[x] E[x2] E[x] E[x2] E[x] E[x2]
PF 88.8 8141 56.3 3359 55.9 3272
SF 86.4 7864 67.4 4868 64.8 4675
MH 77.6 6300 65.3 4522 63.7 4390
BP 77.9 6573 37.2 1443 36.7 1403
Age 39 1716 41 1905 37 1512
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TABLE 142 Estimated utility scores
Calculation model
General population
(mean age 39 years)
Group 1: IRA
(mean age 41 years)
Group 2: IPAA
(mean age 37 years)
Utility score
Model 1 0.873 0.583 0.575
Model 2 0.877 0.590 0.585
Model 3 0.881 0.596 0.589
Model 4 0.909 0.650 0.642
Model 5 0.895 0.639 0.632
Model 6 0.837 0.630 0.623
Model 7 0.852 0.641 0.633
Disutility from general population
Model 1 0.290 0.299
Model 2 0.287 0.293
Model 3 0.285 0.292
Model 4 0.259 0.267
Model 5 0.255 0.263
Model 6 0.208 0.214
Model 7 0.211 0.218
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Appendix 13 Estimating costs of colorectal
cancer surgery
TABLE 143 Mapping procedures to HRGs and corresponding reference costs
Procedure Relevant OPCS codes Corresponding HRGs
HRG unit cost
(2011–12
prices151) (£)
Unit costs
uprated to
2013–14
prices (£)
Segmental resection
(proximal without
exteriorisation)
H061, H062, H063 Extended right
hemicolectomy
H071, H072, H073 Right hemicolectomy
H081, H082, H083 Transverse colectomy
FZ75 Proximal colon
procedures, 19 years
and over
5576 5969
Segmental resection
(distal without
exteriorisation)
H091, H092, H093 Left hemicolectomy
H101, H102, H103 Sigmoid colectomy
FZ76 Distal colon
procedures, 19 years
and over
5411 5792
Segmental resection
(with exteriorisation)
H114 Colectomy and Ileostomy NEC
H115 Colectomy and exteriorisation of
bowel NEC
FZ74 Complex large
intestine procedures,
19 years and over
6831 7313
Subtotal colectomy
with IRA
H051 Total colectomy and anastomosis of
ileum to rectum
H053 Total colectomy and ileostomy NEC
FZ74 Complex large
intestine procedures,
19 years and over
6831 7313
Anterior resection H331 Abdominoperineal excision of
rectum and end colostomy
H332 Proctectomy and anastomosis of
colon to anus
H333 Anterior resection of rectum and
anastomosis of colon to rectum using
staples
H334 Anterior resection of rectum and
anastomosis NEC
H336 Anterior resection of rectum and
exteriorisation of bowel
H338 Other specified excision of rectum
FZ74 Complex large
intestine procedures,
19 years and over
6831 7313
Proctocolectomy
with IPAA
H042 Panproctocolectomy and
anastomosis of ileum to anus and creation
of pouch HFQ
FZ74 Complex large
intestine procedures,
19 years and over
6831 7313
Stoma reversal H154 Closure of colostomy FZ50 Intermediate large
intestine procedures,
19 years and over
451 482
HFQ, however further qualified; NEC, not elsewhere classified.
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The costs of subtotal colectomy with IRA, anterior resection and proctocolectomy with IPAA were
therefore £7313 for all patients, plus stoma reversal costing £482 for the proportion of patients who
required stomas and whose stomas were subsequently reversed. In the study by Trueman and
colleagues,134 67% of rectal cancer patients and 14.5% of colon cancer patients require a stoma, with
26.6% of stomas subsequently reversed. Therefore, the cost of stoma reversal is incurred by 17.8% of
rectal cancer patients and 3.9% of colon cancer patients. All subtotal colectomy patients will have colon
cancer and hence 3.9% of subtotal colectomies are followed by a stoma reversal, giving a total cost of
£7313 + 0.039 × £482 = £7331. All anterior resection patients will have rectal cancer and hence 17.8% of
anterior resections are followed by a stoma reversal, giving a total cost of £7313 + 0.178 × £482 = £7399.
Proctocolectomy patients may have colon cancer or rectal cancer but the nature of the operation is such
that most patients will require a temporary stoma,302 so we assumed that 26.6% of proctocolectomies
would be followed by stoma reversal, giving a total cost of £7313 + 0.266 × £482 = £7441.
It is documented by Dinh and colleagues (within an online appendix)55 that LS colon cancers have a greater
tendency to be located in the proximal colon (81% of colon cancers in the proximal colon), whereas
sporadic colon cancers are more evenly spread (in 2010, 10,499/21,664= 48% of colon cancers were
proximal to the splenic flexure119). The cost for segmental resection in our model is therefore dependent on
whether or not the CRC patient has LS.
For LS patients receiving segmental resection, we assumed that 81% of segmental resections would be in
the proximal colon with the remainder in the distal colon. We assumed that 14.5% of segmental
resections would require a stoma, independent of whether they were proximal or distal. We assumed that
26.6% of segmental resections requiring a stoma would be followed by a stoma reversal. Therefore, the
expected cost of a segmental resection in a LS colon cancer patient is 0.145 × (£7313+ 0.266 × £482)+
(1 – 0.145) × (0.81 × £5969+ 0.19 × £5792)= £6154.
For sporadic CRC patients receiving segmental resection, we assumed that 48% of segmental resections
would be in the proximal colon with the remainder in the distal colon. Similarly to the calculation for LS
cost, we calculate 0.145 × (£7313+ 0.266 × £482)+ (1 – 0.145) × (0.48 × £5969+ 0.52 × £5792)= £6104.
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Appendix 14 Net health benefit
Let Ci denote the total costs of strategy i, and similarly let Bi denote the total health benefits of strategy i(measured in, for example, QALYs). If one is willing to pay λ units of cost for a unit of health benefit
then the NHB of strategy i is
NHBi = Bi−
Ci
λ
(15)
The INHB of strategy i versus the base strategy (strategy 1) is
ΔNHBi =NHBi−NHB1 = (Bi−
Ci
λ
)−(B1−
C1
λ
)= (Bi−B1)−(
Ci−C1
λ
) (16)
Suppose that Bi and Ci can be expressed as weighted sums across random variables and an intercept term:
Bi = bi þ∑
j
ai jX j (17)
Ci = ci þ∑
j
ai jY j (18)
We can also then express the INHBs as weighted sums across random variables with intercept terms:
ΔNHBi = ((bi−b1)þ∑
j
(ai j−a1 j)X j)−
1
λ
((ci−c1)þ∑
j
(ai j−a1 j)Y j)= (bi−b1)−
1
λ
(ci−c1)
þ∑
j
(ai j−a1 j)(X j−
Y j
λ
) (19)
We can therefore calculate the variance of the INHB as a function of the variances of Xj and Yj:
Var½ΔNHBi ¼ ∑
j
(ai j−a1 j)2(Var½X j þ Var½Y j
λ2
) (20)
This is applied in our setting where Xj and Yj are, respectively, the discounted total QALYs and the discounted
total costs for patient group j and aij is the number of patients in patient group j using strategy i.
Tables 144–146 give the results in the base case.
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TABLE 144 Discounted total QALYs and costs for patient groups
j Proband/relative LS LS diagnosed LS surveillance Male
Xj Yj (£)
Mean SE Mean SE
1 Relative False False False True 16.316 0.0636 743 39
2 Relative False False False False 16.394 0.0587 604 36
3 Relative False True False True 16.284 0.0634 747 39
4 Relative False True False False 16.402 0.0585 2061 37
5 Relative False True True True 16.341 0.0635 5693 32
6 Relative False True True False 16.495 0.0586 7137 32
7 Relative True False False True 15.590 0.0639 6032 122
8 Relative True False False False 15.453 0.0611 6373 114
9 Relative True True False True 15.618 0.0642 5747 118
10 Relative True True False False 15.532 0.0615 7552 117
11 Relative True True True True 16.515 0.0624 7286 65
12 Relative True True True False 16.282 0.0598 9244 67
13 Proband False False False True 7.611 0.0744 16,110 70
14 Proband False False False False 7.641 0.0758 16,403 66
15 Proband False True False True 7.608 0.0744 16,117 69
16 Proband False True False False 7.497 0.0746 17,718 66
17 Proband False True True True 7.669 0.0747 19,046 52
18 Proband False True True False 7.660 0.0755 20,592 50
19 Proband True False False True 7.458 0.0713 21,888 101
20 Proband True False False False 7.024 0.0687 22,850 99
21 Proband True True False True 7.303 0.0714 22,252 99
22 Proband True True False False 7.109 0.0701 23,582 99
23 Proband True True True True 8.542 0.0803 20,504 74
24 Proband True True True False 8.382 0.0780 22,175 73
SE, standard error.
APPENDIX 14
NIHR Journals Library www.journalslibrary.nihr.ac.uk
382
TABLE 145 Numbers of patients in each patient group according to strategy
j
aij
1(1) 1(2) 2 3 4 5 6 7 8
1 3097 3058 3050 3052 3045 3046 3046 3038 3015
2 5084 5021 5008 5011 5000 5002 5002 4988 4950
3 0 19 23 23 26 25 25 29 41
4 0 32 38 37 42 41 41 48 67
5 0 19 23 23 26 25 25 29 41
6 0 32 38 37 42 41 41 48 67
7 119 108 57 57 49 49 49 40 38
8 195 177 93 93 80 80 80 66 62
9 0 5 23 23 26 26 26 29 30
10 0 9 37 37 42 42 42 47 48
11 0 5 40 40 45 45 45 50 51
12 0 9 65 65 73 73 73 82 84
13 815 798 813 814 813 814 814 812 798
14 742 727 740 741 740 741 741 739 727
15 0 5 1 0 0 0 0 1 5
16 0 4 1 0 0 0 0 1 4
17 0 11 1 1 1 1 1 2 12
18 0 10 1 1 1 1 1 2 11
19 75 58 33 33 28 28 28 23 21
20 68 53 30 30 26 26 26 21 19
21 0 5 9 9 10 10 10 11 11
22 0 4 8 8 9 9 9 10 10
23 0 12 33 33 37 37 37 41 42
24 0 10 30 30 33 33 33 37 39
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TABLE 146 Resulting INHBs (and uncertainties) of strategies
Calculation
Strategy
1(1) 1(2) 2 3 4 5 6 7 8
bi (QALY decrement
due to genetic testing)
0 0 −4.122 −3.939 −4.545 −4.412 −4.412 −5.267 −8.241
ci (diagnostic costs) (£) 0 85,000 1,177,000 1,106,000 1,057,000 1,051,000 1,149,000 1,909,000 2,017,000
INHB vs.
strategy 1(1)
(ΔNHBi)
Mean – 16.2 77.7 82.2 101.3 102.3 97.3 76.1 62.3
SE – 6.4 12.5 12.4 14.0 13.9 13.9 15.7 18.1
INHB vs.
strategy 5
Mean −102.3 −86.1 −24.5 −20.1 −1.0 – −4.9 −26.2 −39.9
SE 13.9 9.9 1.5 1.5 0.2 – 0.0 1.9 5.2
SE, standard error.
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Appendix 15 Scenario analysis 2 (BRAF replaced
by methylation testing)
There is currently one further test used in the diagnostic process for LS: a methylation test to examine forhypermethylation. It is used in a similar manner to BRAF, after MSI or an abnormal MLH1 IHC result, to
rule out sporadic cancers. However, instead of testing for a BRAF V600E mutation, the methylation test
considers MLH1 promoter hypermethylation as an indicator for sporadic CRCs. As this has only recently
been implemented in the UK, we have not included it in the base case, but have included it as a separate
scenario analysis. The values of sensitivity and specificity of methylation have been pooled from two 2010
studies: Bouzourene and colleagues303 and Chang and colleagues,304 which were identified from the
Gudgeon and colleagues study from 2011.69
The study by Chang and colleagues (2010)304 from Taiwan identified few MSH6 mutations and no PMS2
mutations among their cohort. The patients were identified for methylation testing using either a MSI
result or an abnormal IHC result, but they did not have to fulfil the Revised Bethesda criteria, which
probands in our model do automatically (as CRC onset under 50 years of age is one of the criteria that
fulfil the Revised Bethesda criteria). Those patients who did not fulfil the Revised Bethesda criteria had to
receive a MSI result to then undergo further testing. The value of sensitivity in Chang’s study was 92%,
with 72% specificity.
Bouzourene and colleagues’ study303 looked specifically at LS patients in Switzerland with a MLH1
mutation, plus a group of patients identified with sporadic CRC who had MSI and an abnormal MLH1
result on IHC. The sensitivity in Bouzourene’s study was 94% with 100% specificity. Both studies have
relatively small sample sizes: 27 patients in Bouzourene’s cohort and 42 in Chang’s. Using these studies,
our values for sensitivity and specificity of methylation testing are 93% and 80%, respectively, regardless
of which prior tumour test it follows. Methylation therefore has a higher specificity and lower sensitivity
than BRAF testing in our evaluation. We received the cost of methylation via personal correspondence with
our clinical expert Ian Frayling (£160), and inflated it to 2013–14 costs using methods previously described
in Chapter 5, Adjustments to 2013–14 prices, such that the cost of methylation used in the model is £166.
This is currently higher than the cost of BRAF used in the model.
As BRAF was only used in strategies 3, 5, 6 and 7, the other strategies remain unchanged by the
introduction of methylation in place of BRAF. Furthermore, the long-term simulations based on a patient’s
diagnosis and surveillance status remain unchanged; for example, in the model the average long-term cost
and survival of a TP patient with surveillance remains the same. However, as methylation has a different
sensitivity, specificity and cost compared with BRAF, the short-term costs and distribution of diagnoses
(the proportion of patients diagnosed positive or negative and their surveillance status) are altered. As
such, the overall costs and QALYs are also different from BRAF’s costs and QALYs. In much the same
way, the costs and QALYs of strategies 2 and 4 differ in the base case (same number of tumour tests,
but the tests have different costs and accuracies, resulting in different short-term and therefore
long-term outcomes).
As the overall ROC plot (Figure 132) for probands and relatives demonstrates, the sensitivity and specificity
in strategies 3, 5, 6 and 7 have changed. These differences are highlighted in Table 147. Here, the use of
methylation in place of BRAF appears to increase the specificity and reduce the sensitivity in most
strategies, which agrees with the difference in the tests themselves.
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Figures 133 and 134 show the proportions of probands and relatives, respectively, testing positive for LS
when BRAF is replaced with methylation.
Despite the higher cost of methylation compared with BRAF, in general the diagnostic costs per
proband and relative and for the cohort of probands and relatives are reduced in strategies 3, 5, 6 and 7
(Table 148 and Figures 135–137). This happens because a smaller proportion of patients test negative for
hypermethylation than for the BRAF V600E mutation, which means that fewer patients go on to further
testing, particularly genetic testing which is much more costly. There is a more dramatic cost reduction for
strategy 6 than for strategy 5 (despite these having the same diagnostic accuracy) as there is a reduced
cost for probands in both the genetic test and the IHC testing.
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FIGURE 132 Overall ROC plot for both probands and their relatives, when BRAF is replaced with methylation.
TABLE 147 Difference in sensitivity and specificity when using methylation in place of BRAF
Strategy Scenario Sensitivity (%) Specificity (%)
3 Base case (BRAF) 56.5 98.6
Scenario 2 (methylation) 55.2 98.7
5 Base case (BRAF) 63.4 98.4
Scenario 2 (methylation) 59.0 98.6
6 Base case (BRAF) 63.4 98.4
Scenario 2 (methylation) 59.0 98.6
7 Base case (BRAF) 71.1 98.2
Scenario 2 (methylation) 70.1 98.2
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TABLE 148 Difference in diagnostic costs when using methylation in place of BRAF
Strategy Scenario
Diagnostic cost
per proband (£)
Diagnostic cost
per relative (£)
Total diagnostic
cost of cohort (£)
3 Base case (BRAF) 317 4.71 578,496
Scenario 2 (methylation) 317 4.59 577,767
5 Base case (BRAF) 318 5.29 586,043
Scenario 2 (methylation) 295 4.91 543,440
6 Base case (BRAF) 348 5.29 636,862
Scenario 2 (methylation) 316 4.91 577,738
7 Base case (BRAF) 595 5.97 1,061,637
Scenario 2 (methylation) 575 5.87 1,026,400
Per patient costs reported to three significant figures. Total cost reported to nearest £.
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FIGURE 135 Cost per proband under methylation scenario.
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Given the change in number of patients tested positive for LS (and their true LS status), the long-term costs
and benefits are also changed. The strategies have reduced long-term QALYs when using methylation
compared with BRAF (Figure 138). This would appear to occur because of a decrease in patients testing TP
(and an increase in FNs). Similarly, there is a reduction in long-term costs, as fewer patients undergo
surveillance colonoscopy and prophylactic TAHBSO (Figure 139).
With the reduction in QALYs for those strategies using methylation, there is a change in the order of
effectiveness of the strategies. In this scenario, strategy 3 becomes less effective (has a lower QALY gain)
than strategy 2, and strategies 5 and 6 become less effective than strategy 4. Strategy 3 has approximately
four fewer discounted QALYs than strategy 2, and strategies 5 and 6 have 13 fewer discounted QALYs
than strategy 4.
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FIGURE 138 Incremental discounted QALYs vs. strategy 1(1), when BRAF is replaced with methylation.
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The cost-effectiveness plane showing all strategies when BRAF is replaced with methylation is shown in
Figure 140, and the INHB of strategies versus strategy 1(1) in this scenario is shown in Figure 141. These
results are also summarised in Table 149.
The ICERs versus strategy 1(1) remain < £10,000 per QALY, as they did in the base case. However, the
change in order of effectiveness results in a change in the ICERs when the strategies are compared with
each other. Strategies 1(2), 2, 3 and 6 are still dominated by other strategies and the ICER for strategy 5 is
slightly reduced to £5436 per QALY gained over strategy 1(1), but strategy 4 is no longer extended
dominated, instead having an ICER versus strategy 5 of £7965 per QALY gained. The ICERs for strategies 7
and 8 remain > £25,000 per QALY gained, as demonstrated in Table 149. Given these results it would
appear that strategy 4, MSI followed by genetic testing, is now the most cost-effective strategy.
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Appendix 16 Summary of parameters in the
health economic model
Parameter name
Base-case
value Source
Relevant section
in report
Diagnostic accuracy
MSI MLH1 and
MSH2
Sensitivity 89% Palomaki et al. 200965 Chapter 5, Test accuracy
Specificity 90.2% Palomaki et al. 200965
MSH6 Sensitivity 77% Palomaki et al. 200965
Specificity 90.2% Palomaki et al. 200965
PMS2 Sensitivity 77% Assumed
Specificity 90.2% Assumed
IHC Sensitivity 77.0% Palomaki et al. 200965
Specificity 88.8% Palomaki et al. 200965
BRAF after IHC
MLH1 abnormal
Sensitivity 100% Palomaki et al. 200965
Specificity 69% Palomaki et al. 200965
BRAF after MSI Sensitivity 100% Domingo et al. 200484
Specificity 40% Domingo et al. 200484
AC II Sensitivity 39% Hampel et al. 2005,103
Salovaara et al. 2000,180
Green et al. 2009,181
Barnetson et al. 2006,175
Balmana et al. 2008182
Specificity 98% Hampel et al. 2005,103
Salovaara et al. 2000,180
Green et al. 2009,181
Barnetson et al. 2006,175
Balmana et al. 2008182
Genetic test MLH1,
MSH2 and MSH6
(for probands)
Sensitivity 90% Dinh et al. 2011,55
Palomaki et al. 200965
Specificity 99.97% Dinh et al. 2011,55
Palomaki et al. 200965
Genetic test PMS2
(for probands)
Sensitivity 62% Dinh et al. 2011,55
Palomaki et al. 200965
Specificity 99.97% Dinh et al. 2011,55
Palomaki et al. 200965
Targeted genetic
test (for relatives)
Sensitivity 100% Assumed
Specificity 100% Assumed
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Parameter name
Base-case
value Source
Relevant section
in report
Numbers of probands and relatives
Number of probands CRC aged < 50 years 1699 ONS cancer registration
statistics, England 2010119
Chapter 5, Numbers
of probands
Prevalence of LS in probands 8.4% Hampel et al. 2008120
Distribution of mutations in LS-positive patients 32% MLH1 Palomaki et al. 200965
39% MSH2
14% MSH6
15% PMS2
FP IHC results for probands 90% MLH1 Mvundura et al. 201054
6% MSH2
2% MSH6
2% PMS2
Number of relatives Five per
proband
Barrow et al. 2009,121
unpublished data provided
by Ian Frayling
Chapter 5, Numbers
of relatives
8495 total
Proportion of relatives FDRs 42% Jenkins et al. 2006,114
Hampel et al. 2008120
Chapter 5, Number of
first-degree relatives
Proportion of relatives testing positive 44% Jenkins et al. 2006,114
Hampel et al. 2008,120
Ian Frayling (unpublished),
Munaza Ahmed
(unpublished)
Chapter 5, Proportion of
relatives testing positive
Adherence to testing and counselling
MSI 100% Ramsey et al. 200349
confirmed by expert
Ian Frayling
Chapter 5, Acceptance of
testing and surveillance
IHC 100% Assumed
BRAF 100% Assumed
First genetic test (proband) 90% Ladabaum et al. 201148
Second genetic test (proband) 100% Assumed
Genetic counselling (proband) 92.5% Clinical experts
(Ian Frayling) gave
range 90–95%
FH assessment after genetic test (proband) 100% Assumed (as included
in counselling)
FH assessment when genetic counselling or test
declined (proband)
100% Assumed
Genetic test (relative) 96% Calculated from
Palomaki et al. 200965
Genetic counselling (relative) 45% Calculated from
Palomaki et al. 200965
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
396
Parameter name
Base-case
value Source
Relevant section
in report
CRC parameters
Probability of different surgery types for index CRC, for patients not diagnosed with LS
Colon cancer Segmental resection 96% National Bowel Cancer
Audit report 2011135
Chapter 5, Colorectal
cancer surgical
management pathwaysSubtotal colectomy 4%
Anterior resection 0%
Proctocolectomy 0%
Rectal cancer Segmental resection 0%
Subtotal colectomy 0%
Anterior resection 98%
Proctocolectomy 2%
Probability index CRC is colon cancer
With LS 0.94 males
and females
Dinh online appendix55 Chapter 5, Colorectal
cancer incident site
Without LS 0.58 males ONS cancer registration
statistics, England 2010119
0.61 females
Parameters for CRC incidence model in patients with LS
β0 0.464 males Bonadona et al. 20112 Chapter 5, Incidence
rates in patients with
Lynch syndrome0.435
females
β1 0.107 males
0.108
females
β2 55.5 males
61.3 females
Proportion with Dukes’ stage at diagnosis
Dukes’ A 0.164 Adapted from table 4.2
of the National Bowel
Cancer Audit 2011135
Chapter 5, Dukes’ stage
on diagnosis
Dukes’ B 0.317
Dukes’ C 0.271
Dukes’ D 0.248
Relative survival of patients with CRC by Dukes’ stage across all ages
1 year since diagnosis Dukes’ A 0.969 NCIN170 Chapter 5, Mortality due
to colorectal cancer
Dukes’ B 0.917
Dukes’ C 0.815
Dukes’ D 0.380
2 years since diagnosis Dukes’ A 0.965
Dukes’ B 0.872
Dukes’ C 0.681
Dukes’ D 0.193
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Parameter name
Base-case
value Source
Relevant section
in report
3 years since diagnosis Dukes’ A 0.957
Dukes’ B 0.831
Dukes’ C 0.583
Dukes’ D 0.116
4 years since diagnosis Dukes’ A 0.945
Dukes’ B 0.799
Dukes’ C 0.522
Dukes’ D 0.083
5 years since diagnosis Dukes’ A 0.932
Dukes’ B 0.770
Dukes’ C 0.477
Dukes’ D 0.066
HRs for CRC mortality by age at diagnosis, compared with CRC mortality across all ages
< 70 years First year 0.599 ONS cancer survival
statistics 2011147
Chapter 5, Mortality due
to colorectal cancer
Following 4 years 0.972
Thereafter 1
70–79 years First year 0.956
Following 4 years 0.966
Thereafter 1
≥ 80 years First year 1.797
Following 4 years 1.116
Thereafter 1
HR survival for LS carriers
Dukes’ A 0.57 Lin et al. 1998176 Chapter 5, Mortality due
to colorectal cancer for
patients with Lynch
syndrome
Dukes’ B 0.57
Dukes’ C 1 Barnetson et al. 2006175
Dukes’ D 1
LS surveillance colonoscopy parameters
Effect of colonoscopy on index CRC incidence
rates (HR)
0.387 Jarvinen et al. 200094 Chapter 5, Effect of
colonoscopy on index
colorectal cancer
incidence rates
Stage distribution of CRCs
for individuals undergoing
colonoscopic surveillance
Dukes’ A 0.686 Mecklin et al. 2007188 Chapter 5, Effect of
colonoscopy on Dukes’
stage of incident
colorectal cancers
Dukes’ B 0.105
Dukes’ C 0.128
Dukes’ D 0.081
Morbidity and mortality
of colonoscopy
Mortality 0.83 per
10,000
Cairns et al. 20109 Chapter 5, Morbidity
and mortality of Lynch
syndrome surveillance
colonoscopyPerforation 4 per
10,000
Gavin et al. 2013189
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Parameter name
Base-case
value Source
Relevant section
in report
Bleeding 26 per
10,000
of which
required
admission
21%
of which were
mild
73%
of which were
moderate
18%
of which were
severe
9%
Adherence to LS colonoscopic surveillance
Proband tested LS mutation positive 80% Ladabaum et al. 201148 Chapter 5, Acceptance
of testing and
surveillanceProband LS assumed 70% Expert opinion
from Ladabaum
et al. 201148
Relative tested LS mutation positive 80% Ladabaum et al. 201148
Relative LS assumed 50% Expert opinion
from Ladabaum
et al. 201148
Effect of colonoscopy on metachronous CRC
incidence (HR)
0.533 Cirillo et al. 2012187 Chapter 5, Effect of
colonoscopy on
metachronous colorectal
cancer incidence
CRC surgery
Effect of CRC surgery on CRC
incidence (HRs)
Segmental
resection
1 Assumed Chapter 5, Effectiveness
of colorectal cancer
surgery
Anterior
resection
0.94 Calculated based on
CRC incidence
Subtotal
colectomy
0.06 Calculated based on
CRC incidence
Proctocolectomy 0 Assumed
Probability patient diagnosed with LS
receives more aggressive CRC surgery
0 Clinical expert opinion Chapter 5, More
aggressive colorectal
cancer surgery for
individuals diagnosed
with Lynch syndrome
EC
Cumulative incidence of EC 0% by age
30 years,
2% by age
40 years,
8% by age
50 years,
23% by age
60 years,
34% by age
70 years,
35% by age
80 years
Bonadona et al. 20112 Chapter 5, Endometrial
cancer incidence
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Parameter name
Base-case
value Source
Relevant section
in report
Screening for EC Not
modelled
Assumption Chapter 5, Screening for
endometrial cancer
Probability of dying of EC by year after diagnosis 9.9% in first
year, 5.0%
per annum
in years 2–3,
2.6% per
annum in
years 4–5,
0.7% per
annum in
years 5–10,
0% thereafter
ONS,147 NCIN170
and Cancer Research UK150
Chapter 5, Mortality due
to endometrial cancer
Age when given prophylactic TAHBSO 45 years for
individuals
aged
≤ 45 years,
otherwise
age when
tested
positive
for LS
Expert opinion Chapter 5, Endometrial
cancer in the Peninsula
Technology Assessment
Group model
Probability of mortality from TAHBSO 0.0002 Average over studies
reported in Palomaki
et al. 200965
Incidence of EC after TAHBSO 0% Schmeler et al.
2006146
Chemotherapy for EC Six cycles of
TAP
(paclitaxel,
doxorubicin,
cisplatin)
Havrilesky et al.
2009152
Adherence to EC prevention and treatment
Adherence to prophylactic TAHBSO for
LS-positive probands
55% Personal communication
with Lorraine Cowley,
Northern Genetics
Service
Chapter 5, Acceptance
of prophylactic total
abdominal hysterectomy
with bilateral salpingo-
oophorectomy
Adherence to prophylactic TAHBSO for
LS-positive relatives
55%
Adherence to TAHBSO on diagnosis of EC 100% Expert opinion Chapter 5, Endometrial
cancer in the Peninsula
Technology Assessment
Group model
Adherence to radiotherapy 33% of
stage I
patients,
100% of
stage II and
III patients,
50% of
stage IV
patients
Havrilesky et al.
2009152
Adherence to chemotherapy 50% of
stage II and
III patients,
100% of
stage IV
patients
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Parameter name
Base-case
value Source
Relevant section
in report
General mortality
Mortality from other causes Age specific ONS life tables 2008–10179
adjusted to remove death
from CRC
Chapter 5, Mortality due
to other causes
Utilities
CRC disutilities Dukes’ A 0 Ramsey et al. 2000217 Chapter 5, Impact of
colorectal cancer on
quality of life according
to Dukes’ stage
Dukes’ B 0
Dukes’ C 0
Dukes’ D 0.13 Mittman et al.
2009225
CRC surgery disutility 0 Assumed Chapter 5, Impact of
colorectal cancer surgery
on quality of life
EC disutility 0 Assumed Chapter 5, Impact of
endometrial cancer on
quality of life
TAHBSO disutility 0 Assumed Chapter 5, Impact of
prophylactictotal
abdominal hysterectomy
with bilateral salpingo-
oophorectomyon quality
of life
Colonoscopy disutility 0 Assumed based on Whyte
et al. 2012214
Chapter 5, Impact of
Lynch syndrome
surveillance colonoscopies
on quality of life
Psychological disutilities
Proband Kuppermann et al.
2013212
Chapter 5, Psychological
impacts of Lynch
syndrome testing and
management on quality
of life
Test declined, surgery not offered 0.04
Test declined, accept TAHBSO (females only) 0.05
Test declined, decline TAHBSO (females only) 0.11
Test accepted, LS negative 0.00
Test accepted, LS positive, surgery not offered 0.02
Test accepted, LS positive, accept TAHBSO
(females only)
0.03
Test accepted, LS positive, decline TAHBSO
(females only)
0.09
Relative
Test declined, surgery not offered 0.04
Test declined, accept TAHBSO (females only) 0.08
Test declined, decline TAHBSO (females only) 0.11
Test accepted, LS negative 0.00
Test accepted, LS positive, surgery not offered 0.02
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Parameter name
Base-case
value Source
Relevant section
in report
Test accepted, LS positive, accept TAHBSO
(females only)
0.06
Test accepted, LS positive, decline TAHBSO
(females only)
0.09
Length of time psychological disutility applied for 4 months Assumption based on
Heshka et al. 2008239
Costs
Diagnostic costs
MSI £202 Average of Oxford Medical
Genetics Laboratories,122
All Wales Molecular
Genetics Laboratory,123
West Midlands Regional
Genetics Laboratory
(via the UKGTN)244
Chapter 5, Costs of
tumour testing and Cost
of genetic testing
IHC £238 Dr Mark Arends
(Department of Pathology,
University of Cambridge)
and Dr Ian Frayling (on
behalf of All Wales
Genetics Service)
BRAF £118 Average of personal
communication with
Mr Michael Gandy
(UCL-Advanced
Diagnostics), East of
Scotland Regional Genetics
Service,124 All Wales
Molecular Genetics
Laboratory123
Proband genetic test MLH1, MSH2 and MSH6 £812 Average of Oxford Medical
Genetics Laboratories,122
All Wales Molecular
Genetics Laboratory,123 East
Anglian Medical Genetics
Laboratories,125 Yorkshire
Regional Genetics
Service126
Proband genetic test PMS2 £735 Yorkshire Regional
Genetics Service126
Proband genetic test MLH1 £464 Average of All Wales
Molecular Genetics
Laboratory,123 East of
Scotland Regional Genetics
Service,124 East Anglian
Medical Genetics
Laboratories,125 Yorkshire
Regional Genetics
Service126
Proband genetic counselling £67 The PSSRU243 and personal
communication with
Professor Mary Porteous
(South East Scotland
Genetic Service)
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Parameter name
Base-case
value Source
Relevant section
in report
Taking FH £22 The PSSRU243 and personal
communication with
Professor Mary Porteous
(South East Scotland
Genetic Service)
Targeted genetic test for relatives (MLH1) £169 Average of Oxford Medical
Genetics Laboratories,122
All Wales Molecular
Genetics Laboratory,123 East
of Scotland Regional
Genetics Service,124 East
Anglian Medical Genetics
Laboratories,125 Yorkshire
Regional Genetics
Service126
Targeted genetic test for relatives (MSH2) £172 Average of Oxford Medical
Genetics Laboratories,122
All Wales Molecular
Genetics Laboratory,123
Yorkshire Regional
Genetics Service126
Targeted genetic test for relatives (MSH6) £172 Average of Oxford Medical
Genetics Laboratories,122
All Wales Molecular
Genetics Laboratory,123
Yorkshire Regional
Genetics Service126
Targeted genetic test for relatives (PMS2) £176 Yorkshire Regional
Genetics Service126
Relative genetic counselling £67 The PSSRU243 and personal
communication with
Professor Mary Porteous
(South East Scotland
Genetic Service)
CRC prevention costs
Cost of colonoscopy £395 Department of Health
reference costs
2011–12151
Chapter 5, Costs of
Lynch syndrome
surveillance colonoscopies
Cost of morbidity and
mortality due
to colonoscopies
Mortality £5134 Whyte et al. 2012214 Chapter 5, Costs of
morbidity and mortality
due to Lynch syndrome
surveillance colonoscopies
Perforation £5134 Department of Health
reference costs
2011–12151
Mild bleeding not
requiring admission
£0 Assumption
Mild bleeding
requiring admission
£318 Whyte et al. 2012214
Moderate bleeding £490 Department of Health
reference costs
2011–12151
Severe bleeding £1984 Department of Health
reference costs
2011–12151
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Parameter name
Base-case
value Source
Relevant section
in report
CRC treatment costs: colon cancer
Diagnosis (incurred at diagnosis for all
Dukes’ stages)
£499 Based on
Trueman et al. 2007134
Chapter 5, Costs of
colorectal cancer
treatment in the
Peninsula Technology
Assessment
Group model
Primary chemotherapy
and radiotherapy
(incurred at diagnosis)
Dukes’ A £0
Dukes’ B £5755
Dukes’ C £13,133
Dukes’ D £13,133
Follow-up surveillance (mean annual cost incurred
for maximum 5 years from index CRC for all
Dukes’ stages)
£269
Recurrence surgery and chemotherapy (incurred in
last year of life if patient dies of CRC within 5 years
of diagnosis, for all Dukes’ stages)
£12,578
Stoma care (annual cost incurred every year after
surgery for all Dukes’ stages)
£1684 for
11%
of patients
Palliative care (incurred in last year of life if patient
dies of CRC, for all Dukes’ stages)
£10,141
CRC treatment costs: rectal cancer
Diagnosis (incurred at diagnosis for all
Dukes’ stages)
£499 Based on
Trueman et al. 2007134
Chapter 5, Costs of
colorectal cancer
treatment in the
Peninsula Technology
Assessment
Group model
Primary chemotherapy
and radiotherapy
(incurred at diagnosis)
Dukes’ A £0
Dukes’ B £2848
Dukes’ C £7628
Dukes’ D £7628
Follow-up surveillance (mean annual cost incurred
for maximum 5 years from index CRC for all
Dukes’ stages)
£256
Recurrence surgery and chemotherapy (incurred in
last year of life if patient dies of CRC within 5 years
of diagnosis, for all Dukes’ stages)
£12,216
Stoma care (annual cost incurred every year after
surgery for all Dukes’ stages)
£1684 for
49%
of patients
Palliative care (incurred in last year of life if patient
dies of CRC, for all Dukes’ stages)
£9236
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Parameter name
Base-case
value Source
Relevant section
in report
CRC surgery costs
CRC surgery costs for
sporadic CRC
Segmental resection £6104 Department of Health
reference costs
2011–12151
Chapter 5, Colorectal
cancer surgery costs
Subtotal
colectomy IRA
£7331
Anterior resection £7399
Proctocolectomy IPAA £7441
CRC surgery costs for
LS CRC
Segmental resection £6154
Subtotal
colectomy IRA
£7331
Anterior resection £7399
Proctocolectomy IPAA £7441
EC costs
Cost of prophylactic TAHBSO £3322 Department of Health
reference costs
2011–12151
Chapter 5, Cost
of endometrial
cancer prevention
Cost of EC treatment TAHBSO £3877 Department of Health
Reference Costs 2011/12151
Chapter 5, Cost
of surgery for
endometrial cancer
Radiotherapy £2753 Havrilesky et al.
2009152
Chapter 5, Cost of
radiotherapy for
endometrial cancer
Chemotherapy £3005 Fleming et al. 2004,256
eMit database,153
Department of Health
reference costs
2011–12151
Chapter 5, Cost of
chemotherapy for
endometrial cancer
Follow-up £0 Assumption Chapter 5, Cost of
follow-up management
of endometrial cancer
Other parameters
Discount rate 3.5% costs
and benefits
NICE reference case132 Chapter 5, Perspective,
discounting, time horizon
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